



2-6 October 2023
Hamburg, Germany

59TH ANNUAL MEETING

EUROPEAN ASSOCIATION
FOR THE STUDY OF DIABETES



EASD.ORG

[#EASD2023](https://twitter.com/EASD2023)

59TH EASD ANNUAL MEETING

Content	Page
Welcome Address	2
About EASD	4
About EFSD	5
General Information	8
Registration	8
Certificates	9
In person attendance onsite in Hamburg	9
Floorplan	10
Transportation	14
Online attendance via Virtual Meeting platform	16
Speakers and Chairpersons	17
EASD Early Career Academy	18
Programme	20
Programme Committee	20
Abstract Review	21
Programme Overview	22
Tuesday, 3 October 2023	30
Claude Bernard Lecture	30
Short Oral Discussions Event A	39
Short Oral Discussions Event B	41
Camillo Golgi Lecture	50
Wednesday, 4 October 2023	54
Albert Renold Lecture	55
Short Oral Discussions Event C	66
Short Oral Discussions Event D	68
Diabetes Prize for Excellence Lecture	77
Thursday, 5 October 2023	80
Rising Star Symposium	81
Short Oral Discussions Event E	91
Short Oral Discussions Event F	93
Minkowski Lecture	102
Friday, 6 October 2023	108
Centennial Anniversary Prize Lecture	108
Short Oral Discussions	131
Abstract Presenter Index - Orals and Short Orals	230
Invited Speaker Index	243
Satellite Symposia on the occasion of the 59th EASD Annual Meeting	245
Industry Sessions on the occasion of the 59th EASD Annual Meeting	261

WELCOME ADDRESS

Dear Members and Guests,

As the current President of the European Association for the Study of Diabetes, I have the honour and pleasure to welcome you to the 59th EASD Annual Meeting.

The meeting will be another great opportunity to connect the global diabetes community, share ground-breaking diabetes science and research, and to provide educational opportunities.



You can look forward to an exceptional scientific programme that not only looks to the future, but also deals extensively with current treatments, technologies and care as well as outstanding scientific research. Across 8 parallel tracks, you are invited to attend stimulating symposia, thought-provoking debates, award lectures, a dedicated e-Learning track as well as numerous oral and short oral presentations.

You are invited to actively join the discussions during the short oral presentations, take advantage of the opportunity to debate many new research findings with colleagues coming from all over the world, promote interdisciplinary exchange and establish new research collaborations – we know that the quality of the meeting is to a large extent determined by you – the people who are with us.

Hamburg, host city of the 59th EASD Annual Meeting, is also known as Germany's gateway to the world and it will offer ample opportunities to socialise and network with peers from all over the world. Needless to say, this city offers great options outside of the scientific programme hours. History, architecture, culture, gastronomy and entertainment provide a variety of choices on how to spend your evenings.

On behalf of the EASD Board and the entire EASD team, I invite you to join us in Hamburg and – to those who might not be able to travel – I invite you to join us virtually!

We look forward to welcoming all of you! Let's get together and continue fighting diabetes!

Chantal Mathieu
President EASD/EFSD

WELCOME ADDRESS

Dear Colleagues and Friends,

On behalf of the 2023 Scientific Programme Committee, I have the pleasure of welcoming you to the 59th EASD Annual Meeting in Hamburg, Germany.

As this is my first year serving as the EASD Honorary Secretary I am exceptionally excited about the scientific programme we have composed for this years' meeting and I hope that everyone will find interesting topics which help us advance the field of diabetes research and care.



The Scientific Programme Committee together with the Abstract Review Committee reviewed 1430 submitted abstracts and selected 1007 for presentation. The outstanding programme will comprise of stimulating symposia and debates, numerous oral and short oral presentations as well as award lectures, honouring the achievements of distinguished scientists and promising talents in diabetes research.

Regardless of whether you are a clinician, basic scientist, nurse, healthcare professional, or young academic, the scientific programme of the EASD Annual Meeting 2023 will deliver an abundance of new knowledge covering the latest innovations and developments in the treatment of type 1 and type 2 diabetes and their associated complications.

Obviously, attending the EASD Annual Meeting 2023 is more than just following the scientific programme – it is also the perfect place to interact and communicate with colleagues from all over the world and offers a unique opportunity for exchange, dialogue and debate.

We invite you to join us and look forward welcoming you in Hamburg from 2 – 6 October 2023.

Tina Vilsbøll

Honorary Secretary EASD

ABOUT EASD

The **European Association for the Study of Diabetes (EASD) e.V.** is a non-profit, medical scientific association with the aim to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

EASD is one of the largest networks for diabetologists worldwide.

Membership is open to health care professionals, scientists, nurses and students from all over the world who are interested in the field of diabetes.

The EASD Annual Meeting is one of the largest diabetes-related conferences in the world, the scientific programme includes more than 1,200 talks and presentations on the latest results in basic and clinical diabetes research.

EASD is also actively involved in postgraduate education with a portfolio ranging from e-Learning activities to basic hands-on training courses including workshops to focused meetings on specific topics of diabetes research and care to collaborations with national associations across the globe.

In 2000, EASD increased its commitment to stimulate diabetes research in Europe by creating the European Foundation for the Study of Diabetes (EFSD). Since its inception, the EFSD has committed over €120 million to diabetes research in Europe by various funding means.

EASD is the publisher of the journal *Diabetologia*, a major monthly international diabetes journal with a high and rising impact factor.

For more information, please visit: www.easd.org.

EASD and EFSD Board:

Chantal Mathieu, Belgium (President)
Francesco Giorgino, Italy
Ruth Loos, Denmark
Julia Mader, Austria
Hindrik Mulder, Sweden
Patrick Schrauwen, Netherlands
Michele Solimena, Germany
Coen Stehouwer, Netherlands
Tina Vilsbøll, Denmark
Petra Wilson, Belgium
Wilfried Winzer, Germany

EASD Headquarters:

European Association for the Study of Diabetes (EASD) e.V.

Rheindorfer Weg 3
40591 Düsseldorf
Germany

Phone: +49 211 758 469 0
Email: info@easd.org

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

ABOUT EFSD

The **European Foundation for the Study of Diabetes (EFSD)** was created by the European Association for the Study of Diabetes (EASD) in order to support more actively diabetes research in Europe and to serve the goals of EASD.

The EFSD began its work in 2000 and has become a significant European funding agency for diabetes research, and is continually striving to enhance diabetes awareness in Europe.

Since inception, EFSD has committed over €120 million to European diabetes research by way of a wide range of grant and fellowship funding initiatives.

For more information, please visit:
www.europeandiabetesfoundation.org.

EFSD Scientific Board:

C. Stehouwer, Netherlands (Chair)
H. Al-Hasani, Germany
M. Blüher, Germany
F. Bosch, Spain
A. Boulton, UK
M. Donath, Switzerland
G.P. Fadini, Italy
P. Fioretto, Italy
N. Lalic, Serbia
M. Nauck, Germany
E. Renard, France
M. Roden, Germany
U. Smith, Sweden

EFSD is greatly indebted to the following companies and organisations for their most generous support of European diabetes research:

Boehringer Ingelheim:

EFSD/Boehringer Ingelheim European Research Programme on “Multi-System Challenges in Diabetes”

This Programme is intended to stimulate and accelerate European research on the interrelation and crosstalk of different organs (e.g. heart, kidney, pancreas, gut, liver and brain) and related pathophysiology in diabetes and its complications and the impact of therapeutic interventions for this complex condition.

Japan Diabetes Society:

EFSD/JDS Reciprocal Travel Research Fellowships

The objective of these Fellowships is to encourage collaborative research between Europe and Japan in the field of diabetes.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Lilly:

EFSD/Lilly European Diabetes Research Programme

This Programme aims to promote increased European diabetes research and to raise public awareness and political understanding of the magnitude and burden of the disease. Grants are offered for any area of basic or clinical diabetes research.

EFSD/Lilly Young Investigator Research Award Programme

The objective of these Young Investigator Research Awards is to encourage innovative research in the field of diabetes and its complications, and to promote excellence in medical education.

EFSD/Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme

This Programme aims to assess with dedicated research projects, potential strategies that could be implemented in Europe and rolled out in low-and middle income countries to favour the improvement of quality of care for all people living with diabetes.

Merck Sharp & Dohme:

EFSD European Research Programme on “New Targets for Diabetes or Obesity-related Metabolic Diseases” supported by MSD

This Programme is intended to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes or obesity-related metabolic diseases.

Novo Nordisk A/S:

EFSD/Novo Nordisk Programme for Diabetes Research in Europe

This Programme aims to promote high-quality diabetes research in Europe, and accepts applications from all fields of clinical and basic diabetes research.

EASD Rising Star Symposium & EFSD Research Fellowship Programme supported by Novo Nordisk

This combined EASD/EFSD initiative aims to identify promising and innovative young researchers in basic and clinical diabetes research.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Novo Nordisk Foundation:

EFSD/Novo Nordisk Foundation Future Leaders Award Programme

This Programme is intended to identify outstanding clinical and basic scientists in European diabetes research in the transition from post-doctoral/clinical fellow to a tenured academic appointment in diabetes research in Europe and support them through significant career development awards over 5 years and fostering their development into the leaders of tomorrow.

EFSD/Novo Nordisk Foundation Precision Diabetes Medicine Award Programme

This Programme is based on scientific quality, innovation potential and a clear translational focus; bringing basic knowledge to use at the patient level in terms of e.g. disease prognosis, treatment prediction or patient stratification.

Sanofi:

EFSD/Sanofi “Outlook to the next 100 years of insulin: Innovative insulin delivery and monitoring systems”

The Programme is intended to stimulate and accelerate European research aimed at understanding and improving insulin delivery and action.

EFSD/Sanofi European Diabetes Research Programme in diabetes associated with cardiovascular disease

This Programme is intended to stimulate and accelerate European research aimed at improving understanding of cardiovascular disease associated with diabetes.

In addition, the **EFSD Albert Renold Travel Fellowships** enables young scientists to stay at other institutions in order to learn new techniques in basic or clinical diabetes research.

EFSD awards are strictly competitive and decisions are based upon a rigorous and fully independent peer-review process.

Further information on EFSD programmes can be found under:
www.europeandiabetesfoundation.org

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

GENERAL INFORMATION

Format

The 59th EASD Annual Meeting will take place as a hybrid event from 2 to 6 October 2023, providing the option to join us in person in Hamburg, Germany or online via the Virtual Meeting platform.

All sessions in the scientific programme will take place onsite at the meeting venue in Hamburg at the times indicated in the programme and will be live-streamed for delegates attending the meeting virtually.

Recordings of all sessions will be available, access to recordings will be limited to registered delegates until 3 November 2023.

Meeting venue

The in person meeting will take place at:

Hamburg Exhibition and Congress

Messeplatz 1
20357 Hamburg, Germany
www.hamburg-messe.de/en/

For online attendance, the [Virtual Meeting platform](#) can be accessed directly or via the EASD website www.easd.org.

Registration

Children under the age of 18 are not permitted to access the 59th EASD Annual Meeting.

Types of registration for the Annual Meeting:

In person attendance to join onsite at the meeting venue in Hamburg, Germany. In person registration includes:

- Name Badge / Congress Material
- Access to the Scientific Programme
- Access to the Exhibition
- Public transportation ticket valid 2 - 6 October 2023
- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates in person and / or virtual attendance

Advisory Note

Please be aware of “fraudulent” third party companies offering EASD services e.g. registration or hotel accommodation.

EASD is the official registration provider and all EASD activities are handled via the official EASD website: www.easd.org.

Interplan is the official accommodation provider handling all hotel requests. Booking platform: easd23.interplan.de/Booking.html

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Virtual attendance to follow the Annual Meeting online. Virtual registration includes:

- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates watch time

All registrations prior to the EASD Annual Meeting dates have to be made by means of the secured online registration system. For more information, please visit: www.easd.org/annual-meeting/easd-2023.html.

During the EASD Annual Meeting dates, in person registrations can be made by the online registration system or at the onsite registration counter at the venue in Hamburg, Germany.

Virtual registrations can only be made by the online registration system.

Certificates

Certificates will be available for download via your [MyEASD](#) account. It will be mandatory to complete the congress evaluation survey to receive certification.

EACCME® Certificate:

The 59th EASD Annual Meeting is currently under review by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide Continuing Medical Education (CME) credits.

German CME / Fortbildungspunkte:

The 59th EASD Annual Meeting is currently under review by the Ärztekammer Hamburg.


Information for in person attendance onsite in Hamburg


Registration counters are open:

Sunday	1 October 2023	12:00 - 18:00
Monday	2 October 2023	08:00 - 18:00
Tuesday	3 October 2023	07:30 - 19:00
Wednesday	4 October 2023	08:00 - 19:00
Thursday	5 October 2023	08:00 - 19:00
Friday	6 October 2023	08:00 - 15:00

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION





EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Badges:

The delegates' name badges serve as an admission pass to all scientific sessions and the exhibition. Delegates are asked to keep their name badges displayed at all times during the meeting. Badges can be replaced and will be charged for.

EASD EFSD				
--------------	--	--	--	--

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

--	--	--

First Aid:

The First Aid is located in Hall A2. In case of emergency, please contact the nearest security or staff member.

Restaurants:

There are various restaurants all over the venue..

Cloakroom/Lost and Found Counter:

A cloakroom with facilities for luggage storage and lost and found is located in the Entrance Hall, next to the registration.

Suitcases (except cabin trolleys) are not allowed in the halls.

Silence Room:

The Silence Room (A3.4) is located in hall A3 on the first floor.

EASD Community Plaza:

The EASD Community Plaza is located in Hall A1 and includes the **EASD Member Lounge**, the **EASD/EFSD Booth**, the **Diabetologia** and **EASD Early Career Academy Booth**, Virtual Meeting Tower, **EASD TV Studio**, seating areas and charging stations for mobile devices.

Opening hours EASD Booth and Member Lounge:

Monday	2 October 2023	08:00 - 18:00
Tuesday	3 October 2023	08:00 - 18:30
Wednesday	4 October 2023	08:00 - 18:30
Thursday	5 October 2023	08:00 - 18:30
Friday	6 October 2023	08:00 - 15:00

Exhibition - Opening Hours:

Tuesday	3 October 2023	09:00 - 16:30
Wednesday	4 October 2023	09:30 - 16:30
Thursday	5 October 2023	09:30 - 16:30
Friday	6 October 2023	09:00 - 15:00

EASD
EFSD

GENERAL
INFO

Hotels:

INTERPLAN Congress, Meeting & Event Management AG

Phone: +49 89 548 2340

Email: hotels.easd@interplan.de

Booking platform: easd23.interplan.de/Booking.html

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Security:

Any suspicious or unidentified items onsite at the meeting venue are to be reported immediately to the nearest staff member. Security staff are on duty to ensure that all persons entering the venue are wearing a badge. For your safety, it is strongly advised to leave all your valuables in a safe at your hotel.

Insurance:

The registration fees do not include the insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate insurance especially with regards to travel.

Travel

Special Lufthansa Group airlines fares:

The Lufthansa Group airlines (Austrian Airlines, Lufthansa, SWISS, Brussels Airlines and Eurowings) offer reduced fares via their [booking platform](#) and with event code **DEAUWRE** for travelling to the EASD 2023 destination Hamburg, Germany. The reduced fares are automatically displayed.

Please enable pop-ups permanently in your browser while booking, otherwise the window in the booking platform will not open.

PUBLIC TRANSPORT

EASD EFS
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION




MAP HAMBURG

chnellbahn-/Regionalverkehr
apid Transit / Regional Rail



hvv.de Information · Service
040 / 19 449 Fahrpläne / Timetables



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Special Deutsche Bahn train fares:

The Deutsche Bahn offers reduced fares for travelling by train to the EASD 2023 destination Hamburg, Germany via its [booking platform](#).

Bookings on the platform are only available for travel between Saturday, 30 September and Sunday, 8 October 2023.

Transportation

Free public transportation during the Meeting within Hamburg. The “hvv Fahrkarte” logo which is printed on your name badge is your public transportation ticket, which is valid for 5 days, starting from Monday 2 October through to and including Friday 6 October 2023.



The venue Hamburg Messe can easily be reached by four different train and metro stations within walking distance.

Information for online attendance via the Virtual Meeting platform

Registered delegates can access the [Virtual Meeting platform](#) by using the email address / MyEASD account connected to the registration (respective email is provided on the registration confirmation).

The [Virtual Meeting platform](#) can be accessed directly or via the EASD website www.easd.org.

Technical requirements:

Delegates must ensure at their own expense that they meet the technical requirements necessary for following the EASD Annual Meeting virtually.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

In addition to the necessary hardware, the following requirements will be needed:

- A stable internet connection with a minimum of 5 MBITs (data speed) to follow the online programme,
- A browser in an up-to-date version e.g. Chrome®, Firefox® or Safari®.

EASD recommends the participation via PC/Mac Computers and a resolution of Full HD 1920x1080 pixels or higher. Cookie and Pop-Up blocking measures may lead to problems. On smart phone/tablet devices only basic viewing features are being supported. It is recommended to use the Safari® browser for Apple® devices.

Please note: When using the Safari® browser on Apple® devices, you will need to enable pop-ups. Pop-ups are disabled by default in the Safari® browser. Please go to the settings of your Safari® browser and enable pop-ups.

For further instructions how to enable pop-ups, please see [here](#).

EASD is not responsible if delegates are unable to successfully access the virtual meeting platform if they do not fulfil the technical requirements.

Speakers and Chairpersons

All speakers and chairpersons are expected to attend the EASD Annual Meeting in Hamburg, Germany, in person to participate live at the time indicated in the programme.

Speakers' Lounge:

The Speakers' Lounge is located in hall B1 on the 1st floor. All speakers are asked to check their presentations at the Speakers' Lounge at least three hours before the scheduled presentation time. If the presentation is scheduled in the morning, speakers are kindly asked to check their presentation at the Speakers' Lounge the day before.

Short Oral Discussions Events:

Short Oral Discussions rank equally with Oral Presentations. All Short Oral Discussions will take place during six events which will be held on Tuesday, Wednesday and Thursday

Short Oral Discussions Event A	Tuesday	12:30 - 13:30
Short Oral Discussions Event B	Tuesday	13:45 - 14:45
Short Oral Discussions Event C	Wednesday	12:45 - 13:45
Short Oral Discussions Event D	Wednesday	14:00 - 15:00
Short Oral Discussions Event E	Thursday	12:45 - 13:45
Short Oral Discussions Event F	Thursday	14:00 - 15:00

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Disclaimer

All efforts will be made to adhere to the programme as provided. However, EASD and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Meeting, for any case beyond their reasonable control. EASD and the local conference organisers are not liable for any other loss or inconvenience caused as a result of such changes.

EASD
EFSD

EASD EARLY CAREER ACADEMY

GENERAL
INFO

The EASD Early Career Academy will host several activities during the EASD Annual Meeting in Hamburg.

PROGRAMME

TUESDAY

Showcasing EASD's future: an EASD Early Career Academy Symposium

Tuesday, 3 Oct 2023, 17:15 - 18:15 CEST, London Hall

WEDNESDAY

EASD Early-Career Academy Social Event

Tuesday, 3 Oct 2023, 18:30 - 18:30 CEST, EASD Member Lounge

THURSDAY

The social networking event is open to all early career researchers and clinicians interested in developing their career. The programme includes networking opportunities with drinks and discussion about the EASD Early Career Academy activities. Details on how to register for the event will be announced soon.

FRIDAY

SHORT ORAL
DISCUSSIONS

Career development in diabetes research: an EASD Early Career Academy panel discussion

Thursday, 5 Oct, 12:45 - 13:45 CEST, Spotlight Stage

PRESENTER
INDEX

The EASD Early Career Academy will also have a booth at the EASD Networking Plaza in Hall A1. We invite you to visit us there and learn more about us and our activities

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



NETWORKING



RESEARCH



ANNUAL MEETING



JOURNAL

Be part of our global diabetes expert community!

JOIN EASD

European Association for the Study of Diabetes



EDUCATION



MEDIA CENTRE



EARLY CAREER ACADEMY



AWARDS

PROGRAMME COMMITTEE

Chaired by Tina Vilsbøll, Denmark, Honorary Secretary, EASD



Karim Bouzakri,
France



Sofia Carlsson,
Sweden

EASD
EFSD

GENERAL
INFO



Martin Clodi,
Austria



Leszek Czupryniak,
Poland

PROGRAMME

TUESDAY



Dana Dabelea,
USA



Lena Eliasson,
Sweden

WEDNESDAY

THURSDAY



Martin Haluzik,
Czech Republic



Christian Herder,
Germany

FRIDAY

SHORT ORAL
DISCUSSIONS



Joris Hoeks,
Netherlands



Janaka Karalliedde,
UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA



Thomas Nyström,
Sweden



John Petrie,
UK

INDUSTRY

PROGRAMME



Maria Rohm,
Germany



Niina Sandholm,
Finland

EXHIBITION



Anna Solini,
Italy



Allan A Vaag,
Denmark

ABSTRACTS

1430 abstracts were received by the Association and 1007 abstracts were accepted for inclusion. All abstracts were reviewed anonymously and scored by the Abstract Review Committee members.

The Programme Committee members designed the programme and created Oral and Short Oral Discussion sessions upon the accepted abstracts.

Publication of Abstracts

Accepted abstracts are published in the Abstract Volume by Diabetologia. Abstracts are also available online.

Embargo Policies

Information contained in abstracts may not be released until 1 July 2023 when the abstracts are published online. Oral Presentations are under embargo until the commencement of the speaker's presentation. Short Oral Discussion Presentations are under embargo until 112:30 CEST on Tuesday, 3 October 2023.

Abstract Review Committee

In addition to the members of the Programme Committee, the Abstract Review Committee comprises the following members:

Andreas Andersen, Denmark	Luigi Laviola, Italy	Robert Ritzel, Germany
Bjørn Olav Åsvold, Norway	Bernhard Ludvik, Austria	Femke Rutters, Netherlands
Erika Bezerra Parente, Finland	Maciej Malecki, Poland	Lars Stechemesser, Austria
Amelie Bonnefond, France	Shivani Misra, UK	Karin Stenkula, Sweden
Malin Flodström Tullberg, Sweden	Mototsugu Nagao, Japan	Apostolos Tsapas, Greece
Samy Hadjadj, France	Peter Novodvorsky, UK, Slovakia	Sarah Wild, UK
Kurt Højlund, Denmark	Romano Regazzi, Switzerland	Anja Zeigerer, Germany
Niels Jessen, Denmark	Michael Resl, Austria	

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

TUESDAY, 3 OCTOBER 2023

	TIME	HAMBURG HALL	LONDON HALL	PARIS HALL	BARCELONA HALL
EASD EFSD	09:00 - 09:30	Presidential Address			
GENERAL INFO	09:30 - 10:15	55th Claude Bernard Lecture			
PROGRAMME	10:30 - 12:00	OP 1	OP 2	OP 3	OP 4
TUESDAY					
WEDNESDAY	12:30 - 13:30	Short Oral Discussion Sessions Event A			
THURSDAY					
FRIDAY					
SHORT ORAL DISCUSSIONS	13:45 - 14:45	Short Oral Discussion Sessions Event B			
PRESENTER INDEX					
	15:15 - 16:45	OP 8	OP 9	OP 10	OP 11
SATELLITE SYMPOSIA					
INDUSTRY	17:15 - 18:15	38th Camillo Golgi Lecture	Showcasing EASD's future: an EASD Early Career Academy Symposium	SGLT2 inhibitors and GLP-1 receptor agonist: mechanisms of beneficial action beyond glycaemic controls	Healing the feelings in type 1 diabetes
PROGRAMME					
EXHIBITION					

TUESDAY, 3 OCTOBER 2023

MUMBAI HALL	LIMA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
				09:00
				09:30
				09:30
				10:15
OP 5	OP 6	OP 7		10:30
				12:00
Short Oral Discussion Sessions Event A		EASD e-Learning expert session	Debate: Initial combined therapy for type 2 diabetes: Should diabetes follow hypertension?	12:30 13:30
Short Oral Discussion Sessions Event B		EASD e-Learning expert session	The 1-hour plasma glucose as a novel biomarker for detecting dysglycaemia, complications and mortality	13:45 14:45
OP 12	OP 13	OP 14		15:15
				16:45
Understanding and treating severe insulin resistance with lipodystrophy	Stay tuned for optimal circadian rhythms and glucose control!	Islet cross-talk in endocrine hormone regulation		17:15 18:15

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

WEDNESDAY, 4 OCTOBER 2023

	TIME	HAMBURG HALL	LONDON HALL	PARIS HALL	BARCELONA HALL
EASD EFSD					
GENERAL INFO	09:00 - 10:30	Obesity heterogeneity: clinical aspects	17th Albert Renold Lecture (09:00 - 10:00)	The ongoing impact of the DCCT/EDIC Study at 40 Years	The evolving enigma of type 1 diabetes
PROGRAMME					
TUESDAY	10:45 - 12:15	OP 15	OP 16	OP 17	OP 18
WEDNESDAY					
THURSDAY	12:45 - 13:45	Short Oral Discussion Sessions Event C			
FRIDAY					
SHORT ORAL DISCUSSIONS					
PRESENTER INDEX	14:00 - 15:00	Short Oral Discussion Sessions Event D			
SATELLITE SYMPOSIA	15:30 - 17:00	OP 22	OP 23	OP 24	OP 25
INDUSTRY					
PROGRAMME	17:30 - 18:30	EASD-Novo Nordisk Foundation Diabetes Prize for Excellence	Michael Berger Debate: Is it time to reclassify diabetes complications because microvascular and macrovascular classification is no longer sufficient?	Debate: Should non-insulin-treated women with diabetes during pregnancy be offered Continuous Glucose Monitoring?	Obesity and cachexia: Two sides of the same coin?
EXHIBITION	18:45 - 19:45				

WEDNESDAY, 4 OCTOBER 2023

MUMBAI HALL	LIMA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
Cystic fibrosis derived diabetes from clinic to research and back	Hypo-RESOLVE	EASD/JDRF Symposium: Are youth with diabetes at risk for cardiovascular disease?		09:00 10:30
OP 19	OP 20	OP 21	EFSD Mentorship Programme 10:00 - 11:00, Sofia Hall	10:45 12:15
Short Oral Discussion Sessions Event C		EFSD/Novo Nordisk Foundation Future Leaders Symposium	Artificial Intelligence in diabetes care: potential and concerns	12:45 13:45
Short Oral Discussion Sessions Event D		EASD e-Learning expert session	Beyond technology to physiologic solutions for type 1 diabetes: the case for islet cell replacement	14:00 15:00
OP 26	OP 27	OP 28		15:30 17:00
Diabetic retinopathy biomarkers and treatment targets from discovery to the clinic	NAFLD and diabetes: chicken or egg?	Debate: Is lasting remission of type 2 diabetes feasible in the real world setting?		17:30 18:30
			EASD General Assembly	18:45 19:45

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THURSDAY, 5 OCTOBER 2023

	TIME	HAMBURG HALL	LONDON HALL	PARIS HALL	BARCELONA HALL
EASD EFSO	09:00 - 10:30	Diabetologia Symposium: Incredible incretins - and where to find them	What have cohort studies taught us about the natural history of type 2 diabetes?	Rising Star Symposium (08:50 - 10:30)	Image-in' what noninvasive techniques can do for diabetes research and care!
GENERAL INFO	10:45 - 12:15	OP 29	OP 30	OP 31	OP 32
PROGRAMME	12:45 - 13:45	Short Oral Discussion Sessions Event E			
TUESDAY	14:00 - 15:00	Short Oral Discussion Sessions Event F			
WEDNESDAY	15:30 - 17:00	OP 36	OP 37	OP 38	OP 39
THURSDAY	17:30 - 18:30	58th Minkowski Lecture	'With a little help from my friends': What can we learn from other specialities?	SURMOUNT-4 Trial results: the impact of tirzepatide on maintenance of weight reduction and benefits of continued therapy	Adipose tissue heterogeneity: cellular and molecular aspect
FRIDAY					
SHORT ORAL DISCUSSIONS					
PRESENTER INDEX					
SATELLITE SYMPOSIA					
INDUSTRY					
PROGRAMME					
EXHIBITION					

THURSDAY, 5 OCTOBER 2023

MUMBAI HALL	LIMA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
Metabolic disease and the circle of life	7th EASD-AASD Joint Symposium: Can COVID-19 help us deliver a whole system holistic healthcare?	Precision medicine in diabetes: complexity and pragmatism		09:00 10:30
OP 33	OP 34	OP 35		10:45 12:15
Short Oral Discussion Sessions Event E		EASD e-Learning expert session	Career development in diabetes research: an EASD Early Career Academy panel discussion	12:45 13:45
Short Oral Discussion Sessions Event F		EASD e-Learning expert session	Immunotherapy and beta cell preservation in type 1 diabetes: from clinical trials to clinical practice	14:00 15:00
OP 40	OP 41	OP 42		15:30 17:00
Sweet Odyssey 2022: computing optimal care for complications	Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes	Chronic Kidney Disease in type 1 diabetes		17:30 18:30

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

FRIDAY, 6 OCTOBER 2023

	TIME	HAMBURG HALL	LONDON HALL	PARIS HALL	BARCELONA HALL
EASD EFSD					
GENERAL INFO	09:00 - 10:00	EASD-Lilly Centennial Anniversary Prize Lecture (09:00 - 09:45)	Current status on stem cell derived islets: Ready for the clinic?	Turning down the thermostat for metabolic health!	Debate: SGLT- 2 or not 2 that is the question? All people with diabetes and CKD should be on SGLT-2 Inhibition by default
PROGRAMME					
TUESDAY					
WEDNESDAY					
THURSDAY					
FRIDAY					
SHORT ORAL DISCUSSIONS	10:30 - 11:30	OP 43	OP 44	OP 45	OP 46
PRESENTER INDEX					
	12:00 - 13:00	OP 50	OP 51	OP 52	OP 53
SATELLITE SYMPOSIA					
INDUSTRY	13:30 - 15:00	Hyperglycaemic crises in adult patients with diabetes consensus report	EASD/ADA Symposium	Facing the unexpected: how to fight diabetes while fighting the war or disaster...	Diabetic neuropathy from genetics to clinical practice
PROGRAMME					
EXHIBITION					

FRIDAY, 6 OCTOBER 2023

MUMBAI HALL	LIMA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
EASD/ESC Symposium: Does increased glucose variability harm the vessels or organs?	Sexual orientation, gender identity and cardiometabolic risk	Treatment strategies to prevent or attenuate renal impairment in type 2 diabetes		09:00 10:00
OP 47	OP 48	OP 49	European elections 2024: the role of EUDF and the diabetes community in raising diabetes on the policy agenda	10:30 11:30
OP 54	OP 55	OP 56	The SARS-CoV-2 virus is directly responsible for the increased incidence of type 1 diabetes during the early COVID-19 pandemic	12:00 13:00
The old and the new risk factors for diabetic kidney disease	Brain control of islet function	Cognition and related conditions in diabetes		13:30 15:00

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Presidential Address

Speaker: Chantal Mathieu, Belgium
President EASD/EFSD

55th Claude Bernard Lecture

Chair: Chantal Mathieu, Belgium

Speaker: Åke Lernmark, Sweden
Dissecting etiologies of autoimmune type 1 diabetes

Åke Lernmark is Senior Professor in Experimental Diabetes Research at Lund University Clinical Research Centre in Malmö, Sweden. His major research interest is the genetic and environmental etiology of autoimmune type 1 diabetes. He is principal investigator for Sweden in The Environmental Determinants of Diabetes in the Young (TEDDY) study.



He was trained at the University of Umeå and obtained his Doctor of Medicine (PhD) degree in 1971 on studies of insulin release from isolated mouse pancreatic islets and developed a method for single islet cells. A nine-year docent ship from the Swedish Government made it possible to join Donald F. Steiner's laboratory, first as Post Doc and then as an Assistant Professor at the University of Chicago. He later continued his research at the Hagedorn Research Laboratory in Gentofte, Denmark where he was the Director of Research (1979-1987). The first islet autoantigen was identified and molecular genetics studies allowed the discovery of HLA-DQ.

As Honorary Secretary of EASD he was responsible for the scientific programme at the Annual Meetings 1984-1988.

Åke Lernmark's contributions have been honored with the Minkowski Award (1984), Kellion Medal (1985), David Rumbough Award (1985), Hamdan Award for Medical Science Excellence (2002), 18th Annual J. Allan Taylor International Prize (2002), Johnny Ludvigsson Prize (2009), Oscar Medin Prize (2019), George Eisenbarth Award (2020) and Kund Lundbæk Award (2021).

The research output is 657 peer-reviewed publications, 57 chapters in text books, and 26 peer-reviewed reviews. His H-index is 87, there are 33,309 citations and 907 publications in Web of Science. Åke Lernmark has mentored 33 graduate students and 29 postdoctoral fellows.

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD CLAUDE BERNARD MEDAL AND LECTURE

The Claude Bernard Medal and Lectureship is the EASD's highest award in recognition of contributions to the advancement of knowledge in the field of diabetes and related metabolic diseases.

The aim of the Lectureship is to honour an individual's innovative leadership and lifetime achievements in diabetes research.

The Claude Bernard Prize is generously supported by Sanofi.

EASD
EFSD

GENERAL
INFO

EASD Claude Bernard Lecturers

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

2022 M.A. Nauck (DE)
2021 J.R. Zierath (SE)
2020 T. Kadowaki (JP)
2019 S.E. Kahn (US)
2018 J. Tuomilehto (KW)
2017 B. Thorens (CH)
2016 M.E. Cooper (AU)
2015 H.-U. Häring (DE)
2014 D. Accili (US)
2013 M. Laakso (FI)
2012 D. Drucker (CA)
2011 E. Ferrannini (IT)
2010 M. Kasuga (JP)
2009 O. Pedersen (DK)
2008 R.A. deFronzo (US)
2007 E. Van Obberghen (FR)
2006 L. Groop (SE)
2005 J.J. Holst (DK)
2004 C.R. Kahn (US)
2003 M. Brownlee (US)
2002 M.-R. Taskinen (FI)
2001 P.E. Cryer (US)
2000 W. Malaisse (BE)
1999 J.-P. Assal (CH)
1998 C. Wollheim (CH)
1997 C.E. Morgensen (DK)
1996 J.D. Ward (UK)

1995 M. Berger (DE)
1994 G. Reaven (US)
1993 D. Andreani (IT)
1992 P.H. Bennett (US)
1991 E. Shafrir (IL)
1990 K.G. Alberti (UK)
1989 G. Tchobrousky (FR)
1988 T. Deckert (DK)
1987 H. Keen (UK)
1986 W.K. Waldhäusl (AT)
1985 E.F. Pfeiffer (DE)
1984 P.J. Lefévre (BE)
1983 C. Hellerström (SE)
1982 J. Mirouze (FR)
1981 G.R. Meyer-Schwickerath (DE)
1980 R.H. Unger (US)
1979 D.A. Pyke (UK)
1978 W. Creutzfeldt (DE)
1977 D.L. Coleman (US)
1976 H.G. Hers (BE)
1975 R.G. Spiro (US)
1974 T.R. Fraser (UK)
1973 A.E. Renold (CH)
1972 K. Lundbaek (DK)
1971 M. Dérot (FR)
1970 E.W. Sutherland (US)
1969 C. de Duve (BE)

OP 01 Tirzepatide: all things must SURPASS

Chair: K. Toulis, Greece, A. Tsapas, Greece

1 Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI)

J. Linge, I.J. Neeland, O. Dahlqvist Leinhard, N. Sattar, L. Fernández Landó, R. Bray, A. Rodriguez, Sweden, USA, UK

2 Tirzepatide reduces muscle fat infiltration relative to insulin degludec in people with type 2 diabetes (SURPASS-3 MRI)

N. Sattar, J. Linge, I.J. Neeland, O. Dahlqvist Leinhard, L. Fernández Landó, R. Bray, Á. Rodríguez, UK, Sweden, USA

3 Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5

R.J. Wiese, H.J. Heerspink, K.R. Tuttle, I. Pavo, A. Haupt, Z. Yang, A. Hemmingway, D.Z. Cherney, N. Sattar, USA, Netherlands, Canada, UK

4 Time spent with sustained HbA_{1c} ≤6.5% (47.5 mmol/mol) and weight loss ≥5% after initiating tirzepatide vs semaglutide: an exploratory analysis of SURPASS-2

B.K. Bergman, J. Rosenstock, T. Garvey, R.L. Batterham, Y. Chen, M. Liu, V.T. Thieu, USA, UK

5 Tirzepatide compared to subcutaneous semaglutide for type 2 diabetes: a network meta-analysis

T. Karagiannis, I. Avgerinos, K. Malandris, A. Stamati, A. Liakos, N. Kakaletsis, A. Tsapas, E. Bekiari, Greece, UK

6 “Surpass(ing)” an era of basal-bolus insulin therapy: tirzepatide vs insulin lispro tid added-on to poorly controlled basal insulin-treated type 2 diabetes

J.P. Frías, J. Rosenstock, H.W. Rodbard, S. Tofé, E. Sears, R. Huh, L. Fernández Landó, H. Patel, USA, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 02 Present, future and future future of insulin therapy

Chair: R. Buzzetti, Italy, M. Dabrowski, Poland

7 The effectiveness of closed-loop systems is maintained after one year of use

A. Romero Gregori, L. Albert Fàbregas, D. Subías Andújar, I. Capel Flores, A. Cano Palomares, I. Mazarico, M. Luchtenberg, M. Rigla, Spain

8 Better glycaemic control with once-weekly insulin icodec versus once daily insulin degludec in adults with insulin-naïve type 2 diabetes (ONWARDS 3)

I. Lingvay, M. Asong, C. Desouza, P. Gourdy, S. Kar, A. Vianna, T. Vilsbøll, S. Vinther, Y. Mu, USA, Denmark, France, India, Brazil, China

9 Efficacy and safety of once-weekly insulin icodec versus once-daily insulin degludec in type 1 diabetes: ONWARDS 6

D. Russell-Jones, T. Babazono, R. Cailleateau, S. Engberg, C. Irace, M.I. Kjaersgaard, C. Mathieu, J. Rosenstock, V. Woo, D.C. Klonoff, UK, Japan, Denmark, Italy, Belgium, USA, Canada

10 Once-weekly insulin efsitora alfa and daily degludec achieve comparable glycaemic control in 3 patient populations during phase 2: clinical insights from CGM assessments

C. Kazda, J. Bue-Valleskey, Q. Zhang, A. Haupt, J. Frias, D. Dahl, USA, Germany

11 Efficacy and safety of a functionally selective insulin: a 26-week randomised, double blind trial versus insulin glargine in people with type 2 diabetes

T. Heise, H. Haraldsson, T. Herbrand, L. Johansson, J. Jordan, E. Nishimura, L. Plum-Mörschel, J. Tank, Ó. Thórisdóttir, K. Lyby, Germany, Sweden, Denmark

12 Ultra-rapid lispro is more protective against exercise-associated hypoglycaemia over lispro in adults with type 1 diabetes on continuous subcutaneous insulin infusion

J. Leohr, A. Abibol, E. Smith LaBell, A. Ghosh, L.V. Turner, D. Shakeri, T. Fukuda, M.C. Riddell, USA, Canada

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 03 Pregnancy and diabetes: lessons from cohort studies

Chair: D. Jensen, Denmark, Y. Winhofer-Stoeckl, Austria

13 Pregnancy and neonatal outcomes following bariatric surgery in Queensland, Australia: a data-linkage matched cohort study

J. Eccles-Smith, Australia

EASD
EFSD

GENERAL
INFO

14 Altered postprandial glucose metabolism and enteropancreatic hormone response during pregnancy following Roux-en-Y gastric bypass: a prospective cohort study

L.L. Stentebjerg, L.R. Madsen, R.K. Støving, B. Hartmann, J.J. Holst, C.A. Vinter, C.B. Juhl, K. Højlund, D.M. Jensen, Denmark

15 Screening of gestational diabetes in early pregnancy by oral glucose tolerance test and biomarkers: a multi-centre cohort study

E.A. Huhn, T. Fischer, M. Todesco Bernasconi, M. Kreft, M. Kunze, E. Dölzlmüller, H. Jaksch-Bogensperger, S. Heldstab, N. Ochsenbein-Koelble, A. Richter, E. Bätz, B. Winzeler, A. Tura, I. Hösli, C.S. Göbl, Switzerland, Germany, Austria, Italy

16 Implementation of a screening protocol for the detection of Maturity Onset Diabetes of the Young (MODY) in pregnancy: a retrospective preliminary analysis

R. Farrelly, I. Blinkhorn, M. Rathod, E. Scott, UK

17 Maternal overweight and obesity is associated with metabolic changes and foetal overgrowth in the absence of gestational diabetes

G. Kotzaeridi, C. Monod, T. Linder, G. Yerlikaya-Schatten, S. Wegener, B. Mosimann, W. Henrich, A. Tura, C.S. Göbl, Austria, Switzerland, Germany, Italy

18 Effect of an interdisciplinary lifestyle and psychosocial intervention on metabolic and mental health outcomes in women with gestational diabetes: the MySweetheart trial

J.J. Puder, D.Y. Quansah, L. Gilbert, A. Arhab, E. Gonzalez-Rodriguez, D. Hans, J. Gross, S. Lanzi, B. Stuijzand, A. Lacroix, A. Horsch, Switzerland

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 04 Diet and exposome

Chair: A. Pantea-Stoian, Romania, S. Schlesinger, Germany

19 Exploring the use of metabolomics to evaluate compliance to a mediterranean diet intervention for cardiometabolic health

E. Smith, U. Ericson, S. Hellstrand, M. Orho-Melander, P.M. Nilsson, C. Fernandez, P. Antonini, S. Di Somma, F. Ottosson, O. Melander, Sweden, Italy, Denmark

20 Diet in the management of type 2 diabetes: an umbrella review of the evidence of randomised controlled trials

E. Szczerba, J. Barbaresko, T. Schieman, A. Stahl-Pehe, L. Schwingshackl, S. Schlesinger, Germany

21 The associations between metabolomic responses to a liquid mixed meal and incidence of type 2 diabetes: Are there novel biomarkers beyond glucose and triglyceride response?

R. Li-Gao, C. Lu, D.A. Hughes, J.B. Van Klinken, R. De Mutsert, F.R. Rosendaal, N.J. Timpson, D.O. Mook-Kanamori, J.J. Goeman, H. Putter, K. Willems van Dijk, Netherlands, UK

22 A randomised controlled trial of intermittently-scanned continuous glucose monitoring as an adjunct to lifestyle modification in impaired glucose tolerance

E. Chow, N. Chu, J. He, H. Leung, C. So, E. Poon, R. Chan, A. Kong, J. Chan, Hong Kong

23 Enteroviral infections are not associated with type 2 diabetes

K. Maedler, H. Liu, S. Geravandi, A. Pugliese, Germany

24 Low dose radiation exposure and the risk of diabetes: a 10-year retrospective cohort study

H. Hu, T. Okubo, Japan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 05 Walking towards better treatments for diabetic feet and neuropathy

Chair: N. Papanas, Greece, V. Lyssenko, Norway

25 Efficacy of autologous cell therapy in the treatment of chronic limb-threatening ischaemia in people with diabetes: a randomised controlled trial

M. Dubsky, J. Husakova, D. Sojakova, V. Fejfarova, R. Jarosikova, A. Nemcova, V. Lovasova, K. Sutoris, V. Woskova, Czech Republic

26 Effect of macrophage-regulating new drug in treatment of diabetic foot ulcers: from phase 3 MRCT to real-world

K. Lin, C. Chen, Y. Tarng, M. Kuo, J. Chen, Y. Wu, C. Li, S. Chang, Taiwan

27 Demographics and baseline characteristics of patients with Charcot foot: a multi-centre cohort analysis

N. Tentolouris, C. Siafarikas, M. Dubský, J. LaFontaine, K. Marie-France, T. Tankova, J. Pappachan, A. Rastogi, E. Jude, Greece, Czech Republic, USA, UK, Bulgaria, India

28 Anti-RANKL antibody for active charcot neuroarthropathy of foot in chronic kidney disease: randomised, placebo controlled study

A. Rastogi, R. Dangwal, S.K. Bhadada, India

29 LX9211 in individuals with painful diabetic peripheral neuropathy: results from a randomised, double-blind, placebo-controlled, parallel-group, multicentre study

R. Pop-Busui, A. Patel, C. Sang, C. Granowitz, P. Banks, P. Pierce, F. Sun, S. Gopinathan, USA

30 The impact of obstructive sleep apnoea treatment on peripheral neuropathy in patients with type 2 diabetes: results from a 2-year feasibility rct

A.A. Tahrani, E. Makhdum, A. Maher, R. Ottridge, M. Nicholls, R. Mahto, M. Patel, J. Young, A.U. Nayak, M.Z. Chen, J. Kyaw-Tun, S. Gonzalez, R. Gouni, A. Subramanian, S. Patel, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 06 Adipocytes and adipose tissue plasticity

Chair: L. Kazak, Canada, G. Sancar, Germany

31 Functional genomics approach for discovery of novel regulators of human adipose tissue plasticity

M. Verma, N. Tolstrup, S. Hatch, G. Ettridge, J. Ast, L. Veizaj, C. Sun, M.Z. Mendoza, D. Ebner, A. Epanchintsev, A. Agrawal, V. Jurtz, E.M. Toledo, B. Gilboa, C. Ämmälä, UK, Denmark

EASD
EFSD

32 Estrogen receptor in adipocyte precursor cells: implications for diabetes after breast cancer therapy

E.A. Wellberg, R.L. Scalzo, N.S. Thomas, USA

GENERAL
INFO

33 Ehd2 regulates plasma membrane integrity and downstream insulin signalling events

K.G. Stenkula, C. Fryklund, A. Borreguero-Muñoz, H. Taylor, F. Kopietz, H. Ardalani, O. Rogova, P. Spegel, N. Bryant, G. Gould, M. Neuhaus, Sweden, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

34 Gpr146 deficiency preserves a lean, metabolically healthy phenotype in mice during diet-induced obesity

S. Brachs, A. Harutyunyan, J. Sbierski-Kind, R. Sun, A. Liu, M. Brachs, L. Spranger, S. Kunz, S. Ki, L. Ehrlich, K. Hu He, M. Bielohuby, P. Wohlfart, K. Mai, J. Spranger, Germany, USA

SHORT ORAL
DISCUSSIONS

35 Arctic diet prevents postprandial hyperglycaemia in Tbc1d4-deficient mice

A.K. Scheel, S. Pirseyedi, L. Espelage, H. Al-Hasani, A. Chadt, Germany

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 07 Regulation of islet function through gene editing and modification

Chair: A. Martinez-Sanchez, UK, R. Regazzi, Switzerland

37 Establishment of pancreatic beta cell-specific gene knockout system based on CRISPR-Cas9 technology with AAV8-mediated gRNA delivery

K. Ueki, Y. Nishida, H. Uzawa, A. Kanai, T. Miyatsuka, H. Watada, Japan

38 Depletion of 14-3-3 ζ in pancreatic beta cells by antisense oligonucleotides promotes beta cell proliferation and increases beta cell mass

G.E. Lim, F. Paré, S. Djerroud, T.P. Prakash, E. Pirie, N. Wijesekara, Canada, USA

39 Direct beneficial effects of truncated C1QL1 on mouse and human islet function in vitro

M. Billert, P. Atanes, I. Ruz-Maldonado, M. Zhao, S. Persaud, UK

40 Suppression of microRNA-33 improves pancreatic beta cell function and mass in murine and human islets

R. Ortega, I. Ruz-Maldonado, P. Atanes, N. Price, M. Zhao, C. Fernandez-Hernando, S. Persaud, B. Liu, UK, USA

41 Human pancreatic islet miRNA-mRNA regulatory networks associated with insulin secretion and type 2 diabetes development

A. Karagiannopoulos, E. Cowan, M. Maziarz, J.L. Esguerra, L. Eliasson, Sweden, Denmark

42 Can long non-coding RNA derived micropeptides impact the pathogenesis of type 1 diabetes?

J. Mentxaka Salgado, K. García Etxeberria, L. Bergara, L. Mendoza Gómez, A. Castellanos Rubio, I. Santin, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT A

12:00 - 13:30	Short Oral Discussion Area	Page
SO 01	Weight across the lifespan	<u>131</u>
SO 07	Mechanistic insights.	<u>137</u>
SO 13	Monogenic diabetes	<u>144</u>
SO 19	Transplantation of islet and stem cells today and tomorrow	<u>150</u>
SO 25	Exercise as medicine	<u>155</u>
SO 31	It's in the brain	<u>161</u>
SO 37	Hormonal control of obesity	<u>167</u>
SO 43	Small molecules to combat a large disease	<u>174</u>
SO 49	Therapies: here, there and everywhere	<u>180</u>
SO 55	Nutrition: strawberry fields or glass onions?	<u>187</u>
SO 61	Refining and redefining insulin therapy in type 1 diabetes	<u>194</u>
SO 67	Un/successful fitting diabetes in a health care system.	<u>201</u>
SO 73	More or less likely but still important determinants of diabetes care	<u>207</u>
SO 79	Diabetic complications: observational studies from nerves to blood vessels	<u>214</u>
SO 85	Diabetes, lipids and the vessels	<u>219</u>
SO 91	Experimental models of diabetes: related complications	<u>224</u>

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD e-Learning expert session

Chair: TBA*Speaker:* TBAEASD
EFSD

12:45 - 13:30

Spotlight Stage

GENERAL
INFO**Debate: Initial combined therapy for type 2 diabetes: Should diabetes follow hypertension?***Chair:* Leszek Czumpryński Poland*Speaker:* Peter Gaede, Denmark:
Yes! The more intensive therapy from the start, the better: all to scare the disease off

Harald Sourij, Austria:

No! Too much care may kill the cat (and costs too much)**followed by discussion**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT B

13:45 - 14:45	Short Oral Discussion Area	Page
SO 02	Lifestyle matters	<u>132</u>
SO 08	Coming from the heart.	<u>139</u>
SO 14	Heterogeneity of diabetes.	<u>145</u>
SO 20	Roads leading to apoptosis in beta cells	<u>151</u>
SO 26	Hormones from the gut and the liver.	<u>156</u>
SO 32	Keeping focus on GLP1	<u>162</u>
SO 38	Fantastic fats and where to find them	<u>168</u>
SO 44	I heard the news today: novel incretins	<u>175</u>
SO 50	Type 1 diabetes.	<u>182</u>
SO 56	Devising diabetes devices	<u>188</u>
SO 62	If it is Tuesday, it is time for insulin injection	<u>195</u>
SO 68	Where do the happiest people with diabetes live?	<u>202</u>
SO 74	Clinical observations to improve the prediction and progression of diabetic kidney disease	<u>208</u>
SO 80	Beyond the clinical examination: emerging diagnostics in diabetic neuropathy	<u>215</u>
SO 86	Diabetic complications from head to toe	<u>219</u>
SO 92	Cognitive impairment in diabetes	<u>225</u>

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

14:45 - 14:30

Spotlight Stage

The 1-hour plasma glucose as a novel biomarker for detecting dysglycaemia, complications and mortality

Chair: Peter M Nilsson Sweden

Speaker: Michael Bergman, USA:
Background (rationale, pathophysiology) and overview

Jaakko Tuomilehto, Finland:
Detection of prediabetes and diagnosis of type 2 diabetes

Rafael Gabriel, Spain:
Cardiovascular outcomes and mortality

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

OP 08 Towards curing obesity*Chair:* U. Riserus, Sweden**43 Effects of gastric bypass on regional brain glucose uptake during normo- and hypoglycaemia**

G. Fanni, S. Radhi, S. Kvernby, M. Sundbom, S. Haller, E. Roman, J. Wikström, M. Lubberink, J.W. Eriksson, Sweden

44 The metabolomic signature of weight loss interventions: insight from clinical trials

M.L. Smith, L.J. Goudswaard, L.J. Corbin, The By-Band-Sleeve Trial Management Group, D.A. Hughes, A. McConnachine, P. Welsh, R. Taylor, M.E. Lean, N. Sattar, N.J. Timpson, UK

45 Remission of type 2 diabetes 5 years after gastric bypass versus sleeve gastrectomy: the Oseberg RCT

J.W. Hauge, H. Borgeraas, J.K. Hertel, M.C. Småstuen, R. Sandbu, L.K. Johnson, M. Svanevik, K.I. Birkeland, R.L. Kolotkin, T.G. Valderhaug, H.L. Gulseth, J. Hjelmæsæth, D. Hofsv, Norway, USA

46 Synergistic effects of tirzepatide and pioglitazone on insulin sensitivity and beta cell function in diet-induced obese rats

M. Abu-Farha, I. Al-Khairi, M. Qaddoumi, S. Al-Sabah, A. AlSabbagh, V. Lopez, T. Alessa, J. Kumar, N. Abukhalaf, P. Cherian, S. Al-Sabah, F. Al-Mulla, J. Abubaker, M. Abdul-Ghani, Kuwait, USA

47 High-throughput proteomics of human adipose tissue reveals exercise and type 2 diabetes induced changes

R. Kruse, J.K. Larsen, N. Sahebekhtiari, R.M. Justicia, G. Gomez, M.H. Petersen, M.E. De Almeida, N. Ørtenblad, A.S. Deshmukh, K. Højlund, Denmark

48 GUBamy: a novel long-acting amylin analogue with significant therapeutic potential for mono- and combination therapy in obesity

M. Tozzi, M. Cavallera, N. Sonne, L. Holm, M. Ougaard, S. Rasmussen, H.B. Hansen, M. Kræmer, T. Porsgaard, N. Vrang, S. Jørgensen, Denmark

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 09 Treatment beyond metformin

Chair: G. Kostopoulos, Greece, T. Stulnig, Austria

49 The genetics of the response to second-line drug therapies for type 2 diabetes: genome-wide association studies in the GRADE clinical trial

L. Szczerbinski, J.H. Li, H. Liu, M. Tripputi, A. Kretowski, S.E. Kahn, J.M. Lachin, N. Younes, J.M. Mercader, J.C. Florez, the GRADE Research Group, Poland, USA

EASD
EFSD

GENERAL
INFO

50 Effect of glucagon-like-peptide 1 analogues and sodium-glucose transport 2 inhibitors on MACE in an elderly population: a target trial emulation in Danish register data

V. Kosjerina, M. Parsa, B. Carstensen, M.Z. Ankarfeldt, K.K. Sorensen, B. Brock, H.R. Christensen, J. Rungby, D. Vistisen, K. Clemmensen, Denmark

51 Lower risk of severe hypoglycaemia with SGLT2 inhibitor compared to DPP4 inhibitor use in subjects with type 2 diabetes: a propensity score-matched cohort study

S. Moon, E. Kim, H.-S. Kwon, K. Han, Y.-B. Ahn, K.-H. Song, Republic of Korea

52 Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes

K.K. Clemmensen, B. Zareini, T. Gerds, K.K. Sørensen, K. Kvist, J.-P. David, C. Torp-Pedersen, Denmark

53 Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes

B. Zareini, T. Gerds, K.K. Sørensen, K.K. Clemmensen, K. Kvist, J.-P. David, C. Torp-Pedersen, Denmark

54 Precision medicine in type 2 diabetes: development and validation of a treatment selection algorithm for SGLT2-inhibitors and GLP1-receptor agonist therapies

P. Cardoso, A.T. Nair, K.G. Young, R. Hopkins, A.G. Jones, N. Sattar, R.R. Holman, E.R. Pearson, A.T. Hattersley, B.M. Shields, T.J. McKinley, J.M. Dennis, on behalf of the MASTERMIND consortium, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 10 Activating two or three G's; one of us is lonely

Chair: R. Golubic, UK, M.A. Nauck, Germany

55 CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in 4 weeks in overweight and obese adults

M.V. Chakravarthy, F.A. Arguelles-Tello, A.A. Sun, M. Elliott, L. Acosta, J.E. Rankin, S.K. Hansen, USA, Mexico, Australia

56 Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA_{1c} and body weight reductions to people with type 2 diabetes: a 36-week, phase 2 study

T. Coskun, J. Rosenstock, J. Frias, A. Jastreboff, Y. Du, J. Lou, S. Gurbuz, M.L. Hartman, A. Haupt, Z. Milicevic, USA

57 Once-weekly triple receptor (GIP/GLP-1/glucagon) agonist retatrutide (LY3437943): efficacy and safety in a 48-week obesity phase 2 trial

A.M. Jastreboff, L.M. Kaplan, J.P. Frias, Q. Wu, Y. Du, S. Gurbuz, T. Coskun, A. Haupt, Z. Milicevic, M.L. Hartman, USA

58 Efficacy of cotadutide dual GLP1-glucagon receptor agonist on albuminuria and glycaemic control in patients with diabetic kidney disease

D. Robertson, V. Selverajah, L. Hansen, L. Jermutus, K. Smith, C. Frickleton, A. Coggi, J. Sanchez, Y.-T. Chang, V.E. Parker, UK, USA, Sweden

59 A Phase II, randomised, double-blind, placebo-controlled, dose-finding study of BI 456906 in people living with overweight/obesity

C.W. Le Roux, O. Steen, K.J. Lucas, L. Borowska, A. Unseld, E. Startseva, Ireland, Canada, USA, Germany

60 Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis

L. Aronne, M.S. Harris, M.S. Roberts, J. Suschak, S. Tomah, L. He, J. Yang, J.P. Frias, S.K. Browne, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 11 Be(a)ware of hypoglycaemia unawareness*Chair:* S.R. Heller, UK**61 ZT-01, a somatostatin receptor 2 antagonist, increases glucagon response to hypoglycaemia in a phase 1b glycaemic clamp study in type 1 diabetes**

A. Abitbol, R. Liggins, S. Peers, E. Simonson, M.C. Riddell, M. Midmer, Canada

EASD
EFSDGENERAL
INFO**62 HIT4HYPOS CGM analysis: high intensity interval training reduces nocturnal hypoglycaemia in people with type 1 diabetes and impaired awareness of hypoglycaemia**

C.M. Farrell, G. Cappon, D. West, A. Facchinetti, R.J. McCrimmon, UK, Italy

PROGRAMME

TUESDAY

63 Targeted metabolomics of impaired awareness of hypoglycaemia in individuals with type 1 diabetes

B.H. Wolffenbuttel, R.D. Varkevisser, A. Cecil, C. Prehn, D. Mul, H.-J. Aanstoot, M.M. Van der Klauw, Netherlands, Germany

WEDNESDAY

THURSDAY

FRIDAY

64 ZT-01, a somatostatin receptor 2 antagonist (SSTR2a), increases pulsatile glucagon release during hypoglycaemia in type 1 diabetes

R. Liggins, A. Abitbol, M.C. Riddell, S. Peers, E. Simonson, M. Midmer, Canada

SHORT ORAL
DISCUSSIONS**65 Meta-genome-wide association studies identify potential SNPs and enriched pathways for impaired awareness of hypoglycaemia**

M.M. Van der Klauw, R.D. Varkevisser, N. Ali, A. Alaswad, IAH GWAS research group, Dutch Diabetes Pearl Genomics consortium, C.-J. Xu, Y. Li, C.J. Tack, B.H. Wolffenbuttel, B.E. De Galan, Netherlands, Germany

PRESENTER
INDEXSATELLITE
SYMPOSIA**66 Reduced defensive responses to hypoglycaemia are associated with a loss of neuronal activation in the dorsomedial hypothalamus in mice**

L. Sheppard, E. Staricoff, E. Naden, M. Josipovic, C. Riches, B. De Galan, B. Thorens, U. Pedersen-Bjergaard, A. McNeilly, R. McCrimmon, M. Evans, UK, Netherlands, Switzerland, Denmark

INDUSTRY

PROGRAMME

EXHIBITION

OP 12 Diabetes and the brain

Chair: G. Daniele, Italy, J. Rungby, Denmark

67 Associations of lower time in range with cognitive dysfunction and hippocampal damage in adults with type 2 diabetes

Z. Zhang, C. Yu, Y. Bi, China

68 Decreased cerebral glucose and increased cerebral fatty acid utilisation during fasting in type 2 diabetes

M. Schain, E. Johansson, I. Laitinen, A. Frödén Löwenmark, M. Lubberink, A. Gummesson, P. Nuutila, R. Esterline, J. Oscarsson, L. Johansson, K. Heurling, Sweden, Finland, USA

69 The role of microglial SCAP in diabetes-associated cognitive dysfunction

W. Zhu, H. Zhang, T. Niu, K. Liu, S. Wang, China

70 Intracerebrospinal fluid AAV-FGF21 gene therapy prevents high fat diet-associated cognitive decline in mice

I. Grass, I. Elias, V. Sacristan, A. Ribera, C. Jambrina, E. Casaña, V. Jimenez, F. Bosch, Spain

71 Remnant cholesterol is an independent risk factor for dementia in patients with type 2 diabetes: a nationwide population-based cohort study

H. Jung, J. Huh, E. Rho, S. Lee, S.-H. Ihm, K.-D. Han, J. Kang, Republic of Korea

72 An assessment of factors contributing to the decline in risk of stroke complicating type 2 diabetes over recent decades: the Fremantle Diabetes Study

T.M. Davis, W.A. Davis, Australia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 13 Concerning insulin resistance

Chair: B. De Galan, Netherlands, M. Heinzl, Austria

73 Insulin resistance is associated with unbalanced GIP and GLP-1 secretion

G. Di Giuseppe, G. Ciccarelli, L. Soldovieri, M. Brunetti, F. Cinti, S. Moffa, U. Capece, A. Mari, J.J. Holst, A. Giaccari, T. Mezza, Italy, Denmark

74 The relative contribution of insulin secretion and insulin sensitivity in the progression to type 2 diabetes in Asians

M.H. Lee, E. Febriana, M. Lim, S. Jin, A.R. Cook, S. Baig, I.Y. Ang, A. Nastar, J.B. Halter, F. Magkos, S.-A. Toh, Singapore, USA, Denmark

75 Dep-1 is a novel brain insulin receptor phosphatase and transcriptome regulator

S. Chopra, J. Ulke, L. Schmidt, O.L. Kadiri, M. Krüger, K. Kappert, A. Kleinriders, Germany

76 Renal cortical glucose uptake rate is decreased in insulin resistance and correlates inversely with serum free-fatty acids, ketone bodies and citrate levels

E. Rebelos, A. Mari, M.-J. Honka, L. Pekkarinen, S. Laurila, A. Latva-Rasku, J. Rajander, E. Saukko, H. Iida, P. Salminen, E. Ferrannini, P. Nuutila, Finland, Italy

77 The mechanisms of duodenal mucosal resurfacing procedure in reversing type 2 diabetes

N. LiJuan, C. Zhe, S. YaoHuan, Y. XinYi, Z. XiQiao, China

78 ¹³C glucose breath test analysis as an accurate index of insulin resistance in people with type 1 diabetes

J. Mertens, R. Braspenning, L. Roosens, S. Francque, C. De Block, Belgium

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 14 Regulation of islet hormone secretion in type 1 diabetes and type 2 diabetes

Chair: L. Eliasson, Sweden, A. Tomas, UK

79 Loss of electrical beta to delta cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type 1 diabetes

R. Gao, T. Hill, A. Benrick, L. J. B. Briant, L. Kothegeali, H. Dou, Q. Zhang, P. Rorsman, UK, Sweden

EASD
EFSD

80 Glucose inhibits glucagon secretion of mice with alpha cell specific deletion of KATP channels

M. Parambath, B. Lai, H. Chae, E. Gattineau, P. Gilon, Belgium

GENERAL
INFO

81 Recombinant PSP/reg treatment improves beta cell function in islets isolated from glucose intolerant and type 2 diabetic donors

I. Louvet, M. Moreno-Lopez, A. Acosta-Montalvo, V. Gmyr, J. Kerr-conte, T. Reding, C. Saponaro, F. Pattou, R. Graf, C. Bonner, France, Switzerland

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

82 Functional genomics highlights type 2 diabetes-associated purinergic receptor P2RY1 as a new modulator of insulin secretion in humans

A. Dance, M. Derhourhi, M. Boissel, M. Marre, G. Charpentier, A. Khamis, P. Froguel, A. Bonnefond, France, UK

SHORT ORAL
DISCUSSIONS

83 A peptide-amino acid transporter axis regulates pancreatic beta cell maintenance and function

M. Nakazato, W. Zhang, H. Sakoda, Japan

PRESENTER
INDEX

84 Genome-wide screening for regulators of degradation of insulin secretory granules with a fluorescent reporter

A. Kanai, Y. Nishida, K. Ueki, H. Uzawa, H. Watada, Japan

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

38th Camillo Golgi Lecture

Chair: Chantal Mathieu, Belgium

Speaker: Stephan Herzig, Germany

Diabetes complications: from classical to emerging

Stephan Herzig is Research Director at Helmholtz Center Munich (HMGU), Scientific Director of the Helmholtz Diabetes Center, and Director of the Institute for Diabetes and Cancer. He holds a full professorship for molecular metabolic control at the medical faculty of the Technical University Munich and is honorary professor at the University of Heidelberg.



After obtaining his PhD from the University of Göttingen in 1999, he moved to the U.S. for a postdoctoral training at the Salk Institute for Biological Studies in La Jolla, California. In 2003, he relocated to Germany to establish an independent junior group at the German Cancer Research Center, where he was promoted to department head in 2010. In 2012, he became full professor at the University of Heidelberg and eventually accepted an offer from the Helmholtz Center Munich in 2015.

The Herzig lab aims at identifying novel therapeutic targets for treating metabolic dysfunction in obesity and diabetes long-term complications.

To date, he has published more than 170 peer-reviewed papers including numerous publications in Nature, Nature Medicine, Science, and Cell Metabolism, and holds several patents. A number of prestigious awards have been granted to Stephan Herzig, exemplified by an Emmy-Noether Award (German Research Association, DFG), a Marie-Curie Excellence Award (European Commission) and most recently the Werner-Creutzfeldt Award (German Diabetes Association DDG).

Herzig is serving the scientific community by a number of coordinating functions in national and international consortia, and he is Editor-in-Chief of Molecular Metabolism.

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

EASD CAMILLO GOLGI PRIZE

The EASD Camillo Golgi Prize is awarded for outstanding contributions in the field of the histopathology, pathogenesis, prevention and treatment of the complications of diabetes, which have been carried out in Europe by a member of EASD normally resident in Europe.

Publications in internationally recognized scientific journals over the last 5 years should demonstrate continuing activity, originality and excellence in the field.

The Camillo Golgi Prize is generously supported by Novo Nordisk.

EASD Camillo Golgi Lecturers

2022	M. Horowitz (AU)	2003	A. Boulton (UK)
2021	H.L. Heerspink (NL)	2002	J. Tuomiletho (FI)
2020	N. Sattar (UK)	2001	A. Flyvbjerg (DK)
2019	R.A. Malik (QA)	2000	U. Di Mario (IT)
2018	P.P. Nawroth (DE)	1999	E. Standl (DE)
2017	B.M. Frier (UK)	1998	D.R. Tomlinson (UK)
2016	P. Rossing (DK)	1997	H.-H. Parving (DK)
2015	H.-P. Hammes (DE)	1996	M.-R. Taskinen (FI)
2014	S. Tesfaye (UK)	1995	R. Landgraf (DE)
2013	T. Lauritzen (DK)	1994	J.E. Tooke (UK)
2012	G. Pugliese (IT)	1993	K.F. Hansen (NO)
2011	A. Bierhaus (DE)	1992	E. Kohner (UK)
2010	D. Ziegler (DE)	1991	R. Osterby (DK)
2009	P.-H. Groop (FI)	1990	P.J. Watkins (UK)
2008	A. Avogaro (IT)	1989	G.B. Bolli (IT)
2007	P. Fioretto (IT)	1988	C.E. Morgensen (DK)
2006	M. Laakso (FI)	1987	D.J. Ewing (UK)
2005	C. Stehouwer (NL)	1986	G.C. Viberti (UK)
2004	A. Ceriello (IT)		

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:15 - 18:15

London Hall

Showcasing EASD's future: an EASD Early Career Academy Symposium

Chair: TBA

Speaker: Domenico Trico, Italy:
Beta cell overdrive: a quest for balance

EASD
EFSD

GENERAL
INFO

17:15 - 18:15

Paris Hall

SGLT2 inhibitors and GLP-1 receptor agonist: mechanisms of beneficial action beyond glycaemic control

Chair: Tina Vilsbøll, Denmark

Speaker: André JL Scheen, Belgium:
The Heart

Katherine Tuttle, USA:
The Kidney

Norbert Stefan, Germany:
The Liver

Apostolos Tsapas, Greece:
Dual action time for combination?

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:15 - 18:15

Barcelona Hall

Healing the feelings in type 1 diabetes

Chair: Femke Rutters, Netherlands

Speaker: William H Polonsky, USA:
On detecting and measuring diabetes distress

Agnieszka Szadkowska, Poland:
Parental well-being and clinical outcomes: How much of an association?

Timothy W Jones, Australia:
Hybrid closed loop and QoL: How much of an impact?

17:15 - 18:15

Mumbai Hall

Understanding and treating severe insulin resistance with lipodystrophy

Chair: John Petrie, UK

Speaker: Rachel M Williams, UK:
Avoiding missed diagnoses: who to test

D Araújo-Vilar, Spain:
Lifestyle management

Joel K Elmquist, USA:
The role of leptin replacement

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

17:15 - 18:15

Lima Hall

Stay tuned for optimal circadian rhythms and glucose control!

Chair: Juleen R. Zierath, Sweden

Speaker: Charna Dibner, Switzerland:
When circadian rhythms go wrong in islet cells

Frank AJL Scheer, USA:
Circadian disruption and glucose tolerance

Christian Benedict, Sweden:
Disrupted sleep and type 2 diabetes risk

17:15 - 18:15

Cairo Hall

Islet cross-talk in endocrine hormone regulation

Chair: Patrik Rorsman, UK

Speaker: Bethany P Cummings, USA:
Alpha-cell paracrine signalling in the regulation of beta-cell insulin secretion

Zong Wei, USA:
Interorgan crosstalk in pancreatic islet function and pathology

INDUSTRY

PROGRAMME

EXHIBITION

Obesity heterogeneity: clinical aspects*Chair:* Maria Rohm, Germany*Speaker:* Roy Taylor, UK:**Role and determinants of individual tolerability of obesity in diabetes development: lessons from the DiRECT study and beyond**EASD
EFSDGENERAL
INFO

Matthias Blüher, Germany:

Metabolic healthy obesity: fact or fiction?

Mikael Rydén, Sweden:

Intrinsic adipose tissue dysfunctions in obesity and its complications

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17th Albert Renold Lecture

Chair: Francesco Giorgino, Italy

Speaker: Yuval Dor, Israel

Disrupted RNA editing as a path to type 1 diabetes

Yuval Dor, PhD, is a Professor of biology at the Hebrew University-Hadassah Medical School. He earned his PhD in vascular biology at the Hebrew University in 2001 with Prof. Eli Keshet, and trained as a post-doc at Harvard University with Doug Melton until 2004.

His lab studies postnatal tissue dynamics: the molecular mechanisms by which cells regenerate and die. Much of his work focuses on pancreatic beta-cells in the context of type 1 and type 2 diabetes, as well as on pancreatic cancer. He is also using DNA methylation-based liquid biopsies to assess pathologies.

Since 2017 he is the chair of biology and medicine at the Israel Science Foundation



EASD ALBERT RENOLD PRIZE

Prize for an EASD member's outstanding achievements in research on the islets of Langerhans.

The Albert Renold Prize honours the memory of Albert Renold, the distinguished diabetologist, researcher and also one of the founding members of EASD

The Albert Renold Prize is generously supported by Lilly.

EASD Albert Renold Lecturers

2022	M. Sander (US)
2021	P.L. Herrera (CH)
2020	G.A. Rutter (UK)
2019	T. Otonkoski (FI)
2018	R.N. Kulkarni (US)
2017	J. Ferrer (UK)
2016	M.S. German (US)
2015	A. Hattersley (UK)

2014	S. Kahn (US)
2013	P. Rorsman (UK)
2012	D. Eizirik (BE)
2011	M. Prentki (CA)
2010	S. Seino (JP)
2009	B. Thorens (CH)
2008	J.-C. Henquin (BE)
2007	F. Ashcroft (UK)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Paris Hall

The ongoing impact of the DCCT/EDIC Study at 40 Years

Chair: TBA

Speaker: TBA

EASD
EFSD

09:00 - 10:30

Barcelona Hall

The evolving enigma of type 1 diabetes

Chair: Lars Christian Stene, Norway

Speaker: Maria J Redondo, USA:
Heterogeneity of type 1 diabetes in children: implications for treatment, prognosis, and prevention

R David Leslie, UK:
Autoimmune diabetes in adults-subtypes, treatment, prognosis, and prevention

Emily K Sims, USA:
Universal screening: Is it around the corner?

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Mumbai Hall

Cystic fibrosis derived diabetes from clinic to research and back

Chair: Lena Eliasson, Sweden

Speaker: Andrea Kelly, USA:
Dysregulated insulin in pancreatic insufficient cystic fibrosis

James AM Shaw, UK:
Exocrine-endocrine cross-talk in CFRD

Charlotte Boughton, UK:
Insulin delivery for people living with diabetes: a clinical study

Hypo-RESOLVE

- Chair:* Bastiaan E de Galan, Netherlands:
Introduction to the project and hypoglycaemia in CVD
- Speaker:* Pratik Choudhary, UK:
Clinical and psychological relevance of sensor-detected low glucose: the Hypo-METRICS study
- Jill Carlton, UK:
Health-economic impact of hypoglycaemia
- Simon R Heller, UK:
The classification of hypoglycaemia: then and now
- Brian Frier, UK:
Commentary

EASD/JDRF Symposium: Are youth with diabetes at risk for cardiovascular disease?

- Chair:* Dana Dabelea, USA and Aaron J Kowalski, USA
- Speaker:* Amy K Mottl, USA:
Adverse vascular outcomes in youth-onset type 1 and type 2 diabetes: the SEARCH and TODAY experience
- Elaine M Urbina, USA:
Evidence of cardiac target organ damage in young adults with youth-onset diabetes
- Janet Snell-Bergeon, USA:
Novel biomarkers of CVD in people with youth-onset diabetes

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

EFSD Mentorship programme*Chair:* Andrew JM Boulton, UK*Speaker:* Andrew JM Boulton, UK**Welcome and Introduction of the Mentorship Programme****Presentation of the Mentees 2019 cohort:**

Claudia Cavelti-Weder, Switzerland

Caterina Conte, Italy

Konstantinos Toulis, Greece

Presentation of the Mentees 2020 cohort:

Thomas Ebert, Germany

Peter van Dijk, Netherlands

Andrew JM Boulton, UK

Closing remarksEASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 15 Incretins and glucagon in action

Chair: J. Brix, Austria, J. Jonker, Netherlands

85 Signs of glucagon resistance after a two-week hypercaloric diet intervention

M.P. Suppli, J.I. Bagger, G. Van Hall, M.B. Christensen, N. Wewer Albrechtsen, J.J. Holst, F.K. Knop, Denmark

86 Estimation of insulin resistance and beta cell function by i.v. glucagon-insulin tolerance test in novel subgroups of adult-onset diabetes in Vaasa diabetes registry

A. Laitinen, A. Käräjämäki, A. Käräjämäki, H. Liisa, S. Kurki, L. Kaj, E. Ahlqvist, T. Tuomi, Finland, Sweden

87 Role of K_{ATP} channels in regulating glucagon secretion under low and high glucose conditions

E. Lee, R. Hatano, T. Noda, S. Acreman, Q. Zhang, T. Miki, Japan, UK

88 Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 do not account for the entire incretin effect in healthy humans

S. Veedfald, Y. Sun, C. Xiang, C. Xie, T. Wu, M. Bound, J. Grivell, B. Hartmann, K. Jones, M. Horowitz, J.J. Holst, C.K. Rayner, Australia, Denmark

89 Restoration of impaired portal glucose sensing by targeted manipulation of GLP-1r density in a translational model of insulin resistance

C. Malbert, R. Allouche, M. Horowitz, K.L. Jones, France, Australia

90 Body weight independent effects of CT-868, a signalling biased dual GLP-1/GIP receptor modulator, on glucose homeostasis in overweight and obese adults with type 2 diabetes

M. Hompesch, M. Elliott, M. Hernandez, S. Hansen, A. Macias, M. Chakravarthy, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 16 What new in type 1 diabetes treatment: focus on the islet cells

Chair: S. Speier, Germany, M. Igoillo-Esteve, Belgium

91 Treatment of 355 early type 1 diabetes with a combination of multiple immune modulatory drugs

Z. Talaeerad, K. Khodabakhshi Pirkalani, Islamic Republic of Iran

92 Using a somatostatin receptor-2 antagonist to restore hypoglycaemia-induced glucagon secretion in type 1 diabetes

T.G. Hill, R. Gao, J.G. Knudsen, N.J. Rorsman, Q. Zhang, A. Clark, P. Rorsman, UK, Denmark

93 Modulating the Hippo regulator YAP promotes beta cell regeneration in a model of type 1 diabetes

M. Madduri, S. Baskaran, M. Elawour, S. Rafizadeh, A. Ardestani, K. Maedler, Germany

94 Higher levels of autoantibodies directed against IFN-alpha in latent autoimmune diabetes in adults compared to type 1 diabetes

R. Amendolara, L. D'Onofrio, C. Castrucci, E. Maddaloni, S. Di Giulio, C. Mignogna, A. Siena, G. Giannini, R. Buzzetti, Italy

95 Beta cell autophagy in type 1 diabetes pathogenesis: real-time in vivo discoveries

O. Melnyk, C. Muralidharan, J.J. Crowder, B.E. Duffett, M.M. Martinez, A.K. Linnemann, USA

96 Heterogeneity of islet cell physiology in the pathogenesis of type 1 diabetes

C.M. Cohrs, A.K. Mojica Avila, S. Speier, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 17 New approaches: a magical mystery tour

Chair: A. Da Porto, Italy, P.M. Nilsson, Sweden

97 The effect of 14-day exogenous ketone supplementation on fasting metabolic outcomes in adults with type 2 diabetes: a randomised controlled trial

K. Falkenhain, H. Neudorf, K. Madden, J. Walsh, J. Little, Canada

98 ENT-03 rapidly decreases glucose prior to weight loss and activates brain regions involved in satiety and appetite regulation: comparison with semaglutide

D. Barbut, J. Hecksher-Sorensen, J. Baur, P. Titchenell, J. Davis, A. Fleming, M.B. Zemel, A. Moses, M.A. Zasloff, USA, Denmark

99 New pharmacological approaches to improve insulin secretion in type 2 diabetes

B. Merino, A. Sanz-González, I. Cózar-Castellano, C. Broca, J. Sabatier, G. Acosta, M. Royo, C. Hernándo-Muñoz, T. Torroba, G. Perdomo, Spain, France

100 Pancreatic gene therapy durably improves glycaemia and delays disease progression in a murine model of type 2 diabetes

H. Rajagopalan, C. Lubaczeuski, E. Cozzi, N. Picard, J. Wainer, R. Reese, J. Caplan, J. West, A.P. Liou, USA

101 Electroporation therapy (ReCET) of the duodenum combined with GLP-1RA to replace insulin in type 2 diabetes patients: 12 months results from the first-in-human study

C.B. Busch, S. Meiring, A.C. Van Baar, F. Holleman, M. Nieuwdorp, J.J. Bergman, Netherlands

102 Study of Multi-eLectrode EndovaScular denervaTiOn in patieNts with type 2 diabetes mEllitus (MILESTONE): 6-month analysis from the first-in-human proof-of-concept study

T. Pan, Z. Wang, G.-J. Teng, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 18 Highlights in type 1 diabetes

Chair: S. Carlsson, Sweden, C. Daniel, Germany

103 Incidence trends of type 1 and type 2 diabetes in children and adolescents in Germany, 2002-2020

A. Stahl-Pehe, C. Bächle, S. Lanzinger, C. Kamrath, R.W. Holl, J. Rosenbauer, Germany

EASD
EFSD

GENERAL
INFO

104 Secular trends in the occurrence of islet autoimmunity and type 1 diabetes by the age of 5 years in genetically susceptible children: a birth cohort analysis

A. Kyrönneemi, T. Pokka, T. Valtanen, J. Lempainen, H. Hyöty, J. Ilonen, J. Toppari, J. Kero, M. Knip, R. Veijola, Finland

105 Residual insulin after anti-viral treatment with pleconaril and ribavirin in new onset type 1 diabetes: a randomised, placebo-controlled, double blind, clinical trial

I. Mynarek, L. Krogvold, E. Ponzi, F.C. Mörch, T.W. Hessel, T. Roald, N. Lindblom, J. Westman, P. Barker, J. Ludvigsson, K.F. Hanssen, H. Hyöty, J. Johannesen, K. Dahl-Jørgensen, Norway, Denmark, Sweden, UK, Finland

106 Time trends in the incidence of diabetic ketoacidosis among adults with type 1 diabetes: a nationwide Danish register study

E. Buur Stougaard, H. Amadid, E. Søndergaard, B. Carstensen, M. Eika Jørgensen, K. Nørgaard, P. Rossing, F. Persson, D. Vistisen, Denmark, Greenland

107 Enhanced immune response to cow's milk is associated with the development of islet autoimmunity and type 1 diabetes: the TRIGR birth cohort study

S. Niinistö, D. Cuthbertson, M.E. Miettinen, L. Hakola, A. Nucci, T. Korhonen, H. Hyöty, J.P. Krischer, O. Vaarala, M. Knip, E. Savilahti, S.M. Virtanen, TRIGR Investigators, Finland, USA

108 Spatio-temporal association between COVID-19 incidence and type 1 diabetes incidence in children and adolescents in Germany

J. Rosenbauer, A. Stahl-Pehe, C. Baechele, S. Lanzinger, C. Kamrath, O. Kuß, R.W. Holl, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 19 Why does diabetes make one sad?

Chair: T. Andersen, Denmark, J. Gumprecht, Poland

109 Circulating metabolites as mediators in the association between depression and type 2 diabetes

N. Wang, Y. Yu, Y. Sun, Y. Wang, B. Wang, Y. Lu, China

110 The correlation between diabetes severity and depression

Y. Cho, K. Jo, E. Kim, J. Han, K. Han, S.-D. Moon, Republic of Korea

111 Risk of mental illness in new-onset type 1 diabetes in adulthood: nationwide cohort study

S. Kim, S. Cho, R. Oh, Y.-B. Lee, S.-M. Jin, G. Kim, J. Kim, Republic of Korea

112 Association between chronic complications of diabetes and diabetes distress: Can we prove it?

J. Konečná, D. Lacko, E. Horová, N. Křesáková, K.D. Riegel, Czech Republic

113 Mental health coping strategies and glycaemic management among people with diabetes in Europe

E. Cox, E. Lin, T. Bell, T. Bristow, R. Wood, USA

114 Acceptability and feasibility of CGM for people with severe mental illness: a mixed-methods study

J.V. Brown, P.A. Coventry, N. Siddiqi, R.A. Ajjan, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 20 NAFLD and omics

Chair: J.K. DiStefano, USA, A. Gastaldelli, Italy

115 Efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease and type 2 diabetes: results from an active-comparator-controlled study

S.S. Engel, R.R. Shankar, R.L. Lam, K.D. Kaufman, USA

EASD
EFSD

116 Social jetlag induces fatty liver via perturbed serum prolactin rhythm mediated circadian reprogramming of hepatic lipid metabolism

P. Zhang, X. Ma, Y. Bi, China

GENERAL
INFO

117 Chronic treatment of mice with hepatocyte-released lipotoxic small extracellular vesicles causes liver and pancreas inflammation and alters insulin action

I. Garcia-Martinez, R. Alén, N. Cobo-Vuilleumier, B.R. Gauthier, A.M. Valverde, Spain

118 Targeting NAFLD with umbilical cord-derived mesenchymal stromal cells: a preclinical study

M.J. Meneses, I. Sousa-Lima, I. Ferreira, H. Cruz, J.M. Santos, M.P. Macedo, Portugal

119 Change in Fibrosis-4 Index is associated with risk of liver events, cardiovascular events, and all-cause mortality in patients with obesity and/or type 2 diabetes

K. Khunti, T.L. Berentzen, L.M. Nitze, M. Jara, A. Jensen, M.S. Kjær, K.K. Mangla, J.M. Tarp, Q.M. Anstee, UK, Denmark

120 Oral insulin alleviates liver fibrosis and reduces fat in patients with NASH and type 2 diabetes: results of phase II clinical trial

M. Kidron, Y. Ishay, J. Neutel, Y. Kolben, R. Gelman, O. Sneh Arbib, O. Lopez, H. Katchman, R. Sotolongo, Y. Ilan, Israel, USA

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 21 New strategies for diabetic retinopathy from mice to the clinic

Chair: J. Sokolovska, Latvia

121 Fasting prevents cholesterol crystal formation and the development of diabetic retinopathy

J. Busik, T.F. Dorweiler, Y. Adu Agyeiwaah, N. El-Darzi, N. Mast, G. Abela, I. Pikuleva, M.B. Grant, USA

122 NOD1 deficiency ameliorates the progression of diabetic retinopathy via modulating bone marrow-retina crosstalk

Y. Duan, J. Wu, W. Chen, D. Liu, China

123 Anti-ceramide immunotherapy: a systemic treatment for diabetic retinopathy

T.F. Dorweiler, A. Singh, G.J. Blanchard, R.N. Kolesnick, J.V. Busik, USA

124 Glucose tolerance and insulin resistance/sensitivity associate with retinal layer characteristics: the LIFE-Adult-Study

T. Ebert, F.G. Rauscher, T. Elze, M. Francke, Y. Li, K. Wirkner, A. Tönjes, C. Engel, J. Thiery, M. Blüher, M. Stumvoll, T. Kirsten, M. Loeffler, M. Wang, Germany, USA

125 Risk factors for retinopathy in persons with type 1 diabetes followed from diagnosis and onward

S. Seyed Ahmadi, J. Ludvigsson, T. Nyström, M. Lind, Sweden

126 Incidence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77681 patients from the Swedish National Diabetes Registry

S. Sofizadeh, C. Zhou, K. Eeg-Olofsson, M. Lind, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT C

	12:45 - 13:45	Short Oral Discussion Area	Page
		SO 03 From single nutrients to dietary patterns	<u>133</u>
EASD EFSD		SO 09 Novel risk factors and treatments	<u>140</u>
		SO 15 Transcriptional regulation in islet cells	<u>146</u>
GENERAL INFO		SO 21 Protection of beta cells	<u>152</u>
PROGRAMME		SO 27 Glucagon secretion and peripheral hormone action . . .	<u>157</u>
TUESDAY		SO 33 Weight loss rules.	<u>163</u>
WEDNESDAY		SO 39 Fat across organs	<u>170</u>
THURSDAY		SO 45 Dual agonism: two of us.	<u>176</u>
FRIDAY		SO 51 SGLT2 inhibitors: trying new directions	<u>182</u>
SHORT ORAL DISCUSSIONS		SO 57 How to make a good script for insulin therapy for the demanding audience	<u>190</u>
		SO 63 Patient-centered perfecting of insulin therapy	<u>196</u>
PRESENTER INDEX		SO 69 "When I'm sixty-four" (low and not-so-young)	<u>203</u>
SATELLITE SYMPOSIA		SO 75 Clinical outcomes and biomarkers in diabetic kidney disease	<u>209</u>
INDUSTRY		SO 81 Diabetes and the heart.	<u>216</u>
PROGRAMME		SO 87 Diabetic complications: the heart, the kidney and the bone	<u>220</u>
EXHIBITION		SO 93 The Liver: from cell to clinic	<u>226</u>

EFSD/Novo Nordisk Foundation Future Leaders Symposium

Chair: TBA

Speaker: TBA

Artificial Intelligence in diabetes care: potential and concerns

Chair: Peter EH Schwarz Germany

Speaker: Moshe Phillip, Israel:
AI for diabetes management and state-of-the art today

Tadej Battelino, Slovenia:
Implementing AI: roadmap and guidelines

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT D

	14:00 - 15:00	Short Oral Discussion Area	Page
		SO 04 Viruses and infections	<u>134</u>
EASD EFSD		SO 10 Body and brain	<u>141</u>
GENERAL INFO		SO 16 Different approaches to study hormone secretion regulation	<u>147</u>
PROGRAMME		SO 22 Inflammation in type 1 diabetes	<u>152</u>
TUESDAY		SO 28 Pregnant with type 1 diabetes and adverse pregnancy outcomes	<u>158</u>
WEDNESDAY		SO 34 Metabolic flames	<u>164</u>
THURSDAY		SO 40 Metabolism in humans	<u>171</u>
FRIDAY		SO 46 GLP-1 receptor agonists: action beyond glycaemia . . .	<u>177</u>
SHORT ORAL DISCUSSIONS		SO 52 Targeting muscle, kidney and liver	<u>184</u>
		SO 58 To hell with the hypo.	<u>191</u>
PRESENTER INDEX		SO 64 Quantifying hypoglycaemia: from mild to mad	<u>197</u>
		SO 70 Will rise of the machines terminate diabetes?	<u>204</u>
SATELLITE SYMPOSIA		SO 76 Diabetic kidney disease pathophysiology from cells to mice, and humans	<u>210</u>
INDUSTRY		SO 82 Trends in cardiovascular complications	<u>216</u>
PROGRAMME		SO 88 Pathogenic mechanism of diabetic complications	<u>221</u>
EXHIBITION		SO 94 Diabetes and NAFLD.	<u>226</u>

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

14:00 - 14:45

Spotlight Stage

Beyond technology to physiologic solutions for type 1 diabetes: the case for islet cell replacement

Chair: Lorenzo Piemonti, Italy

Speaker: Katarina Braune, Germany:
Automated insulin delivery: delivering more of what people want

Peter A Senior, Canada:
Safety, efficacy and desirability of islet cell transplants: the benchmark for stem cells

followed by discussion

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

OP 22 Improving the diagnosis and prediction of kidney disease progression

Chair: L. Stechemesser, Austria

127 Receptor-interacting protein kinase (RIPK)3 regulates podocyte structure and function in diabetic kidney disease

E. Lee, J. Kang, N.-J. Cho, S. Lee, J.-H. Lee, J. Lee, M. Choi, S. Son, M. Park, J. Park, Republic of Korea

EASD
EFSD

GENERAL
INFO

128 Renal function based on serum cystatin C versus creatinine in determining mortality risk in type 2 diabetes: the Fremantle Diabetes Study Phase II

W.A. Davis, P. Chubb, D.G. Bruce, T.M. Davis, Australia

PROGRAMME

TUESDAY

129 Preliminary results from iBEAt ancillary-study: a novel classification of renal damage in diabetes

P. Pontrelli, M. Rossini, F. Conserva, F. Pesce, T. Ardillo, M. Moschetta, F. Giorgino, L. Laviola, S. Sourbron, K.M. Gooding, M.F. Gomez, M. Kretzler, L. Gesualdo, Italy, UK, Sweden, USA

WEDNESDAY

THURSDAY

FRIDAY

130 External validation of kidney failure risk equation in a multi-ethnic cohort of more than 7000 people with type 2 diabetes and chronic kidney disease

A. Goubar, A. Mangelis, S. Thomas, P. Vas, J. Collins, S. Ayis, J. Karalliedde, UK

SHORT ORAL
DISCUSSIONS

131 Utility of molecular markers in urine to differentiate diabetic kidney disease from non-diabetic kidney disease and possible role in pathogenesis

S. Ghosh, M. Basu, A. Raychaudhury, N. Bhattacharyya, P. Mukhopadhyay, India

PRESENTER
INDEX

SATELLITE
SYMPOSIA

132 Nox5: a promising therapeutic target for diabetic kidney disease

J.C. Jha, A. Dai, H.R. Kankanamalage, J. Meister, J. Vincent, M.E. Cooper, K. Jandeleit-Dahm, Australia, Germany, Switzerland

INDUSTRY

PROGRAMME

EXHIBITION

OP 23 More news from SGLT2s

Chair: I. Caruso, Italy, J.P.H. Wilding, UK

133 SGLT2 inhibitor dapagliflozin enhances skeletal muscle fatty acid uptake in subjects with type 2 diabetes: a positron emission tomography study

A. Latva-Rasku, J. Tuisku, A. Bhowmik, H. Keskinen, E. Rebelos, S. Laurila, J. Koffert, L. Nummenmaa, K. Heurling, J. Oscarsson, P. Nuutila, Finland, Sweden

134 Anti-inflammatory and antioxidant effects of SGLT-2 inhibitors in epicardial adipose tissue of subjects with severe heart failure

M. Mraz, B.J. Kasperova, S. Stemberkova-Hubackova, P. Svoboda, D. Hlavacek, J. Mahrik, O. Kuda, T. Cajka, I. Pleyerova, K. Reznickova, P. Novodvorsky, P. Ivak, V. Melenovsky, I. Netuka, M. Haluzik, Czech Republic

135 Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

G. Leibowitz, Y. Riahi, O. Mosenzon, I. Abramovich, B. Agranovich, L. Hinden, L. Kadosh, R. Ben-Haroush Schyr, D. Kleiman, E. Cerasi, D. Ben-Zvi, E. Gottlieb, J. Tam, A. Kogot-Levin, Israel

136 Tolerability and effectiveness of gliclazide MR-SGLT2i combination in type 2 diabetes people fasting during Ramadan: a subgroup analysis of the real-world DIA-RAMADAN study

M. Hassanein, A. Durocher, V. Cortese, United Arab Emirates, France

137 Risk of diabetic microvascular complications, heart failure, hospitalisation and all-cause mortality with SGLT2i and GLP1-ra in type 2 diabetes: a real-world data study

A. Eleftheriadou, D. Riley, P. Austin, G. Hernandez, U. Alam, UK, USA

138 Socioeconomic disparities in the use of SGLT-2 inhibitors and GLP-1 receptor antagonists in adults with type 2 diabetes in Germany

M. Auzanneau, J. Seufert, S. Zimny, T. Haak, A. Zeyfang, I. Hugenberg, M. Pavel, J. Rosenbauer, R.W. Holl, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 24 All around pregnancy

Chair: I. Danquah, Germany, D. Löffler, Germany

139 Prediabetes and diabetes 11 years after pregnancy in ethnic minority groups with and without gestational diabetes

C. Waage, I. Mdala, A. Brænd, A.K. Jenum, K.I. Birkeland, Norway

140 Metabolites of diacylglyceride and unsaturated fatty acid synthesis improves prediction of gestational diabetes

E.C. Francis, R.K. Johnson, C.C. Cohen, D. Dabelea, W. Perng, USA

141 Continuous glucose monitoring-derived glycaemic metrics and adverse pregnancy outcomes among women with gestational diabetes

J. Zheng, China

142 Methylation risk score for gestational diabetes on DNA methylation patterns associated with type 2 diabetes

T. Linares-Pineda, N. Frago Bargas, M. Picón, M. Molina-Vega, A.K. Jenum, L. Sletner, S. Lee-Ødegård, J.O. Opsahl, G.-H. Moen, E. Qvigstad, R.B. Prasad, K.I. Birkeland, S. Morcillo, C. Sommer, Spain, Norway, Sweden

143 Kidney disease in women with previous gestational diabetes: a nationwide, register-based cohort study

M.H. Christensen, C. Bistrup, K.H. Rubin, E.A. Nohr, C.A. Vinter, M.S. Andersen, S. Möller, D.M. Jensen, Denmark

144 Replication of interaction between PTPN22 susceptibility variants and caesarean section in type 1 diabetes risk: the Norwegian mother, father and child cohort study

L. Stene, K. Størdal, T. Skrivarhaug, G. Tapia, Norway

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 25 Muscles at work

Chair: D. Pesta, Germany, B. Stocks, Denmark

145 Deletion of the type 2 diabetes candidate gene SLC16A11 worsens whole body insulin sensitivity via impaired skeletal muscle metabolism in mice

N.N. El-Agroud, T. Schumann, A. Kurzbach, C. Hermann, L. Sandforth, B. Hamilton, G.I. Shulman, A.L. Birkenfeld, Germany, Egypt, USA

146 A long non-coding RNA regulating skeletal muscle protein metabolism

I. Sen, E. Caria, M. Savikj, J. Smith, J. Zierath, A. Krook, Sweden

147 The insulin-sensitising effect of high-intensity interval training (HIIT) is associated with increased hydroxyphenyllactic acid levels in plasma and skeletal muscle

P.M. Møller, M.H. Petersen, M.E. De Almeida, N. Ørtenblad, J. Havelund, N.J. Færgeman, K. Højlund, Denmark

148 The effect of 12 weeks of high intensity interval training (HIIT) on 24h rhythmicity in substrate metabolism of individuals at risk for developing type 2 diabetes

M. Kotte, J.-F. Harmsen, I. Habets, S.S. De Kam, J. Jorgensen, F. Bosschee, K. Frenken, J.F. Cissen, T. Van de Weijer, M. Buitinga, J. Hoeks, P. Schrauwen, Netherlands

149 High-fat diet impairs temporal dynamics of acute exercise in mice

L.A. Pendergrast, L. Dollet, S.P. Ashcroft, A.M. Ehrlich, J.T. Treebak, A. Krook, J.R. Zierath, Sweden, Denmark

150 Acute exercise simultaneously increases GDF15 and unfolded protein response/integrated stress response signalling in skeletal muscle in obesity and type 2 diabetes

R. Sabaratnam, J.M. Kristensen, A.J. Pedersen, R. Kruse, A. Handberg, J.F. Wojtaszewski, K. Højlund, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 26 Many digits in digital diabetes

Chair: L. Czupryniak, Poland, S. Jacob, Germany

151 Correlation of glycaemic variability in the ICU, with mortality in critically ill patients, based on data visual analytics of real world evidence

G.E. Dafoulas, I. Kalamaras, K. Votis, A. Bargiota, Greece

152 A machine learning model for basal insulin titration of people with type 2 diabetes: preliminary results

C.H. Thomsen, T. Kronborg, S. Hangaard, P. Vestergaard, O. Hejlesen, M.H. Jensen, Denmark

153 Improvement in time in range after smart pen initiation in routine clinical practice

P. Adolfsson, N.V. Hartvig, A. Kaas, N.N. Knudsen, J.K. Mader, Sweden, Denmark, Austria

154 Effect of smartphone app-based intervention on physical activity and glycemic control in patients with type 2 diabetes: a randomised controlled trial

R. Oh, S. Kim, S. Cho, Y.-B. Lee, S.-M. Jin, G. Kim, J. Kim, Republic of Korea

155 Effectiveness of a mobile platform on pregnancy outcomes in women with gestational diabetes

J. Wang, Y. Liu, Y. Gong, T. Wei, X. Li, Q. Wang, S. Luo, X. Zheng, J. Weng, China

156 Efficacy of a digital diabetes logbook: findings from a randomised controlled trial

B. Kulzer, D. Ehrmann, S. Silbermann, J. Kober, K. Finke-Groene, T. Roos, V. Schäfer, I. Vesper, N. Hermanns, Germany, Austria

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 27 Adipocyte impact on obesity and metabolic health

Chair: A. Bartelt, Germany, A. Kerr, Sweden

157 Metabolic crosstalk between beta cells and adipocytes in obese youths with primary insulin hypersecretion

D. Trico, M. Chiriaco, J. Nouws, A. Vash-Margita, R. Kursawe, E. Tarabra, A. Galderisi, A. Natali, C. Giannini, M. Hellerstein, E. Ferrannini, S. Caprio, Italy, USA

158 IGF2 promotes healthy white adipose tissue expansion by increasing preadipocyte proliferation early in life

I. Altun, X. Yan, V. Miok, R. Karlina, S. Ussar, Germany

159 Loss of glucose control is precipitated in formerly obese mice re-exposed to obesogenic diet

C. Rebière, C. Rouault, F. Merabtene, K. Clément, G. Marcelin, France

160 Relatively low plasma leptin concentrations are associated with a more favourable metabolic phenotype

M. Chiriaco, L. Nesti, A. Flyvbjerg, A. Golay, J.A. Nazare, C.H. Anderwald, A. Mitrakou, R. Bizzotto, A. Mari, D. Tricò, A. Natali, EGIR-RISC Study Group, Italy, Denmark, Switzerland, France, Austria, Greece

161 Homozygous nonsense mutation in LAMA4 in two siblings with partial lipodystrophy and severe metabolic syndrome

Y. Karusheva, M. Muso, J. Tadross, B. Lam, S. Lockhart, S. Gancheva, M. Bombrich, D. Savage, M. Roden, S. O'Rahilly, UK, Germany

162 Metabolic effects of sodium-glucose-co-transporter-4 (SGLT4) inhibition: from mouse studies to clinical translation

M. Moreno-López, C. Saponaro, A. Acosta-Montalvo, I. Louvet, G. Pasquetti, J. Thevenet, V. Gmyr, V. Raverdy, J. Kerr-Conte, F. Pattou, C. Bonner, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 28 Novel signalling pathways regulating islet function

Chair: C. Dibner, Switzerland, T. Pullen, UK

163 Driving the pancreatic beta cell function through nanoscale features: the influence of nuclear mechanotransduction

A. Galli, N. Dule, P. Marciani, M. Castagna, P. Milani, C. Lenardi, G. Tedeschi, C. Perego, Italy

EASD
EFSD

GENERAL
INFO

164 Leader beta cells within the pancreatic islets are a functionally stable subpopulation in vitro and in vivo

L. Delgadillo Silva, P. Chabosseau, F. Yong, L. Lopez-Noriega, S. Larouche, A. Provencher-Girard, A. Prat, G. Rutter, Canada, Singapore, UK

PROGRAMME

TUESDAY

165 Acute and long term somatostatin signalling via the beta cell primary cilium

T. Incedal Nilsson, Ö. Dumral, G. Sanchez, O. Idevall-Hagren, Sweden

WEDNESDAY

THURSDAY

166 Identification of transcriptional regulators controlling beta cell differentiation

D. Balboa, S. Moratinos, J. García-Hurtado, M.A. Maestro, J. Ferrer, Spain, UK

FRIDAY

SHORT ORAL
DISCUSSIONS

167 Nutrient sensor OGT & mTORC1 crosstalk to coordinate beta cell mass and function

S. Jo, E. Alejandro, USA

PRESENTER
INDEX

168 Ex vivo mapping of beta cell glutamate pathways by in situ enzymatic activities and metabolic profiling using ToF-SIMS in mouse islet cryosections

Y. Zhou, N. Baez, T. Fu, T. Brun, P. Maechler, Switzerland

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD-Novo Nordisk Foundation Diabetes Prize for Excellence

Chair: Chantal Mathieu, Belgium

Speaker: Roman Hovorka

Automated insulin delivery – diabetes tech at its best

Roman Hovorka, PhD, FMedSci, is Professor of Metabolic Technology Research at the Institute of Metabolic Science and Department of Paediatrics at University of Cambridge, UK.

He made seminal contributions to diabetes technology including the "Artificial Pancreas", a device that delivers insulin in glucose responsive fashion.

He has been Chief Investigator on several trials evaluating the Artificial Pancreas in populations such as young children and newly diagnosed type 1 diabetes.



EASD-NOVO NORDISK FOUNDATION DIABETES PRIZE FOR EXCELLENCE

The EASD-Novo Nordisk Foundation Diabetes Prize for Excellence awards an internationally recognised researcher who has contributed significantly to advances in the understanding, prevention or treatment of diabetes or its complications.

The awardee's research may focus on prevention, treatment and/or basic research in physiological biochemistry.

The EASD-Novo Nordisk Foundation Diabetes Prize for Excellence is generously supported by the Novo Nordisk Foundation.

EASD-Novo Nordisk Foundation Diabetes Prize for Excellence Lecturers

2022	A.-G. Ziegler (DE)
2021	J.A. Todd (UK)
2020	J.C. Brüning (DE)
2019	D.J. Drucker (CA)

2018	G.S. Hotamisligil (US)
2017	P.E. Scherer (US)
2016	A. Hattersley (UK)
2015	S. O'Rahilly (UK)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

London Hall

Michael Berger Debate: Is it time to reclassify diabetes complications because microvascular and macrovascular classification is no longer sufficient?

Chair: Martin Clodi, Austria

Speaker: Michael Roden, Germany:
Pro

Guntram Schernthaner, Austria:
Contra

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Paris Hall

Debate: Should non-insulin-treated women with diabetes during pregnancy be offered Continuous Glucose Monitoring?

Chair: Rebecca M Reynolds, UK

Speaker: Helen R Murphy, UK:
Yes

Elisabeth R Mathiesen, Denmark:
No

17:30 - 18:30

Barcelona Hall

Obesity and cachexia: Two sides of the same coin?

Chair: Maria Rohm, Germany

Speaker: Stephan Herzig, Germany:
Neuroendocrine dysregulation in obesity and cachexia

Anthony P Coll, UK:
Body weight and body composition: lessons learned from obesity and cachexia

Stefan D Anker, Germany:
Diabetes, cardiovascular disease, sarcopenia and cachexia

17:30 - 18:30

Mumbai Hall

Diabetic retinopathy biomarkers and treatment targets from discovery to the clinic

Chair: Luigi Gnudi, UK

Speaker: Viktor Rotbain Curovic, Denmark:
New biomarkers for diabetic retinopathy: What do they offer?

Evelyn Mensah, UK:
New treatment approaches and clinical strategies for improving outcomes for people with advanced diabetic retinopathy?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

17:30 - 18:30

Lima Hall

NAFLD and diabetes: chicken or egg?

Chair: Zobair M Younossi, USA

Speaker: Catherine C Cohen, USA:
Developmental origins of NAFLD

Luca VC Valenti, Italy:
Is NAFLD a cause or a consequence of type 2 diabetes?

Johanna K DiStefano , USA:
What can we learn from NAFLD genetics?

17:30 - 18:30

Cairo Hall

Debate: Is lasting remission of type 2 diabetes feasible in the real world setting?

Chair: TBA

Speaker: Roy Taylor, UK:
Yes

Kamlesh Khunti, UK
No

INDUSTRY

PROGRAMME

EXHIBITION

Diabetologia Symposium: Incredible incretins - and where to find them

Chair: Anna Krook, Sweden

Speaker: Jens J Holst, Denmark:

Introduction to the field of incretins

Fiona M Gribble, UK:

Mechanisms of incretin release from the intestine

Erin Mulvihill, Canada:

Cardiovascular effects of incretin-based therapies

Jonathan E Campbell, USA:

Pharmacology of incretins'

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

What have cohort studies taught us about the natural history of type 2 diabetes?

Chair: Amalia Gastaldelli, Italy

Speaker: Sun Kim, USA):

The Stanford cohort

Femke Rutters, Netherlands:

The Hoorn Study

Andrea Natali, Italy:

The EGIR-RISC study

Lars Lind, Sweden:

ULSAM

Amalia Gastaldelli, Italy:

Summary giving the clinical perspective for the future

Rising Star Symposium

Chair: Tina Vilsbøll, Denmark

Speaker: Luca D'Onofrio:
Small fiber neuropathy in autoimmune diabetes: the role of inflammation



EASD
EFSD

Alessandro Mengozzi, Switzerland:
Cardiometabolic epigenetics: targeting the early damage



GENERAL
INFO

Theresia Sarabhai, Germany:
Overnutrition and its impact on whole-body insulin sensitivity: a look behind the curtain



PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Lærke Smidt Gasbjerg:
The physiology of gut hormones within human postprandial nutrient handling



SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

RISING STAR SYMPOSIUM AND FELLOWSHIP

The EASD Rising Star Symposium and EFSD Rising Star Fellowship Programme aims to identify promising and innovative young researchers who are developing their research activities in Europe.

The Rising Star Symposium and Fellowship is generously supported by Novo Nordisk.

INDUSTRY

PROGRAMME

EXHIBITION

Image-in' what noninvasive techniques can do for diabetes research and care!

Chair: Roy Taylor, UK

Speaker: Louise Thomas, UK:

Adipose tissue distribution and non-invasive tissue characterization in insulin resistance

Lars Johansson, Sweden:

Novel insights from nuclear imaging techniques

Vera Schrauwen-Hinderling, Netherlands:

Magnetic Resonance Spectroscopy in the investigation of insulin resistance and diabetes

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Metabolic disease and the circle of life

Chair: Allan A Vaag, Denmark

Speaker: Susan E Ozanne, UK:

Developmental programming of metabolic disease by maternal obesity

Raffaele Teperino, Germany:

Paternal genetics and epigenetic programming of offspring health

J Andrew Pospisilik, USA:

Is there a role of factors operating beyond genes and environment in metabolic diseases?

7th EASD-AASD Joint Symposium: Can COVID-19 help us deliver a whole system holistic healthcare?

Chair: Sean Dinneen, Ireland and Kyu Chang Won, Korea

Speaker: Marc Evans (UK):
Lessons from COVID-19: approaching the challenge of dealing whole system health care value: What can we learn in diabetes care?

Masaki Uchihara (JP):
Impact of COVID-19 on diabetes care in Japan

Rose Stewart (UK):
Lessons learned from COVID-19: a diabetes psychologist's perspective

Andrea OY Luk (HK):
Telemedicine in people with diabetes: COVID-19 and beyond

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Precision medicine in diabetes: complexity and pragmatism

Chair: Marie-France Hivert (US)

Speaker: Paul W Franks (SE):
ADA/EASD Precision Medicine in Diabetes Initiative: executive summary of the second consensus report

Claudia Langenberg (UK):
Multimics for precision medicine in diabetes

Shivani Misra (UK):
Precision medicine in diabetes: generalisability and equity

OP 29 Cardiac complications in type 1 and type 2 diabetes

Chair: V. Fejfarova, Czech Republic, J. Petrie, UK

169 Trends in survival after first myocardial infarction in people with diabetes

L. Wedén, T. Andersson, M. Lind, B. Eliasson, R. Hofmann, T. Nyström, Sweden

EASD
EFSD

GENERAL
INFO

170 Acute myocardial infarction and heart failure in young patients with type 1 and type 2 diabetes

P. Dikaiou, M. Lind, J. Ludvigsson, G. Lappas, L. Björck, A. Rosengren, Sweden

PROGRAMME

TUESDAY

171 Effects of dapagliflozin in type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction across the background of glucose-lowering therapy in DELIVER

M. Vaduganathan, S.E. Inzucchi, B.L. Claggett, I. Kulac, R.A. De Boer, A.S. Desai, K.F. Docherty, A.F. Hernandez, M.N. Kosiborod, P.S. Jhund, C.S. Lam, F.A. Martinez, S.J. Shah, J.J. McMurray, S.D. Solomon, USA, Netherlands, UK, Singapore, Argentina

WEDNESDAY

THURSDAY

FRIDAY

172 Association of clinical characteristics with sudden cardiac arrest in people with type 2 diabetes with and without CVD: a longitudinal case-control study on primary care data

P.P. Harms, L.H. Van Dongen, F.C. Bennis, K.M. Swart, M. Hoogendoorn, J.W. Beulens, H.L. Tan, P. Elders, M.T. Blom, RESCUED, Netherlands

SHORT ORAL
DISCUSSIONS

173 Duration of type 2 diabetes increases risk of third-degree atrioventricular block

S. Haxha, K.K. Sørensen, S.B. Haugaard, M.H. Ruwald, A. Halili, B.T. Philbert, L. Køber, G.H. Gislason, C. Torp-Pedersen, C.N. Bang, Denmark

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

174 Glycaemia and cardiac arrhythmias in people with type 1 diabetes: a prospective observational study

P.G. Hagelqvist, A. Andersen, K. Maytham, C.R. Andreasen, S. Engberg, T. Lindhardt, J.L. Forman, U. Pedersen-Bjergaard, F.K. Knop, T. Vilsbøll, Denmark

PROGRAMME

EXHIBITION

OP 30 Years and years

Chair: S. Gudbjornsdottir, Sweden, A. Sandforth, Germany

175 Effect of low dose aspirin on incident diabetes among older adults: post hoc analysis of the ASPREE randomised placebo-controlled trial

S. Zoungas, Z. Zhou, A.J. Owen, A.J. Curtis, S.E. Espinoza, M.E. Ernst, R.L. Woods, S.G. Orchard, J.J. McNeil, A.M. Murray, M.R. Nelson, C.M. Reid, J. Ryan, R. Wolfe, Australia, USA

176 Incident type 2 diabetes among users of denosumab and alendronate: a Danish cohort study

R. Viggers, J. Starup-Linde, I. Leegaard, P. Vestergaard, Denmark, Germany

177 Prescribing trends of anti-diabetes medications near end of life among older adults with type 2 diabetes: a nationwide cohort study

A. Kutz, D.H. Kim, E. Patorno, USA

178 Age discrepancies in the use of glucose-lowering medications: a nationwide cohort study

K. Johansson, T. Petersen, M. Christensen, Denmark

179 UKPDS blood pressure study 34 year follow-up

R.L. Coleman, A.I. Adler, P. Clarke, J. Leal, W. Whiteley, R.R. Holman, UK

180 MODY in older onset diabetes is common and identification can improve treatment: analysis of >72,000 people

L. Sharp, L. Mirshahi, K. Colclough, J. Haley, A. Hattersley, D. Carey, M. Weedon, K. Patel, UK, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 31 Future for type 1 diabetes treatment

Chair: D. Balboa, Spain, I. Artner, Sweden

181 Exploring the role of transcription factors HNF1A, HNF1B, and HNF4A in human induced pluripotent stem cell-derived pancreatic islet cell differentiation

L. Unger, A. Friestad, T.A. Legøy, L.M. Ghila, S. Chera, Norway

182 Both MAFA and MAFB are required for acquisition of glucose-stimulated insulin secretion (GSIS) in human pluripotent stem cell-derived islets

A. Allouch, A. Diane, R. Abdulmuumin, H.H. Al-Siddiqi, Qatar

183 Role of arginine methylation of Neurogenin 3 in hESCs during development into the pancreatic endocrine cell in vitro

Y.-M. Han, Republic of Korea

184 Islet allotransplantation into pre-vascularised Sernova Cell Pouch™: results from the first patient cohort

M. Ogledzinski, W. Lin, S. Gondek, K. Milejczyk, B. Juengel, L. Basto, L. Perea, L.-J. Wang, M. Tibudan, R.N. Barth, J.J. Fung, P. Witkowski, USA

185 ADO12, a new allogenic islet encapsulation device for islet transplantation without immunosuppression

A.-L. Gaffuri, A. Geissler, O. Jouannot, X. Gaume, C. Gautier, Y. Courbebaisse, R. Eloy, K. Bouzakri, O. Soula, France

186 Multi-component pancreatic islet cells-encapsulated microfiber grafts for treatment of diabetes

Z. Huan, L. Li, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 32 Obesity, liver and beyond

Chair: C. Cohen, USA, J. Gojda, Czech Republic

187 The effect of five days eucaloric changes in dietary carbohydrate and fat availability in the regulation of hepatic lipid content in obese men

A. London, M.M. Richter, K.A. Sjøberg, N.J. Albrechtsen, M. Povazan, L. Madsen, J. Øyen, S. Madsbad, J.J. Holst, G. Van Hall, H.R. Siebner, E.A. Richter, B. Kiens, A. Lundsgaard, K.N. Bojsen-Møller, Denmark, Norway

188 Epigenetic and gene regulatory effects on liver metabolism in systemic dyslipidaemia and insulin resistance in a preclinical model

P. Fahlbusch, A. Nikolic, N.-K. Riffelmann, S. Jacob, S. Hartwig, U. Kettel, H. Al-Hasani, J. Kotzka, B. Knebel, Germany

189 Preadipocyte-secreted Cilp1 mediates the communication of adipose with liver and promotes hepatic steatosis

Y. Bi, S. Huang, China

190 Normal-weight visceral obesity promotes a higher 10-year atherosclerotic cardiovascular disease risk in patients with type 2 diabetes

J. Zheng, Y. Hu, H. Xu, Y. Lei, J. Zhang, Q. Zheng, L. Li, W. Tu, R. Chen, Q. Guo, X. Zang, Q. You, Z. Xu, Q. Zhou, X. Wu, China

191 Glycaemic control determines the relationship of whole-body insulin resistance with liver mitochondrial capacity in obesity

S. Kahl, K. Straßburger, G. Pacini, N. Saatmann, K. Pafili, T. Sarabhai, S. Trenkamp, I. Esposito, M. Schlensak, F.A. Granderath, M. Roden, Germany, Italy

192 Hepatology referral of outpatients with type 2 diabetes and suspected NAFLD: comparison between EASL and AGA algorithms

T. Vidal Trecan, L. Castera, T. El Khoury, J.-B. Julla, J.-P. Riveline, V. Paradis, D. Valla, J.-F. Gautier, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 33 Are we what we eat?

Chair: N. Guess, UK, F. Pattou, France

193 The effect of a dietary intervention on insulin requirements in type 1 diabetes: a 12-week randomised clinical trial

H. Kahleova, T. Znayenko-Miller, K. Smith, R. Holubkov, N. Barnard, USA

EASD
EFSD

194 The effect of carbohydrate intake on glycaemic control in type 1 diabetes: a randomised cross-over study

S. Sterner Isaksson, A.F. Ólafsdóttir, S. Ivarsson, H. Imberg, E. Toft, S. Hallström, U. Rosenqvist, M. Ekström, M. Lind, Sweden

GENERAL
INFO

195 Effect of intestinal exposure to endogenous bile acids on the incretin axis in type 2 diabetes

C. Xie, W. Huang, M. Bound, J. Grivell, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia

PROGRAMME

TUESDAY

WEDNESDAY

196 The effect of dietary branched-chain amino acid restriction during forearm immobilisation on whole-body and muscle insulin sensitivity

M.L. Dirks, T.S. Jameson, L. Domingos, R.C. Andrews, F.B. Stephens, UK, Netherlands

THURSDAY

FRIDAY

197 The effect of adding different volumes of exercise training to diet-induced weight loss on body composition in persons with type 2 diabetes

C. Durrer, M.P. Lyngbæk, G.E. Legaard, N.S. Nielsen, T.P. Almdal, M.A. Lund, B. Liebetrau, C. Ewertsen, C. Lauridsen, T.T. Soloman, K. Karstoft, B.K. Pedersen, M. Ried-Larsen, Denmark, UK

SHORT ORAL
DISCUSSIONS

198 The effect of circuit training, empagliflozin or "vegeterranean diet" on metabolic and physical functions in older adults with type 2 diabetes (CEV-65 trial)

A. Buch, O. Kis, Y. Greenman, N. Stern, R. Eldor, Israel

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 34 Diabetic neuropathy from the brain to the bowels

Chair: B.A. Perkins, Canada, H. Shah, USA

199 Preservation of thalamic mitochondrial and neuronal function in Painful-Diabetic Peripheral Neuropathy: a multi-modal cerebral imaging study

G. Sloan, D. Selvarajah, A. Anton, K. Teh, I.D. Wilkinson, S. Tesfaye, UK

200 Association of microvascular complications with reduced neuronal activity and cognitive impairment in type 2 diabetes: a resting-state fMRI study

W. Wang, X. Yang, B. Lu, P. Gu, X. Hui, J. Shao, China

201 Lipid parameters and risk of diabetic polyneuropathy in type 2 diabetes: a Danish cohort study

F.P. Kristensen, D.H. Christensen, B.C. Callaghan, H.T. Sørensen, R.W. Thomsen, Denmark, USA

202 Preclinical efficacy of the novel GPR40 agonist CPL207-280 in neuropathy

T. Jaworski, M. Janiszewski, P. Buda, V. Vialichka, K. Bazydło-Guzenda, M. Mach, K. Gałązka, J. Dominowski, M. Górka, K. Sałat, P. Popik, K. Dubiel, J. Pieczykolan, M. Wiecek, Poland

203 Prevalence of diabetic neuropathies in individuals with type 1 and type 2 diabetes in a tertiary outpatient clinic: the DANES cohort study

H. Mizrak, H. Kufaishi, S.K. Hecquet, T.W. Hansen, R. Pop-Busui, P. Rossing, B. Brock, C.S. Hansen, Denmark, USA

204 Overall gastrointestinal symptom burden is associated with diabetic autonomic neuropathy: a DANES cohort study

H. Kufaishi, H.I. Mizrak, B. Brock, P. Rossing, C.S. Hansen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 35 Omics and more: unbiased approaches to tackle obesity

Chair: K. Højlund, Denmark, A. Loft, Denmark

205 Metabolic heterogeneity in obesity: the interplay between metabolome and microbiome reflects visceral adipose tissue physiology beyond BMI

R. Chakaroun, M. Pradhan, H. Brolin, M. Schöler, G. Bergström, V. Tremaroli, F. Bäckhed, Sweden

206 Deep phenotyping of glucose stimulation response in human adipocytes at scale

P. Kubitz, H. Dashti, F.R. Dos Santos, R. Kaalia, J. Perez-Schindler, H. Hauner, M. Claussnitzer, Germany, USA

207 Whole-body measurement of fatty acid uptake in fasting and postprandial conditions

I. Laitinen, S. Ekström, H. Haraldsson, S. Pierrou, K. Kalliokoski, M. Kiugel, M. Scheinin, S. Southekal, M. Lu, T. Coskun, Z. Milicevic, L. Johansson, P. Nuutila, Sweden, Finland, USA

208 Genetic dissection of serum vaspin highlights its causal role in lipid metabolism

M. Würfel, J. Breitfeld, K. Horn, D. De Duc, A. Velluva, C. Marzi, H. Grallert, N. Friedrich, M. Pietzner, U. Völker, H. Völzke, E. Ahlqvist, A. Tönjes, M. Scholz, P. Kovacs, Germany, Sweden

209 Genetic variants in the adiponectin receptor genes are associated with adiponectin and insulin levels

L. Kedenko, T. Kiesslich, I. Kedenko, B. Paulweber, Austria

210 Investigating gut epithelial adaptations to metabolic disease

M. Jacobs, Y. Lei, N. Haq, M. Wilson, T. Pullen, P. Pavlidis, B. Hayee, G. Bewick, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT E

12:45 - 13:45	Short Oral Discussion Area	Page
SO 05	Autoimmunity in diabetes	<u>135</u>
SO 11	Obesity and prediabetes	<u>142</u>
SO 17	Modulators of beta cell signal transduction: How do they work?	<u>148</u>
SO 23	Drug interventions in diabetes and associated disease .	<u>153</u>
SO 29	Gestational diabetes	<u>159</u>
SO 35	Sex and time matters	<u>165</u>
SO 41	Novel players in adipocyte biology.	<u>172</u>
SO 47	Incretin trials: trying new directions	<u>178</u>
SO 53	Miscellaneous: The White Album.	<u>185</u>
SO 59	How does AID aid the patients?	<u>192</u>
SO 65	Yin and yang of CGMing.	<u>199</u>
SO 71	Making it all work	<u>205</u>
SO 77	New insights to the drivers of diabetic retinopathy progression.	<u>211</u>
SO 83	Predicting cardiovascular events in diabetes	<u>217</u>
SO 89	Diabetes: a systemic disease	<u>222</u>
SO 95	NAFLD: relevant biomarkers	<u>227</u>

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

Career development in diabetes research: an EASD Early Career Academy panel discussion

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Chair: Shivani Misra, UK

Panellists: Cantal Mathieu, Belgium

Amalia Gastaldelli, Italy

Paloma Alonso-Magdalena, Spain

Abd Tahrani, UK

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT F

14:00 - 15:00	Short Oral Discussion Area	Page
SO 06	Diagnosis and prediction	<u>136</u>
SO 12	Epigenetics	<u>143</u>
SO 18	Role of immune cells in type 1 diabetes and type 2 diabetes	<u>149</u>
SO 24	Grades of insulin sensitivity	<u>154</u>
SO 30	Insulin secretion: for better or for worse	<u>160</u>
SO 36	Obesity and diabetes across generations	<u>166</u>
SO 42	Tirzepatide: SURPASSing the vibe check	<u>173</u>
SO 48	Incretins: a day in the life	<u>179</u>
SO 54	Carbohydrates: time matters	<u>186</u>
SO 60	How bright is the hybrid?	<u>193</u>
SO 66	Insulin therapy can be better and cheaper.	<u>200</u>
SO 72	When diabetes goes digital	<u>206</u>
SO 78	Biomarkers and risk factors for diabetic foot disease and peripheral neuropathy	<u>213</u>
SO 84	Macrovascular disease: basic science.	<u>218</u>
SO 90	Epidemiology of cardiovascular disease in diabetes: What is new?	<u>223</u>
SO 96	NAFLD: future treatment	<u>228</u>

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD e-Learning expert session

Chair: TBA*Speaker:* TBAEASD
EFSD

14:00 - 14:45

Spotlight Stage

GENERAL
INFO

Immunotherapy and beta cell preservation in type 1 diabetes: from clinical trials to clinical practice

Chair: TBA*Speaker:* Peter A Senior Canada:
Immunotherapies in type 1 diabetes: Are they worth the hype?Colin M Dayan UK:
Immune therapies in type 1 diabetes: translation into your clinical practice**Discussion and closing remarks**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 36 Cardiovascular risk, complications and fitness

Chair: A. Andersen, Denmark, M. Haluzik, Czech Republic

211 Detailed metabolic biomarker profiling improves cardiovascular risk assessment in type two diabetes patients already receiving statin therapy

H. Julkunen, J. Barrett, P. Würtz, Finland

212 Effects of type 2 diabetes and obesity on cardiopulmonary performance

L. Nesti, N. Pugliese, L. Santoni, M. Chiriaco, L. Sacchetta, D. Tricò, A. Natali, Italy

213 Increase in cardiorespiratory fitness during a lifestyle intervention associates with lower progression and higher regression of subclinical atherosclerosis

K. Kantartzis, J. Machann, F. Schick, A. Birkenfeld, L. Fritsche, A. Peter, A. Fritsche, N. Stefan, A. Lehn-Stefan, Germany

214 Hypoglycaemia-related disorders are associated with preclinical atherosclerosis in patients with type 1 diabetes without high cardiovascular risk

A. Mesa, M. Giménez, V. Perea, C. Viñals, J. Blanco, I. Vinagre, T. Serés-Noriega, L. Boswell, E. Esmatjes, I. Conget, A. Amor, Spain

215 Mortality in the Swedish Obese Subjects (SOS) study over up to 30 years in relation to 2-year diabetes remission after bariatric surgery or usual care

K. Sjöholm, B. Carlsson, P. Jacobson, C. Karlsson, J. Andersson-Assarsson, F. Kristensson, S. Ahlin, P.-A. Svensson, M. Taube, I. Näslund, K. Karason, M. Peltonen, L. Carlsson, Sweden, Finland

216 Exploring potential risk factors for lower limb amputation in people with diabetes: an observational cohort study of 66,565 individuals with diabetes in Sweden

S.P. Jansson, S. Ramstrand, M. Carlberg, G.A. Johannesson, A. Hiyoshi, G. Jarl, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 37 Inflammation: foe or friend?

Chair: M. Ried-Larsen, Denmark, C.D.A. Stehouwer, Netherlands

217 A longitudinal clinical trajectory analysis examining the accumulation of co-morbidity in people with type 2 diabetes compared with non-type 2 diabetes

R. Qin, K. McCay, R. Williams, W. Ollier, Y. Peng, J.J. Warner-Levy, J.M. Gibson, A. Heald, UK

EASD
EFSD

GENERAL
INFO

218 Mediation of the association between abdominal adiposity and subclinical inflammation in type 2 diabetes

S.L. Domazet, T.B. Olesen, J.V. Stidsen, C.K. Svensson, J.S. Nielsen, R.W. Thomsen, N. Jessen, P. Vestergaard, M.K. Andersen, T. Hansen, C. Brøns, V.H. Jensen, A. Vaag, M.H. Olsen, K. Højlund, Denmark, Sweden

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

219 Interleukin 1 β regulates white adipose tissue remodelling by targeting adipocyte precursors

K. Hofwimmer, J. De Paula Souza, N. Subramanian, M. Vujičić, I. Wernstedt Asterholm, M. Rydén, M. Böni-Schnetzler, D.T. Meier, M.Y. Donath, J. Laurencikienė, Sweden, Switzerland

220 Bariatric arterial embolisation vs bariatric surgery: comparison of effects in obese patients with type 2 diabetes

R.O. Oliveira, F.O. Martins, S.V. Conde, T. Bilhim, F.V. Gomes, V.S. Reuters, Portugal

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

221 Inflammatory markers are elevated in type 1 and type 2 diabetes and linked to long-term complications

J.I. Van Heck, R. Stienstra, L.A. Joosten, C.J. Tack, Netherlands

222 Netosis mediates diet-induced metabolic impairment by sensing the microbiota leading to type 2 diabetes

M. Albiero, L. Migliozi, S. Ciciliot, A. Rodella, F.I. Amendolagine, C. Boscaro, L. Treu, S. Campanaro, G.P. Fadini, Italy

INDUSTRY

PROGRAMME

EXHIBITION

OP 38 How dreaming about artificial pancreas enters the real world (data)

Chair: T. Battelino, Slovenia, T. Klupa, Poland

223 The use of optimal system settings in real-world MiniMed 780G system users has a large impact on increasing the time in tight glucose range

J. Castaneda, T. Van den Heuvel, A. Arrieta, O. Cohen, Switzerland

224 Real-world evidence from MiniMed 780G system users in Europe, Middle East, and Africa: results from 61 481 users across 31 countries

A. Arrieta, J. Castaneda, T. Van den Heuvel, O. Cohen, Switzerland

225 Real-world glycaemic outcomes of >12,200 adults with type 1 diabetes using the Omnipod® 5 Automated Insulin Delivery (AID) system with cloud-based data management

E.G. Wilmot, R.A. Lal, G. Aleppo, L.M. Huyett, K. Snow, J.J. Mendez, I. Hadjiyianni, T.T. Ly, UK, USA

226 Sustained improvement of glycaemic control and patient-reported outcomes after 12 months of advanced hybrid closed-loop in type 1 diabetes in real-world

J. De Meulemeester, M. M. Visser, B. Keymeulen, C. Vercammen, M. Strivay, G. Vanhaverbeke, C. De Block, L. Van Huffel, L. Winne, I. Lowyck, K. Spincemaille, R. Radermecker, D. Ballaux, C. Mathieu, P. Gillard, Belgium

227 Fully closed loop system for the treatment of type 1 diabetes: a real-world prospective observational study

A.C. Van Bon, H. Blauw, T.J. Jansen, G.D. Laverman, A.H. Mulder, M. Out, B.J. Schouwenberg, M.A. Vermeulen, M.N. Gerding, J.P. Van Wijk, M. Klaassen, M. Witkop, J.H. DeVries, Netherlands

228 What does upgrading from hybrid closed-loop systems to advanced hybrid closed-loop systems mean for children and adults with type 1 diabetes in real-world practice?

P. Beato-Víborá, E. Gil-Poch, F.J. Arroyo-Díez, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 39 Pregnancy, diabetes and metabolic health (of mother and child)

Chair: F. Dunne, Ireland, A. Kautzky-Willer, Austria

229 Copenfast trial: foetal growth and glycaemic control in pregnant women with type 1 or type 2 diabetes randomised to faster-acting insulin aspart or insulin aspart

S. Nørgaard, J. Søholm, E. Mathiesen, K. Nørgaard, T. Clausen, P. Holmager, N. Do, P. Damm, L. Ringholm, Denmark

230 Randomised trial of automated insulin delivery in pregnant women with type 1 diabetes

H.R. Murphy, T.T. Lee, C. Collett, S. Bergford, S. Hartnell, E.M. Scott, R.S. Lindsay, K.F. Hunt, D.R. McCance, R.M. Reynolds, M.E. Wilinska, J. Sibayan, C. Kollman, R. Beck, R. Hovorka, UK, USA

231 Reducing sedentary time in obese pregnant women is related to greater placenta IL-6 expression: a mechanism linking reduced sedentary behaviour with lower neonatal adiposity

P. Acosta Manzano, G. Desoye, D. Hill, M. Van Poppel, the DALI core investigator group, Austria, Canada

232 Maternal diet, nutrition and metabolism in the first trimester influences offspring beta cell function at birth

C.L. Meek, Z. Stewart, S. Furse, S. Neoh, D. Feig, A. Koulman, H.R. Murphy, UK, Australia, Canada

233 One-hour versus two-hour post-load hyperglycaemia subtypes of gestational diabetes and the risk of adverse pregnancy outcomes

Y. Gong, J. Wang, X. Zheng, S. Luo, China

234 Identification of miRNAs associated to peroxisome proliferator-activated receptor gamma in pancreatic metabolic adaptation during pregnancy

P. Corrales-Cordon, L. Torres, L. Ramirez-Jimenez, M. Martin-Taboada, P. Fernandez-Garcia, D. Horrillo, A. Izquierdo-Lahuerta, R. Vila-Bedmar, M. Peña-Chilet, C. Martinez, J. Dopazo, M. Ros, G. Medina-Gómez, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 40 What is new in 2023 for the treatment of diabetic kidney disease?

Chair: J. Karalliedde, UK, D.H. Van Raalte, Netherlands

235 Renal effects of empagliflozin alone or in combination with semaglutide in albuminuric type 2 diabetes: a randomised, placebo-controlled trial

S. Sivalingam, V. Soendergaard Wasehuus, V. Rotbain Curovic, T. Willum Hansen, F. Persson, P. Rossing, Denmark

236 The impact of obstructive sleep apnoea treatment on chronic kidney disease in patients with type 2 diabetes: results from a 2-year feasibility RCT

E.A. Makhdom, A. Maher, R. Ottridge, M. Nicholls, A. Ali, B.G. Cooper, R. Ajjan, S. Bellary, W. Hanif, F. Hanna, D. Hughes, V. Jayagopal, N. Adderley, S. Patel, A.A. Tahrani, UK, Saudi Arabia

237 Sodium-glucose cotransporter-2 inhibitors decrease oxygen consumption in adults with type 2 diabetes: a randomised clinical trial using ¹¹C-Acetate PET imaging

D.H. Van Raalte, A.C. Hesp, L.I. Snel, P.R. Schober, L.A. Schwarte, R. Boellaard, P. Bjornstad, Netherlands, USA

238 Liraglutide's kidney-protective effect in type 1 diabetes: modulating macrophage polarisation via selective NADPH oxidase activity

A. Eid, N. Youssef, M.H. Noureldain, S. Al Moussawi, Lebanon

239 Additive effect of SGLT2 inhibition and CB1R antagonism in the fight against diabetic nephropathy

O. Pointeau, A. Ba, A. Geissler, P. Passilly-Degrace, M. Nivot, J. Leemput, L. Demizieux, B. Vergès, P. Degrace, G. Crater, T. Jourdan, France, Canada

240 Cystatin C-based eGFR increases with administration of estradiol and decreases with testosterone, indicating biological effects of sex hormones on kidney function

S. Van Eeghen, C. Wiepjes, N. Nokoff, P. Bjornstad, M. Den Heijer, D. Van Raalte, Netherlands, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 41 SNPs, risk scores and gene therapy

Chair: C. Ling, Sweden, G. Sebastiani, Italy

241 Analyses of type 2 diabetes partitioned polygenic scores among Asian Indian and European populations

A.L. Melhem, R.M. Anjana, M. Bigossi, S. Srinivasan, R. Venkatesan, V. Mohan, C.N. Palmer, M. Siddiqui, UK, India

EASD
EFSD

GENERAL
INFO

242 Impact of the TCF7L2 rs7903146 type 2 diabetes risk variant on clinical presentation in recently diagnosed patients with type 2 diabetes

A.L. Hansen, L.M. Engelhard, C. Brøns, N. Jessen, J.S. Nielsen, P. Vestergaard, K. Højlund, M.K. Andersen, T. Hansen, M.H. Olsen, R.W. Thomsen, H.T. Sørensen, A. Vaag, Denmark, Sweden

PROGRAMME

TUESDAY

243 Discovery of a new treatment for a novel form of rare diabetes caused by an insulin gene mutation using patients' iPSC-derived beta cells

Y. Tong, M. Becker, U. Schierloh, Y. Cai, F. Natividade da Silva, F. Fantuzzi, T. Sawatani, C. Vinci, N. Pachera, L. Haataja, P. Arvan, C. De Beaufort, M. Cnop, Belgium, Luxembourg, USA

WEDNESDAY

THURSDAY

FRIDAY

244 Pnliprp1 (pancreatic lipase related protein 1) hypermethylation in the exocrine pancreas links type 2 diabetes to pancreatic cancer development: an EWAS study

L. Maurin, L. Ning, M. Boissel, L. Marselli, F. Pattou, J. Kerr-Conte, P. Marchetti, A. Bonnefond, P. Froguel, A. Khamis, France, Italy, UK

SHORT ORAL
DISCUSSIONS

245 Application of multiomics to identify novel molecular mechanisms of atherosclerotic plaque instability in type 2 diabetes patients

V. Das, X. Zhang², D. Djordjevic, O. Bergman, M. Chemaly, D. Shungin, N. Michaelsen, K. Knape, U. Hedén, L. Matic, Denmark, Sweden

246 Gene therapy for maturity-onset diabetes of the young type 3 (MODY3)

E. Casana, V. Jimenez, M. Garcia, A. Casellas, M. Morró, A. Pujol, T. Ferré, V. Sacristan, C. Jambrina, X. León, L. Vila, S. Franckhauser, F. Bosch, Spain

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 42 Risk factors and biomarkers of CVD

Chair: D. Dabelea, USA, T. Dejgaard, Denmark

247 Real-life use of novel glucose lowering agents in coronary artery disease: experience from the SWEDHEART-registry

V. Ritsinger, K. Avander, B. Lagerqvist, P. Lundman, A. Norhammar, Sweden

248 Impact of remission of type 2 diabetes on cardiovascular structure and function, exercise capacity and risk profile: a propensity matched analysis

E.M. Brady, J.M. Bilak, J.L. Yeo, G.S. Gulsin, A.-M. Marsh, A. Dattani, S.L. Ayton, K. Parke, M. Bain, W. Pang, S. Boulous, T. St Pierre, M.J. Davies, T. Yates, G.P. McCann, UK, Australia

249 Association of low muscle mass with increased all-cause and cardiovascular disease mortality in patients with diabetes

J.-M. Yu, C.-M. Oh, S. Moon, D. Kim, Republic of Korea

250 Risk of cardiovascular and mortality outcomes in Korean type 2 diabetes and prediabetes: a nationwide population-based cohort study

J.-S. Yun, E.-Y. Lee, K.-H. Song, Y.-B. Ahn, K. Kim, S.-H. Ko, Republic of Korea

251 Central obesity and the risk of coronary artery disease event according to albuminuria stages in adults with type 1 diabetes

E. Bezerra Parente, V. Harjutsalo, P.-H. Groop, Finland

252 Adult-onset type 1 diabetes subphenotypes: a cluster analysis

K. Prystupa, A. Fritsche, G.J. Boenhof, A. Strom, M. Heni, J. Seissler, J. Szendroedi, A.F. Pfeiffer, M. Stumvoll, S.M. Meyhoefer, O.-P. Zaharia, K. Strassburger, V. Burkart, M. Roden, R. Wagner, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

58th Minkowski Lecture

Chair: Chantal Mathieu, Belgium

Speaker: Timo Müller, Germany:

Novel insights into regulation of energy and glucose metabolism by GIP and GIPR:GLP-1R co-agonists

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Dr. **Timo Müller** studied Animal Physiology at the Philipps-University Marburg, Germany. In 2009, he received his PhD at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Germany.



He then moved on to work as a postdoctoral fellow at the Metabolic Disease Institute, University of Cincinnati, USA. In 2011, Timo Müller returned to Germany, where he ever since leads the Division of Molecular Pharmacology at the Institute for Diabetes and Obesity (IDO), Helmholtz Munich. Since 2018 Timo Müller is the acting director of the IDO.

In 2019, he received the Venia legendi for experimental pharmacology from the Medical Faculty at the University of Tübingen, Germany. Dr. Müllers research is focused on the development and evaluation of novel unimolecular pharmacotherapies to treat the metabolic syndrome, and in particular obesity and diabetes.

He published >150 manuscripts, including articles in Cell, Cell Metabolism, Nature Medicine, Nature Metabolism, and Nature Communications. As postdoctoral fellow, he discovered that adipose-specific loss of p62 leads to extreme obesity in mice (Müller et al., J Clin Invest 2013) and identified GPR83 as a regulator of energy metabolism (Müller et al., Nat Commun 2013). He established the concept of glucagon-mediated hepatic delivery of T3 to enhance lipid and cholesterol metabolism (Finan et al. Cell 2016) and showed GLP-1-mediated delivery of oestrogen to restore beta-cell mass in diabetic mice (Sachs et al. Nat Metab 2020), while GLP-1-mediated delivery of Tesaglitazar improves systemic glucose metabolism (Quarta et al., Nat Metab 2021). He further refuted the concept that alternatively activated macrophages regulate adaptive thermogenesis (Fischer et al., Nat Med 2017), identified the signal mechanism of how p62 regulates energy metabolism (Fischer et al., Nat Commun 2020) and identified the CNS GIP receptor as a key regulator of body weight (Zhang et al., Cell Metab 2021). He also published two of the most cited manuscripts of Molecular Metabolism (Müller et al., Mol Metab 2015 and Müller et al., Mol Metab 2019) and demonstrated the importance of the GIP receptor for the insulinotropic action of Tirzepatide (El et al., Nat Metab 2023).

EASD MINKOWSKI PRIZE

The Minkowski Prize awards research contributing to the advancement of knowledge concerning diabetes which has been carried out by an EASD member normally residing in Europe.

The prize will be awarded to an outstanding researcher with no more than ten years full time experience as an independent investigator in the year of the nomination.

The Minkowski Prize is generously supported by Lilly.

EASD
EFSD

GENERAL
INFO

EASD Minkowski Lecturers

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

2022	M. Heni (DE)
2021	A. Bonnefond (FR)
2020	G.P. Fadini (IT)
2019	F.K. Knop (DK)
2018	F. Bäckhed (SE)
2017	E.R. Pearson (UK)
2016	P. Schrauwen (NL)
2015	M. Blüher (DE)
2014	A. Gloyn (UK)
2013	M. Cnop (BE)
2012	T.M. Frayling (UK)
2011	N. Sattar (UK)
2010	F. Gribble (UK)
2009	G. Perseghin (IT)
2008	J.C. Brüning (DE)
2007	M. Stoffel (CH)
2006	M. Roden (DE)
2005	P. Rossing (DK)
2004	G.A. Rutter (UK)
2003	M. Stumvoll (DE)
2002	B.O. Roep (NL)
2001	J.R. Zierath (SE)
2000	H. Edlund (SE)
1999	R. Scharfmann (FR)
1998	J.H. Auwerx (FR)
1997	P. Froguel (FR)
1996	P. Rorsman (DK)
1995	J. Todd (UK)
1994	T. Mandrup Poulson (DK)

1993	H. Yki-Järvinen (FI)
1992	E. van Schaftingen (BE)
1991	C. Boitard (FR)
1990	P. Halban (CH)
1989	H.-U. Häring (DE)
1988	J.C. Hutton (UK)
1987	J.-L. Carpentier (CH)
1986	D. Pipeleers (BE)
1985	E. Van Obberghen (FR)
1984	A. Lernmark (DK)
1983	S.L. Howell (UK)
1982	G.F. Bottazzo (UK)
1981	P. De Meyts (BE)
1980	I.-B. Taljedal (SE)
1979	S.J. Ashcroft (UK)
1978	J. Nerup (DK)
1977	J. Wahren (SE)
1976	K.D. Hepp (DE)
1975	P. Freychet (FR)
1974	E. Cerasi (SE)
1973	L. Orci (IT/CH)
1972	W.J. Malaisse (BE)
1971	C.N. Hales (UK)
1970	B. Jeanrenaud (CH)
1969	B. Hellman (SE)
1968	L.A. Carlson (SE)
1967	E.R. Froesch (CH)
1966	P.J. Randle (UK)

17:30 - 18:30

London Hall

‘With a little help from my friends’: What can we learn from other specialities?

Chair: Jelizaveta Sokolovska, Lithuania

Speaker: Anna Tomaszuk-Kazberuk, Poland:

Diabetes and heart failure

Simon HC Anderson, UK:

Diabetes and the bowel/intestines

Venu Kavarthapu, UK:

Diabetic foot surgery

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Paris Hall

SURMOUNT-4 Trial results: the impact of tirzepatide on maintenance of weight reduction and benefits of continued therapy

Chair: John PH Wilding UK

Speaker: Naveed Sattar, UK:

SURMOUNT-4 background, rationale, design and baseline characteristics

Louis J Aronne, USA:

SURMOUNT-4 Study efficacy and safety results

Filip K Knop, Denmark:

Commentary

17:30 - 18:30

Barcelona Hall

Adipose tissue heterogeneity: cellular and molecular aspects

Chair: Bilal N Sheikh, Germany

Speaker: Alexander Bartelt, Germany:
Adipocyte health and metabolic disease

Anne Loft, Denmark:
Human adipose tissue adaptation and crosstalk in response to obesity and weight loss

Lauren M Sparks, USA:
Healthy ageing, physical activity and adipose tissue metabolism: roles in insulin resistance and type 2 diabetes

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Mumbai Hall

Sweet Odyssey 2022: computing optimal care for complications

Chair: Anna Solini, Italy

Speaker: Andrew J Barkmeier, USA:
Can AI save the eye? Protecting vision through enhanced screening and management of diabetic retinopathy

Marjolein M Iversen, Norway:
Treating diabetic foot and not touching it: magic or real possibility?

Juliana CN Chan, Hong Kong:
mHealth for unhealthy kidneys in diabetes

17:30 - 18:30

Lima Hall

Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes

Chair: Stefano Del Prato, Italy

Speaker: Gary D Lopaschuk, Canada:
Diabetic Cardiomyopathy: molecular mechanism

TBA:

Diagnosis of Diabetic Cardiomyopathy based on circulating marker of disease, lessons from the baseline analysis of the ARISE-HF study

followed by Q&A

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Cairo Hall

Chronic Kidney Disease in type 1 diabetes

Chair: Peter Rossing, Denmark


Speaker: Katherine R Tuttle, USA:
Unmet need the epidemiology of CKD and type 1 diabetes

Hiddo JL Heerspink Netherlands:
Clinical trials in type 1 with CKD

Q&A

Peter Rossing, Denmark:
Summary and close

EFSD European Foundation
for the Study of Diabetes

The background of the entire page is a light blue-tinted photograph of laboratory glassware. In the foreground, a glass dropper is suspended, with a single drop of liquid hanging from its tip. Behind it, several round-bottom flasks are visible, some containing liquids. The image is slightly out of focus, creating a sense of depth and scientific atmosphere.

EFSD **FUNDING** **DIABETES RESEARCH**

SINCE 2000

GRANTS & FELLOWSHIPS
AVAILABLE THROUGHOUT THE YEAR

www.EuropeanDiabetesFoundation.org

EASD-Lilly Centennial Anniversary Prize Lecture

Chair: Francesco Giorgino, Italy

Speaker: Gerald Shulman:
**The role of ectopic lipid in insulin resistance and
 cardiometabolic disease**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Dr. **Gerald Shulman** is the George R. Cowgill Professor of Physiological Chemistry, Professor of Internal Medicine and Cellular & Molecular Physiology at Yale University. He is also Co-Director of the Yale Diabetes Research Center and an Investigator of the Howard Hughes Medical Institute for 21 years.



Dr. Shulman has pioneered the use of magnetic resonance spectroscopy combined with stable isotopes and mass spectrometry to non-invasively examine intracellular glucose and fat metabolism in humans that have led to several paradigm shifts in our understanding of type 2 diabetes, including the molecular mechanisms by which ectopic lipids promote liver and muscle insulin resistance, as well as developing new drugs for the treatment of type 2 diabetes, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Dr. Shulman is the recipient of the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation, the Outstanding Clinical Investigator Award from the Endocrine Society, the Solomon Berson Award from the American Physiological Society and the Banting Medal for Lifetime Scientific Achievement from the American Diabetes Association.

Dr. Shulman is a Fellow of the American Association for the Advancement of Science, Inaugural Fellow of the American Physiological Society, Mastership in the American College of Physicians, Mastership in the American College of Endocrinologists, Fellowship in the Royal College of Physicians (Lon) and he has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Sciences.

EASD-LILLY CENTENNIAL ANNIVERSARY PRIZE

The EASD-Lilly Centennial Anniversary Prize recognise individual researchers who have significantly contributed through innovative approaches to the development and evolution of treatment and management of diabetes.

Starting in 2022, the award will be bestowed for three consecutive years on the occasion of the EASD Annual Meeting. Each year will identify the awardee among those who have contributed to three different fields:

- 2022:** Innovative pharmacologic therapies, awarded to M.Tschöp, Germany
- 2023:** Landmark achievements in the pathogenesis of diabetes
- 2024:** Clinical and diagnostic innovation in the management of diabetes and its complications

The EASD-Lilly Centennial Anniversary Prize is generously supported by Lilly.

09:00 - 10:00

London Hall

Current status on stem cell derived islets: Ready for the clinic?

Chair: Karim Bouzakri (FR)

Speaker: Timo Otonkoski (FI):
Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells

Malin Fex (SE):
Generation of glucose responsive stem cells: a way to better understand mechanisms that regulate insulin secretion

Miriam Cnop (BE):
Stem cells to understand the role of specific mutations in impaired insulin secretion and diabetes development

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Turning down the thermostat for metabolic health!

Chair: Joris Hoeks, Netherlands

Speaker: Denis Blondin (CA):
Cold exposure as a therapeutic strategy for type 2 diabetes

Lawrence Kazak (CA):
Novel pathways of thermogenesis in adipose tissues

Tore Bengtsson (SE):
Beta-adrenergic stimulation and glucose homeostasis

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Debate: SGLT- 2 or not 2 that is the question? All people with diabetes and CKD should be on SGLT-2 Inhibition by default

Chair: Erika Bezerra Parente, Finland

Speaker: Andrew H Frankel, UK:
Yes

Daniel R. van Raalte, Netherlands:
No

EASD/ESC Symposium: Does increased glucose variability harm the vessels or organs?

Chair: Tina Vilsbøll, Denmark

Speaker: Michael Resl, Austria:
Cell and animal studies and data in non-diabetic subjects!

Guillermo Umpierrez, USA:
What data do we have from studies in diabetic patients?

Sexual orientation, gender identity and cardiometabolic risk

Chair: Christian Herder, Germany

Speaker: Carl G. Streed, USA:
Epidemiologic trends and disparities in diabetes risk factors among LGBTQ populations

Dorte Glintborg, Denmark:
Cardiometabolic aspects of transgender healthcare

EASD
EFSD

GENERAL
INFO

Treatment strategies to prevent or attenuate renal impairment in type 2 diabetes

Chair: Martin Haluzik, Czech Republic

Speaker: Ofri Mosenzon, Israel:
Non-insulin therapies in patients with type 2 diabetes and renal impairment in 2023: current status and new perspectives

Tahseen Chowdhury, UK:
Treatment of diabetes in patients with severe renal impairment

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 43 Old dogs, new tricks

Chair: R. Cordiner, UK, M. Löndahl, Sweden

253 Efficacy and safety of pioglitazone/metformin fixed-dose formulation vs uptitrated metformin in type 2 diabetes with inadequate glycaemic control: a randomised trial

L. Guo, China

EASD
EFSD

GENERAL
INFO

254 Treatment outcomes with oral anti-hyperglycaemic therapy for people with diabetes secondary to chronic pancreatitis: matched population based cohort study

R. Hopkins, K.G. Young, N.J. Thomas, A.G. Jones, A.T. Hattersley, B.M. Shields, J.M. Dennis, A.P. McGovern, UK

255 The impact of timing of metformin administration on glycaemic and glucagon like peptide 1 responses to intraduodenal glucose in type 2 diabetes

T. Wu, C. Xie, P. Iroga, M. Bound, J. Grivell, W. Huang, Y. Sun, K. Jones, M. Horowitz, C. Rayner, Australia

256 A systematic review and meta-analysis of participant characteristics in the prevention of gestational diabetes: a summary of evidence for precision medicine

S. Lim, W. Takele, K.K. Vesco, L. Redman, ADA/EASD Precision Medicine in Diabetes Initiative GDM Prevention Working Group, J. Josefson, Australia, USA

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 44 Checking in on beta cell function

Chair: M. Buitinga, Netherlands, M. Laimer, Switzerland

257 An improved ⁶⁸Ga-exendin4 PET-CT method to assess noninvasively pancreatic beta cell mass: studies in long standing type 1 diabetes patients and in obese people

R.C. Bonadonna, S. Migliari, M. Scarlattei, R.E. Ledda, V. Spigoni, G. Baldari, R. Aldigeri, G. Cinquegrani, A. Dei Cas, L. Ruffini, Italy

258 Residual beta cell function associates with lower glycaemic variability and more time in range in individuals with type 1 diabetes

C.M. Fuhri Snethlage, T.J. McDonald, E. Rampanelli, P. De Groen, A.W. Schimmel, C.B. Brouwer, R. Oram, D.H. Van Raalte, B.O. Roep, M. Nieuwdorp, N.M. Hanssen, Netherlands, UK

259 Association between dynamics of circulating proteins and of beta cell function in type 2 diabetes: an IMI DIRECT study

C. Rossi, A. Viñuela, E.R. Pearson, J.M. Schwenk, A. Mari, R. Bizzotto, Italy, UK, Sweden

260 The C-peptide-glucose ratio as a marker for insulin secretion predicts future insulin treatment and glycaemia in persons with recent-onset type 2 diabetes

R. Jumpertz von Schwartzberg, K. Bódis, J. Martin, M. Schön, M. Hrabé de Angelis, N. Perakakis, S. Kabisch, A. Pfeiffer, M. Blüher, J. Szendrödi, N. Stefan, R. Wagner, A.L. Birkenfeld, M. Roden, A. Fritsche, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 45 Thinking outside the box to protect the kidney and the foot

Chair: P. Vas, UK, G. Gruden, Italy

261 Dapagliflozin protects against urban particulate matter-induced EMT in tubular epithelial cells

J. Kim, C. Kang, W. Lee, Republic of Korea

262 Up-regulation of ICAM-1 and ESM 1 by intermittent hypoxia via down-regulation of microRNA-181a1 in vascular endothelial cells

S. Takasawa, M. Makino, A. Yamauchi, S. Sakuramoto-Tsuchida, R. Hirota, R. Fujii, K. Asai, Y. Takeda, T. Uchiyama, R. Shobatake, H. Ota, Japan

263 The effect of treatment with umbilical cord blood platelet lysate gel on diabetic foot ulcer: an open-label randomised controlled study

A. Kountouri, F. Psahoulia, A. Lazaris, E. Michalopoulos, P. Mallis, I. Eleftheriadou, K. Balampanis, E. Korakas, L. Pliouta, M. Sarris, G. Geroulakos, C. Stavropoulos-Giokas, G.D. Dimitriadis, N. Tenrolouris, V. Lambadiari, Greece

264 Inhibition of microRNA-34a signalling impairs wound healing in diabetes through regulating macrophage polarisation

B. Yan, A. Zhao, S.E. Angelstig, S. Narayanan, J. Grünler, M. Navid, C. Xu, D. Li, N.X. Landén, M. Stähle, I.R. Botusan, N.R. Ekberg, Q. Deng, X. Zheng, S.B. Catrina, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 46 Endothelium and diabetes complications*Chair:* T. Nyström, Sweden**265 Activation of the Nrf2 pathway offers microvascular protection against recurrent hypoglycaemia in type 1 diabetes**

A.D. McNeilly, C. Forteath, J.R. Gallagher, H.J. Merchant, A.T. Dinkova-Kostova, F. Khan, M.L. Evans, B. Thorens, U. Pederson-Bjergaard, B.E. De Galan, R.J. McCrimmon, UK, Switzerland, Denmark, Netherlands

EASD
EFSD

266 Recombinant SIRT1 rescues metabolic cardiomyopathy in the Db^{+/+} mice by reprogramming the myocardial lipid signature

A. Mengozzi, S. Costantino, S.A. Mohammed, E. Gorica, A. Mongelli, N.R. Pugliese, S. Masi, A. Virdis, S. Velagapudi, A. Akhmedov, C.M. Matter, F. Ruschitzka, T.F. Luscher, F. Paneni, Switzerland, Italy, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

267 Continuous representation of type 2 diabetes heterogeneity on a tree-like graph structure stratifies risk of complications

M. Schön, K. Prystupa, T. Mori, O.P. Zaharia, K. Bódis, Y. Kupriyanova, A.T. Nair, A. Strom, R. Guthoff, G.J. Bönhof, V. Schrauwen-Hinderling, O. Kuss, E.R. Pearson, M. Roden, R. Wagner, Germany, UK

268 Endothelial-specific deletion of lysine methyltransferase Set7 protects mice from obesity and insulin resistance-related endothelial dysfunction

J. Sánchez-Ceinos, P. Döttling, M. Jakobsson, A. Vegvari, F. Cosentino, Sweden

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 47 Senescence and age*Chair:* U. Smith, Sweden**269 The RNA-binding protein ZMAT3 is increased by insulin and contributes to hyperinsulinaemia-induced senescence and insulin resistance in human cells**

R. Spinelli, P. Florese, F. Beguinot, A. Nerstedt, U. Smith, Sweden, Italy

270 Positive effects of bariatric surgery are associated with attenuation of cellular senescence

S. Stemberkova Hubackova, T. Havrlantova, I. Simonik, M. Mraz, M. Haluzik, Czech Republic

271 Loss of the armadillo-repeat protein Plakophilin-2 in obesity breaks cell cycle dynamics to breed adipocyte senescence

A. Lluch, J. Latorre, N. Oliveras-Cañellas, I. Espadas, E. Caballano-Infantes, J. Moreno-Navarrete, W. Ricart, A. Martin-Montalvo, M. Malagón, J. Fernández-Real, F. Ortega, Spain

272 Defining the role of adipose-glucocorticoid signalling in age-related cardiometabolic disorders

C. Beaupere, H. Soula, K. Poussin, A. Grosfeld, C. Vigouroux, M. Moldes, B. Fève, France

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 48 Different approaches to map signal pathways in islet cells

Chair: J.-C. Jonas, Belgium

273 The heterogeneity of islets in the healthy pancreas: calcium reveals different responses

E. Nikitina, C.M. Cohrs, S. Speier, Germany

274 Ex vivo mapping of metabolic pathways assessed by in situ enzymatic activities in pancreatic islets during development of diabetes in mice and humans

N. Baez, Y. Zhou, E. Schöniger, N. Kipke, D. Friedland, M. Barovic, Y. Morgenroth, M. Distler, T. Brun, M. Solimena, P. Maechler, Switzerland, Germany

275 Signal Regulatory Protein Alpha (SIRPA) mitigates STAT1 activity and protects human beta cells by targeting HDAC6

K. Afi Leslie, C. Lekka, S.J. Richardson, M.A. Russell, N.G. Morgan, UK

276 Pleiotropic effects of imeglimin on pancreatic alpha cells at single-cell resolution

T. Tsuno, R. Inoue, K. Nishiyama, J. Shirakawa, Japan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 49 Caring for care delivery

Chair: P. Kempler, Hungary, A. Solini, Italy

277 Estimating health resource utilisation cost reduction through provision of specialist obesity reduction services by sex and age groups in main health localities in England

M.R. Davies, M.P. Stedman, M. Whyte, J.J. Warner-Levy, A.H. Heald, UK

278 Age and sex as mediators of response to an online self-management package (nutritional, behavioural and psychological) in type 2 diabetes: the BEATdiabetes study

K. Hart, S. Carrod, K. Bennett-Eastley, P. Grob, J. Harris, A. Heald, M. Stedman, M.B. Whyte, D. Cooke, UK

279 AMD Annals: an initiative for the continuous quality improvement of diabetes care

G. Russo, P. Di Bartolo, G. Di Cianni, R. Candido, G. Lucisano, V. Manicardi, A. Nicolucci, A. Rocca, M. Rossi, AMD Annals Study Group, Italy

280 Temporal trends in the achievement of treatment targets among men and women with type 1 and type 2 diabetes in Sweden

S. Karayiannides, S.-B. Catrina, N. Rajamand-Ekberg, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

European elections 2024: the role of EUDF and the diabetes community in raising diabetes on the policy agenda

Chair: Stefano Del Prato, Italy

Speaker: Stefano Del Prato, Italy
Welcome and opening remarks, raising diabetes on the European policy agenda

Niti Pall, UK:
What are we asking for? Diabetes Manifesto for the European Elections

Bart Torbeyns, Belgium:
How can you support the diabetes election campaign? Toolkit for countries

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 50 Fatty liver, faulty liver

Chair: B. Ludvik, Austria, K. Roumans, Netherlands

281 Mildly elevated liver fat content is characterised by central insulin resistance: evidence from a positron emission tomography study

M.-J. Honka, N. Tuomola, M. Bucci, H. Immonen, V. Saunavaara, S. Laine, T. Sjöros, T. Garthwaite, K.A. Virtanen, J.C. Hannukainen, K.K. Kalliokoski, I.H. Heinonen, E. Rebelos, P. Nuutila, Finland, Japan, Sweden, Italy

282 Elucidation of hepatic insulin resistance by species-specific analysis of diacylglycerols

M. Piribauer, S. Trenkamp, B.-F. Belgardt, M. Rieck, H. Al-Hasani, M. Roden, G. Heilmann, Germany

283 Impact of 4-week carbohydrate overfeeding on postprandial nutrient metabolism in low birth weight versus normal birthweight men

L.M. Engelhard, L.O. Elingaard-Larsen, L. Justesen, T. Hansen, G.V. Hall, A. Vaag, C. Brøns, Denmark, Sweden

284 Genome-wide CRISPR screening to identify regulators of hepatic insulin signalling

E. Martin Perez, A. Veprik, F. Klimm, A. Epanchintsev, A. Chandran, B. Gilboa, G.D. Ettridge, P. Wu, C.A. Prada Medina, A. Agrawal, R. Kitchen, C. Ämmälä, R.W. Klemm, M.A. Ruby, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 51 "With a little help from my friends": therapies and combinations

Chair: J. Eriksson, Sweden, N. Rajamand Ekberg, Sweden

285 Efficacy of initial triple combination therapy with metformin, dapagliflozin and saxagliptin in drug-naïve patients with type 2 diabetes: a randomised controlled trial

N. Kim, J. Kim, J. Moon, Y.-H. Lee, T. Kim, H. Cho, S. Kwak, S. Lim, D. Kim, M. Moon, S. Kim, Republic of Korea

287 Effect of orforglipron versus placebo and dulaglutide on glycaemic control and body weight in patients with type 2 diabetes

K.J. Mather, J.P. Frias, S. Hsia, S. Eyde, R. Liu, X. Ma, M. Konig, C. Kazda, E. Pratt, A. Haupt, D. Robins, USA

288 The gut hormone GIP contributes to the postprandial gastrointestinal hyperaemia in humans

L.S. Gasbjerg, R.S. Rasmussen, L.S. Langberg, F. Østergaard, M.B. Vestergaard, A. Asmar, B. Hartmann, J.J. Holst, B. Haddock, H.B. Larsson, U.B. Andersen*, M.M. Rosenkilde*, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 52 Looking to the future: risks and benefits of glycaemic control in diabetic retinopathy

Chair: E. Bezerra Parente, Finland, E. Mensah, UK

289 Clinical benefit vs risk of diabetic retinopathy progression with semaglutide: watch the eyes

M. Jose, L. Varadhan, UK

290 Effects of semaglutide, empagliflozin or their combination on oxygenation, vascular autoregulation, and central thickness of the retina in persons with type 2 diabetes

P. Løgstrup, Denmark

291 Does glycaemic variability impact on the onset of sight threatening diabetic retinopathy in multi-ethnic cohort of people with type 1 diabetes?

A. Muthukumar, T. Mangelis, S. Ayis, A. Goubar, S. Thomas, P. Vas, S. Mann, L. Webster, J. Karalliedde, UK

292 Blood glucose derived GMI and HbA_{1c} have similar associations with retinopathy progression: further analysis of the Diabetes Control and Complications Trial (DCCT)

I.B. Hirsch, Y. Xu, T.C. Dunn, Y. Dabiri, Y. Ram, R. Ajjan, R.M. Bergenstal, USA, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 53 Elevating and (making) exciting diabetes education

Chair: A. Majchrzak, Poland, F. Toti, Albania

293 Relationship between education and non-alcoholic fatty liver disease: a two-sample Mendelian randomisation analysis

Z. Ren, A. Wesselius, C.D. Stehouwer, M.C. Brouwers, Netherlands

294 The effect of education on glycaemic control in patients with type 1 diabetes with initiation of continual or flash glucose monitoring

E. Horová, V. Navrátilová, J. Šoupal, J. Škrha jr, D.Q. Do, L. Radovnická, A. Hásková, M. Prázný, Czech Republic

295 My diabetes my way: online support for diabetes self-management

S.G. Cunningham, B. Allardice, J. Dickson, N.T. Conway, D. Little, D.J. Wake, UK

296 Development of noninvasive diabetes management method using glycated albumin in tears

M. Aihara, N. Kubota, T. Yamauchi, Japan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 54 Risk factors for complications and mortality

Chair: M. Jorgensen, Greenland, A. Rawshani, Sweden

297 Metabolomic biomarker profiling for chronic kidney disease prediction in 10,000 individuals with type 2 diabetes

P. Würtz, J. Barrett, H. Julkunen, Finland

298 Infection risk is substantially increased in a hyperinsulinaemic type 2 diabetes subgroup: a Danish cohort study

J.S. Nielsen, F.P. Kristensen, S.L. Domazet, J. Stidsen, K. Højlund, P. Vestergaard, H. Beck-Nielsen, N. Jessen, M.H. Olsen, T. Hansen, C. Brøns, A. Vaag, H.T. Sørensen, R.W. Thomsen, Denmark, Sweden

299 Risk of long term mortality in patients with recurrent diabetic ketoacidosis admissions

S. Penswick, M. Lyall, F. Gibb, UK

300 Large and small peripheral artery disease in people with type 1 diabetes

T. Avdic, B. Eliasson, J. Nordanstig, A. Rawshani, A. Rawshani, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 55 How the beta cells die and can be rescued

Chair: T. Mezza, Italy, M. Raoux, France

301 A 3D imaging toolbox for islet biology: utilisation of human islet microtissues in high-content 3D confocal microscopy

M. Karsai, A. Title, S. Jawurek, C. Rufer, F. Forschler, J. Mir Coll, S. Sonntag, O. Yavas, B. Yesildag, Switzerland

302 OGT is essential for postnatal beta cell identity maintenance through transcription factor Pdx1

A. Wong, E. Alejandro, USA

303 Mesenchymal stromal cell secretory peptides improve human islet functional survival

T. Hong, S. Caxaria, M. Zhao, L. Daniels Gatward, A. King, C. Rackham, P. Jones, UK

304 UFMylation in pancreatic beta cells plays an important role in maintaining cellular homeostasis and glucose tolerance

Y. Nishida, H. Uzawa, A. Kanai, K. Ueki, M. Komatsu, H. Watada, Japan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 56 The brain in control

Chair: B. Ukropcova, Slovakia, H. Le Stunff, France

305 Hypothalamic FSTL1 modulates energy homeostasis and glucose/lipid metabolism via the Akt-/Foxo1-AgRP pathway

H. Dai, M. Yang, L. Li, G. Yang, China

EASD
EFSD

306 Effects of triglycerides enriched at the sn-2 position in saturated fatty acids on peripheral and central insulin resistance: role of ceramide metabolism

H. Le Stunff, J.E. Miyamoto, R. Magno, J. Guitton, A. Reginator, M.A. Torsoni, A. Torsoni, L. Souza, M. Taouis, C. Magnan, M. Milanski, France, Brazil

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

307 Reversion of obesity and insulin resistance by intracerebrospinal fluid AAV-FGF21 gene therapy

I. Elias, I. Grass, V. Sacristán, A. Ribera, C. Jambrina, V. Sánchez, V. Jiménez, E. Casaña, T. Ferré, F. Bosch, Spain

308 Gpr75 knockout mice are protected against diet-induced obesity via reduced food intake and increased energy expenditure, independent of non-shivering thermogenesis

T. Kroon, D. Kakol-Palm, J. Vestlund, I. Ahlstedt, S. Wallin, A. Ahnmark, B. Zarrouki, N. Dekker, A. Johansson, J. Yanolatos, D. Baker, C.J. Rhodes, M. Sleeman, J. Altarejos, Sweden, USA, UK

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

The SARS-CoV-2 virus is directly responsible for the increased incidence of type 1 diabetes during the early COVID-19 pandemic

Chair: TBA

Speaker: TBA:
In favour

Mikael Knip Finland:
Against

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

13:30 - 15:00

Hamburg Hall

Hyperglycaemic crises in adult patients with diabetes consensus report

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

13:30 - 15:00

London Hall

EASD/ADA Symposium

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Chair: TBA

Speaker: TBA

13:30 - 15:00

Paris Hall

Facing the unexpected: how to fight diabetes while fighting the war or disaster...

Chair: Andrew JM Boulton, UK

Speaker: Boris Mankovsky, Ukraine:
...in Europe

Butheinah A Al-Sharafi, Yemen:
...in South-West Asia

Brij M Makkar, India:
...in South-East Asia

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Diabetic neuropathy from genetics to clinical practice

Chair: Prashant RJ Vas, UK

Speaker: Hetal Shah, USA:
Genetics of diabetic neuropathy

Troels S Jensen, Denmark:
Diagnosis of neuropathy: Who, what, when, where, why?

Dinesh Selvarajah, UK:
Treatment of diabetic neuropathy: What can we do better?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

The old and the new risk factors for diabetic kidney disease

Chair: Chair: Niina Sandholm, Finland

Speaker: Bruce A Perkins, Canada:
eGFR: Is it more than an equation? Role of trajectories in predicting outcomes

Parker C Wilson, USA:
Single-cell sequencing for diabetic kidney disease

Joanne B Cole, USA:
Genetics of diabetic kidney disease

Brain control of islet function

Chair: Chair: Hideli Katagiri, Japan

Speaker: Rory J McCrimmon, UK:
Central deficiency of IL-6Ra in mice impairs glucose-stimulated insulin secretion

Sushil G Rane, USA:
A distinct hypothalamus-to-beta cell circuit modulates insulin secretion

Peter Thorn, Australia:
Local activation of focal adhesion kinase orchestrates the positioning of presynaptic scaffold proteins and Ca²⁺ signalling to control glucose-dependent

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Cognition and related conditions in diabetes

Chair: Miriam Cnop, Belgium

Speaker: Thomas T van Sloten, Netherlands:
Diabetes related conditions and dementia: a lifespan perspective

Jose A Luchsinger, USA:
Noninvasive blood-based biomarkers of neuropathology in people with diabetes

Jørgen Rungby, Denmark:
Neuroprotective mechanisms from antidiabetic agents

SO 01 Weight across the lifespan

Chair: N. Esser, Belgium

309 Impact of birthweight on macrovascular complications in type 2 diabetes: a cohort study

A.A. Vaag, A.L. Hansen, C. Brøns, L.M. Engelhard, N. Jessen, J.S. Nielsen, P. Vestergaard, K. Højlund, M.K. Andersen, T. Hansen, M.H. Olsen, H.T. Sørensen, R.W. Thomsen, Sweden, Denmark

EASD
EFSD

310 Associations of infant feeding patterns with adiposity in childhood: the Healthy Start study

C.C. Cohen, E.C. Francis, D.H. Glueck, K.K. Harrall, W. Perng, K.A. Sauder, K. Shankar, D. Dabelea, USA

GENERAL
INFO

311 Asian population-based visceral adiposity indices outperform western population-based those as indicators of CKD in a Korean population

H. Kim, J. Jin, B. Ha, N. Kim, K.-G. Park, Republic of Korea

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

312 Metabolic syndrome in people living with type 1 diabetes in Belgium

A. Lavens, P. Oriot, J.-C. Philips, A. Verhaegen, C. De Block, F. Nobels, C. Mathieu, on behalf of the IQED Group of Experts, Belgium

SHORT ORAL
DISCUSSIONS

313 Prevalence of obesity in people living with type 1 diabetes across countries: an IMI2 SOPHIA analysis of data from Belgium, Kuwait, and Mexico

S. Pazmino, E. Al-Ozairi, A. Al Attar, J. Al Kandari, P. Almeda-Valdes, N. Antonio-Villa, C. Delfin, R. Faradji, J. Rosen, J. Soderberg, T. Sparsø, N. Steenackers, C. Mathieu, B. Van der Schueren, C. Le Roux, Belgium, Kuwait, Mexico, Denmark, USA, Sweden

PRESENTER
INDEX

SATELLITE
SYMPOSIA

314 Effect of body weight on glycaemic indices in patients with type 1 diabetes using continuous glucose monitoring

S. Tigas, P. Christou, G. Markozannes, A. Siolos, D. Katsarou, E. Georga, D. Fotiadis, M. Christou, Greece

INDUSTRY

PROGRAMME

EXHIBITION

315 Association of body composition with glucose metrics in patients hospitalised with community-acquired pneumonia

M. Olsen, A. Dunga, C. Rysø, M. Hegelund, A. Jensen, R. Krogh-Madsen, D. Faurholt-Jepsen, P. Kristensen, B. Lindegaard, Denmark

316 Body mass index history and mortality among persons with recently diagnosed type 2 diabetes

S.F. Kristoffersen, J. Tarp, S.L. Domazet, D. Christensen, J.V. Stidsen, J. Rungby, C. Brøns, K. Højlund, N. Jessen, P. Vestergaard, T. Hansen, M.H. Olsen, A. Vaag, J.S. Nielsen, R.W. Thomsen, Denmark, Sweden

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 02 Lifestyle matters

Chair: P.L.D. Ruiz, Norway

317 Cardiorespiratory fitness, obesity, diabetes and longevity: a two-sample Mendelian randomisation study

A.D. Kjaergaard, C. Ellervik, N. Jessen, S.J. Lessard, Denmark, USA

318 The effect of preprandial versus postprandial physical activity on glycaemia: systematic review and meta-analysis of human intervention studies

R. Slebe, E. Wenker, L.J. Schoonmade, E.J. Bouman, D.P. Blondin, D.J. Campbell, A.C. Carpentier, J. Hoeks, P. Raina, P. Schrauwen, M.J. Serlie, D. Stenvers, R. De Mutsert, J.W. Beulens, F. Rutters, Netherlands, Canada

319 Occupational physical activity and sedentary behaviour, and 10-year incidence of type 2 diabetes: a population-based cohort study

M. Brännholm Syrjälä, M. Fortuin-De Smidt, F. Bergman, M. Nordendahl, J. Otten, R. Renklint, O. Rolandsson, P. Wennberg, Sweden

320 Does better cardiorespiratory fitness increase the chance of a partial clinical remission among adults with type 1 diabetes?

J. Flotyńska, D. Naskręt, P. Niedźwiecki, A. Grzelka-Woźniak, A. Kaczmarek, A. Pypeć, A. Cieluch, D. Zozulińska-Ziólkiewicz, A. Uruska, Poland

321 Updated cardiovascular health metrics adding sleep health and incident diabetes and cardiovascular events in older adults with prediabetes

S. Han, K. Ha, D. Kim, J. Jeon, K.-W. Lee, Republic of Korea

322 Metabolic profiling of smoking, associations with type 2 diabetes and interaction with genetic susceptibility

Y. Wei, S. Carlsson, Sweden

323 Lifestyle profiles are linked to gut microbiota for different cardiometabolic profiles in the MetaCardis study

S. Adriouch, E. Belda, E. Prifti, J.-D. Zucker, K. Clément, France

324 Is the association between social jetlag and BMI mediated by lifestyle? A cross-sectional survey study in the general population

E.J. Bouman, J.D. Mackenbach, L. Raimondo, J.W. Beulens, P.J. Elders, F. Rutters, Netherlands

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 03 From single nutrients to dietary patterns

Chair: TBA

325 Circulating short-chain fatty acids and Mediterranean food patterns: a potential role for the prediction of type 2 diabetes risk

G. Llauro, J. Badia, G. Rojo-Martínez, O. Yanes, X. Correig, D. Mauricio, S. Fernández-Veledo, J. Vendrell, Spain

326 Effects of a high-protein-high-UFA intervention in glucose metabolism and type 2 diabetes in adults aged 50-80y: the NutriAct multicentre randomised trial

L. Pletsch-Borba, C. Wernicke, N. M. T. Meyer, T.-H. Nguyen, A. Pohrt, A. F. H. Pfeiffer, J. Spranger, K. Mai, Germany

327 The mediating role of BMI and waist circumference on the prospective association between urinary sucrose and incidence of diabetes in a sub-cohort of the EPIC-Norfolk

A. Lang, O. Kuss, T. Filla, G. Kuhnle, S. Schlesinger, Germany, UK

328 Do measures of overall and regional obesity modify dietary diversity effects on type 2 diabetes? Findings from the EPIC-InterAct case-cohort study

H. Mozaffari, F. Imamura, R. Murphy, M. Mahsa Jessri, N. Wareham, A. Conklin, Canada, UK

329 Tea consumption is associated with increased urinary glucose excretion, improved insulin resistance and reduced risk of dysglycaemia, in Chinese community-dwelling adults

T. Li, M. Sang, J. Wang, Z. Sun, C. Xie, C. Rayner, M. Horowitz, S. Qiu, T. Wu, Australia, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

330 Dietary patterns and cancer outcomes in individuals with type 2 diabetes: a systematic review and meta-analysis of prospective studies

J. Barbaresco, A. Lang, T. Schieman, E. Szczerba, L. Schwingshackl, M. Neuenschwander, S. Schlesinger, Germany

331 Substitution of animal-based with plant-based foods and risk of type 2 diabetes: a systematic review and meta-analysis

S. Schlesinger, M. Neuenschwander, J. Stadelmaier, J. Eble, K. Grummich, E. Szczerba, E. Kiesswetter, L. Schwingshackl, Germany

332 Intakes or circulating levels of beta-carotene, vitamin C, and vitamin E and risk of type 2 diabetes: a systematic review and meta-analysis

A.-M. Lampousi, T. Lundberg, J.E. Löfvenborg, S. Carlsson, Sweden

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 04 Viruses and infections

Chair: M. Knip, Finland

333 SARS-CoV-2 infection in people with type 1 diabetes and hospital admission: an analysis of risk factors for England

R. Williams, J.J. Warner-Levy, B. Ollier, J.M. Gibson, A.H. Heald, UK

334 Rates of SARS-CoV-2 infection or severe COVID-19 in persons with diabetes after initial and booster COVID-19 vaccination in the Netherlands

J.M. Van den Berg, M.T. Blom, K.M. Swart, J.A. Overbeek, S. Remmelzwaal, R.M. Herings, P.J. Elders, Netherlands

335 Pioglitazone for patients with type 2 diabetes admitted with COVID-19 infection

K. Baagar, T. Alessa, A. Jayyousi, J. Ceruto, A. Alattar, M. Hamad, H. Almatrouk, S. Abdulrahman, H. Alhumaidi, A. Alandaleeb, A. Esmaeel, M. Abu-Farha, F. Al-Mulla, M. Abdul-Ghani, Pioglitazone and COVID-19 Study Group, Qatar, Kuwait, USA

336 Nonstructural protein 1 from SARS-CoV2 inhibits insulin granule biosynthesis and beta cell function

K.-P. Knoch, A. Sönmez, K. Ganss, C. Wegbrod, F. Fakir, M. Solimena, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

337 Pancreatic dysregulation of innate antiviral immune pathways in type 1 diabetes

M. Høj Jensen, K. Pedersen, S. Kaur, A. Jensen-Dahm, F. Pociot, M. Haupt-Jorgensen, Denmark

338 Infectious disease and the risk of latent autoimmune diabetes in adults and type 2 diabetes

J. Edstorp, M. Rossides, E. Ahlqvist, L. Alfredsson, B. Rasouli, T. Tuomi, S. Carlsson, Sweden, Finland

339 Increased gingival crevicular fluid extracellular vesicles are involved in the crosstalk between periodontitis and gestational diabetes

M.L. Mizgier, O. Realini, M.J. Bendek, S. Monje, A. Figari, V. Ramirez, M. Hernandez, A. Chaparro, Chile

Short Oral Discussion Event E Thursday, 12:45 - 13:45

SO 05 Autoimmunity in diabetes

Chair: T. Rodriguez-Calvo, Germany

340 Type 1 diabetes exchange online registry: characteristics of diabetes management among over 14,500 individuals with type 1 diabetes

K.M. Miller, H. Nguyen, M.E. Peter, C.S. Kelly, D. Finan, W.A. Wolf, USA

341 Screening for paediatric type 1 diabetes: a qualitative exploration of parent and stakeholder views [ELSA 1 Study]

M.J. Randell, T. Horgan, R. Dias, R. Rashid, J. Garstang, D. Shukla, P. Narendran, S.M. Greenfield, A. Richter, F. Boardman, I. Litchfield, L.M. Quinn, UK

342 Association of GADA-positivity with beta cell function in individuals without diabetes in Botnia Prospective and PPP-Botnia studies

L. Hakaste, M. Lehtovirta, O.P. Dwivedi, K. Lahti, T. Tuomi, Finland

343 Implementation of genetic risk score for type 1 diabetes in children with newly diagnosed diabetes

M. Skopkova, Z. Dobiasova, M. Karhanek, F. Gregus, D. Lobotkova, E. Jancova, L. Barak, J. Stanik, D. Gasperikova, Slovakia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

344 Islet autoimmunity and progression to type 1 diabetes in children with and without an affected first-degree relative in the Finnish DIPP study

S. Kuusela, J. Koskenniemi, T. Valtanen, T. Pokka, T. Härkönen, J. Ilonen, J. Lempainen, A. Kyrönniemi, J. Toppari, M. Knip, P. Keskinen, R. Veijola, Finland

345 Heterogeneity of human islet-derived extracellular vesicles and their roles in the cross-talk between beta cells and immune cells during type 1 diabetes pathogenesis

X. Wang, T. Zhao, W. Deng, Z. Luo, R. Lindsay, Z. Jin, K. Singh, G. Christoffersson, D. Espes, P.-O. Carlsson, Sweden, USA

346 Study of genetic association of HLA-B alleles (HLA-B*39:06, HLA-B*39:01, HLA-B*38:01) differentially associated with type 1 diabetes

A.W. Amarajeewa, A. Ozcan, A. Mukhtiar, W. Qianyu, R. Xu, P. Ozbek, M.A. Garstka, O. Sercinoglu, China, Turkey

347 Descriptive analysis of solid organ transplants among individuals with type 1 diabetes in the United States

M. Wijkstrom, K. Hagan, L. Titievsky, K. Chandarana, B. Bruinsma, C. Vick, A. Joyce, J. Snyder, USA

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 06 Diagnosis and prediction

Chair: W. Rathmann, Germany

348 Differences in glucose concentrations from whole blood and sodium-fluoride citrate plasma impact on assessment of diabetes prevalence

G. Heilmann, S. Trenkamp, I. Yurchenko, K. Strassburger, M.M. Rodríguez, C. Möser, M. Bombrich, M. Schön, O.P. Zaharia, V. Burkart, R. Wagner, M. Roden, Germany, Spain

349 Incidence trend of type 2 diabetes in Germany from 2012 to 2021

C.T. Lehner, M. Eberl, E. Donnachie, L.F. Tanaka, G. Schauburger, F. Schederecker, S.J. Klug, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

350 Implementation of diabetes screening recommendations in adults over 40 years of age in the Czech Republic during 2014 and 2019: a cross-sectional study

J. Urbanová, M. Lustigová, A. Frúhaufová, P. Krollová, P. Kankanala, K. Jahrami, J. Brož, Czech Republic

351 Differences in screening-detected type 2 diabetes: evidence from two campaign setups in Denmark

T. Thybo, N. Cayuelas i Mateu, Denmark

352 Diagnosing diabetes and assessing its prevalence in individuals attending A&E in an acute hospital in England

E. Jude, S. Anderson, A. Heald, UK, Barbados

353 Predicting 5-year risk of type 2 diabetes in New Zealand primary care patients using primary care and national routinely collected data: PREDICT cohort study

R. Pylypchuk, V. Selak, S. Wells, K. Poppe, R. Jackson, New Zealand

354 Validation of existing non-invasive diabetes risk models to predict incident diabetes risk in a Swedish cohort: Västerbotten Intervention Programme

M.C. Fortuin-de Smidt, O. Rolandsson, S.J. Griffin, P. Wennberg, Sweden, UK

355 Risk factors for new onset diabetes after transplant (NODAT) and one year outcome in NODAT and diabetic kidney disease patients undergoing renal transplant

D. Sanyal, P. Das, India

Short Oral Discussion Event A,

Tuesday, 12:30 - 13:30

SO 07 Mechanistic insights

Chair: M. Rovira, Spain

356 Role of ACSL1 in pancreatic beta cell function and the pathogenesis of type 2 diabetes

S. Gheibi, S. Hladkou, M. Fex, A.L. Madsen, S. Bonàs-Guarch, J. Ferrer, T. Hansen, H. Mulder, Sweden, Denmark, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

357 Small-RNA seq profiling reveals a signature of beta cell enriched isomiRs and its possible involvement in the progression from normal glucose tolerance to type 2 diabetes

S. Auddino, E. Aiello, G.E. Grieco, G. Di Giuseppe, G. Ciccarelli, M. Brunetti, R. Bizzotto, A. Mari, A. Giaccari, F. Dotta, T. Mezza, G. Sebastiani, Italy

358 Severe endogenous insulin deficiency is rare in long standing type 2 diabetes and usually reflects misclassified autoimmune aetiology diabetes

S. Chakka, N.J. Thomas, D. Fraser, A. Hattersley, K. Patel, A.G. Jones, UK

359 XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across diverse ancestries

M.K. Siddiqui, T. Dupuis, A. Mohan, S. Srinivasan, S. Hodgson, A. Sartori, R. Mathur, S. Finer, A.Y. Dawed, J. Cantley, R. Venkatesan, G. Pradeepa, C.N. Palmer, V. Mohan, A. Brown, UK, India, Switzerland

360 MiRNAs as in-situ and circulating biomarkers of beta cell glucose sensitivity and functional impairment in the progression of type 2 diabetes

E. Aiello, S. Auddino, D. Fignani, G. Di Giuseppe, E. Di Piazza, L. Soldovieri, R. Bizzotto, A. Mari, A. Giaccari, F. Dotta, G. Sebastiani, T. Mezza, Italy

361 An AAV8-Ins1Cre mediated reduction of insulin gene dosage in young adult NOD mice

N.S. Nahirney, P. Overby, K. Chan, Y.-C. Chen, B. Verchere, J.D. Johnson, Canada

362 Knock-out of the neutral amino acid transporter gene Slc6a19 prevents diet-induced diabetes in male NOD^k mice

M. Shamoon, J.E. Dahlstrom, C.J. Nolan, Australia

363 SGLT1 functional polymorphisms are associated with 1h OGTT glucose levels

G.C. Mannino, A. Palummo, C. Averta, M. Melina, E. Mancuso, A. Sciacqua, V. Fiorentino, E. Succurro, F. Andreozzi, G. Sesti, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 08 Coming from the heart*Chair:* M. Rizzo, Italy**364 Presenting symptoms and comorbidities in type 2 diabetes patients at their first visit in a tertiary care centre in Eastern Nepal**

U. Mainali, D. Sigdel, R. Sharma, K. Koirala, Nepal

365 Increased interleukin-6 is associated with higher risk of heart failure in people with type 2 diabetes: the hoorn diabetes care system cohort

S. Remmelzwaal, S.M. Yeung, M.T. Blom, M.H. De Borst, P.J. Elders, J.W. Beulens, Netherlands

366 Natriuretic peptide-based screening for heart failure among adults with diabetes: a multicentre US experience

S. Chatur, T. Meng, A. John, G. Bobba, M. Vaduganathan, USA, Switzerland

367 Composite macrovascular risk and its association with HbA_{1c} in individuals with and without cardiovascular disease: a large UK observational cohort study

T.S. Crabtree, R. Aldafas, Y. Vinogradova, J. Gordon, I. Idris, UK

368 Age-dependent association of NT-proBNP with obesity, insulin resistance, and inflammation in type 2 diabetes: a cross-sectional study in the DD2 cohort

T. Olesen, J.V. Stidsen, S.L. Domazet, J.S. Nielsen, K. Højlund, A.L. Hansen, F.P. KKristensen, P. Vestergaard, M.H. Olsen, Denmark

369 Type 2 diabetes, glycaemic indexes, and cerebral small vessel disease: genetic overlap, causal relationship and drug targets

K.-J. Lee, J. Lee, S. Lee, H.-J. Bae, J. Sung, Republic of Korea

370 Investigating long-term complications of gestational diabetes using real-world data

G. Goldet, F. Tam, A. Frankel, Z. Ul-Haq, R. Dattani, T. Kamalati, UK

371 Prediction of mortality and validation of the ATC-code based Rx-risk comorbidity index in the “Outcomes & Multi-Morbidity In Type 2 diabetes” (OMIT) cohort

E.S. Buhl, J. Igland, R. Forster, A. Jenum, R.B. Strandberg, T.J. Berg, J. Røssberg, M.M. Iversen, Norway

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 09 Novel risk factors and treatments*Chair:* TBA**372 Incidence of type 2 diabetes with verapamil treatment compared with other calcium channel blockers**

J.W. Sacre, J.M. Wentworth, D.J. Magliano, J.E. Shaw, Australia

EASD
EFSD**373 Two population-based studies showed that several environmental contaminants were related to diabetes**

M. Lind, L. Dunder, L. Lind, S. Salihovic, Sweden

GENERAL
INFO**374 Association of serum and urinary ionome with dysglycaemia and diabetic complications**

Z. Sun, M. Sang, P. Wang, S. Qiu, T. Wu, D. Wang, F. Wang, Y. Gu, China, Australia, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS**375 Estradiol and estrone levels are associated with prevalent diabetes in postmenopausal women: a cross sectional study in a Swedish cohort**

K. Ottarsdottir, M. Hellgren, U. Lindblad, C. Ohlsson, B. Daka, Sweden

376 Associations of transportation noise and nighttime temperature with the metabolome of the Dutch adult population: a cross-sectional study

M. Mulwijk, S. Remmelzwaal, F. Rutters, A. Huss, Q. Tardif, S. Picavet, C. Stehouwer, C. Van der Kallen, A. Koster, M. Van Greevenbroek, I. De Jonge, R. De Mutsert, B. Penninx, J. Lakerveld, J. Beulens, Netherlands

PRESENTER
INDEXSATELLITE
SYMPOSIA**377 Perceived stress and insulin resistance in a population study in Southwestern Sweden**

G. Szalo, M. Eriksson, M. Hellgren, U. Lindblad, B. Daka, Sweden

378 Metabolic modelling reveals a switch in the metabolic exchange of the gut microbiome of patients with diabetes

S. Alban, C. Kaleta, Perfood GmbH, Germany

INDUSTRY

PROGRAMME

379 Human fecal microbiome transplantation does not alter diabetes incidence in NOD mice

R. Minab, E. Rampanelli, N.M. Hanssen, C.M. Fuhri Snethlage, D.H. Van Raalte, B.O. Roep, M. Nieuwdorp, B.A. Vallance, C.B. Verchere, Canada, Netherlands

EXHIBITION

SO 10 Body and brain*Chair:* D. Witte, Denmark**380 Inequity in type 2 diabetes management in New Zealand: clinical targets and prescribing**

L. Chepulis, M. Rodrigues, J. Scott Jones, R. Keenan, A. Moffitt,
R. Lawrenson, T. Kenealy, R. Murphy, L. Te Karu, P. Clark, R. Paul,
New Zealand

EASD
EFSD

381 Impact of diabetes on physical functioning and musculoskeletal pain in persons who are close to retirement age

S. Molsted, J. Hansen, C.J. Nilsson, O. Ekholm, H. Hansen, Denmark

GENERAL
INFO

382 Fracture patterns in type 1 diabetes and their associated risk factors: a retrospective cohort study

N.H. Rasmussen, J. H.M. Driessen, A. Vestergaard Kvist, M. Brodersen,
L. Rosengren Kaldahl, I. Leegaard, P. C. Souverein, J. Van den Bergh,
P. Vestergaard, Denmark, Netherlands

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

383 Nephropathy in south Asians with diabetes compared to Europeans: higher risk and faster progression. Results from The HinDu The Hague Diabetes Study

P.H. Duijvestijn, J. Van Niel, N.A. Traa, J.M. Kist, M.E. Numans, R.C. Vos,
Netherlands

SHORT ORAL
DISCUSSIONS

384 Trajectories of cognitive decline in Chinese middle-aged and older adults with diabetes: a nationally representative longitudinal study

S. Chen, China

PRESENTER
INDEX

385 Psychometric properties and implementation of seven PROMIS computerised adaptive tests in people with type 2 diabetes

F. Rutters, L. Groeneveld, P. Elders, M. Blom, J. Beulens, C. Terwee,
Netherlands

SATELLITE
SYMPOSIA

386 The association of dietary total, animal, and plant-based protein intake with depressive symptoms in Dutch adults with type 2 diabetes: the Hoorn Diabetes Care System cohort

S.H. Kremers, M.M. Migchelbrink, N.R. Den Braver, L. Groeneveld,
P.J. Elders, M.T. Blom, J.W. Beulens, F. Rutters, Netherlands

INDUSTRY

PROGRAMME

EXHIBITION

387 Autonomic Nervous System (ANS) controls glucose regulation in type 2 diabetes by homeostasis: a randomised controlled trial using pain sensitivity as a measure of ANS

J. Faber, S. Ballegaard, N. Oersted, E. Eldrup, B. Karpatschhof, F. Gyntelberg, S.K. Hecquet, B. Bibby, A. Gjedde, Denmark

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 11 Obesity and prediabetes

Chair: A. Hulman, Denmark

388 Trends in drugs for diabetes and obesity 2004-2021 in Norway

P.L. Ruiz, K. Nøkleby, Ø. Karlstad, H.L. Gulseth, K. Sveen, E. Qvigstad, K. Furu, Norway

389 The effect of breastfeeding on weight and the risk of prediabetes and type 2 diabetes one year after birth in women with gestational diabetes

U. Kampmann, S. Prange, L.L. Knudsen, C. Wolff, L.R. Madsen, L.S. Mortensen, H.H. Thomsen, L. Sørensen, J. Fuglsang, P.G. Ovesen, S.K. Johnsen, Denmark

390 Effect of early versus late time-restricted eating on inter-day glycaemic variability, measured by continuous glucose monitoring, in adults at risk for type 2 diabetes

A.H. Heald, J.J. Warner-Levy, K.A. Davies, UK

391 Effects of TM6SF2 rs58542926 polymorphism on liver triglycerides and insulin resistance in early type 2 diabetes

K. Bódis, M. Bombrich, M. Schön, B. Knebel, O.-P. Zaharia, G. Bönhof, Y. Kupriyanova, J. Kotzka, R. Guthoff, V. Schrauwen-Hinderling, H. Al-Hasani, J. Szendroedi, R. Wagner, D. Markgraf, M. Roden, Germany

392 Saliva dyslipidaemia in young type 1 diabetes patients

M. Haupt-Jorgensen, K. Pedersen, N. Tom, M. Bilgin, A.M. Pedersen, Denmark

393 Engineering of functionally active human myotubes and myobundles in vitro

S.I. Dreher, P. Grubba, C. Von Toerne, A. Moruzzi, J. Maurer, T. Goj, A.L. Birkenfeld, A. Peter, S. Hauck, P. Loskill, C. Weigert, Germany

SO 12 Epigenetics*Chair:* S. Misra, UK**394 Histone epigenetic signature and gestational diabetes: role of the acetyltransferase p300 in the transmission of the maternal phenotype to the offspring**

N. Di Pietrantonio, J. Sánchez-Ceinos, L. Pelusi, P. Di Tomo, D. Mandatori, G. Formoso, T. Bonfini, I. Cappellacci, M.P. Baldassarre, C. Pipino, F. Cosentino, A. Pandolfi, Italy, Sweden

395 Differences in DNA methylation in genes involved in vitamin D metabolism are related with insulin requirement in pregnant women with gestational diabetes

N. Peña-Montero, T. Linares-Pineda, F. Lima-Rubio, A. Fernández Valero, A. Fernández Ramos, C. Gutiérrez Repiso, M. Suárez Arana, M. Picón César, M. Molina Vega, S. Morcillo Espina, Spain

396 Placental microRNAs in pregestational diabetes: effects on offspring and functional study

C. Valverde Tercedor, A. Ibarra, N. Perdomo Ugarte, V. Dávila Batista, Y. Novoa Medina, Y. García Delgado, L. Hernandez-Baraza, R. Jiménez Monzón, M. Barreiro Bautista, A. González LLeó, Y. Brito Casillas, B. Vega Guedes, A. Wägner, Spain

397 Epigenome wide association study identifies CpGs associated with the growth pattern in offspring from mothers with gestational diabetes

S. Morcillo Espina, T. Linares-Pineda, N. Peña-Montero, F. Lima-Rubio, A. Fernández-Valero, A. Fernández-Ramos, M. Suárez-Arana, F. Tinahones, M. Picón, M. Molina-Vega, Spain

398 Obesity associated epigenetic reprogramming of leptin enhancer elements in large adipocytes

N. Taege, S.C. Schriever, C. Geißler, H. Kirchner, Germany

399 Is epigenetic editing a way to a more personalised treatment approach in type 2 diabetes?

S. Ruhrmann, T. Rönn, A. Perfilyev, J. Jönsson, J. Ofori, L. Scisciola, S. Barthel, K. Rocksches, K. Bacos, M. Rots, C. Ling, Sweden, Italy, Netherlands

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

400 Establishment of beta cell heterogeneity via differential CpG methylation at Nnat

S.J. Millership, V. Yu, F. Yong, A. Marta, K. Chen, E. Georgiadou, S. Bhattacharya, N. Parveen, S. Khadayate, Z. Stamoulis, Y. Ali, S. Dhawan, D.J. Withers, G.A. Rutter, UK, Singapore, USA, Canada

401 Large scale blood mitochondrial genome wide associations study provides novel insights into diabetes and mitochondrial disease related traits

S. Cannon, T. Hall, G. Hawkes, K. Colclough, R. Boggan, C.F. Wright, S. Pickett, A.T. Hattersley, M.N. Weedon, K.A. Patel, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 13 Monogenic diabetes

Chair: T. Tuomi, Finland

402 Mapping the impact of high fat diet challenge in a HNF1A-MODY mouse model

S. Sharmine, T.A. Legøy, A.F. Mathisen, L. Ghila, S. Chera, Norway

403 The Welander distal myopathy TIA1 mutation promotes a proinsulin to insulin processing defect in human insulin producing EndoC-betaH1 cells

T. Zhao, X. Wang, J. Cen, A. Ngamjariyawat, Å. Sjöholm, N. Welsh, Sweden

404 Deep mutational scanning of the insulin receptor ectodomain to facilitate genetic diagnosis and translational studies of insulin receptoropathy

V. Aslanzadeh, G. Brierley, G. Kudla, R.K. Semple, UK

405 In vitro differentiation of ZNF808 knockout human embryonic stem cells reveals impaired pancreatic lineage specification

S. Muralidharan, H. Montaser, J.S. Vire, H. Ibrahim, S. Eurola, E. De Franco, N.D. Owens, M. Imbeault, A. Hattersley, D. Balboa, T. Otonkoski, Finland, UK, Spain

406 Disease modelling MODY5 in zebrafish to investigate mechanisms for pancreas development

E. Mchaina, E. Denker, R. Hoff, O.V. Fløtre, L.B. Gundersen, S. Ellingsen, Norway

407 Identification of PAM as a novel monogenic diabetes gene

J. Feiner, N. Perrot, M. Chong, R. Lali, R. Morton, P. Mohammadi-Shemirani, S. Yusuf, Z. Punthakee, H. Gerstein, G. Pare, M. Pigeyre, Canada

408 Rare missense and protein truncating variants in NEUROD1 and PDX1, but not APPL1, cause MODY with reduced penetrance

K. Colclough, L. Sharpe, T. Laver, A. Hattersley, M. Weedon, K. Patel, UK

409 Developing a MODY calculator for use at time of diagnosis in the paediatric population

B. Shields, A. Carlsson, K. Patel, K. Colclough, H. Elding Larsson, G. Forsander, U. Samuelsson, A. Hattersley, J. Ludvigsson, UK, Sweden

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 14 Heterogeneity of diabetes

Chair: R. Wagner, Germany

410 Characterising diabetes in Kazakhstan: a cluster analysis

B. Taurbekova, R. Sarsenov, S. Fazli, K. Atageldiyeva, S. Zhumambayeva, A. Sarria-Santamera, Kazakhstan

411 Diabetes classification models have high performance when prospectively validated in adults with new onset diabetes

J. Knupp, A. Hill, T.J. McDonald, N. Thomas, R. Oram, A.T. Hattersley, T. McKinley, B.M. Shields, A.G. Jones, StartRight Consortium, UK

412 Heterogeneity of temporal trajectories for the main functional parameters of glucose metabolism in non-diabetic individuals: an IMI DIRECT study

R. Bizzotto, E.R. Pearson, A. Mari, for the IMI DIRECT Consortium, Italy, UK

413 Longitudinal HbA_{1c} patterns before first treatment of diabetes in routine clinical care: a latent class trajectory analysis

S.K. Nicolaisen, S. Le Cessie, R.W. Thomsen, D.R. Witte, O.M. Dekkers, H.T. Sørensen, L. Pedersen, Denmark, Netherlands

414 Cardio-metabolic risk stratification by meal response profiles: paving the way towards to personalised nutrition

K. Deng, D.A. Hughes, R.D. Mutsert, A.V. Vlieg, F.R. Rosendaal, D.O. Mook-Kanamori, K.W. Dijk, N.J. Timpson, R. Li-Gao, Netherlands, UK

415 Subphenotype-dependent benefits from bariatric surgery of individuals at risk for type 2 diabetes

L. Sandforth, E. Lembo, O. Verrastro, A. Sandforth, K. Zhou, R. Archid, R. Wagner, L. Fritsche, A. Fritsche, R. Jumpertz-von Schwartzberg, G. Mingrone, A. Birkenfeld, Germany, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

416 Algorithms to define diabetes type using data from electronic health records and administrative databases: a systematic review of the evidence

S. Sajjadi, J.W. Sacre, L. Chen, S. Wild, J.E. Shaw, D.J. Magliano, Australia, UK

417 C peptide testing and reclassification of type of diabetes in adults: the outcome of a pilot study

A. Tabasum, C. Evans, C. Dayan, UK

EASD
EFSD

GENERAL
INFO

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 15 Transcriptional regulation in islet cells

Chair: F. Cinti, Italy

PROGRAMME

TUESDAY

418 A small molecule screen for regulators of Ins2 gene activity dynamics

J. Chu, X. Hu, W. Sun, J. Johnson, Canada

WEDNESDAY

THURSDAY

419 Novel interaction between Nkx6.1 and Pdx1 is needed for proper beta cell function

J.S. Tessem, C.C. Littlefield, J.T. Hill, J.C. Price, USA

FRIDAY

SHORT ORAL
DISCUSSIONS

420 Islet maturation and ageing is governed by the Hnf1a transcription factor

A.F. Mathisen, T.A. Legoy, U. Larsen, L. Ghila, S. Chera, Norway

PRESENTER
INDEX

421 Effect of mitochondrial fission in glucagon secretion after long term free fatty acids treatment

Q. Wen, N. Afrin, A. Fatallah, A.I. Chowdhury, P. Bergsten, Sweden

SATELLITE
SYMPOSIA

422 Cholinergic modulation of pancreatic hormone secretion is dependent on vagus nerve anatomical integrity

C.B. Lobato, J.J. Holst, Denmark

INDUSTRY

PROGRAMME

423 Decoding pancreatic endocrine cell differentiation and beta cell regeneration in Zebrafish

O. Andersson, J. Mi, K.-C. Liu, Sweden

EXHIBITION

424 Mechanism of beta cell failure in diabetes and the associated single-cell gene expression change

N. Sinha, V.A. Salunkhe, S. Hua, A.H. Rosengren, Sweden

SO 16 Different approaches to study hormone secretion regulation

Chair: B. Merino Antolin, Spain

425 Islets-on-microfluidic chips to monitor their electrical activity and hormone secretion

M. Lallouet, M. Monchablon, E. Puginier, T. Sawatani, S. Renaud, M. Cnop, M. Raoux, J. Lang, France, Belgium

EASD
EFSD

426 Microfluidic muscle-islet-on-chip for functional investigations in diabetology

D. Chapeau, M. Monchablon, E. Papasavva, F. Bouvet, A. Milochau, A. Pirog, P. Scotti, J. Lang, S. Renaud, A. Bouter, M. Raoux, France

GENERAL
INFO

427 IDE deficiency leads to the preferential accumulation of older insulin secretory granules

L.-M. Kretschmar, K.-P. Knoch, O. Topcheva, M. Neukam, A. Sönmez, K. Ganß, C. Münster, A. Müller, P. Van Endert, M. Solimena, Germany, USA, France

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

428 Impact of pancreatic PCSK9 on intracellular organelles distribution and dynamics in beta cells: implication in insulin processing and secretion

C. Perego, A. Galli, N. Dule, L. Da Dalt, G. Finzi, S. La Rosa, G.D. Norata, Italy

SHORT ORAL
DISCUSSIONS

429 Effects of a bitter tasting substance, denatonium benzoate, on pancreatic hormone secretion

C.K. Rayner, W. Huang, S.E. O'Hara, C. Xie, L.M. Nicholas, T. Wu, Australia

PRESENTER
INDEX

430 Pleiotrophin: a new player in the morphology and functioning of the pancreas

C. Ballesteros-Pla, J. Sevillano, M. Sánchez-Alonso, M. Limones, J. Pita, J. Pizarro Delgado, A. Izquierdo, G. Medina Gómez, I. Valladolid-Acebes, G. Herradón, M. Ramos Álvarez, Spain

SATELLITE
SYMPOSIA

431 A novel actin filament remodelling protein regulating beta cell function

L. Martin Diaz, M. Patrikainen, R. Parveen, V. Chandra, J. Saarimäki, J. Laiho, H. Hyöty, T. Otonkoski, K. Viiri, Finland

INDUSTRY

PROGRAMME

EXHIBITION

SO 17 Modulators of beta cell signal transduction: How do they work?

Chair: M. Fex, Sweden

432 Identification and validation of eIF2A binding partners and effectors involved in beta cell resilience

J.A. Zhang, A. Rahardjo, E. Panzhinskiy, E. Jan, J.D. Johnson, Canada

433 Glycine and β -alanine promote pancreatic islet cell proliferation via activation of PI3K/mTORC1/p70S6K pathway

Z. Zhang, A.L. Piro, D.-S. Wang, A. Untereiner, A. Bhattacharjee, I. Singh, B.A. Orser, F.F. Dai, M.B. Wheeler, China, Canada

434 Glucose distinctly affects cytosolic and mitochondrial NADH and NADPH in rodent beta cells: implications for the stimulation of insulin secretion

Y. Hajj Hassan, C. Vandrisse, M. Tariq, J.-C. Jonas, Belgium

435 Apolipoprotein A-I (ApoA-I) primes beta cells to increase insulin secretion via scarb1 and abca1 receptor pathways upregulating mitochondrial metabolism

E. Cowan, C.L. Lyons, L. Eliasson, J.O. Lagerstedt, Sweden, Denmark

436 DPP-IV inhibition improves pancreatic beta cell function by reducing Fetuin-A expression and intracellular lipid accumulation

S. Nag, S. Mandal, R. Kundu, India

437 Ca^{2+} inhibits GLP-1-induced cAMP formation in beta cells

Y. Hellman, H. Shuai, A. Tengholm, Sweden

438 The myokine irisin is endocytosed and signals through an αV integrin-independent mechanism in pancreatic beta cells

N. Marrano, A. Borrelli, G. Biondi, M. Rella, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, A. Natalicchio, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 18 Role of immune cells in type 1 diabetes and type 2 diabetes

Chair: TBA

439 Cd226⁺Nk cell subsets are associated with progression and remission of type 1 diabetes

K. Lei, X. Li, T. Zhong, X. Li, R. Tang, China

440 Elevated IL-8 and myeloperoxidase levels in recent onset type 1 diabetes

G. Alhamar, S. Fallucca, S. Pieralice, L. Valente, S. Briganti, S. Manfrini, P. Pozzilli, Italy

441 Identification of important shared and diverse immune phenotypes in type 1 diabetes, multiple sclerosis and systemic lupus erythematosus using automated cluster analysis by machine learning

B. Prietl, L. Herbsthofer, J. Vera-Ramos, V. Pfeifer, M. Khalil, M. Stradner, H. Sourij, T.R. Pieber, Austria

442 Expression of autoimmune regulator in peripheral B lymphocytes correlates with remnant islet beta cell function in type 1 diabetes

Y. Liu, Y. Guo, W. Li, M. Xie, C. Fang, X. Wang, China

443 Clinical features associated with glutamic acid decarboxylase autoantibodies (GADA) in adults with type 2 diabetes

N.M. Maruthur, W.C. Knowler, A. Balasubramanyam, C.S. Hampe, S. Pietropaolo, A. Anderson, M. Li, N. Zhao, S.L. Zeger, A. Ramelius, R. Bennet, Å. Lernmark, N.N. Mathioudakis, J.M. Clark, S.J. Pilla, USA, Sweden

444 Glutamic acid decarboxylase autoantibodies (GADA) in type 2 diabetes predict long-term glycaemic control but not complications

S.J. Pilla, W.C. Knowler, A. Balasubramanyam, C.S. Hampe, S. Pietropaolo, A. Anderson, M. Li, N. Zhao, S.L. Zeger, A. Ramelius, R. Bennet, Å. Lernmark, N.N. Mathioudakis, J.M. Clark, N.M. Maruthur, USA, Sweden

445 Biological characterisation of circulating cell-free DNA in diabetes and prediabetes

E. Alexiou Chatzaki, M. Karaglani, M. Panagopoulou, K. Tzitzikou, C. Chemonidou, P. Apalaki, K. Arvanitidis, N. Kessari, S. Gerou, D. Papazoglou, N. Papanas, Greece

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 19 Transplantation of islet and stem cells today and tomorrow

Chair: R. Strollo, Italy

446 Simultaneous evaluation of islet graft and pancreas beta cell mass following intraportal transplantation from the perspective of ¹¹¹In-exendin-4 SPECT/CT

A. Botagarova, T. Murakami, H. Fujimoto, M. Fauzi, S. Kiyobayashi, D. Otani, N. Fujimoto, N. Inagaki, Japan

447 Interleukin (IL)-1 α and IL-1 β released from islet resident macrophages impair the success of islet transplantation

S. Wrublewsky, F. Pohlemann, L. Prates Roma, S. Rother, M. Menger, M. Laschke, E. Ampofo, Germany

448 Stem-cell derived islets for treating diabetes

W. Rust, P. Dalal, A. Koval, J. Ratiu, S. Southard, P. Strumph, C. Welsch, USA

449 Glucose-dependent insulin production and insulin-independence in patients with type 1 diabetes infused with stem cell-derived, fully differentiated islet cells (VX-880)

T. Reichman, C. Ricordi, A. Naji, J.F. Markmann, B. Perkins, B.G. Bruinsma, G. Marigowda, D. Melton, F. Pagliuca, B. Sanna, L.S. Kean, C. Mathieu, A. Peters, P. Witkowski, M.R. Rickels, Canada, USA, Belgium

450 Mesenchymal stem cell-laden composite islet porous microgel for diabetes treatment

J. Sun, L. Li, China

451 Hydrogel encapsulation can protect functionality of transplanted islets in immunocompetent diabetic animals without immunosuppression

H. Stover, Canada

452 A vascularised artificial islet microcapsule based on microfluidic electrostatic spray for diabetes treatment

J. Li, L. Li, China

453 Transgenic porcine neonatal islets expressing human PD-L1 reduce immune cell activation and cellular rejection in humanised NSG mice with type 1 diabetes

Y. Lei, L. Wolf-van Buerck, M. Honarpisheh, Y. Zhang, R. Schwinzer, B. Petersen, J. Seissler, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 20 Roads leading to apoptosis in beta cells*Chair:* L.R. Cataldo, Denmark**454 Catabolic pathways of S1P differentially regulate free fatty acid-induced oxidative stress, mitochondrial dysfunction and ceramide formation in beta cells**

Y. Tang, E. Gurgul-Convey, Germany

455 Stimulation of NMDA receptors in islet cells increases oxidative stress by multiple mechanisms and activates Ca²⁺-dependent K⁺ channels

H. Noguera Hurtado, B. Wunsch, M. Düfer, Germany

456 Palmitic acid enhances the damaging effects of increased insulin folding by accelerated ER stress and apoptosis

S. Lortz, B. Vidrio-Huerta, T. Plötz, Germany

457 Uncovering the secrets of beta cells: targeted ablation of cellular mass as a model of stress

L.-M. Daian, G. Tanko, A. Vacaru, E. Lamba, O.-M. Mardare, A.-M. Vacaru, Romania

458 Direct optical nanoscopy unveils signatures of cytokine-induced beta cell structural and functional stress

F. Cardarelli, L. Pugliese, V. De Lorenzi, M. Bernardi, S. Ghignoli, M. Tesi, P. Marchetti, L. Pesce, Italy

459 Cytokine-mediated autophagy disturbances are mediated by a dysfunctional S1P degradation in pancreatic beta cells

E. Gurgul Convey, Y. Tang, M. Gräler, A. Jörns, Germany

460 Activated pancreatic stellate cells induce pancreatic islet dysfunction in chronic pancreatitis

X. Zhu, G. Li, L. Li, China

461 Pancreatic stellate cells promote pancreatic beta cell death through exosomal microRNA transfer in hypoxia

K.-H. Song, J.-S. Yun, E. Lee, S.-D. Moon, J.-H. Han, Y.-B. Ahn, Republic of Korea

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 21 Protection of beta cells

Chair: K. Bouzakri, France

462 Increased MANF expression in pancreatic beta cells protects from streptozotocin-induced beta cell death and diabetes in mice

H. Li, T. Danilova, E. Palm, E. Pakarinen, J. Konovalova, T. Otonkoski, M. Lindahl, Finland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

463 Small-molecule inhibitors of protein-protein interaction between TYK2 and IFNAR1 as a new strategy to prevent inflammation in early type 1 diabetes

L. Marroqui, D. Guzmán-Llorens, A. Pérez-Serna, J.-A. Encinar, R.S. Dos Santos, Spain

464 Inhibition of mTOR prevents senescence induced by glucotoxicity in mouse islet cells without preserving their electrophysiological features

T.J. Guzmán, C.M. Gurrola-Díaz, M. Düfer, Germany, Mexico

465 Identification of miRNAs able to protect beta cells from glucolipotoxicity using a high throughput screening approach

S. Pinhancos, J.T. Oliveira, J. Santos, C. Alves, L. Ferreira, M. Gotthard, J. Jones, H. Fernandes, Portugal, Netherlands

466 The impact of glucose metabolism upon pancreatic beta cell autophagy is time dependent

A. Williams, M. Georgiou, P.E. Lovat, C. Arden, UK

467 Ripk1 is dispensable for beta cell survival in diabetes

Ö. Veli, X. Hildebrandt, P. Xiao, Y. Estornes, Ö. Kaya, M.J. Bertrand, A.K. Cardozo, N. Peltzer, Germany, Belgium

SO 22 Inflammation in type 1 diabetes

Chair: TBA

468 Effect of chronic pancreatitis on beta cell function and glucose metabolism

G. Ciccarelli, G. Di Giuseppe, L. Soldovieri, M. Brunetti, U. Capece, F. Cinti, S. Moffa, A. Mari, A. Giaccari, T. Mezza, Italy

INDUSTRY

PROGRAMME

EXHIBITION

469 Prohormones processing and exocrine markers in type 1 diabetes

Z.S. Mahmood, C. Dayan, S. Luzio, G. Dunseath, S. Wong, UK

470 Pilot study: non-invasive imaging of CD8+ T-cell infiltration during the development of type 1 diabetes in non-obese diabetic mice

S. Tokgöz, C. Frielink, S. Heskamp, P. Wierstra, I. Hagemans, M. Verdoes, M. Gotthardt, M. Boss, Netherlands

471 Assessing variation of beta cells heterogeneity during diabetes progression

E.-M. Lamba, G. Tanko, O.-A.-M. Mardare, L.M. Daian, A.M. Vacaru, A.-M. Vacaru, Romania

472 Endoc-βH5: a highly functional human pancreatic beta cell that can model type 1 diabetes T-cell mediated beta cell killing

H. Olleik, C. Halliez, S. Thomaidou, M. Pilette, M. Taurand, C. Cavanihac, A. Piet, A. Zaldumbide, R. Mallone, B. Blanchi, France, Netherlands

473 Endoc-βH5: a highly functional human pancreatic beta cell that can model glucolipotoxicity and inflammatory responses

B. Blanchi, M. Pilette, C. Cavanihac, M. Taurand, H. Olleik, France

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 23 Drug interventions in diabetes and associated disease

Chair: TBA

474 Fall/fracture-related healthcare resource utilisation in people with type 2 diabetes receiving insulin glargine 300 U/mL vs long-acting basal insulin/NPH: Fragile study

J. Gill, G. Umpierrez, E. Pogge, X. Li, R. Preblich, N. Pandya, USA

475 Durable improvement in HbA_{1c} in youth-onset type 2 diabetes with and without background insulin therapy: a post hoc analysis of the DINAMO trial of empagliflozin and linagliptin vs placebo

S. Willi, L.M. Laffel, T. Danne, W.V. Tamborlane, G.J. Klingensmith, D. Neubacher, I. Tartakovsky, J. Marquard, P. Zeitler, USA, Germany

476 ATGC-300, drug candidates for type 2 diabetes based on novel hybrid IgG fusion protein combined with GLP-1RA

H. Kim, H. Kim, D. Choi, J. Lee, Y. Jung, W. Lee, H. Ji, J. Lee, H. Lee, S. Jang, Republic of Korea

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

477 Plasma levels of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) decrease in response to weight loss and treatment with liraglutide and exercise

S. Byberg, S.K. Holm, R.M. Sandsdal, S.B. Jensen, C.R. Juhl, M.H. Noer, J.R. Lundgren, C. Janus, M.B. Blond, B.M. Stallknecht, B. Holst, J.J. Holst, S. Madsbad, B. Hartmann, S.S. Torekov, Denmark

478 Empagliflozin improves insulin sensitivity in patients with a recent coronary syndrome and newly detected dysglycaemia

G. Ferrannini, E. Fortin, L. Mellbin, A. Norhammar, P. Näsman, S. Smetana, E. Ferrannini, L. Ryden, Sweden, Italy

479 The effect of hypokalaemia during the treatment of diabetic ketoacidosis: a retrospective, single centre analysis

S. Darawshi, A. Miller, M. Qassum, I. Hochberg, Israel

480 The effect of preconceptional gastric bypass surgery on glucose metabolism in pregnancy

T. Linder, G. Kotzaeridi, D. Eppel, I. Rosicky, A. Tura, C. Göbl, Austria, Italy

481 Insulin pump therapy in pregnant women with type 1 diabetes: intermittently scanned glucose monitoring vs sensor augmented pump

C. Sola, K. Mariaca Riveros, C. Milad, D. Roca, A. Amor, M. Giménez, J. Bellart, I. Vinagre, Spain

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 24 Grades of insulin sensitivity

Chair: H. Stingl, Austria

482 Magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium

L.C. Drenthen, J.H. De Baaij, L. Rodwell, A.E. Van Herwaarden, C.J. Tack, B.E. De Galan, Netherlands

483 Skeletal muscle insulin sensitivity does not match whole-body insulin sensitivity in patients with pancreatic cancer

K. Koudelkova, E. Vokaty, P. Kuncicky, R. Simak, M. Krbcova, J. Hrudka, L. Rossmeislova, M. Andel, P. Tuma, J. Gojda, Czech Republic

484 Unique signature of circular RNA in skeletal muscle of different insulin sensitivity

M. Yepmo, E. Meugnier, M. Pinget, K. Bouzakri, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

485 A minimal circadian clock network for glucose tolerance in mice

K.B. Koronowski, J.G. Smith, A. Verlande, S. Chen, T. Mortimer, O. Deryagin, P. Liu, V. Orlando, P. Baldi, C. Jang, S. Masri, S.A. Benitah, P. Munoz-Canoves, P. Sassone-Corsi, USA, Spain, Saudi Arabia

486 Sex differences in the association between insulin resistance indexes and myocardial infarction in individuals with different glycaemic states

A. Riccio, L. Mellbin, A. Norhammar, P. Näsman, L. Rydén, G. Sesti, G. Ferrannini, Italy, Sweden

487 Chronic effects of an antifibrotic agent eplerenone on insulin sensitivity and cardiac function in high-fed diet induced insulin resistance mice

A.K. Banah, V. Musale, C.Z. Murdoch, L. Kang, UK

488 High 1 hour glucose in youths with obesity as marker of prediabetes and cardiovascular risk

M. Manco, D. Fintini, L. Ravà, M. Mariani, A. Deodati, E. Inzaghi, S. Pedicelli, C. Bizzarri, M. Cappa, S. Cianfarani, Italy

489 Conversion and reversion rate of metabolic syndrome in middle-aged and older adults: the China Health and Retirement Longitudinal study

W. Li, S. Ding, F. Wang, T. Qiao, Q. Li, J. Zhao, China

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 25 Exercise as medicine

Chair: B. Ukropcova, Slovakia

490 The effect of insulin-sensitising high-intensity interval training on selected exer kines and adipokines in obesity and type 2 diabetes

M.H. Petersen, K.J. Kolnes, M.E. De Almeida, E.K. Wentorf, K. Jensen, A. Handberg, N. Ørtenblad, K. Højlund, Denmark

491 Morning exercise reduces glycaemia in people with type 2 diabetes also being prescribed metformin

B.M. Gabriel, B. Pena Carrillo, O. Duval, E. Cope, S. Gurel, A. Kenny, S. Philip, F. Thies, D. Blana, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

492 The transcriptional response to acute exercise is HIF1a dependent and time-of-day specific

K. MacGregor, A. Ehrlich, L.B. Small, S.P. Ashcroft, J.T. Treebak, J.R. Zierath, Sweden, Denmark

493 Glycaemic management around postprandial exercise in people with type 1 diabetes: challenge accepted

S. Helleputte, J. Stautemas, T. De Backer, J. Marlier, B. Lapauw, P. Calders, Belgium

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

494 Moderate and high-intensity aerobic exercise exert differing metabolic benefits in candidates to undergo bariatric surgery: a randomised controlled trial

S. Martinez-Huenchullan, J. Enriquez-Schmidt, C. Mautner-Molina, M. Kalazich-Rosales, M. Muñoz, F. Fuentes-Leal, M. Monrroy-Uarac, M. San Martin-Correa, C. Carcamo-Ibaceta, P. Ehrenfeld, Chile

495 The effects of a 3-month aerobic-strength training on metabolism, cognition and adiponectin levels in blood and cerebrospinal fluid in the elderly

B. Ukropcová, M. Tomkova, M. Schon, L. Slobodova, I. Straka, P. Matejicka, M. Sedliak, C.-L. Tsai, W. Bogner, M. Krssak, P. Valkovic, J. Ukropec, Slovakia, Taiwan, Austria

496 The role of extracellular vesicles derived from continuous aerobic training and high- intensity interval training in beta cell function

Z. Wang, X. Zheng, Sweden, China

497 Impact of a 4-week intensive track and field training on glycaemia in children and adolescents with type 1 diabetes: the ChildFIT1 study

R.T. Zimmer, F. Aberer, P. Birnbaumer, J. Schierbauer, C. Sternad, M. Hamidi, B. Zunner, M. Fritsch, E. Fröhlich-Reiterer, P. Hofmann, H. Sourij, O. Moser, Germany, Austria

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 26 Hormones from the gut and the liver

Chair: P. Larraufie, France

498 Mapping the druggable targets displayed by human colonic enteroendocrine cells

Y. Lei, M. Jacobs, N. Haq, A. Tsakmaki, B. Hayee, G. Bewick, UK

499 Elevated FGF21 levels after total pancreatectomy and in response to single-dose glucagon receptor antagonist administration in humans

M.F. Grøndahl, C.T. Juel, A.B. Lund, S. Hædersdal, M.M. Andersen, C.P. Hansen, J.H. Storkholm, M.P. Gillum, B. Hartmann, J.J. Holst, T. Vilsbøll, F.K. Knop, Denmark

500 Extrapankreatic effects of endogenous incretin hormones evaluated using incretin hormone receptor antagonists in totally pancreatectomised patients

L. Krogh, C.K. Nielsen, N.C. Bergmann, J.J. Holst, A. Lund, L.S. Gasbjerg, F.K. Knop, Denmark

501 Fasting plasma GIP is related to metabolic derangements in health and type 2 diabetes

M.J. Borg, C. Xie, C. Rayner, M. Horowitz, K. Jones, T. Wu, Australia

502 Estimating the incretin effect from a glucose-insulin-glucagon coupled model of OGTT

V. Subramanian, J.I. Bagger, V. Harihar, J.J. Holst, F.K. Knop, T. Vilsbøll, USA, Denmark

503 Plasma relaxin-2 concentrations are related to parameters of glucose homeostasis in patients with essential hypertension and type 2 diabetes

O. Pankova, O. Korzh, Ukraine

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 27 Glucagon secretion and peripheral hormone action

Chair G. Rega-Kaun, Austria

504 Chloride currents underlie basal and alanine-induced alpha cell activity

A. Hamilton, N.L. Mogensen, A.T. Sanz-Pastor, L. Eliasson, J.G. Knudsen, Denmark, Sweden, Spain

505 Accumulation of sodium is required for glucose inhibition of glucagon secretion from pancreatic alpha cells

S.L. Armour, J.G. Knudsen, Denmark

506 Glucose mediated production of redox equivalents increases the secretory potential of alpha cells

A. Frueh, G. Katzilieris-Petras, S. Armour, J.G. Knudsen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

507 Metabolic effect of epinephrine infusion in people with type 1 diabetes and healthy individuals

R. She, T. Suvisaari, H.U. Andersen, E. Hommel, K. Nørgaard, J. Wojtaszewski, C. Legido-Quigley, U. Pedersen-Bjergaard, Denmark, UK

508 Fibroblast activation protein in patients with growth hormone deficiency: before and after treatment

A. Bæk, M.C. Arlien-Søborg, A.K. Pedersen, N. Jessen, M. Bjerre, J.O. Jørgensen, Denmark

509 Effects of glucose and insulin in the modulation of expression and secretion of human sex hormone binding globulin in HepG2 cells

V.A. Genchi, A. Cignarelli, C. Lauriola, S. Perrini, A. Natalicchio, L. Laviola, F. Giorgino, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 28 Pregnant with type 1 diabetes and adverse pregnancy outcomes

Chair: B. Pintaudi, Italy

510 Delayed attainment of recommended glycaemic metrics in target in women with type 1 diabetes delivering large for gestational age infants

J.C. Sørholm, S.K. Nørgaard, N.C. Do, K. Nørgaard, T.D. Clausen, P. Damm, E.R. Mathiesen, L. Ringholm, Denmark

511 Pregnancy planning and time in range are essential for pregnancy outcomes in type 1 diabetes

A. Juza, L. Kołodziej-Spirodek, M. Dąbrowski, Poland

512 Associations of continuous glucose monitoring metrics and antepartum glucose with the risk of neonatal hypoglycaemia in women with type 1 diabetes

X. Li, Y. Gong, P. Ling, C. Wang, J. Yan, S. Luo, X. Zheng, D. Yang, China

513 Impact of gestational weight gain on maternal-fetal comorbidities in type 1 diabetic pregnancies by trimester

M. Lemaitre, V. Laurent, C. Ternynck, J. Bourry, F. Baudoux, D. Subtil, A. Vambergue, France

514 New clinical score to predict neonatal hypoglycaemia in women with gestational diabetes

B. Silva, C. Pereira, C. Cidade-Rodrigues, C. Chaves, A. Araújo, A. Melo, V. Gomes, C. Machado, A. Saavedra, O. Figueiredo, M. Martinho, M. Céu Almeida, A. Morgado, M. Almeida, F. M Cunha, Portugal

515 Insulin reverts macrosomia in a mouse model of gestational diabetes

L. Hernandez-Baraza, I. Alemán-Cabrera, C. Valverde-Tercedor, A.M. Wägner, L. Fernández-Pérez, B. Guerra, Y. Brito-Casillas, Spain

516 Association between HbA_{1c} levels and materno-foetal complications in type 2 diabetes

A. Vambergue, E. Petit, M. Lemaitre, C. Ternynck, F. Baudoux, E. Drumetz, D. Subtil, France

517 Association between TGFβ1 levels in cord blood and weight progress in the first year of life

N. Kabbani, M. Blüher, T. Ebert, H. Stepan, J. Breitfeld, R. Baber, M. Vogel, W. Kiess, U. Lössner, A. Tönjes, S. Schrey-Petersen, Germany

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 29 Gestational diabetes

Chair: J.K. Mader, Austria

518 mHealth-apps reduce the risks of neonatal complications in mothers with gestational diabetes significantly: a meta-analysis

C. Eberle, C.-M. Grollmann, Germany

519 Glucagon and insulin resistance in Chinese women with gestational diabetes

C. Chen, D. Zhang, T. Wu, H. Zhang, China, Australia

520 Postpartum development of non-alcoholic fatty liver disease in a lean mouse model of gestational diabetes

K. Hribar, D. Eichhorn, N.J. Kloosterhuis, J.K. Kruit, M.H. Oosterveer, E.M. Van der Beek, Netherlands, Switzerland

521 Gestational diabetes diagnosis in the Swedish Pregnancy Register

S. Diurlin, S. Patil, U. Lindblad, B. Daka, M.I. Hellgren, On behalf of CDC4G steering group, H. Backman, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

522 Pregnancy outcomes of women with ‘mild’ gestational diabetes (GDM by WHO 2013 but not by WHO-1999 diagnostic criteria): a population-based cohort study

A.G. Tabák, G.Á. Visolyi, M.M. Svébis, B.A. Domján, L. Zsirai, A. Kun, Hungary, UK

523 Prevalence of thyroid dysfunction in pregnant women with or without gestational diabetes

F. Carrieri, F. Ginestra, M.A. Carlucci, G. Di Dalmazi, M.P. Baldassarre, I. Cipolloni, I. Bucci, G. Napolitano, A. Consoli, G. Formoso, Italy

524 Prediction of gestational diabetes risk with visceral fat tissue in a multiethnic cohort

H. Navarro-Martínez, G. Llauradó-Cabot, D. Benaiges-Boix, J. Chillarón-Jordán, R. Rubio-Salazar, J. Hernández-Sánchez, C. Rueda-García, E. Ferriols-Pérez, J.A. Flores-Le Roux, Spain

525 Adipose tissue insulin resistance, liver fat and fetuin-A in South Asian and Nordic women after gestational diabetes

S. Lee-Ødegård, A. Suntharalingam, H.L. Gulseth, I. Nermoen, S.T. Sollid, E. Qvigstad, K.I. Birkeland, A. Sharma, Norway

Short Oral Discussion Event F Thursday, 14:00 - 15:00

SO 30 Insulin secretion: for better or for worse

Chair: P. Fasching, Austria

526 Inhibition of de novo ceramide synthesis pathway in pancreatic beta cell causes massive defects in insulin secretion

C. Amouyal, S. Chen, J. Denom, I. Raho, N. Kassis, M. Diedischeim, F. Mifsud, J. Lallement, E. Georgiadou, G. Rutter, C. Cruciani-Guglielmacci, H. Le Stunff, C. Magnan, France, UK, Canada

527 The dual incretin coagonist tirzepatide contributes to glucose elimination by increasing both insulin secretion and glucose effectiveness in model experiments in mice

B. Ahrén, G. Pacini, Sweden, Italy

528 Longitudinal changes in sex hormone-binding globulin and free testosterone in men living with HIV: relationships with dysglycaemia, insulin secretion and sensitivity

I.D. Seipone, A.E. Mendham, C. Kufe, T. Olsson, L.K. Micklesfield, J.G. Goedecke, South Africa, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

529 Dried blood spot C-peptide measurements show robust performance in assessing endogenous insulin secretion in individuals with young-onset insulin-treated diabetes

J.C. Katte, M.Y. Dehayem, B.M. Shields, A.T. Hattersley, E. Sobngwi, A.G. Jones, T.J. McDonald, UK, Cameroon

530 Residual insulin secretion is associated with lower BMI and reduced central obesity indices in patients with type 1 diabetes

G. Karamanakos, A. Bampagianni, I.A. Anastasiou, S. Driva, A. Kountouri, V. Lambadiari, S. Liatis, Greece

531 Alterations in G protein-coupled receptor ligand mRNAs in gastrocnemius muscle of diet-induced obese mice

Z. Lyu, O. Olaniru, P. Atanes, S. Persaud, UK

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 31 It's in the brain

Chair: J. Rungby, Denmark

532 Glucagon receptor immunoexpression in brain barrier interfaces in developing human and adult mouse brain

C. Bjørnbak Holst, N.J. Wewer Albrechtsen, K. Møllgård, Denmark

533 Azgp1 signalling in POMC neurons confers protection against diet-induced obesity and hepatic steatosis

S. Qiu, G. Yang, M. Yang, L. Li, China

534 Central p62 contributes to peripheral energy metabolic balance and homeostasis via STAT3-POMC signalling

S. Yang, L. Li, G. Yang, China

535 Hypothalamic GPC4 and its N-glycosylation regulate feeding and energy metabolism through IR/AKT/FoxO1 signalling pathway

X. Xia, L. Li, G. Yang, China

536 The role of sodium-glucose cotransporter-2 inhibitors in the hypothalamic control of energy homeostasis

D. Yi, Republic of Korea

537 Reduced hypothalamic leptin signalling leads to hepatic steatosis, insulin and glucagon resistance, and hyperglucagonaemia in adult rats

N. Gallardo, C. Pintado, L. Mazuecos, Ó. Gómez, B. Merino, E. Burgos-Ramos, E. Casanueva-Álvarez, S. Artigas, M. Villar, E. Moltó, G. Perdomo, I. Cózar-Castellano, C. Arribas, E. Bernal-Mizrachi, A. Andrés, Spain, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

538 Deletion of p38 α in POMC neurons ameliorates obesity via increasing adipose thermogenesis

J. Wang, S. Wu, Y. Ge, H. Zhan, W. Bi, L. Peng, Y. Xu, Y. Liang, X. Jin, J. Zhao, L. Gao, Z. He, China

539 Defective branched-chain amino acids catabolism in the hypothalamus leads to adiposity

X. Ming, M. Yuan, J. Tan, J. Hong, J. Wang, G. Ning, W. Wang, H. Sun, L. Zhou, X. Wang, China

EASD
EFSD

GENERAL
INFO

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 32 Keeping focus on GLP1

Chair: T.D. Müller, Germany

540 Exercise as weight loss maintenance strategy increases postprandial secretion of glucagon-like peptide 1

J. Holt, S.B. Jensen, R.M. Sandsdal, S. Byberg, C.R. Juhl, C. Janus, M.H. Noer, J.R. Lundgren, A. Andresen, B.M. Stallknecht, J.J. Holst, S. Madsbad, S.S. Torekov, Denmark

541 A human enteroid model for study the mechanisms of GLP-1 secretion in obesity and type 2 diabetes

A. Ribeiro, C. Osinski, P. Martinez-Oca, C. Rouault, L. Genser, K. Clément, P. Serradas, France

542 Efficacy and safety of tirzepatide once weekly in Chinese participants with obesity or with overweight and weight-related comorbidities

L. Zhao, Z. Cheng, Y. Lu, M. Liu, H. Chen, M. Zhang, R. Wang, Y. Wang, Y. Yuan, X. Li, China, USA

543 Exercise combined with GLP-1 receptor agonist preserves bone mineral density during weight loss maintenance

R. Sandsdal, S. Jensen, V. Sørensen, E. Lehmann, J. Lundgren, C. Juhl, C. Janus, T. Justinussen, B. Stallknecht, J. Holst, N. Jørgensen, J.-E. Jensen, S. Madsbad, S. Torekov, Denmark

544 Bile acid, fibroblast growth factor-19, and glucagon-like peptide-1 levels in the long term after bariatric surgery in patients with type 2 diabetes

Y.-B. Ahn, J.-S. Yun, E. Lee, K.-H. Song, J.-H. Han, S.-D. Moon, M. Kim, Republic of Korea

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

545 The effects of DPP-4 inhibitors in human macrophages

E. Benetti, V. Bordano, V. Boscaro, S. Cannito, V. Altamura, M. Barberis, A. Rosa, C. Bocca, T. Klein, C. Dianzani, Italy, Germany

546 Oral anti-diabetic drugs reverse diabetogenic proteomic signature of gut-derived extracellular vesicles

A. Teshima, E. Torrejon, A. Carvalho, H.C. Beck, R. Matthiesen, M.P. Macedo, R.M. De Oliveira, Portugal, Denmark

547 Cagrisema eliminates weight loss associated reduction in energy expenditure in diet-induced obese rats

R.E. Kuhre, B. Hald, J.M. Jacobsen, S. Lundh, M.K. Gerstenberg, A. Secher, K. Raun, Denmark

EASD
EFSD

GENERAL
INFO

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 33 Weight loss rules

Chair: C. Conte, Italy

548 The effect of bariatric surgery on blood pressure management in type 2 diabetes: insights from a 13 year follow up study

U. Waheed, P. Ghaffari, A. Syed, R. Donn, H. Soran, A. Heald, UK

549 Opposing patterns in eating behaviours after surgical versus diet-induced weight loss

L. Vuorela, B.J. Berntzen, M. Maheswary, T. Saarinen, S. Meriläinen, V. Koivukangas, L. Suojanen, P.-H. Groop, A. Rissanen, K. Virtanen, A. Juuti, K.H. Pietiläinen, S. Heinonen, Finland

550 Predictors for insufficient weight loss, defined as %EWL < 50% at 1 year after bariatric surgery

V. Parzer, J.M. Brix, S.L. Huber, B. Ludvik, Austria

551 Sarcopenic obesity and associated body composition characteristics in individuals undergoing bariatric surgery: a retrospective study

K. Verboven, F.V. Machado, V. Schildermans, G. Hertogs, W. Bouckaert, Belgium

552 Data-driven clustering of obese patients in a behavioural weight-loss programme

H. Schlögl, A. Kühnapfel, S. Frenzel, M. Blüher, M. Stumvoll, T. Ebert, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

553 The xanthine oxidoreductase inhibitor febuxostat promotes brown adipocyte differentiation and enhances brown adipose tissue function

Y. Li, Y. Fujita, H. Minamino, T. Goto, S. Kawarasaki, N. Isomura, K. Takesue, F. Furuya, Y. He, J. Zhang, N. Inagaki, Japan

554 The metagenomic and metabolomic analysis supports unfavourable risk-benefit balance of the ketogenic diet

J. Shi, N. Hou, F. Han, C. Kan, X. Sun, H. Qiu, China

555 Glutamine supplementation in high fat diet improves glucose tolerance and adipose tissue metabolism in mice

V. Meskarova, R. Coupeau, M. Dzubanov, A. Benova, M. Ferencakova, M. Vodickova, M. Tencerova, Czech Republic

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 34 Metabolic flames

Chair: C. Brons, Denmark

556 Glucose-dependent responses of inflammatory markers in obese compared to lean individuals

M.H. Lundqvist, M.J. Pereira, J.W. Eriksson, Sweden

557 Intracellular metabolites accumulated in metabolically activated macrophages

W. He, A. Künne, M. Ohm, M. Korte, K. Hiller, Germany

558 Methylglyoxal is a mediator of the association between 2-hour glucose, HbA_{1c} and inflammation: The Maastricht Study

D. Sun, M.M. Greevenbroek, J.L. Scheijen, S.J. Eussen, C.D. Stehouwer, K.A. Wouters, C.G. Schalkwijk, Netherlands

559 Changes in inflammatory markers in response to 4-weeks of carbohydrate overfeeding in men born with a low birth weight

L.O. Elingaard-Larsen, A.B. Thuesen, L. Justesen, S.O. Villumsen, T. Hansen, A.A. Vaag, C. Brøns, Denmark, Sweden

560 Inflammatory and endothelial host responses in community-acquired pneumonia: associations with HbA_{1c}, admission plasma glucose, and glycaemic gap: a cross-sectional study

B. Lindegaard, A.T. Lundgaard, C.K. Rysør, M.H. Hegelund, A.V. Jensen, P.L. Kristensen, R. Krogh-Madsen, D. Faurholt-Jepsen, S.R. Ostrowski, K. Banasik, A.M. Dzungu, Denmark

561 Role of the soluble interleukin-6 receptor in obesity, type 2 diabetes and metabolic inflammation

K. Schlicht, C. Geisler, D.M. Schulte, N. Rohmann, T. Demetrowitsch, F. Brix, K. Türk, K. Schwarz, S. Schreiber, S. Rose-John, M. Laudes, Germany

562 Inborn and adaptive immune system responses to remission of type 2 diabetes

A.F. Pfeiffer, J. Zhang, K.J. Rüther, B. Schuppelius, E. Lalama, M. Csanalosi-Artigas, N. Kraenkel, S. Kabisch, S. Nesic, A. Burness, A. Christ, E. Latz, Germany

563 The effect of beta-hydroxybutyrate on the IL-10/TNF- α signalling axis in type 2 diabetes

H. Neudorf, K. Falkenhain, B. Oliveira, H. Islam, G. Jackson, K. Madden, J. Little, Canada

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 35 Sex and time matters

Chair: S. Ozanne, UK

564 The BMAL2 circadian clock gene controls inflammation and metabolic adaptation in adipose tissue during diet-induced obesity

M.A. Philippe, B. Fruchet, E. Challet, A. Lehuen, A. Toubal, U.C. Rogner, France

565 Human proinflammatory cytokines exhibit circadian rhythm of secretion that is tissue specific and perturbed in type 2 diabetes patients

A. Lesniewska, O. Fiammingo, F. Sinturel, E. Lefai, P. Schrauwen, J. Hoeks, V. Petrenko, C. Dibner, Switzerland, France, Netherlands

566 The liver clock drives circadian regulation of adipogenic genes in white adipose tissue

P. Petrus, Sweden

567 The effect of sex and reproductive status on metabolic parameters and liver steatosis in metformin-treated animal model of insulin resistance

I. Markova, D. Miklankova, M. Hüttl, H. Malinska, Czech Republic

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

568 High-fat diet induces sex-specific divergent adaptations in liver and adipose tissue in mice

V. Ribas, S. Moron-Ros, L. Brugnara, M. Azagara, A. Herrero, E. Eyre, M. Claret, I. Marco-Rius, A. Novials, J.-M. Servitja, Spain

569 Sexually dimorphic responses in obesity, glucose tolerance and diabetes caused by CCN5/ WISP2 gene deficiency and adipocyte-specific overexpression

J.-L. Liu, T. Alami, M. Zakikhani, V. Xega, Canada

570 Familial partial lipodystrophy: anthropometric, biochemical, genetic and imaging characteristics in females

W.J. Loh, Y. Jadegoud, A.J. Hooper, S.A. Sadananthan, Y. Kway, S.C. Lim, S.S. Velan, M.K. Leow, J. Khoo, Singapore, Australia

571 Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders in female mice

C. Kan, L. Zhang, Y. Luo, K. Zhang, J. Zhang, F. Han, N. Hou, X. Sun, China

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 36 Obesity and diabetes across generations

Chair: R. Teperino, Germany

572 The dysregulation of energy balance crosstalk between the hypothalamus and the brown adipose tissue in overfed rats exposed to maternal glycation

D. Sousa, A. Amaro, M. Rocha, M. Junior, C. Barra, R. Mello-Gomes, P. Matafome, Portugal, Brazil

573 An abdominal fat partitioning pattern characterises risk for gestational diabetes in Asian women

Y.M. Kway, N. Michael, K.H. Tan, K.M. Godfrey, P. Gluckman, Y. Chong, M.V. Fortier, J.K. Chan, S.-Y. Chan, J. Huang, Y. Lee, J.G. Eriksson, M. Feng, S. Velan, S. Sadananthan, Singapore, UK

574 Paternal childhood obesity induced transgenerational inheritance of obesity in mice up to the F3

M. Mourin, F. Palmieri, I. Palacios-Marin, J. Cebria, M. Ramon-Krauel, C. Lerin, J. Jimenez-Chillaron, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

575 Multi-omics analysis of hepatoblast development reveals sex-specific responses to maternal high-fat diet feeding

C. Uhlemeyer, M. Schouwink, A. Heusch, M. Jonuscheit, B. Korzekwa, V. Schrauwen-Hinderling, S. Hartwig, S. Lehr, T. Wachtmeister, K. Köhrer, E. Lammert, M. Roden, H. Al-Hasani, R. Ensenauer, B.-F. Belgardt, Germany

576 Hyperglycaemia in pregnancy leads to sex-specific differences in metabolism and pancreatic beta cell function in young adult offspring

L. Nicholas, S. O'Hara, K. Gembus, G. Clarke, A. Page, Australia

577 Impact of maternal high caloric feeding on aldehyde dehydrogenase 1a7 (Aldh1a7) expression in E13.5 adipocytes and its role in adipogenic differentiation

M. Schouwink, C. Uhlemeyer, P. Petzsch, K. Köhrer, B.-F. Belgardt, S. Öner-Sieben, R. Ensenauer, Germany

578 Effect of maternal thyroid hormones during gestation on the epigenetic regulation of Leptin transcription

L. Müller, R. Ölkug, J. Mittag, P. Kovacs, K. Krause, M. Keller, Germany

579 Postnatal overfeeding triggers sex-specific neurodevelopmental delay and induces anxious-like behaviour accompanied by brain-region-specific synaptic imbalance

A. Amaro, D. Sousa, M. Sá-Rocha, M. Júnior, L. Saavedra, C. Barra, F.I. Baptista, P. Matafome, Portugal, Brazil

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 37 Hormonal control of obesity

Chair: L. Dollet, Sweden

580 Dopaminergic regulation of neuropeptide Y and Melanocortin systems in the adipose tissue as a therapeutic target to metabolic dysregulation associated with obesity

E. Lopes, D. Rosendo-Silva, P. Matafome, Portugal

581 Subcutaneous adipose tissue dopamine receptor D2 expression is increased in prediabetes and type 2 diabetes

M.J. Pereira, M. Vranic, F. Ahmed, R. Kristófi, S. Hetty, D. Mokhtari, M.K. Svensson, J.W. Eriksson, Sweden

582 Inappropriately high leptin levels are associated with hyperinsulinaemia and insulin resistance in overweight/obese youths

L. Sacchetta, M. Chiriaco, A. Natali, N. Santoro, A. Galderisi, R. Weiss, S. Caprio, D. Tricò, Italy, USA, Israel

583 Dual amylin and calcitonin receptor agonists increase mitochondrial respiratory capacity in adipose tissues of obese rat

E.A. Petersen, I. Blom, S.A. Melander, M.A. Karsdal, S. Larsen, K. Henriksen, A.T. Larsen, Denmark, Switzerland, Poland

584 A role for circulating levels of adipocytokines, miRNA and miRNA variants (isomiRs) in renal dysfunction in patients with morbid obesity

R. Vila-Bedmar, M. Martín-Taboada, B. Lanzón, I. González de Pablos, L. Torres, P. Corrales, P. Gómez-Rodríguez, E. Rodríguez-Cuellar, E. Porrini, E. Morales, G. Medina-Gómez, Spain

585 Fibroblast growth factor 21 restores glucose-lowering action of CL 316,243 in obese mice

S. Stanić, J. Kopecky, P. Zouhar, Czech Republic

586 A novel potential therapeutic target in metabolic disease: role of Ghrelin/GHSR/LEAP2 in type 2 diabetes and obesity

L. Yue, R. Cheng, China

587 Comparative analysis of islet GPCR-targeting adipokine mRNA expression between diet-induced and genetically obese mouse models

T. Ashik, P. Atanes, M. Wilson, T. Pullen, S.J. Persaud, UK

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 38 Fantastic fats and where to find them

Chair: L. Rossmeislová, Czech Republic

588 Role of hepatic sphingosine-1-phosphate in the regulation of insulin sensitivity in response to lipotoxicity

S. Tan-Chen, P. Mesdom, J. Guitton, F. Lachkar, S. Ali-Berrada, A. Blachnio-Zabielska, F. Fougelle, H. Le Stunff, E. Hajduch, France, Poland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

589 Omega-3 polyunsaturated fatty acids prevent increased bone marrow adiposity caused by high fat diet in mice

A. Benova, M. Ferencakova, K. Bardova, J. Funda, M. Dzubanov, T. Balcean, G. Kerckhofs, A. Pecinova, T. Mracek, O. Horakova, M. Rossmeisl, J. Kopecky, M. Tencerova, Czech Republic, Belgium

590 Beneficial effect of empagliflozin on lipid metabolism in heart and liver in a model of prediabetes

H. Malinska, D. Miklankova, I. Markova, M. Hüttl, Czech Republic

591 Ceramides are higher in brown fat than white fat in adult humans

M. U-Din, J. Raiko, T. Saari, M. Monfort-Pires, T. Niemi, M. Taittonen, K. Kristiansen, J. Newman, P. Nuutila, K.A. Virtanen, Finland, Denmark, USA

592 Serum short-chain fatty acids are associated with brown adipose tissue metabolism in humans

M. Monfort-Pires, M. U-Din, V. De Mello, T. Saari, J. Raiko, K. Hanhineva, T. Fromme, R. Landberg, M. Klingenspor, K.A. Virtanen, Finland, Germany, Sweden

593 CD36 regulates FFA-Fetuin-A mediated inflammation and lipid accumulation in pancreatic beta cells

S. Mandal, S. Nag, R. Kundu, India

594 Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor

R. Schürfeld, B. Sandner, A. Hoffmann, N. Klötting, A. Bachmann, A. Frille, A. Dietel, J.-U. Stolzenburg, M. Blüher, M.-Z. Zhang, R. Harris, B. Isermann, M. Stumvoll, A. Tönjes, T. Ebert, Germany, USA

595 Can we leverage CD38 as an NAD⁺-boosting treatment for metabolic dysfunction during ageing?

B. Osborne, M.H. Nielsen, M. Ben Ezra, M.A. Petr, R. McIntyre, R.H. Houtkooper, A. Jafari, M. Kassem, M. Scheibye-Knudsen, Denmark, Netherlands

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 39 Fat across organs*Chair:* TBA**596 Effects of extracellular vesicles on pancreatic beta cells during obesity progression in mice**

S. Morón-Ros, V. Ribas, L. Brugnara, A. Novials, J.-M. Servitja, Spain

597 TRAP α deficiency impairs the early events of insulin biosynthesis causing age- and diet-related impaired glucose tolerance

X. Li, J. Hu, Y. Huang, X. Xu, S. Wang, J. Sun, M. Liu, China

598 The long non-coding RNA β ltr regulates islet beta cell function in obesity

G. Li, D. Liu, L. Li, China

599 TUDCA treatment reduces hepatic glucose production and glucagon secretion in malnourished mice fed with high-fat diet

J.A. Silva Junior, K.M. Oliveira, T.R. Araújo, B.L. Alves, E.M. Carneiro, Brazil

600 N-acetyl-L-cysteine supplementation prevents beta cell oxidative stress and intra-islet stellate cell activation in aging mice undergoing high-fat diet challenge

M.A. Schuurman, J. Nguyen, R. Wang, Canada

601 Inhibition of GPR120 signalling in intestine ameliorates insulin resistance and fatty liver under high-fat diet feeding

T. Yasuda, N. Harada, T. Hatoko, A. Ichimura, E. Ikeguchi-Ogura, Y. Murata, N. Wada, S. Kiyobayashi, S. Yamane, A. Hirasawa, N. Inagaki, Japan

602 Dapagliflozin counteracts the pro-apoptotic effects of the secretome of adipose cells from obese subjects in human cardiac progenitor cells via the SGLT2 co-transporter

G. Palma, C. Caccioppoli, R. D'Oria, V.A. Genchi, I. Calderoni, A. Braun, T. Bottio, G. Santarpino, A. Cignarelli, A. Natalicchio, L. Laviola, A. Pezzolla, A. Milano, F. Giorgino, S. Perrini, Italy

603 New insights into the effect of empagliflozin on hepatic dysmetabolism in diabetic obese Zucker rats

C. Pirozzi, S. Melini, F. Comella, A. Aragón Herrera, A. Lama, Y. Farrag, G. Mattace Raso, O. Gualillo, F. Lago Paz, R. Meli, Italy, Spain

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 40 Metabolism in humans*Chair:* K.I. Birkeland, Norway**604 Adolescents living with obesity in ACTION Teens: unawareness of their obesity affects their perceptions, attitudes and behaviours**

A. Bereket, L.A. Baur, B. Bin-Abbas, W. Chen, F. Fernández-Aranda, N. Garibay Nieto, J.C. Halford, J.P. López Siguero, C. Maffei, V. Mooney, C.K. Osorto, R. Reynoso, Y.J. Rhie, M. Toro-Ramos, Turkey, Australia, Saudi Arabia, Taiwan, Spain, Mexico, UK, Italy, Ireland, Denmark, Switzerland, Republic of Korea, Colombia

605 Bioelectrical impedance derived Phase Angle (PhA) in people living with obesity among different weight status and inflammatory biomarkers

J. Carretero Gómez, P. González González, T. Galeano Fernandez, S. Cordoba Bueno, N. Boyero Calvo, B. Salgado Cardoso, J. Arévalo Llorido, Spain

606 Correlation of body mass index with body fat indices, skeletal muscle mass, neck circumference waist-hip ratio in people with type 2 diabetes

S. Patange, India

607 The interplay between fat deposition and diabetic-status hyperglycaemia: insights from Bayesian-network modelling

T. Waddell, A. Namburete, H. Thomaidis-Brears, M. Brady, UK

608 Adenosinergic system correlates with BMI in dysmetabolic patients

F. Martins, R.E. Figueiredo, R.O. Oliveira, S.V. Conde, Portugal

609 Loss of adipose tissue plasticity as an early hallmark of insulin resistance and metabolic maladaptation in patients with obesity

D. Rosendo-Silva, B. Almeida, P.B. Gomes, S. Viana, F. Reis, R. Seica, P. Matafome, Portugal

610 Impact of HIV and menopause on adipose tissue function, insulin sensitivity and beta cell function in middle-aged black African women

A.E. Mendham, M. Masemola, L.K. Micklesfield, F. Karpe, A. Pascal Kengne, T. Chikowore, N.C. Kufe, N.J. Crowther, C. Pfeiffer, S. Norris, K. Storbeck, T. Olsson, J.H. Goedecke, South Africa, UK, Sweden

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

611 LEAP2 reduces preprandial and postprandial glucose responses and ad libitum food intake in obese men

A. Englund, C.A. Hagemann, L.S. Gasbjerg, F.K. Knop, Denmark

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 41 Novel players in adipocyte biology

Chair: A. Georgiadi, Germany

612 Cables1 expression is reduced in human subcutaneous adipose tissue in obesity and type 2 diabetes but may not directly impact adipocyte glucose and lipid metabolism

S. Hetty, M. Vranic, P.G. Kamble, M.H. Lundqvist, M.J. Pereira, J.W. Eriksson, Sweden

613 Identification and functional investigation of novel candidate genes for type 2 diabetes on chromosome 4

K. Kaiser, S. Görigk, T. Kuhn, D. Altenhofen, J. Khuong, J. Decker, S. Lebek, A. Schürmann, A. Chadt, H. Al-Hasani, Germany

614 Mir-29b-3p: regulator and extracellular biomarker of adipose tissue fibrosis in obesity and prediabetes

M. Clemente-Postigo, E. Garrido-Rascon, L. Ortiz-Hidalgo, C. Tercero-Alcazar, R. Guzman-Ruiz, F.J. Tinahones, M.M. Malagon, Spain

615 IL-27 increases energy storage in white adipocytes by enhancing glucose uptake and fatty acid esterification

C. Scaffidi, D. Konrad, S. Wueest, Switzerland

616 Characterisation of the catecholamine transporter OCT3 in human adipose tissue: implications for age-induced reduction of subcutaneous adipose tissue lipolysis

F. Ahmed, M. Vranic, S. Hetty, V. Patsoukaki, G. Fanni, M.J. Pereira, J.W. Eriksson, Sweden

617 The impact of epigenetic editing within the Sarcospan promoter on adipogenesis

K.A. Dinter, L. Müller, P. Kovacs, M. Keller, Germany

618 Expression of selected microRNAs in adipose tissue-derived mesenchymal stem cells and metabolic syndrome

G. Wystrychowski, K. Simka-Lampa, A. Witkowska, E. Sobecko, A. Skubis-Sikora, B. Sikora, E. Wojtyna, A. Golda, K. Gwizdek, M. Wróbel, T. Francuz, C. Kruszniewska-Rajs, J. Gola, Poland, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

619 Human pancreatic adipocyte spheroids as model to study the role of pancreatic fat in type 2 diabetes

E. Lorza-Gil, E. Ziegler, O. Strauss, S. Singer, S. Nadalin, A.L. Birkenfeld, F. Gerst, Germany

Short Oral Discussion Event F Thursday, 14:00 - 15:00

SO 42 Tirzepatide: SURPASSing the vibe check

Chair: B. Eliasson, Sweden

620 Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials

R. Buzzetti, A.L. Peters, C.J. Lee, I. Pavo, M. Liu, J.S. Paik, Italy, USA

621 Efficacy of tirzepatide in people with young-onset type 2 diabetes in the SURPASS programme

M.J. Davies, Z. Philip, R.J. Galindo, B.K. Bergman, V.T. Thieu, C. Nicolay, S. Allen, C.J. Lee, UK, USA

622 Effect of tirzepatide on the counter-regulatory response to hypoglycaemia during a hypoglycaemic clamp in people with type 2 diabetes

T. Pieber, E. Svehlikova, S. Urva, A. Haupt, C. Zhou, T. Coskun, Z. Milicevic, E.J. Pratt, Austria, USA

623 Tirzepatide improves amino acid profile in people with long-standing diabetes and increased cardiovascular risk in the SURPASS-4 trial

V. Pirro, Y. Lin, J.A. Willency, A. Abadi, R.J. Wiese, K.L. Duffin, I. Pavo, USA

624 Tirzepatide improves health-related quality of life vs insulin lispro in poorly controlled basal insulin-treated adults with type 2 diabetes (SURPASS-6)

K. Boye, H. Sapin, J.-L. Poon, L. Fernandez Lando, R. Huh, M. Wang, H. Patel, USA

625 Baseline HOMA2-B can predict tirzepatide efficacy: post hoc analysis of the SURPASS-1 and SURPASS-2 studies

J. Peleshok, S.H. Hsia, C. Mathieu, M.K. Thomas, H. Wang, USA, Belgium

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

626 Tirzepatide vs basal insulins in people with type 2 diabetes and different baseline glycaemic patterns: post-hoc analyses of the SURPASS-3 and -4 trials

F. Giorgino, D.R. Franco, C. Nicolay, A. Hemmingway, Á. Rodríguez, R.J. Wiese, Italy, Brazil, USA

627 Early reduction in fasting serum glucose during treatment with once-weekly tirzepatide predicts response to therapy in people with type 2 diabetes (SURPASS 1-4)

E. Razzoli, F. Giorgino, I. Lingvay, V.T. Thieu, M. Liu, J.A. Levine, USA, Italy

EASD
EFSD

GENERAL
INFO

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 43 Small molecules to combat a large disease

Chair: F. Gribble, UK

628 Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity

H. Pan, W. Zhai, Z. Zhang, L. Guo, Z. Dong, M. Zhao, D. Liu, China

629 Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects

J. Wu, W. Hu, Y. Du, Q. Zhang, R. Zhou, Q. Zhang, H. Qin, Z. Ye, Y. Xu, S. Feng, C. Shu, Y. Shen, Y. Fan, China

630 Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: a phase 2 study

S. Wharton, T. Blevins, L. Connery, J. Rosenstock, S. Raha, K.J. Mather, A. Haupt, D. Robins, E. Pratt, C. Kazda, M. Konig, Canada, USA

631 Efficacy of novel small molecule GLP-1 receptor agonist AZD0186 on glucose stimulated insulin secretion in obese, male non-human primates

K. Wallenius, N.R. Van Zuydam, A. Boianelli, G.R. Davies, C.A. Brighton, A. Träff Wergeni, D. Eckernäs, M. Persson, S. Omar, D. Pettersen, S.A. Lundqvist, U. Jurva, A. Snijder, M. Polla, Sweden, UK

632 HTD1801 improves glycaemic control in patients with type 2 diabetes: double-blind, placebo-controlled, phase 2 study

L. Ji, J. Ma, J. Ma, Z. Cheng, S. Gan, G. Yuan, D. Liu, S. Li, Y. Liu, X. Xue, J. Bai, K. Wang, H. Cai, S. Li, L. Liu, China

633 Deciphering glucokinase regulation and modulation for diabetes treatment in the model organism zebrafish (Danio rerio)

N. Schmitner, S. Thumer, I. Bergerweiss, D. Regele, S. Berger, C. Helker, D.Y. Stainier, D. Meyer, R.A. Kimmel, Austria, Germany

634 Lactic acid functionalised AuCePt porous hollow nanozyme targeted to alleviate hepatic insulin resistance

Y. Fu, L. Li, M. Yang, China

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 44 I heard the news today: novel incretins

Chair: T. Karagiannis, Greece

635 Evaluation of the pharmacokinetics of glucagon-like-peptide-1 receptor agonist delivered through the BioJet™ biotherapeutic delivery platform in swine

S.N. Lee, C. Stork, R.O. Valenzuela-Rivas, M. Walker, B. Smith, J. Smith, N. Quintana, C. Wahl, S. Singh, USA

636 A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes

R. Thennati, V. Burade, M. Natarajan, P. Shahi, R. Nagaraja, S. Panchal, S. Agrawal, B. Jandrain, T. Duvauchelle, A. Garcia-Ocana, G.A. Rutter, R.E. Pratley, B. Thorens, T. Vilsbøll, India, Belgium, France, USA, Canada, UK, Switzerland, Denmark

637 Pharmacology characterisation of a novel GLP-1R agonist GSB-2657 in a new humanised GLP-1R mouse model

T. Mao, H. Zhang, X. Fang, S. Zhan, T. Wang, Z. Guan, J. Zhang, X. Lin, H. Lei, F. Zhang, China

638 A phase 3, randomised, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of once-weekly PB-119 as add-on to metformin in patients with type 2 diabetes in China

M. Xu, Pegbio study group, China

639 Efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes

D. Anwar, Y. Bao, Y. Zhou, S. Chen, J. Zhou, L. Li, Z. Cheng, X. Dong, X. Shi, N. Zhao, Y. Yang, J. Ma, Y. Li, Q. Wang, W. Jia, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

640 Efficacy and safety of supaglutide monotherapy in patients with type 2 diabetes

Q. Wang, Y. Zhou, L. Li, W. Wang, G. Tong, B. Shi, X. Hu, F. Bian, Q. Li, Y. Wang, N. Zhao, J. Ma, Y. Li, D. Zhu, China

641 Safety and tolerability of multiple ascending doses of once-weekly GL0034 (utreglutide) in healthy individuals

V. Burade, R. Thennati, M. Natarajan, P. Shahi, R. Nagaraja, S. Panchal, S. Agrawal, B. Jandrain, T. Duvauchelle, A. Garcia-Ocana, G.A. Rutter, R.E. Pratley, B. Thorens, T. Vilsbøll, India, Belgium, France, USA, Canada, UK, Switzerland, Denmark

EASD
EFSD

GENERAL
INFO

642 Hsk7653, a novel biweekly DPP-4 inhibitor, versus daily linagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes

Q. Ren, L. Ji, L. Li, X. Su, X. Hu, G. Qin, J. Han, China

PROGRAMME

TUESDAY

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 45 Dual agonism: two of us

Chair: P. Karasik, Israel

643 HbA_{1c} reduction with tirzepatide in people with type 2 diabetes: a mediation analysis using body weight loss as a factor

T. Vilsbøll, C. Nicolay, M. Malecki, V. Thuyanh Thieu, K. Chivukula, J. Kiljanski, Denmark, USA, Poland

644 Fat specific weight loss in diet-induced obesity mouse model when treated with bispecific GLP-1R/GLP-2R agonist vs dual GLP-1R/GIPR agonist

T. Oh, S.-I. Yang, J. Roh, R. Sung, Republic of Korea

645 BI 456906 acts through circumventricular organs in the brain and activates neuronal pathways associated with appetite regulation

T. Zimmermann, P. Haebel, K. Bleyemehl, J. Perens, U. Roostalu, J. Hecksher-Sørensen, R. Augustin, Germany, Denmark

646 A pilot study using [¹⁸F]FDG PET/MRI to investigate dual GLP-1 and glucagon receptor agonism on myocardial glucose uptake and myocardial function in adults with type 2 diabetes

J.D. Goodman, M. Schain, V. Lupson, T. Horn, R. Manavaki, T.D. Fryer, G. Di Stefano, E. Amiss, N. Jalaludeen, H. Haraldsson, L. Jermutus, J. Cheriyan, L. Johansson, P. Ambery, I.B. Wilkinson, UK, Sweden

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

647 Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HRS9531) in healthy subjects

Q. Wen, K. He, F. Wei, H. Chen, Y. Zhang, Z. Sheng, L. Yin, China

648 A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy

F.K. Knop, S. Urva, M. Rettiganti, C. Benson, W.C. Roell, K.J. Mather, A. Haupt, E. Pratt, Denmark, USA

649 Dual amylin and calcitonin receptor agonists alone or in combination with semaglutide result in long-term sustained improvement of metabolic status in obese and diabetic rats

A.T. Larsen, K.E. Mohamed, S.A. Melander, M.A. Karsdal, K. Henriksen, Denmark, Switzerland

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 46 GLP-1 receptor agonists: action beyond glycaemia

Chair: A.F.H. Pfeiffer, Germany

650 The carotid body mediates GLP-1 actions on glucose homeostasis

D.S. Sampaio-Pires, F.O. Martins, A.M. Capucho, C. Barosa, J.F. Sacramento, G.M. Melo, J.G. Jones, S.V. Conde, Portugal

651 Effects of reendothelialisation with exenatide treatment add on to insulin vs insulin alone, both in combination with metformin in subjects with type 2 diabetes: Rebuild study

I. Santos-Pardo, N. Witt, T. Nyström, Sweden

652 The GLP-1 receptor agonist liraglutide alleviates type 2 diabetes-related diastolic dysfunction in a pyruvate dehydrogenase dependent manner

J.S. Chan, A.A. Greenwell, C.T. Saed, M.J. Stenlund, I.A. Mangra-Bala, S. Dakhili, K. Yang, K. Gopal, F. Eaton, J.R. Ussher, Canada

653 Does the hypothalamus-pituitary-adrenal axis play a role in the difference in treatment response to GLP-1 receptor agonists in type 2 diabetes?

M. Boss, S. Tokgöz, T.J. Jansen, R. Meijer, C. Frielink, C.J. Tack, B.E. De Galan, M. Gotthardt, Netherlands

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

654 Efficacy and safety of GLP1RAs in liver-transplanted patients with diabetes: a 12 months follow up evaluation

V. Grancini, I. Cogliati, A. Gaglio, V. Resi, E. Orsi, Italy

655 Effect of exenatide once-weekly (QW) on the blood pressure and glycaemic responses to a mashed potato meal in type 2 diabetes: relationships to gastric emptying

L.Q. Huynh, S. Hatzinikolas, R.J. Jalleh, C.S. Marathe, T. Wu, C.-H. Malbert, N.C. Evans, A.C. Slavotinek, K. Lange, C.K. Rayner, M. Horowitz, K.L. Jones, Australia, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

656 Comparison of changes in the gut microbiota influenced by combinations of liraglutide with metformin and pioglitazone with metformin in overweight patients with diabetes

K. Moskva, O. Kikhtyak, L. Lapovets, F. Lanyush, Ukraine

657 Glucagon-like peptide-1 receptor agonists for diabetes treatment in solid organ transplant recipients: a case series of 30 patients from a tertiary centre

M.S. Serranito, J.O. Torres, A.A. Matias, N. Cunha, D. Martins, J. Silva-Nunes, Portugal

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 47 Incretin trials: trying new directions

Chair: A. Andersen, Denmark

658 A randomised controlled open label trial examining the safety of label-recommended semaglutide 1mg dose escalation vs a slower and flexible titration regimen

R. Eldor, N. Avraham, O. Rosenberg, M. Shpigelman, A. Golan-Cohen, T. Cukierman-Yaffe, E. Merzon, A. Buch, Israel

659 Changes in liver and abdominal fat in tirzepatide-treated patients achieving normoglycaemia in the SURPASS-3 MRI substudy

Á. Rodríguez, K. Cusi, A. Gastaldelli, C. Nicolay, A. Torcello-Gómez, L. Fernández Landó, USA, Italy

660 Safety and efficacy of tirzepatide for SURPASS-2 through -5 participants ≥ 65 years old with BMI < 30 kg/m²: a post hoc analysis

J. Wilding, N. Rasouli, A. Kwan, J. Paik, M. Liu, J. Peleshok, UK, USA

661 Early weight loss and late metabolic outcomes in tirzepatide-treated participants with type 2 diabetes

L.F. Van Gaal, I. Lingvay, F. Giorgino, M. Liu, Á. Rodríguez,
A. Torcello-Gómez, J. Kiljański, Belgium, USA, Italy

662 Glucagon-like peptide-1 receptor agonist-experienced adults with type 2 diabetes switching to once-weekly semaglutide: post hoc analysis of the real-world SURE programme

G. Rudofsky, M. Menzen, L. Potier, A.-M. Catarig, A. Clark, P. Priyadarshini,
C. Abreu, Switzerland, Germany, France, Denmark, India, Spain

663 Saxagliptin in children and adolescents (age 10-17 years) with type 2 diabetes

P. Galassetti, N. Shehadeh, N. Iqbal, C. Stahre, R. Pandherpur, J. Monyak,
W. Tamborlane, USA, Israel, Sweden, India

664 Comparative effectiveness of GLP-1 receptor agonists vs DPP-4 inhibitors in patients with type 2 diabetes and moderate/severe chronic kidney disease

K.R. Tuttle, P. Fioretto, A. Clark, A.B. Jensen, N. Belmar Nazal, P. Rossing,
USA, Italy, Denmark

665 Improved BMI category is associated with better patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide

V. Thieu, C.J. Lee, K. Boye, S. Allen, W. Dong, H. Sapin, USA

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 48 Incretins: a day in the life

Chair: S. Wild, UK

666 Semaglutide therapy resulted in significant sustained reduction in blood glucose and weight over three years in patients with type 2 diabetes in a real world setting

C. Melzer-Cohen, A. Aharonovich, L. Bourvine, S. Gazit, A. Karasik, Israel

667 Trends in use of incretin-based medications among adults with type 2 diabetes: a nationwide cohort study

E. Paterno, H. Tesfaye, E. D'Andrea, D.J. Wexler, A. Kutz, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

668 Clinical outcomes associated with the use of oral semaglutide in an adult population with type 2 diabetes in Canada: a prospective real-world study (PIONEER REAL Canada)

S.M. Reichert, H. Amadid, U.C. Braae, R.M. Bradley, J. Kim, V. Soo, J.-F. Yale, A. Jain, Canada, Denmark

669 Remission of type 2 diabetes with the oral combo semaglutide + dapagliflozin

M.E. Lunati, V. Cimino, E. Lazzaroni, L. Montefusco, I. Pastore, P.S. Morpurgo, A. Gandolfi, C. Tinari, A. Rossi, G. Zuccotti, P. Fiorina, Italy, USA

670 Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes

J.-F. Yale, A. Major-Pedersen, A.-M. Catarig, R.G. Jain, M. Menzen, P. Holmes, Canada, Denmark, India, Germany, UK

671 Impact of GLP-1 receptor agonist compared to basal insulin start on metabolic targets in patients living with type 2 diabetes and chronic kidney disease (Impact GLP-1 CKD)

Y. Ming, R. Bradley, P. Auerbach, A. Abitbol, Canada

672 Eating behaviour and HbA_{1c}-lowering effects of GLP-1 receptor agonists in Japanese individuals with type 2 diabetes: a multicentre, prospective, observational study

Y. Koide, T. Kato, S. Kubota, M. Sakai, Y. Takahashi, K. Takao, M. Mizuno, T. Hirota, Y. Horikawa, K. Nishimura, M. Hayashi, H. Daido, E. Kuroda, T. Maruyama, D. Yabe, Japan

673 Time spent in glucose control after initiating tirzepatide vs comparators: exploratory analysis of fasting serum glucose in SURPASS 1-5 trials

R.L. Batterham, J. Rosenstock, W.T. Garvey, M. Liu, Y. Chen, B.K. Bergman, A. Hemmingway, V.T. Thieu, UK, USA

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 49 Therapies: here, there and everywhere

Chair: TBA

674 Effects of ghrelin infusion on glucose tolerance and insulin sensitivity after sleeve gastrectomy

M.-L. Dichman, N. Hedbäck, A. London, C. Dirksen, K. Bojsen-Møller, N. Jørgensen, V. Kristiansen, B. Hartmann, J. Holst, M. Svane, S. Madsbad, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

675 The ATTRACTIVE 1 trial: a first-in-human, dose escalating, double-blind, placebo-controlled trial of ATR-258 in healthy and type 2 diabetes participants

E. Waara, B. Pelcman, B. Kalsch, S. Armani, A. Schultz, T. Forst, T. Bengtsson, Sweden, Germany

676 Risk factors of gastrointestinal symptoms in adults with newly diagnosed type 1 and type 2 diabetes

A.-T. Klötzsch, V. Ptushkina, K. Bódis, R. Wagner, M. Roden, O. Kuß, W. Rathmann, Germany

677 Metformin counteracts the adverse metabolic effects of glucocorticoids in healthy subjects

E. Seelig, C. Peterson, T. Delko, V. Iten, M. Epstein, N. Zamboni, M. Kuehne, C. Meyer-Zuern, S. Thierry, Switzerland, UK

678 Possibility of clearing oral glucose test in type 2 diabetes patients who underwent complete remission

M. Ganla, P. Tripathi, N. Kadam, A. Vyawahare, B. Sharma, B. Saboo, India

679 Glucagon-like peptide 1 for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes: a systematic comparison of intravenous and subcutaneous routes

D.R. Quast, D. Lancaster, C. Xie, M.J. Bound, J. Grivell, K.L. Jones, M. Horowitz, J.J. Meier, T. Wu, C. Rayner, M.A. Nauck, Germany, Australia

680 Glycaemic improvement and reduction of insulin use at 48 weeks following the duodenal mucosal resurfacing procedure in people with inadequately controlled type 2 diabetes

B. Sorondo, V. Fonseca, J. Bergman, Z. Saeed, H. Rajagopalan, K. White, H. Zhang, G. Mingrone, USA, Netherlands, Italy

681 Stroke, acute myocardial infarction and mortality in type 2 diabetes: a nationwide comparative effectiveness study of GLP-1RA, SGLT2i and DPP-4i treatment

S. Hastrup, J. Hedegaard, G. Andersen, M. Osler, J. Rungby, S. Johnsen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 50 Type 1 diabetes*Chair:* P. Narendran, UK**682 Factors associated with changes in beta hydroxybutyrate with sotagliflozin in adults with type 1 diabetes**

M.J. Davies, S. Boeder, J.B. McGill, R. Pratley, M. Girard, P. Banks, J. Pettus, S. Garg, USA

683 Identifying features of lymphocytes in newly diagnosed type 1 diabetes BANDIT participants after treatment with the JAK inhibitor baricitinib

L. Sanz Villanueva, P. Trivedi, S. Litwak, T. Catterall, M. Waibel, B. Krishnamurthy, H.E. Thomas, T.W. Kay, Australia

684 Adherence affects response to baricitinib in the BANDIT trial in new-onset type 1 diabetes

T. Kay, BANDIT trial study group, Australia

685 Effect of autologous dendritic cell therapy targeting HLA-E restricted CD8+ T regulatory pathway on pancreatic beta cell function in type 1 diabetes

J.L. Gaglia, M. Mackey, H.L. Daley, N.K. Bryant, D. Kim, T. Dong, E.E. Fan, J. Vora, J.S. Skyler, J. Ritz, H. Jiang, USA

686 Dual amylin and calcitonin receptor agonist as an adjunct therapy to insulin prevents weight gain and improve glucose control in an STZ-induced type 1 diabetic rat model

S.A. Melander, A.T. Larsen, M.A. Karsdal, K. Henriksen, Denmark, Swaziland, Switzerland

SO 51 SGLT2 inhibitors: trying new directions*Chair:* A. Ceriello, Italy**687 Effect of ertugliflozin on body weight and HbA_{1c} by baseline BMI: observations from VERTIS CV**

F. Cosentino, D.Z. Cherney, S. Dagogo-Jack, R.E. Pratley, N. Cater, M. Maldonado, A. Xing, C.P. Cannon, Sweden, Canada, USA, UK

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

688 Use of sodium glucose transporter 2 inhibitors for diabetes treatment after solid organ transplantation: a case series of 34 patients from a tertiary centre

J. Oliveira Torres, M. Serranito, A. Abegão Matias, I. Manique, N. Cunha, D. Cruz Martins, J. Silva-Nunes, Portugal

689 Simultaneous PPAR- γ activation and SGLT2 cotransporter inhibition modulate oxidative stress and apoptosis in diabetes-induced cardiomyopathy

A. Cinakova, P. Kreněk, J. Klimas, E. Kralova, Slovakia

690 Effects of sitagliptin versus dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study

K. Takuma, A. Fuchigami, T. Hirose, Japan

691 Dapagliflozin in children and adolescents (age 10-17 years) with type 2 diabetes

N. Shehadeh, P. Galassetti, N. Iqbal, C. Karlsson, J. Monyak, W. Tamborlane, Israel, USA, Sweden

692 Is GFR decline induced by SGLT-2 inhibitor of clinical importance?

M. Günes-Altan, A. Bosch, K. Striepe, M. Schiffer, P. Bramlage, R.E. Schmieder, D. Kannenkeril, Germany

693 Risk of prostatitis in patients with type 2 diabetes: a retrospective database study of canagliflozin vs other antihyperglycaemic agents

Z. Yuan, C. Jeffcoat, R.S. Ali, P. Ryan, A. Sena, M. Schuemie, S. Fonseca, USA

694 Empagliflozin and metformin synergy in proximal tubular epithelial cells: Does the combination alleviates hyperglycaemia-induced metabolic stress?

D. Galuška, L. Pácal, K. Chalássová, K. Kaňková, Czech Republic

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 52 Targeting muscle, kidney and liver*Chair:* K.R. Tuttle, USA**695 Bimagrumab prevents muscle loss associated with low dietary protein intake in healthy volunteers or with weight loss in obesity**

L. Coleman, L. Mindeholm, S. Spruill, L. Klickstein, M. Pruzanski, K. Attie, USA

EASD
EFSD**696 Similarity and difference of intestinal actions of metformin and imeglimin**

K. Sugawara, H. Mizuma, D. Sasaki, A. Kondo, Y. Watanabe, W. Ogawa, Japan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

697 A novel FGF-1 analogue normalises type 2 diabetes, obesity and NAFLD symptoms in ZDF rat model

M. Janiszewski, T. Jaworski, V. Vialichka, E. Swiderska, E. Mroz, M. Choros, J. Hucz-Kalitowska, B. Miedziak, M. Marczak, O. Abramczyk, A. Czyrek, D. Krowarsch, M. Zakrzewska, J. Otlewski, M. Wieczorek, Poland

698 Finerenone increases the likelihood of improved KDIGO risk category in patients with type 2 diabetes and CKD: an analysis from FIDELITY

S.E. Inzucchi, G. Filippatos, S.D. Anker, C. Wanner, T. Shafi, N. Tangri, B. Pitt, R. Weingold, M. Brinker, C. Scott, L. Roberts, P. Rossing, USA, Greece, Germany, Canada, UK, Denmark

699 The novel adrenoceptor agonist ATR-127 targets skeletal muscle and brown adipose tissue to counter diabetes and hepatic steatosis

G.K. Yakala, E. Talamonti, A. Kalinovich, S.M. Van Beek, N.D. Holliday, E. Suna, I. Mutule, S.C. Wright, V.M. Lauschke, S. Nielsen, C. Scheele, R.J. Summers, J. Hoeks, B. Pelcman, T. Bengtsson, Sweden, Netherlands, UK, Latvia, Germany, Denmark, Australia

700 YH40863, a novel long-acting GLP-1xGDF15 dual agonist, elicits potent and sustained body weight reduction and glycaemic control in animal models

D.-E. Hwang, D.-H. Kim, M. Ju, B. Sim, Y. Lee, D.-H. Kim, S. Lim, J. Kim, S.-W. Oh, Republic of Korea

701 Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: subgroup analysis of the FIGARO-DKD trial

P. Li, H. Zheng, J. Ma, W. Lu, L. Li, F. Liu, Q. Su, Y. Li, Y. Fang, Z. Mo, F. Xiong, A. Yin, Y. Zhang, L. Wang, D. Zhu, China

702 Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease

P. Rossing, P. Fioretto, A. Clark, A.B. Jensen, N. Belmar Nazal, K.R. Tuttle, Denmark, Italy, USA

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 53 Miscellaneous: The White Album

Chair: G. Rayman, United Kingdom

703 Non-adherence to glucose lowering medication contributing to treatment intensification: sub-groups at risk and implications for care

S.V. Eastwood, R. Mathur, L. Smeeth, K. Bhaskaran, N. Chaturvedi, UK

704 Testosterone replacement in men with type 2 diabetes lowers HbA_{1c}: ABCD worldwide audit

H. Jones, K. Darzy, R. Troke, U. Dashora, A. Haider, R. Ryder, UK, Germany

705 Oxytocin does not acutely improve glucose homeostasis in men with type 2 diabetes

N. Röhm, N. Moszka, K. Kantartzis, H. Preissl, L. Fritsche, A. Fritsche, M. Hallschmid, Germany

706 Atorvastatin improves glucose metabolism and reverses the diabetic state in a non-genetic mouse model of type 2 diabetes

R. J. Moreira, M. L. Michalani, M. M. Okamoto, C. Y. Yonamine, U. F. Machado, Brazil, Denmark

707 A phase 3 trial to evaluate the efficacy and safety of chiglitazar added to metformin in Chinese patients with type 2 diabetes inadequately controlled on metformin monotherapy

L. Gao, L. Ji, X. Dong, Z. Cheng, X. Zhang, W. Sun, J. Ma, RECAM Study Group, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

708 Alpha-cyclodextrin increases GLP-1 secretion and causes weight loss in mice

M.M. Smits, L. Von Voss, E.E. Beaman, A.O. Brethvad, J.J. Holst, M. Rosenkilde, Denmark, Netherlands

709 Dulaglutide and glomerular hyperfiltration and albuminuria in youth with type 2 diabetes: results from the AWARD-PEDS study

P. Bjornstad, S. Arslanian, T. Hannon, P. Zeitler, J. Francis, A. Curtis, I. Turfanda, D. Cox, USA

EASD
EFSD

710 An adiponectin receptor agonist rescues sarcopenia in aged mice

M. Abou Samra, C.M. Selvais, R. Versele, M.A. Davis-López de Carrizosa, L. Noel, S.M. Brichard, Belgium, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 54 Carbohydrates: time matters

Chair TBA

711 Time-restricted eating and personalised dietary advice induce similar effects on HbA_{1c} over six months in people with type 2 diabetes

E.B. Parr, B.L. Devlin, B.E. Radford, R.C. Hall, S.A. Flint, N. Steventon-Lorenzen, S.L. Halson, R.D. Johnston, L. Brennan, I.W. Kow, J.A. Hawley, Australia, Netherlands

712 Comparative effects of intermittent and continuous enteral feeding on glycaemic control in critically ill patients

I.W. Kow, L.-A.S. Chapple, R. Louis, M. Summers, K. Jones, M. Horowitz, M. Chapman, Netherlands, Australia

713 Food intake chronotype and its association with 75g-oral glucose tolerance test outcome in pregnant women at risk for gestational diabetes

S.E. Siegelaa, D.R. Muller, F. Holleman, S.J. Eussen, R.G. IJzerman, M.G. Wouters, R.C. Painter, D.J. Stenvers, Netherlands

714 Effects of early vs late time-restricted eating on 24-hour glucose profiles and internal circadian time in overweight and obese women

O. Ramich, B. Peters, J. Schwarz, B. Schuppeli, A. Ottawa, D.A. Koppold, T. Int-Veen, T. Manlik, B. Arnrich, A.F. Pfeiffer, A. Michalsen, N. Steckhan, A. Kramer, Germany

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

715 Beneficial effects on anthropometric and metabolic parameters in overweight and obese boys after 1 year nutritional-behavioural intervention

F. Folli, M. Tosi, I.A. Matelloni, M. Mancini, A. Andreassi, A. Scopari, A. Rossi, E. Verduci, C. Berra, R. Manfrini, G. Banderali, F. Pecori Giraldi, Italy

716 Gastric emptying of 75g oral glucose is predictive of the glycaemic response to mixed meals as well as oral glucose, but unrelated to antecedent glycaemia in type 2 diabetes

C. Xiang, Y. Sun, Y. Luo, C. Xie, W. Huang, Z. Sun, K.L. Jones, M. Horowitz, C.K. Rayner, J. Ma, T. Wu, China, Australia

717 Gastric emptying is slower in women than men with type 2 diabetes

M. Horowitz, C. Xiang, C. Xie, Y. Sun, K.L. Jones, C.K. Rayner, J. Ma, T. Wu, Australia, China

718 Natural daylight through windows as opposed to artificial lighting during office hours improves glucose control and 24h substrate metabolism in type 2 diabetes patients

I.S. Habets, J.-F. Harmsen, M. Kotte, D. Hashim, S. De Kam, M. Timmermans, G. Schaart, A. Gemmink, T. Van de Weijer, P. Schrauwen, C. Dibner, J. Hoeks, Netherlands, Switzerland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 55 Nutrition: strawberry fields or glass onions?

Chair: N. Guess, UK

719 Pre-meal ketones reduce postprandial blood glucose and lipids in individuals with type 2 diabetes

M. Bangshaab, S. Bech Smedegaard, N. Møller, M. Svart, N. Rittig, Denmark

720 Nutritional status and frailty in patients with diabetes and end stage renal failure who are on maintenance haemodialysis

V. Wickramaratne, Sri Lanka

721 Impact of a low-carbohydrate versus a low-fat breakfast on blood glucose control in type 2 diabetes

B.F. Oliveira, C.R. Chang, K. Oetsch, K. Falkenhain, K. Crampton, M. Stork, M. Hoonjan, T. Elliott, M.E. Francois, J.P. Little, Canada, Australia

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

722 Glycaemic outcomes of short-term diets differing in macronutrient composition in type 1 diabetes

S. Schmidt, K.B. Kristensen, A.G. Ranjan, O. McCarthy, R. Bracken, K. Nørgaard, Denmark, UK

723 A ketogenic diet reduces myocardial fatty acid oxidation but does not affect myocardial oxygen consumption

E. Søndergaard, T.V. Luong, M.G. Pedersen, C.B. Abild, K.M. Lauritsen, M.L. Kjærulff, L. Tolbod, N. Møller, L.C. Gormsen, Denmark

724 Baseline of the REVERSE-IT study, a 24-week and 600-people randomised placebo-controlled study on the metabolic effects of TOTUM-63, a five plant-extract combination

Y.F. Otero, P. Sirvent, O.E. Johansen, V. Chavanelle, A. Bouchard-Mercier, V. Sapon, M. Cazaubiel, N. Boisseau, T. Maugard, B. Guigas, B. Pereira, S. Hadjadj, S. Peltier, A. Marette, J.-M. Bard, France, Switzerland, Canada, Netherlands

725 Real-world nudging and pricing was insufficient to improve lifestyle and cardiometabolic health: a parallel cluster-randomised supermarket trial

J.W. Beulens, J.M. Stuber, J. Lakerveld, J.D. Mackenbach, Supreme Nudge consortium, Netherlands

726 Food insecurity is common in type 2 diabetes in Bangladesh and associated with diabetes distress and depression

C. Marathe, M. Kamruzzaman, M. Horowitz, K.L. Jones, Australia

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 56 Devising diabetes devices

Chair: Z. Visockiene, Lithuania

727 Duodenal Jejunal Bypass Liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks among 1068 patients treated worldwide

R.E. Ryder, J. Stein, T. Battelino, J. Teare, A. Ruban, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. De Jonge, J.-W. Greve, H. Sourij, P. Sen Gupta, K. Laubner, J. Seufert, UK, Germany, Slovenia, Australia, Israel, Brazil, Netherlands, Austria

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

728 Efficacy and safety of real-time continuous glucose monitoring with remote monitoring for diabetes management in long-term care facilities: a randomised clinical trial

G. Umpierrez, T. Idrees, I. Castro, Z. Zabala, E. Moreno, B. Moazzami, T. Johnson, M. Gavaller, P. Vellanki, L. Peng, R. Galindo, USA

729 Infrared thermography as a non-invasive modality to characterise temperature variations in type 2 diabetics vs healthy controls

P. Jethwani, M. Mittal, H. Kothadia, A.D. Goel, V. Ganakumar, R. Shukla, M.K. Garg, India

730 Endovascular denervation ablates periarterial sympathetic nerves and improves glucose tolerance in a canine model

Z. Wang, G.-J. Teng, China

731 Computational optimisation of insulin release from macroencapsulation devices

L. Trask, R. Tarpey, G.P. Duffy, E.B. Dolan, Ireland

732 Accuracy evaluation of an implantable CGM with chemistry improvements in a 365-day feasibility study

L. Al-Khawi, USA

733 Alleviation of autonomic dysfunction measured as pressure pain sensitivity at the sternum improves empowerment and quality of life in type 2 diabetes: a randomised trial

S. Hecquet, S. Ballegaard, E. Eldrup, C. Hansen, P. Rossing, C. Pichat, T. Watt, F. Gyntelberg, N. Orsted, A. Gjedde, J. Faber, Denmark

734 The use of smartwatch data in a closed loop system may reduce the risk of hypoglycaemia during unannounced physical activities

H. Romero Ugalde, S. Pou, A. Adenis, S. Lachal, M. Louis, Y. Pinaroli, E. Hunecker, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 57 How to make a good script for insulin therapy for the demanding audience

Chair: F. Broglio, Italy

735 Automated insulin delivery tightens glucose control and stabilises circulating endothelial progenitor cells in a 6-months-randomised study

A. Rossi, E. Reseghetti, L. Montefusco, F. D'Addio, C. Loretelli, G. Rossi, A. Abdelsalam, L. Loreggian, I. Pastore, M. Lunati, P. Morpurgo, M. Macedoni, C. Mameli, G. Zuccotti, P. Fiorina, Italy

736 Use of a one-time loading dose of once-weekly insulin efsitora alfa in phase 2 reduces transient hyperglycaemia and is not associated with excess hypoglycaemia risk vs degludec

J. Bue-Valleskey, C. Kazda, Q. Zhang, A. Haupt, D. Dahl, J. Frias, USA, Germany

737 The effect of various degrees of hepatic impairment on the pharmacokinetic characteristics of once-weekly insulin icodec

J.R. Jingst, B. Cieslarova, A.M. Donatsky, J.R. Joseph, N.R. Kristensen, V. Kupčová, H. Haahr, Denmark, Czech Republic, India, Slovakia

738 Pharmacokinetic properties of once-weekly insulin icodec in individuals with renal impairment versus normal renal function

H. Haahr, N.R. Kristensen, J.H. Larsen, F.-D.H. Wagner, S. Ignatenko, Denmark, Germany

739 Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes

J. Du, G.X. Wang, G. Wang, M. Liu, U.K. Thamattoor, Z.J. Luan, A.C. Alibegovic, Y.M. Mu, China, India, Denmark

740 Do people living with type 1 diabetes use the dosing flexibility of degludec and does this depend on patient characteristics?

Y. Winhofer, A. Kaas, N.N. Knudsen, J.H. Martiny, C. Mathieu, Austria, Denmark, Belgium

741 Characteristics of priming behaviour among individuals with diabetes using NovoPen 6 in a real-world setting

P. Choudhary, J. Diogo Da Rocha Fernandes, A. Kaas, M.R. Sørensen, K. Barnard-Kelly, UK, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

742 Real-world utilisation outcomes of shorter warmup and 12-hour grace period in a seventh-generation real-time continuous glucose monitoring system

L. Jepson, J. Welsh, S. Andrade, USA

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 58 To hell with the hypo

Chair: M. Malecki, Poland

743 The potential of predicting nocturnal hypoglycaemia for insulin-treated individuals with type 2 diabetes in telemonitoring

T. Kronborg, S. Hangaard, O. Hejlesen, P. Vestergaard, M.H. Jensen, Denmark

744 Hypoglycaemia self-management among adults with diabetes: gaps and leverage points (iNPHORM study, United States)

S. Harris, A. Ratzki-Leewing, J.E. Black, G. Zou, B.L. Ryan, Canada

745 Dasiglucagon corrects postprandial hypoglycaemia in Roux-en-Y gastric bypass-operated individuals

C. Nielsen, C. Øhrstrøm, I. Houji, M. Helsted, L. Krogh, N. Johansen, B. Hartmann, J. Holst, T. Vilsbøll, F. Knop, Denmark

746 Updated frequency of hypoglycaemic coma in children with type 1 diabetes: single centre observation over 25 years

B. Mianowska, O. Kowalczyk, K. Trzepińska, J. Wykrota, J. Chrzanowski, W. Fendler, I. Pietrzak, A. Szadkowska, Poland

747 Metabolic emergencies in type 1 and type 2 diabetes presenting to a hospital emergency department: frequencies, co-morbidities and mortality outcomes

S.H. Song, B.M. Frier, UK

748 Similar hypoglycaemia duration with once-weekly icodec versus degludec or glargine U100 in insulin-treated type 2 diabetes: a post hoc CGM analysis from ONWARDS 2 and 4

T. Battelino, B. Ásbjörnsdóttir, L. Carstensen, L.L. Lehrskov, C. Mathieu, A. Philis-Tsimikas, H.S. Bajaj, Slovenia, Denmark, Belgium, USA, Canada

749 Studying the IMPact of nasal glucagon on real-Life Experiences of Severe hypoglycemia Treatment (SIMPLEST) in the German population

A. Holstein, B. Mitchell, E. Moennig, S. Odak, D. McSorley, E. Spaepen, L. Jackson, L. Zografos, Y. Yan, A. Ponce-Ibarra, Germany, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

750 Food insecurity doubles the rate of severe hypoglycaemia in adults with diabetes: real-world results from the iNPHORM study (United States)

A. Ratzki-Leewing, J.E. Black, B.L. Ryan, G. Zou, S.B. Harris, Canada

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

EASD
EFSD

SO 59 How does AID aid the patients?

Chair: A. Szadkowska, Poland

GENERAL
INFO

751 Health outcomes and attribute satisfaction for automated insulin delivery systems in six European countries

T. Bell, E. Lin, E. Cox, T. Bristow, R. Wood, USA

PROGRAMME

TUESDAY

752 Patient reported outcome measures after six months of hybrid closed loop therapy

M. Cegarra Baños, N. Ruano Esteban, N. Balsells Bailon, E. Garcia Aguilera, A. Arqué Badia, A. Pomés Aixut, M. Mateu Amorós, L. Capdevila Torrents, A. Lecube Torelló, M. Hernández García, F. Rius Riu, Spain

WEDNESDAY

THURSDAY

FRIDAY

753 Improvements in treatment satisfaction with Omnipod Dash insulin management system are durable over 24 weeks in adults with type 1 diabetes

D.N. O'Neal, Y.W. Kong, C.Y. Yuan, K. Brown, K. Kiburg, S. Trawley, A. Partovi, R. Kerry, N. Harrison, S. Furlanos, E. Ekin, Australia

SHORT ORAL
DISCUSSIONS

754 Clinical outcomes associated with Omnipod DASH use in the real-world: results from the Association of British Clinical Diabetologists (ABCD) Omnipod Worldwide Audit

N. Hasan, T.S. Crabtree, M. Haq, E. Gatdula, R.E. Ryder, A. Lumb, P. Choudhary, E.G. Wilmot, UK

755 Automated insulin delivery use in adults with type 1 diabetes not meeting glycaemic targets despite treatment with insulin pump and CGM: a randomised controlled trial

M.B. Christensen, A.G. Ranjan, K. Rytter, O.M. McCarthy, S. Schmidt, K. Nørgaard, Denmark, UK

756 Efficacy of open-source automated insulin delivery systems compared with commercial hybrid closed-loop insulin pumps: real-world data from a tertiary center

L. Horváth, M. Mráz, J. Kloučková, D. Vávra, R. Bém, M. Haluzík, Czech Republic

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

757 Fully closed-loop with ultra-rapid insulin lispro improves glycaemic control compared to pump therapy with CGM in adults with type 1 diabetes: a randomised crossover study

C.K. Boughton, R. Lakshman, S. Hartnell, M. Nwokolo, J. Ware, J.M. Allen, M.E. Wilinska, M.L. Evans, R. Hovorka, UK

758 Why CGM alone is not enough: low actionability of CGM alerts without considering impact of active insulin

M.B. Smith, G. Im, J. MacLeod, R.A. Vigersky, USA

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 60 How bright is the hybrid?

Chair: S. Hussain, UK

759 A randomised clinical trial comparing the efficacy of a hybrid closed-loop automated insulin delivery system with a sensor-augmented disposable patch pump in type 1 diabetes

J. Kim, S.-M. Jin, E. Kang, S. Kwak, Y. Yang, J. Yoo, J. Bae, J. Moon, C. Jung, J. Bae, S. Suh, S. Moon, S. Song, S. Chon, J. Kim, Republic of Korea

760 Hybrid closed-loop with ultra-rapid insulin lispro increases time in range compared with standard insulin lispro in adults with type 1 diabetes: a randomised crossover study

R. Lakshman, M. Nwokolo, C.K. Boughton, J. Ware, J.M. Allen, M.E. Wilinska, H. Alwan, M.L. Evans, R. Hovorka, UK, Switzerland

761 Improvement in glucose control after switching to advanced hybrid closed-loop: results from a one year real-world study with Minimed 780G

F. Turchi, M.P. Luconi, B. Ciappini, N. Giorgini, S. Rosati, L. Lanari, E. Tortato, Italy

762 Should people with type 2 diabetes treated by multiple daily injections with home healthcare daily support be switched to a hybrid closed-loop system? The Close AP+ study

Y. Reznik, M. Carvalho, S. Fendri, G. Prevost, L. Chaillous, J.-P. Riveline, H. Hanaire, S. Dubois, H. Pasche, P. Houeto, E. Renard, France

763 Glycaemic improvements with the Omnipod 5 AID System across diverse baseline characteristics: learnings from 320 trial participants ages 2-70 years

L. Leelarathna, T.T. Ly, The Omnipod 5 Research Group, UK, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

764 Comparison between a first-generation and a second-generation commercial automated insulin delivery system in glucose management among adults with type 1 diabetes

Z. Wu, M. Lebbbar, A. Bonhoure, M. Raffray, M. Devaux, V. Messier, V. Boudreau, A.-S. Brazeau, R. Rabasa-Lhoret, Canada

765 Comparison of efficacy of automated insulin delivery, sensor-augmented pumps and insulin pumps without advanced functions in adults with type 1 diabetes

M. Müllerová, R. Bém, D. Vávra, K. Sochorová, M. Haluzík, Czech Republic

766 The MiniMed 780G system adapts to substantial changes in daily routine: lessons from real-world users during Ramadan

M. Al-Sofiani, A. Al-Guwaihis, A. Al-Shaikh, A. Adjene, N. Al-Amuddin, D. Mohannadi, A. Arrieta, J. Castaneda, W. Chaar, T. Van den Heuvel, O. Cohen, Saudi Arabia, United Arab Emirates, Bahrain, Qatar, Switzerland

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 61 Refining and redefining insulin therapy in type 1 diabetes

Chair: E. Maddaloni, Italy

767 Catheter changes lead to increased hyperglycaemia in both open and closed loop modes: real-life evidence from pump users with type 1 diabetes

J.-B. Julla, P. Jacquemier, Y. Reznik, C. Virbel-Fleischman, E. Leutenegger, E. Bonnemaïson, H. Hanaire, P. Schaepelynck Belicar, G. Fagherazzi, E. Renard, J.-P. Riveline, France, Luxembourg

768 InPen smart insulin pen plus continuous glucose monitoring (CGM) identifies missed correction opportunities: impact on glycaemia and potential for actionable reminders

R.A. Vigersky, G. Im, M.B. Smith, J. MacLeod, USA

769 Automated insulin delivery systems in adults with type 1 diabetes: A real game changer?

R. Bem, D. Vávra, K. Sochorová, M. Müllerová, M. Haluzik, Czech Republic

770 Safety and performance of an advanced hybrid closed-loop algorithm with ultra rapid lispro and lispro

R.K. Pollom, L. Nosek, H. Veir Coester, E. Zijlstra, A. Ghosh, A. Haidar, R.E. Jones, J.K. Leohr, S.E. Gleissner, E. Dassau, M. Katz, USA, Germany, Canada

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

771 Glucometrics and glycaemic control in adults with type 1 diabetes when switching to insulin degludec

S. Charleer, R. De Groote, E. Lefever, P. Donné, C. De Block, C. Mathieu, P. Gillard, Belgium

772 CamAPS in Poland: the first encouraging experience from two pediatric diabetes centres

P. Jarosz-Chobot, S. Seget, H. Kaminska, E. Rusak, P. Choreza, A. Ochab, E. Ledwon, A. Chobot, Poland

773 Insulin degludec vs glargine U100 in people with type 1 diabetes: Does one size fit all?

S. Hjejle, J.M. Brøsen, R.M. Agesen, B. Thorsteinsson, U. Pedersen-Bjergaard, Denmark

774 The effects of glycaemic markers and insulin resistance on patient-related outcomes in people living with type 1 diabetes

M. Gao, N. Kietsiriroje, S. Pearson, R. Sagar, G. Traviss-Turner, A.J. Hill, R.A. Ajjan, UK, Thailand

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 62 If it is Tuesday, it is time for insulin injection

Chair: S. Di Molfetta, Italy

775 CGM outcomes and hypoglycaemia duration with once-weekly insulin icodec versus once-daily insulin glargine u100 in insulin-naïve type 2 diabetes: ONWARDS 1 exploratory analysis

R. Bergenstal, S. Kehlet Watt, A.S. Matos, I. Lingvay, J.K. Mader, T. Nishida, J. Rosenstock, USA, Denmark, Austria, Japan

776 Improved patient-reported outcomes with once-weekly insulin icodec with a dosing guide app versus once-daily basal insulin analogues in type 2 diabetes (ONWARDS 5)

R. Goldenberg, M. Benamar, L. Carstensen, M. Davies, A.M. Donatsky, E. Franek, M. Kellerer, W. Polonsky, Canada, Denmark, UK, Poland, Germany, USA

777 CGM in insulin-experienced individuals with type 2 diabetes switched to once-weekly insulin icodec versus once-daily comparators in ONWARDS 2 and 4: post hoc analysis

B. Ásbjörnsdóttir, H.S. Bajaj, L.L. Lehrskov, C. Mathieu, A. Philis-Tsimikas, N. Wang, T. Battelino, Denmark, Canada, Belgium, USA, Slovenia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

778 Improved glycaemic control with once-weekly insulin icodec with a dosing guide app vs once-daily basal insulin analogues in insulin-naïve type 2 diabetes: ONWARDS 5

H.S. Bajaj, J. Aberle, M. Davies, A.M. Donatsky, M. Frederiksen, D.G. Yavuz, A. Gowda, I. Lingvay, B. Bode, Canada, Germany, UK, Denmark, Turkey, USA

779 Once-weekly insulin icodec: pharmacokinetic and pharmacodynamic properties in type 1 diabetes

U. Hövelmann, S. Engberg, T. Heise, N.R. Kristensen, L. Nørgreen, R. Ribel-Madsen, E. Zijlstra, H. Haahr, Germany, Denmark

780 Improved treatment satisfaction with once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated type 2 diabetes (ONWARDS 2)

W. Polonsky, M. Benamar, L. Carstensen, M. Davies, A.M. Donatsky, E. Franek, M. Kellerer, R. Goldenberg, USA, Denmark, UK, Poland, Germany, Canada

781 Once-weekly insulin icodec and hospitalisation: insights from the ONWARDS 1-6 trials

A. Philis-Tsimikas, J.K. Bache, T.J. Bari, K. Salvesen-Sykes, M. Kellerer, USA, Denmark, Germany

782 Improved HbA_{1c} and time in range with once-weekly insulin icodec versus insulin glargine U100 in insulin-naïve type 2 diabetes: ONWARDS 1

J. Rosenstock, S.C. Bain, A. Gowda, H. Horio, E. Jodar, L.L. Lehrskov, I. Lingvay, R. Trevisan, O. Mosenzon, USA, UK, Denmark, Japan, Spain, Italy, Israel

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 63 Patient-centered perfecting of insulin therapy

Chair: K. Strojek, Poland

783 Association of achieving time in range clinical targets among people with type 1 diabetes treated with different insulin modalities

A.G. Ranjan, C. Laugesen, K.G. Tidemand, A. Green, C. Selmer, J. Svensson, H.U. Andersen, D. Vistisen, B. Carstensen, K. Nørgaard, Denmark

784 Biphasic bolus meal management analysis

M. Louis, A. Adenis, H. Romero-Ugalde, S. Lachal, E. Hunecker, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

785 Characterisation of glucose-insulin regulation based on modelling of data obtained exclusively from continuous glucose monitoring systems in patients with type 2 diabetes

D. Herzig, L. Bally, P. Des Courtis, T. Castiglione, A. Jaun, Switzerland

786 Performance of simultaneously used real-time CGM versus intermittently scanned CGM around exercise in type 1 diabetes: an exploratory analysis of the ULTRAFLEXI-1 study

O. Moser, A. Müller, F. Aberer, F. Aziz, H. Kojzar, C. Sourij, A. Obermayer, P. Birnbaumer, P.N. Pferschy, N. Tripolt, H. Sourij, Austria

787 Medico-economique approach to the implementation of continuous glucose monitoring for patient hospitalised in a diabetes department

V.M. Pepe, S. Wisniewski, F. Fall-Mostaine, L. Rakotoarisoa, L. Kessler, France

788 Clinical features of type 1 diabetes in older adults and impact of isCGM: association of British Clinical Diabetologist study

H. Deshmukh, K. Adeleke, E. Wilmot, C. Walton, R.E. Ryder, T. Sathiyapalan, UK

789 A review of GMI in a cohort of people with and without type 2 diabetes not on insulin: Does HIV serostatus influence the result?

H. Daultrey, T. Levett, J. Wright, N. Oliver, A.J. Chakera, UK

790 Impact of circadian rhythm parameters on type 1 diabetes control

N. Marhefková, M. Lejnarová, M. Kahle, S. Kalina, J. Svoboda, R. Roland, M. Sládek, A. Sumová, M. Dubský, Czech Republic

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 64 Quantifying hypoglycaemia: from mild to mad

Chair: TBA

791 Plasma agouti-related protein concentrations are decreased in individuals with impaired awareness of hypoglycaemia

R. Varkevisser, A. Petrera, S.M. Hauck, D. Mul, H.-J. Aanstoot, B.H. Wolffenbuttel, M.M. Van der Klauw, Netherlands, Germany

792 Glycaemic overtreatment, severe hypoglycaemia and all-cause mortality in old adults with type 2 diabetes

Y.-T. Chiu, S.-C. Liu, C.-C. Lee, C.-C. Chen, Taiwan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

793 Factors associated with symptomatic hypoglycaemia are different from those for CGM hypoglycaemia in people living with type 1 diabetes: the Hypo-METRICS study

P. Divilly, Z. Mahmoudi, G. Martine-Edith, N. Zaremba, B. De Galan, U. Pedersen-Bjergaard, R. McCrimmon, E. Renard, S. Heller, M. Evans, J. Mader, J. Speight, S. Amiel, F. Pouwer, P. Choudhary, UK, Netherlands, Denmark, France, Austria, Australia

EASD
EFSD

794 How well does sensor-detected hypoglycaemia from short-duration CGM reflect person-reported hypoglycaemia?

P.M. Baumann, M. Cigler, D. Kuznetsov, M. Rosilio, D. Hochfellner, M. Ibberson, S.A. Amiel, S. Heller, M.-A. Gall, B. De Galan, T.R. Pieber, P. Choudhary, J.K. Mader, Hypo-RESOLVE Consortium, Austria, Switzerland, France, UK, Denmark, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

795 Recurrent hypoglycaemia induces pro-inflammatory priming of BMDMs and promotes vascular dysfunction in a mouse model of type 2 diabetes and CVD

C. Forteach, A.D. McNeilly, J. Kerr, J. Deyell, J. Gallagher, A. Iqbal, M.F. Arshad, R. Stienstra, M.L. Evans, B. Thorens, U. Pederson-Bjergaard, B.E. De Galan, R.J. McCrimmon, HypoRESOLVE Constortium, UK, Netherlands, Switzerland, Denmark

796 Metabolic adaptations of a hypothalamic neuronal cell line, mHypoA-2/21, in response to recurrent hypoglycaemia

H.J. Merchant, M.J. Ashford, R.J. McCrimmon, A.D. McNeilly, UK

797 Concordance between self-reported measures of glycaemic control and hypoglycaemia with continuous glucose monitoring tracing data among adults with type 1 diabetes

L. Laffel, K. Hagan, L. Titievsky, K. Chandarana, J. Gaglia, T. Liu, J. Bispham, K. Chapman, D. Finan, J. Liu, H. Nguyen, W. Wolf, R. Bergenstal, USA

798 Quantifying intensity of hypoglycaemia symptoms by diabetes type and hypoglycaemia awareness status: results from the Hypo-METRICS study

G. Martine-Edith, P. Divilly, N. Zaremba, U. S  holm, M. Broadley, P. Baumann, B. De Galan, R.J. McCrimmon, M. Evans, J.K. Mader, S.A. Amiel, J. Speight, F. Pouwer, P. Choudhary, for the Hypo-RESOLVE Consortium, UK, Denmark, Austria, Netherlands, Australia

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 65 Yin and yang of CGMing*Chair:* L. Czupryniak, Poland**799 Treatment satisfaction, patient enablement, and self-rated health among adults with type 1 diabetes changing from finger prick to CGM**

L.B. Pedersen, N.D. Ryg, M.S. Aaskoven, C.B. Juhl, K. Schousboe, Denmark

EASD
EFSD**800 Inpatient continuous glucose monitoring vs capillary blood glucose: a cost-effectiveness analysis**

D. Verissimo, J. Vinhais, V. Machado, S. Silva, C. Ivo, A.C. Martins, J.N. Silva, D. Passos, L. Lopes, J.J. Castro, M. Marcelino, Portugal

GENERAL
INFO**801 Comparison of glycaemic metrics from simultaneous use of intermittently scanned and real-time continuous glucose monitoring in patients with type 1 diabetes**

A. Siolos, M. Christou, D. Katsarou, P. Christou, C. Zessides, E. Georga, D. Fotiadis, S. Tigas, Greece

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

802 Randomised controlled trial of real time continuous glucose monitoring in people with type 2 diabetes on insulin (the 2GO-CGM study)

C.S. Lever, J.A. Williman, A. Boucsein, A. Watson, R.S. Sampson, O.T. Sergel-Stringer, C. Keesing, B.J. Wheeler, M.I. De Bock, R.G. Paul, New Zealand

SHORT ORAL
DISCUSSIONS**803 Continuous glucose monitoring accuracy during labor and delivery in pregnant women with insulin-treated diabetes**

F. Citro, C. Bianchi, M. Aragona, T. Belcari, F. Nicolì, L. Battini, P. Marchetti, A. Bertolotto, Italy

PRESENTER
INDEX**804 Performance of real-time continuous glucose monitoring during 4 weeks of track and field training in adolescents with type 1 diabetes**

J. Schierbauer, R. Zimmer, D. Herz, S. Haupt, P. Zimmermann, N. Wachsmuth, P. Birnbaumer, P. Hofmann, E. Fröhlich-Reiterer, M. Fritsch, C.P. Sternad, F. Aberer, H. Sourij, O. Moser, Germany, Austria

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

805 Frequency and impact of sensor measured hyperglycaemia in persons admitted with an infection

J.J. Bakker, A. Van der Vaart, H.R. Bouma, P.C. Choudhary, P.R. Van Dijk, Netherlands, UK

806 Accuracy and reliability of real-time continuous glucose monitoring in the intensive care unit after major abdominal surgery including solid organ transplantation

B. Hagerf, M. Protus, L. Nemetova, M. Mraz, M. Haluzik, P. Girman, J. Franekova, V. Svirlochova, A. Jabor, Czech Republic

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 66 Insulin therapy can be better and cheaper

Chair: D. Dahl, Germany

807 Detection of glycaemic excursions in people with type 2 diabetes treated with gla-100 in primary care through continuous glucose monitoring: the GPDetect study

V. Bellido, C. Morales, A. Soto, A. Serrano, P. Fuentealba, O. Laclaustra, A. Cebrian, Spain

808 Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 1 diabetes

W. Chen, T. Xie, A. He, L. Li, C. Hao, E.A. Christofides, China, USA

809 Efficacy, safety and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 2 diabetes

E.A. Christofides, T. Xie, A. He, L. Li, C. Hao, W. Chen, USA, China

810 Effect of descending vs ascending modes in short-term intensive insulin therapy on glycaemic outcome in newly diagnosed type 2 diabetes patients

X. Zhang, Z. Zhang, X. Huang, Y. Li, Z. Huang, China

811 Simplifying insulin treatment in persons with type 2 diabetes over 65 years: interim report of the STOP study

M. De Fano, A. Mazzieri, C.G. Fanelli, F. Porcellati, Italy

812 Efficacy of a basal insulin titration app on glycaemic outcomes in people with type 2 diabetes on an oral-basal insulin regimen: results of an RCT

N. Hermanns, D. Ehrmann, K. Finke Groene, T. Roos, B. Kulzer, Germany

813 Mieres study of continuous glucose monitoring: a good idea for the elderly

A. López-Alba, J. Fernandez-Morera, L. Diaz-Mier, E. Mediavilla-Alvarez, F. Menendez-Alvarez, Spain

814 Incorporating shared decision making in clinical practice to improve adoption of connected insulin pens

O. Ebekozien, O. Odugbesan, N. Xavier, USA

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 67 Un/successful fitting diabetes in a health care system

Chair: T. Tankova, Bulgaria

815 Application of current HbA_{1c} reference range to premenopausal (<50) women may lead to under diagnosis of type 2 diabetes

M. Stedman, D. Holland, A.A. Fryer, J.J. Warner-Levy, P. Wu, A.H. Heald, UK

816 Clinical and economic burden of severe hypoglycaemic events in patients with type 1 diabetes in the United States: a retrospective comparative cohort claims analysis

A. Boateng-Kuffour, P. Callahan, C. Acosta, K. Chandarana, M. Hull, V.R. Anupindi, X. Zhou, M. DeKoven, R. Beck, USA

817 Outcomes of the multidisciplinary 'Severe disordered eating in type 1 diabetes (T1DE)' pan-London service

M. Stadler, M. Rosenthal, D. Turner, J. Brown, A. Harrison, Y.-F. Liu, N. Oliver, E. Konstantara, D. Hopkins, J. Treasure, K. Ismail, UK

818 Retrospective controlled study shows intermittently scanned CGM is associated with lower HbA_{1c} and reduced hospitalisation for diabetes events in adults with type 1 diabetes in Sweden

K. Eeg-Olofsson, D. Nathanson, T. Spelman, M. Kyhlstedt, E. Bülow, F. Levrat-Guillen, J. Bolinder, Sweden, UK

819 Impact of insulin resistance measured by estimated glucose disposal rate on continuous glucose monitoring parameters in type 1 diabetes

M. Parise, A. Cutruzzolà, S. Di Molfetta, S. Lucà, C. Irace, A. Gnasso, Italy

820 By how much does red blood cell status affect the accuracy of HbA_{1c}?

S.E. Manley, A. Karwath, R.A. Round, I.M. Stratton, G.V. Gkoutos, S. Mostafa, G.A. Roberts, J. Webber, UK, Ireland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

821 Intermittently-scanned CGM is associated with lower HbA_{1c} and reduced hospital admissions for adults with type 2 diabetes on insulin therapy in Sweden: a retrospective controlled study

D. Nathanson, K. Eeg-Olofsson, T. Spelman, E. Bülow, M. Kyhlstedt, F. Levrat-Guillen, J. Bolinder, Sweden, UK

822 Effectiveness of an HbA_{1c} screening programme for in-patients and its impact on diabetes management in different departments of a large hospital centre in Germany

C. Jacob, A. Staudt, J.-P. Ritz, S. Zimny, H.S. Willenberg, U.D. Lichtenauer, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 68 Where do the happiest people with diabetes live?

Chair: N. Lalic, Serbia

823 Leveraging geographic data to support diabetes prevention efforts

T. Thomas, W. Dyer, M. Yassin, L. Rodriguez, R. Demissie, T. Moin, O. Duru, J. Schmittiel, USA

824 Socioeconomic inequalities in diabetes prevalence in Europe

S. Sidahmed, S. Geyer, J. Beller, Germany

825 Country background, education level, employment and disability in young-onset type 2 diabetes

K. Tibballs, L. Kirkebøen, A. Jenum, J. Straand, E.S. Buhl, Norway

826 Quantifying the benefits of pursuing early and intensive metabolic control in patients with type 2 diabetes in Italy

P. Arietti, K.S. Boye, M. Guidi, J. Rachmann, M. Orsini Federici, R. Raiola, A. Avitabile, W.J. Valentine, Italy, Switzerland, UK

827 Effects of national reimbursement policy supporting test strips on glycaemic control in patients with insulin-treated diabetes: a longitudinal study

S. Cho, S. Kim, R. Oh, Y.-B. Lee, S.-M. Jin, M. Kang, G. Kim, J. Kim, Republic of Korea

828 Regulatory actions to avoid shortage were taken in Sweden when insulin hoarding was observed during the early phase of the COVID-19 pandemic

B. Zethelius, A. Sundström, K. Nordback, K.-M. Kälkner, R. Ljung, Sweden

829 Socioeconomic status as determinant for development of comorbidities in people with type 1 diabetes: a nationwide register study in Denmark from 1998-2018

J.D. Andersen, C.W. Stoltenberg, M.H. Jensen, P. Vestergaard, O. Hejlesen, S. Hangaard, Denmark

830 Consistent performance of the MiniMed 780G system across continents: a world-wide real-world analysis

T. Van den Heuvel, A. Arrieta, J. Castaneda, R. Vigersky, O. Cohen, Switzerland, USA

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 69 “When I’m sixty-four” (low and not-so-young)

Chair: I. Kowalska, Poland

831 The Hypo-RESOLVE QoL: a new patient reported outcome (PRO) to quantify the impact of hypoglycaemia on health-related quality of life

J. Carlton, P. Powell, D. Rowen, M. Broadley, F. Pouwer, J. Speight, S. Heller, M.-A. Gall, M. Rosilio, C.J. Child, J. Comins, R.J. McCrimmon, B. De Galan, Hypo-RESOLVE Consortium, UK, Denmark, Australia, France, Netherlands

832 Relationships between severe hypoglycaemia and impaired awareness of hypoglycaemia with health status and cognition in adults with type 1 diabetes

E. Sepúlveda, R. Poínhos, D. Carvalho, G. Nata, S.A. Amiel, S.G. Vicente, Portugal, UK

833 Naming hypoglycaemia: a narrative tool for young people with type 1 diabetes and their families

F. Rosário, M. Soares, F. Mesquita, J.F. Raposo, Portugal

834 Anticipated reduction in hypoglycaemia fear and diabetes distress from increasing the glucose prediction of current CGM algorithms

D. Ehrmann, T. Glatzer, N. Babio, L. Priesterroth, B. Olesen, B. Kulzer, N. Hermanns, Germany

835 The use of IDegLira in aged frail people with type 2 diabetes: the STOP study

A. Mazzieri, M. De Fano, C. Fanelli, F. Porcellati, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

836 Distinct inflammatory functions of murine BMDMs following exposure to acute vs recurrent hypoglycaemia

J. Kerr, A.D. McNeilly, C. Forteath, J. Deyell, K. Smellie, R. Hall, R. Stienstra, B.D. Galan, M. Evans, U. Pedersen-Bjergaard, B. Thorens, R.J. McCrimmon, UK, Netherlands, Denmark, Switzerland

837 The effectiveness of a light-intensity physical activity intervention on cardiovascular health in people with type 2 diabetes: a randomised controlled trial

E.J. Vandercappellen, R.M. Henry, Y. Chen, P.M. Niessen, M.J. Minten, A.M. Linkens, P.I. Simons, S. Jolani, H.H. Savelberg, A.J. Houben, T.T. Berendschot, K.D. Reesink, J.W. Muris, C.D. Stehouwer, A. Koster, Netherlands

838 Impact of COVID-19 measures on body composition differs among age and gender in persons with diabetes

Y. Yamaguchi, Y. Hamamoto, M. Imura, Y. Yamazaki, K. Izumi, R. Usui, H. Kuwata, T. Hyo, Y. Yamada, Y. Seino, Japan

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 70 Will rise of the machines terminate diabetes?

Chair: A. Araszkievicz, Poland

839 Right patient, right therapy, right time: empowering HCPs and patients: results from the Spotlight-AQ multi-centre randomised controlled trial

R.C. Kelly, H. Price, M. Patel, A. Ali, M. Cummings, E. Barnard, K. Barnard-Kelly, UK

840 Prediction of HbA_{1c} response to second-line anti-diabetic agents in type 2 diabetes using machine learning: preliminary results

C.W. Stoltenberg, S. Hangaard, O. Hejlesen, T. Kronborg, P. Vestergaard, M.H. Jensen, Denmark

841 Machine-learning applied to digital retinal images to predict diabetes and hypertension

V.E. Parker, V. Selvarajah, N. Svargard, T. White, F. Wolfhagen-Sand, T. Hegelund- Myrback, M. Majdanska-Strzalka, K. Kaszubska, R. Esterline, UK, Sweden, Poland, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

842 Evaluation of a clinical artificial intelligence companion for therapeutic decision making in type 2 diabetes management: a retrospective analysis

L. Bally, D. Herzig, C. Piazza, L. Brunschwig, Z. Gabr, Y. Dibner, A. Jaun, Switzerland

843 The efficacy of telemonitoring and integrated personalised diabetes management in people with insulin-treated type 2 diabetes: a preliminary analysis

N. Laichuthai, T. Saetang, P. Greeviroj, S. Thavaraputta, P. Santisitthanon, N. Hounngam, Thailand

844 Impact of Digital Twin app frequency of use on remission and clinical outcomes in type 2 diabetes: results at 18 months of follow up

S. Joshi, J. Mohammed, M. Mohamed, T. Poon, M. Dharmalingam, B. Saboo, S. Damodharan, A. Vadavi, M. Thajudeen, A. Keshavamurthy, S. Bhonsley, P. Shamanna, India, USA

845 Reductions in hyperglycaemic events following use of a digital diabetes logbook: results of a randomised controlled trial

K. Finke-Groene, N. Hermanns, S. Silbermann, D. Ehrmann, J. Kober, T. Roos, I. Vesper, V. Schäfer, B. Kulzer, Germany, Austria

846 Association between treatment adherence and continuous glucose monitoring outcomes in people with diabetes using smart insulin pens in a real-world setting

T. Danne, N.V. Hartvig, A. Kaas, N.N. Knudsen, J.K. Mader, Germany, Denmark, Austria

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 71 Making it all work

Chair: B.H.R. Wolffenbuttel, Netherlands

847 “Stay on top of your diabetes”: A better way to control your diabetes?

A. Nikontovic, D. Juhl Hansen, M. Ørskou Bols, P. Kronholm, H. Ravn Larsen, P. Vestergaard, Denmark

848 Real world evidence of trends in complications and outcomes of diabetic ketoacidosis following implementation of revised Joint British Diabetes Societies’ guidelines

M.A. Skaria, A. Narendran, P.V. Iyer, S. Kauser-Malik, L. Bomphrey, M. Hebbar, L. Rengarajan, P. Narendran, DEKODE Team, P. Kempegowda, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

849 Preconception care for women with diabetes most effective in women with type 1 diabetes receiving continuous subcutaneous insulin infusion: a local perspective

L.A. Allen, A. Ellis, A. Ali, H. Cole, A. Roberts, H. Bolusani, J. Platts, N. Agarwal, M. Choudhury, UK

850 Economic evaluation of healthcare providers for the management of patients with type 1 diabetes equipped with hybrid closed-loop system in France

R. Scarica, M. Schaller, C. Delval, France

851 Prescribing practices of cardioprotective anti-diabetic medications in marginalised patients

A. Pasha, R.M. Khan, A. Khidhir, T.M. Aladesua, J. Mustafa, G.D. Gudleski, S.Y. Bakhai, USA

852 Impact of a specialised team for diabetes management during hospitalisation in a tertiary hospital in Spain

J. Amigó, O. Simó Servat, A. Ortiz Zúñiga, M. Sanchez, F. Cuadra, M. Dos Santos, M. Lara, C. Hernandez, R. Simó, Spain

853 Diabetes shared value programme in the South African private sector: year two results

N. Bagirathi, C. Pastellides, South Africa

854 Understanding the natural history of people admitted with DKA to facilitate better services and reduced length of hospitalisation: experiences from DECODE LOS study

A. Gupta, B. Brazier, P. Kempegowda, L. Rengarajan, D. Arshad, D. Zhang, UK

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 72 When diabetes goes digital

Chair: L. Laviola, Italy

855 Miniaturised near-infrared spectroscopy device in screening for diabetes

X. Cos, D. Lazaro, J. Salter, P.M. Paldánus, P. Choudhary, Spain, UK, Finland

856 The determinants of using Digital Health Solutions for people living with type 1 and type 2 diabetes in France

P. Cerletti, J. Laurent, N. Hermanns, Switzerland, France, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

857 Glycaemia risk index (GRI) uncovers distinct glycaemic variability patterns associated with remission status in type 1 diabetes

X. Li, T. Zhong, X. Li, K. Lei, R. Tang, China

858 Digital Twin-based personalised diet improves glycaemic control in type 2 diabetes: findings from a 6-month randomised controlled trial

P. Shamanna, J. Mohammed, M. Mohammed, T. Poon, M. Dharmalingam, B. Saboo, S. Damodharan, A. Vadavi, M. Thajudeen, A. Keshavamurthy, S. Bhonsley, S. Joshi, India, USA

859 Evaluation of glucometrics knowledge and its relationship with glycaemic control in people living with type 1 diabetes: Glukometrics study

R. Reyes-Garcia, O. Moreno-Perez, C. Tejera-Perez, M. Brito-Sanfiel, P. Pines, E. Aguilera, M. Gargallo-Fernandez, J. Escalada San Martin, Spain

860 Association between circadian rhythm and daily glycaemic status

I. Jung, D. Lee, J.-B. Lee, S. Park, J. Yu, J. Seo, H.-J. Lee, N. Kim, Republic of Korea

861 Describing a 3D innovation in digital diabetes from a tertiary care diabetes centre in India

P. Gangadhara, R. Harish, V. Mohan, J. S, S. B, R. Unnikrishnan, R.M. Anjana, India

862 Digital platform for awareness and screening peripheral neuropathy in Thailand: transformation on diabetes management

A. Salaiwarakul, E. Wanothayaroj, Thailand

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 73 More or less likely but still important determinants of diabetes care

Chair: T. Zerekidze, Georgia

863 Attitudes and beliefs regarding use of time in range among diabetes healthcare professionals: early results from an online survey conducted in Canada, UK and USA

A.Y. Cheng, C. De Block, A. Agrawal, G. Anil, J.M. D'Cruz, A. Ginovker, Canada, Belgium, India, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

864 Trust in sources of diabetes information in six European countries

E. Lin, E. Cox, T. Bell, T. Bristow, R. Wood, USA

865 Socioeconomic gender has an impact on diabetes risk, but not on gestational diabetes risk

T. Gisinger, J. Harreiter, D. Simmons, M. Van Poppel, G. Desoye, A. Kautzky-Willer, Austria, Australia, Netherlands

EASD
EFSD

866 The association between blood glucose levels of children with type 1 diabetes and parental economic status in a mobile health app

W. Zhang, C. Wang, Y. Ding, X. Zheng, S. Luo, China

GENERAL
INFO

867 Precision medicine in type 2 diabetes: validation of an treatment selection model for SGLT2-inhibitor and DPP4-inhibitor therapies in people of non-white ethnicity

J.M. Dennis, K. Young, P. Cardoso, R. Hopkins, E. Pearson, A. Hattersley, T. McKinley, A. Jones, B.M. Shields, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

868 Depression is associated with lower adherence to antihypertensive and lipid-lowering treatment in individuals with type 1 diabetes

R. Lithovius, S. Mutter, E.B. Parente, V. Harjutsalo, P.-H. Groop, Finland

869 Diabetes distress and depression frequently co-exist in people with type 2 diabetes in Bangladesh

J.A. Marathe, M. Kamruzzaman, R.J. Jalleh, M. Horowitz, K.L. Jones, C.S. Marathe, Australia, Bangladesh

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

870 Clinical benefit of a diabetes management solution for HCPs: a cross sectional analysis across ES, UK, US and BR

N. Orive Milla, D. Radiceska, H. Koenig, Spain, USA, Germany

SATELLITE
SYMPOSIA

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

INDUSTRY

PROGRAMME

SO 74 Clinical observations to improve the prediction and progression of diabetic kidney disease

Chair: TBA

871 Machine learning model for predicting worsening renal function using one-year time series data of urinary protein and eGFR in patients with type 2 diabetes

M. Watanabe, S. Meguro, K. Kimura, M. Furukoshi, T. Masuda, M. Enomoto, H. Itoh, Japan

EXHIBITION

872 Glucose variability and recognition of hypoglycaemia in patients with type 1 diabetes and different diabetic kidney disease progression rate

J. Janevica, A. Fedulovs, L. Kruzmane, O. Kucaja, J. Sokolovska, Latvia

873 Genome wide association study of premorbid disease histories converging on chronic kidney disease in individuals with and without comorbid type 2 diabetes from the UK Biobank

M.J. Ennis, P. McClean, P. Shukla, J. Sharman-Soares, S. Watterson, UK

874 Association of physical activity with incident chronic kidney disease among cardiovascular metabolic disease: a prospective cohort study

H. Liu, X. Shao, P. Yu, China

875 Hemoglobin glycation index as a novel risk factor for incident chronic kidney disease

Y. Nakasone, T. Miyakoshi, K. Hirabayashi, H. Koike, K. Yamashita, T. Aizawa, Japan

876 A patatin-like phospholipase domain-containing 3 gene variant associates with progressive kidney disease in diabetes endotypes

O.P. Zaharia, K. Strassburger, B. Knebel, Y. Kupriyanova, V. Schrauwen-Hinderling, J. Kotzka, H. Al-Hasani, K. Bódis, C. Möser, K. Prystupa, M. Bombrich, M. Schön, K. Jandeleit-Dahm, R. Wagner, M. Roden, Germany

877 Exploring the relationship between baseline eGFR and composite renal event rate: a meta-analysis of type 2 diabetes outcome trials

Y. Du, A. Curtis, F.T. Botros, Z. Milicevic, M.C. Bunck, I. Turfanda, USA

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 75 Clinical outcomes and biomarkers in diabetic kidney disease

Chair: N. Panduru, Romania

878 Cardiorenal outcomes among people with diabetes and chronic kidney disease in the French CKD-REIN cohort: influence of the achievement of therapeutic goals at baseline

F. Bonnet, B. Balkau, Y. Diawara, M. Metzger, N. Alencar de Pinho, D. Fouque, B. Stengel, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

879 Platelet aggregation and aspirin response in type 1 diabetes with and without albuminuria

C.G. Poulsen, L.F. Ferreira-Divino, O.B. Pedersen, V. Rotbain Curovic, T.W. Hansen, M. Frimodt-Møller, A.-M. Hvas, P. Rossing, Denmark

880 Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating hematopoietic stem/progenitor cells

G. Fadini, B. Bonora, M. Morieri, M. Marassi, R. Cappellari, A. Avogaro, Italy

881 Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform

R.W. Thomsen, I.T. Andersen, F.P. Kristensen, P.V. Munch, M. Pladevall-Vila, C. Johannes, N. Saigi-Morgui, R. Ziemiecki, J. Layton, D. Vizcaya, A. Gay, A. Farjat, F. Liu, N. Oberprieler, C.F. Christiansen, Denmark, Spain, USA, Germany, UK, Norway

882 Need for newer pillars of therapy for reno-protection: pronounced eGFR slope improvement by SGLT2i and GLP-1RA in people with rapid eGFR decline

K. Kashima, H. Shimizu, Japan

883 Effect of dapagliflozin on circulating biomarkers of extracellular matrix remodelling in type 2 diabetes with albuminuria: a randomised clinical trial

V. Wasehuus, V.R. Curovic, M.K. Eickhoff, A.L. Møller, D.G. Rasmussen, F. Genovese, M. Frimodt-Møller, T.W. Hansen, P. Rossing, F. Persson, Denmark

884 Urinary Fetuin-A as a candidate biomarker for differentiation of diabetic kidney disease phenotypes in adults with type 2 diabetes

M. Giambalvo, D. Lucchesi, M. Capobianco, G. Mancini, G. Penno, S. Del Prato, M. Garofolo, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

SO 76 Diabetic kidney disease pathophysiology from cells to mice, and humans

Chair: L. Gnudi, UK

885 Single-cell sequencing reveals the expression of immune-related genes in macrophages of diabetic nephropathy

X. Shao, H. Liu, P. Yu, China

886 Glucose and fatty acid induced expression and nuclear distribution of mitochondrial ribosomal recycling factor GFM2 accompanied by impaired mitochondrial respiration

M. Zhang, C. Hogstrand, M. Afshan, UK

887 Rab27a promotes diabetic kidney disease progression by affecting m6A levels in renal tubular epithelial cells

D. Wenhui, X. Yaoming, China

888 Renal effects of a novel mitochondrial complex I modulator in a mouse model of type 2 diabetes

A. Aboolian, A. Romero, J. Jha, M. Martin Taboada, A. Cramer, O. Dürrschmidt, C. Granata, N. Saatmann, A. Dai, M. Roden, S. Urner*, K. Jandeleit-Dahm*, J. Meister*, *Co-senior authors, Germany, Australia, Spain

889 Role of ND-13, a DJ-1/Nrf2 pathway activator, in the prevention of inflammasome activation in diabetic nephropathy

S. Cuevas, M. Caballero-Herrero, E. Jumilla, F. Rosique, L. Martinez-Alarcon, L. Andujar, C. Molina, A. Nuñez, L. Hurtado, P. Pelegri, Spain

890 Mir-34a as a potential marker in diabetic kidney disease

S. Liu, V. Das, W. Ju, V. Nair, L. Goea, D. Delic, F. Burdet, M. Bitzer, C. O'Connor, R.G. Nelson, H.C. Looker, A. Thorenz, M. Kretzler, A. Karihaloo, T. Huber, Germany, Denmark, USA, Switzerland

891 Role of regenerating protein 1a in the progression of UACR in DKD patients

N. Huang, X. Wu, S. Chen, X. Zhu, L. Li, China

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 77 New insights to the drivers of diabetic retinopathy progression

Chair: M. Garofolo, Italy

892 Choriocapillaris perfusion correlates with retinal capillary perfusion in all three retinal plexuses in individuals with type 2 diabetes

K.M. Gooding, N. Rolinska, S. Balma, A. Forbes Brown, C. Ball, C. Kelsall, D. Mawson, K. Aizawa, A. Govier, M. Gilchrist, R. Ling, A. Shore, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

893 Effects of 32 weeks' treatment with semaglutide, empagliflozin or the combination on retinal oxygenation, vessel diameter and central retinal thickness

S. Gullaksen, L.V. Hald, S.S. Sørensen, K.L. Funck, L. Petersen, T. Bek, E. Laugesen, P.L. Poulsen, Denmark

894 Evaluation of sitagliptin eye drops in TRPV2+/- rats, a non-diabetic model with diabetic retinopathy-like lesions

H. Ramos Abellán, J. Augustine, B.M. Karan, C. Hernández, A.W. Stitt, T.M. Curtis, R. Simó, Spain, UK

EASD
EFSD

GENERAL
INFO

895 Discovering biomarkers for diabetic eye complications by single-cell RNA sequencing

C.B. Brandt, T.S. Voss, L. Petersen, T. Bek, L. Lin, N. Jessen, Y. Luo, Denmark

PROGRAMME

TUESDAY

896 Soluble CD163 and haemoglobin A_{1c} were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes

E.O. Melin, S. Hector, H.O. Thulesius, M. Hillman, M. Landin-Olsson, Sweden

WEDNESDAY

THURSDAY

897 Epicardial adipose tissue volume and retinopathy in people living with diabetes: the Opht-EAT study

S. Tatulashvili, A. Khalife, M. Boubaya, H. Bihan, L. Allard, M. Sal, I. Rezgani, Z. Elfekih, P.-Y. Brillet, A. Giocanti, E. Cosson, France

FRIDAY

SHORT ORAL
DISCUSSIONS

898 Are automated insulin delivery systems the best treatment option for adults with type 1 diabetes and retinopathy?

D. Vávra, R. Bem, K. Sochorová, M. Müllerová, M. Haluzik, Czech Republic

PRESENTER
INDEX

899 Rapid reduction of HbA_{1c} and early worsening of diabetic retinopathy: a real-world population-based study in subjects with type 2 diabetes

R. Simo, J. Franch-Nadal, B. Vlacho, J. Real, E. Amado, J. Flores, M. Mata-Cases, E. Ortega, M. Rigla, J.-A. Vallés, C. Hernández, D. Mauricio, Spain

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 78 Biomarkers and risk factors for diabetic foot disease and peripheral neuropathy

Chair: S. Azmi, UK

900 Have PAD and microcirculation status impact on the tissue availability of intravenously administered antibiotics in patients with infected diabetic foot (DFIATIM study)?

V. Fejfarova, R. Jarošíková, J. Kepertová, J. Husáková, V. Wosková, P. Beca, P. Tůma, J. Polák, M. Dubský, D. Sojáková, V. Lánská, M. Petrлік, Czech Republic

901 Main factors influencing limb salvage in patients with chronic limb-threatening ischaemia after autologous cell therapy

D. Sojakova, V. Fejfarova, J. Husakova, A. Nemcova, R. Jarosikova, V. Woskova, K. Sutoris, M. Kahle, M. Dubsky, Czech Republic

902 Surface swaps of diabetic foot ulcers carry a distinct protein biomarker profile compared with healing ulcers

M. Petkovic, J.A. Raguz, K. Kirketerp-Møller, R.R. Jersie-Christensen, E.C. Leal, E. Carvalho, H. Jenssen, A. Rasmussen, P. Rossing, T.S. Ahluwalia, L.T. Dalgaard, Denmark, Portugal

903 Advanced glycation end-products as serum biomarkers for diabetic peripheral neuropathy in type 1 diabetes

M. Sjøgaard, C. Buhl, R. Brødsgaard, K. Schousboe, H. Mizrak, H. Kufaishi, T. Flemming, P. Nawroth, T.S. Jensen, N.B. Finnerup, C. Stevns, K. Yderstræde, J.R. Nyengaard, N. Ejksjaer, P. Karlsson, Denmark, Germany

904 Optimising examination-time for functional assessment of small C-fiber function in diabetes utilising the histamine-induced axon-reflex flare response

M.K. Borbjerg, S.S. Croosu, T.M. Hansen, J.B. Frøkjær, L. Arendt-Nielsen, N. Ejksjaer, C.D. Mørch, J. Røikjer, Denmark

905 Cathepsin C and platelet-derived growth factor receptor A are potential novel biomarkers of distal sensorimotor polyneuropathy: KORA F4/FF4 study

C. Herder, H. Maalmi, A. Strom, W. Rathmann, M. Heier, M. Waldenberger, W. Koenig, D. Ziegler, M. Roden, A. Peters, G.J. Bönhof, B. Thorand, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

906 Blood oxygen saturation and associations with autonomic and peripheral neuropathy in diabetes

R.B. Brødsgaard, J.C. Laursen, H.I. Mizrak, H. Kufaishi, S.K. Hecquet, B. Brock, P. Rossing, C.S. Hansen, Denmark

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

EASD
EFSD

SO 79 Diabetic complications: observational studies from nerves to blood vessels

Chair: D. Selvarajah, UK

GENERAL
INFO

907 Cardiovascular risk factors associations with long-term weekly heart rate variability in prediabetes: the ADDITION-PRO study

J.R. Schaarup, L. Bjerg, C.S. Hansen, A. Sandbæk, D. Vistisen, D.R. Witte, Denmark

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

908 Association of systolic and diastolic blood pressure with the risk of end-stage renal disease in older diabetes patients: a nationwide population-based study

S. Yu, S. Hong, J. Park, K. Han, C. Lee, Republic of Korea

909 Persons with type 2 diabetes without cardiovascular disease but with albuminuria has increased coronary artery pathology

I.K. Rasmussen, R. Ripa, A.-C. Skriver-Møller, P. Hasbak, V. Wasehuus, K. Hadji-Turdeghal, E.H. Zobel, M.L. Lassen, L. Holmvang, P. Rossing, A. Kjaer, T.W. Hansen, Denmark

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

910 Diabetic cardiac autonomic neuropathy: the impact of sleep quality, insulin resistance, chronic inflammation and arterial stiffness

V. Serhiyenko, L. Serhiyenko, A. Serhiyenko, V. Segin, Ukraine

SATELLITE
SYMPOSIA

911 Recent trends in neuropathy-related hospitalisations in Romania: a retrospective nation-wide study

C. Bala, A. Rusu, C. Bondor, L. Podariu, I. Bujor, N. Gavan, H. Coman, Romania

INDUSTRY

PROGRAMME

912 Mortality from diabetic kidney disease before and during the COVID pandemic

G.A. Lewis, J. Cardwell, K.J. Hardy, UK

EXHIBITION

SO 80 Beyond the clinical examination: emerging diagnostics in diabetic neuropathy

Chair: V. Lyssenko, Norway

913 Assessment of diabetic peripheral neuropathy in type 1 diabetes using magnetic resonance neurography

S. Croosu, J. Røikjer, S. Tahami, T. Hansen, C. Mørch, J. Frøkjær, N. Ejsskjaer, Denmark

914 Soluble urokinase plasminogen activator receptor is associated with cardiovascular autonomic neuropathy in type 1 diabetes

C. Hansen, S. Theilade, J. Eugen-Olsen, S. Lyngbaek, J.L. Jeppsen, T.W. Hansen, P. Rossing, Denmark

915 Association of early sensory deficits identified by QST with dysmetabolism and their relationship with peripheral neuropathy development

Z. Kender, L. Seebauer, L. Schimpfle, E. Von Rauchhaupt, A. Sulaj, H. Bartl, J. Szendroedi, S. Kopf, D. Tsilingiris, Germany

916 Cerebral dopamine receptor engagement and treatment response: a resting-state functional magnetic resonance imaging study in painful diabetic neuropathy

D. Selvarajah, K. Teh, G. Sloan, S. Pallai, S. Tesfaye, UK

917 Abnormal combined DPN-check and Sudoscan results predict all-cause mortality in people with diabetes: the Sheffield prospective study

M. Goonoo, D. Selvarajah, O. Binns-Hall, G. Sloan, J. Walker, S. Tesfaye, UK

918 Neurochemical imaging identifies neuroprotection mechanisms counteracting excitotoxicity and neurovascular changes in the visual cortex of type 2 diabetic animal models

B. Caramelo, T. Monteiro-Alfredo, J. Martins, J. Sereno, J. Castelhamo, B. Manadas, M. Castelo-Branco, P. Matafome, Portugal

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 81 Diabetes and the heart

Chair: J. Skrha, Czech Republic

1919 CILP2 deficiency ameliorates diabetes related myocardial injury by regulating inflammation and autophagy via AMPK pathway

L. Hu, K. Li, China

1920 Beneficial effects of SGLT2i after acute myocardial infarction are independent of diabetes status: a sub-group analysis of the EMMY trial

F. Aziz, A. Oulhaj, N. Tripolt, P. Pferschy, F. Von-Lewinski, D. Von-Lewinski, H. Sourij, Austria, United Arab Emirates

1921 Lower NT-proBNP and higher cardiovascular risk factors in south Asian vs Nordic women 1-3 years after gestational diabetes

A. Sharma, I. Nermoen, S. Lee-Ødegaard, E. Qvigstad, H.L. Gulseth, S.T. Sollid, K.I. Birkeland, P.L. Myhre, Norway

1922 Hypoglycaemia decreases myocardial work efficiency and increases dyssynchrony in left ventricular segmental contractions in individuals with and without diabetes

C.R. Andreasen, A. Andersen, P.G. Hagelqvist, K. Maytham, M. Sengeløv, F.K. Knop, T. Biering-Sørensen, F.J. Olsen, T. Vilsbøll, Denmark

1923 Associations between arterial basement membrane proteins, clinical characteristics and follow-up events after coronary artery bypass graft operations in type 2 diabetes

A.-S.A. Faarvang, M. Overgaard, P.S. Jensen, L.B. Steffensen, L.P. Riber, L.M. Rasmussen, Denmark

Short Oral Discussion Event D

Wednesday, 14:00 - 15:00

SO 82 Trends in cardiovascular complications

Chair: J. Snell-Bergeon, USA

1924 Coronary artery disease (CAD) in type 2 diabetes and association with social disadvantage: a 50 year perspective

K. McCay, J.J. Warner-Levy, A.H. Heald, UK

1925 Prevalence of heart failure in patients with diabetes: a SwissDiab study

F. Renström, L. Knaus, M. Quarella, M. Buser, M.T. Maeder, M. Brändle, SwissDiab Study Group, Switzerland

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

926 Temporal shift in heart failure medications prescribed to hospitalised patients with and without diabetes in a large US integrated health system

C. Granowitz, S. Chiu, D. Rider, P. Tseng, J. Mudd, J. Remick, S. Sikirica, A. Carroll, M. Canonico, J. Hsia, M. Bonaca, T.J. Gluckman, USA

927 Comparison of SGLT2 inhibitors versus DPP-4 inhibitors as combination with metformin in patients with acute myocardial infarction with diabetes

Y. Lyu, S. Oh, J. Kim, M. Jeong, S. Kim, Republic of Korea

928 Potential different effects of metformin, empagliflozin and semaglutide against hyperglycaemia-induced cardiac damage: preliminary results of an in vitro study

P. Senesi, A. Ferrulli, I. Terruzzi, L. Luzi, Italy

929 Association of echocardiographic parameters and diabetic foot examination with risk of heart failure and all-cause mortality: a prospective observational study

D.S. Tesic, D.D. Andric, M. Petrovic, A. Ilic, T. Miljkovic, J. Dejanovic, T. Popov, M.T. Tomic, S.P. Andric, M.D. Tomic, Serbia

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 83 Predicting cardiovascular events in diabetes

Chair: C. Guja, Romania

930 Mid-regional pro-adrenomedullin predicts cardiovascular events and mortality in patients with type 2 diabetes independently of subclinical inflammation and organ damage

E. Gauffin, S. Chisalita, J. Engvall, F. Nyström, C. Östgren, Sweden

931 Network analysis of circulating microRNAs reveals novel therapeutic targets in subjects with type 2 diabetes and cardiovascular disease

G.E. Grieco, Z.M. Besharat, A. Mori, S. Trocchianesi, L. Farina, M. Petti, C. Alfano, S. Auddino, M. Bruttini, A. Po, L. Nesti, A. Natali, G. Sebastiani, E. Ferretti, F. Dotta, Italy

932 Acute-to-chronic glycaemic ratio as a mortality predictor in ischaemic stroke

E. Climent, A. Rodriguez-Campello, S. Ballesta, J. Jiménez-Conde, G. Llauroadó, E. Cuadrado, Á. Ois, F.G. Cambi, J.A. Flores, J.J. Chillarón, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

933 Hepamet fibrosis score is associated with an increased risk of non-fatal myocardial infarction in individuals with different degree of glucose tolerance

C.M. Cefalo, A. Riccio, C. Mazzanti, L. Vero, T.V. Fiorentino, E. Succurro, M. Perticone, A. Sciacqua, F. Andreozzi, G. Sesti, Italy

934 Relative contributions of CRP, glycaemia and type 2 diabetes to the risk of cardiovascular events in the general population: observational and Mendelian randomisation studies

M.G. Rolver, F.K. Lemvig, B.G. Nordestgaard, M. Benn, Denmark

935 Formulae to estimate the glucose disposal rate and future coronary artery disease in type 1 diabetes

S. Mutter, E.B. Parente, A. Januszewski, J.R. Simonsen, V. Harjutsalo, P.-H. Groop, A.J. Jenkins, L.M. Thorn, on behalf of the FinnDiane Study Group, Finland, Australia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event F

Thursday, 14:00 - 15:00

SO 84 Macrovascular disease: basic science

Chair: G.A. Rutter, Canada

936 Glyoxalase-1 overexpression attenuates arterial stiffness in a mouse model of diabetes

M.G. Pencheva, E. Berends, K.W. Van der Laan, A. Giudici, J.L. Scheijen, P. Leenders, K.D. Reesink, S. Foulquier, B. Spronck, C.G. Schalkwijk, Netherlands, Australia

937 Pharmacological inhibition of myocardial succinyl CoA:3-ketoacid CoA transferase with pimoziide alleviates the progression of diabetic cardiomyopathy

J.R. Ussher, S. Tabatabaei Dakhili, C.T. Saed, C.S. Wagg, J.S. Chan, K. Yang, F. Eaton, K. Gopal, G.D. Lopaschuk, A.A. Greenwell, Canada

938 Epitranscriptomic analysis of m6A RNA methylation in AGES-treated human artery endothelial cells (HAECs)

L. Tang, K. Hu, H. Zhang, X. Chen, H. Zhang, X. Wu, China

939 The use of plasminogen activator inhibitor-1 specific Affimers as a tool to modulate fibrinolysis and thrombosis risk in diabetes

R. Altalhi, N. Pechlivani, C. Tiede, F. Hawkins, D. Tomlinson, K. Naseem, R. Ajjan, UK

940 Chronic glucose overflow increases unfolded protein response in GLUT4-overexpressing cardiomyoblasts

B. Stratmann, Y. Mattern, T. Silva de Carvalho, D. Tschoepe, Germany

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

SO 85 Diabetes, lipids and the vessels

Chair: C. Dibner, Switzerland

941 Lipoprotein(a) a marker for cardiovascular risk stratification in youth with type 1 diabetes

F. Iafrate-Luterbacher, V. Schwitzgebel, Switzerland

942 Possible role of superoxide and nitric oxide in predisposition of female aorta to injury in Zucker diabetic fatty rats: sex specific responses

R. Rahimian, S. Shaligram, F. Akther, X. Han, USA

943 GPR40 agonist, an emerging antidiabetic agent, regulates foam cell formation and endothelial cytotoxicity

H.-J. Hwang, J. Kim, S. Yun, M. Park, E. Song, S. Jang, A. Jang, K. Choi, S. Baik, H. Yoo, Republic of Korea

944 Dapagliflozin induced myocardial flow reserve improvement is not associated to HDL ability to modulate nitric oxide production

U. Capece, A. Ossoli, F. Cinti, G. Sorice, G. Di Giuseppe, G. Ciccarelli, L. Soldovieri, M. Brunetti, S. Moffa, T. Mezza, L. Leccisotti, L. Calabresi, A. Giaccari, Italy

945 The mechanism of ferroptosis induced by advanced glycation end products in human aortic endothelial cells and the intervention of GLP-1

K. Hu, L. Tang, H. Zhang, X. Ye, E. Wo, T. Xiang, Y. He, S. Ma, X. Wu, China

Short Oral Discussion Event B

Tuesday, 13:45 - 14:45

SO 86 Diabetic complications from head to toe

Chair: R. Bem, Czech Republic

946 Olfactory dysfunction and diabetic complications in type 2 diabetes

A. Cardella, F. Mozzanica, A. Ferrulli, L. Luzi, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

947 Conservative treatments effectiveness on chronic venous disease symptoms and quality of life in patients with type 2 diabetes: results from the Vein Step observational study

T. Feodor, Z. Tazi Mezalec, A.J. Ochoa, J.H. Ulloa, Romania, Morocco, Mexico, Colombia

948 Hands tied: how upper extremity impairments impact work and everyday life of people with type 1 diabetes

S. Wagner, K. Nørgaard, I. Willaing, K. Olesen, H.U. Andersen, Denmark

EASD
EFSD

949 Periodontitis: an underappreciated diabetes-related complication

F. Valentim Bitencourt, G. G. Nascimento, S. Arouche Costa, A. Andersen, A. Sandbæk, F. Renato Manzolli Leite, Denmark, Singapore, Brazil

GENERAL
INFO

950 Anti-inflammatory and antibacterial DNA-Ag hydrogel as an antibody delivery system for in situ diabetic alveolar bone rebuilding

L. Peng, C. Wang, W. Li, G. Peng, L. Gou, Y. Zhou, Y. Zhang, China

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Discussion Event C Wednesday, 12:45 - 13:45

SO 87 Diabetic complications: the heart, the kidney and the bone

Chair: A.K. Mottl, USA

951 Fenofibrate lowers cardiac lipid accumulation and attenuates diabetic cardiomyopathy in db/db mice

S. Moon, C.-M. Oh, J. Yu, Republic of Korea

952 Functional and gene regulatory changes in liver of C57Bl6 mice after chronic stress

A. Nikolic, P. Fahlbusch, N. Wahlers, M. Dille, S. Jacob, S. Hartwig, U. Kettel, H. Al-Hasani, J. Kotzka, B. Knebel, Germany

953 Circulating metabolites with race free eGFR and risk of kidney disease in individuals with type 2 diabetes: insights from the UK Biobank study

A.H. Bjorgvinsdottir, F. Persson, T.W. Hansen, M. Frimodt-Møller, P. Rossing, T.S. Ahluwalia, Denmark

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

954 The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalised patients with COVID-19 in the capital region of Denmark

V. Kliim-Hansen, K. S. Johansson, L. S. Gasbjerg, E. Jimenez-Solem, T. S. Petersen, M. E. Nyeland, A.-M. Ellegaard, M. G. Pedersen, F. K. Knop, M. B. Christensen, Denmark

955 Comparison of bone mass density and trabecular bone quality in type 1 diabetes patients on multiple daily insulin regimens and with continuous subcutaneous insulin infusion

E. Kardalas, T. Stratigou, V. Antonopoulou, M. Giannakou, E. Sampanioti, E. Partsalaki, A. Diamantopoulos, M. Koulenti, V. Mitavela, P. Mouchtouris, M. Tzanela, Greece

EASD
EFSD

GENERAL
INFO

Short Oral Discussion Event D Wednesday, 14:00 - 15:00

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 88 Pathogenic mechanism of diabetic complications

Chair: P. Novodvorsky, Slovakia

956 Methylglyoxal impairs the pro-angiogenic ability of mouse adipose-derived stem cells (mADSCs) via a senescence-associated mechanism

A. Leone, A. Nicolò, I. Prevenzano, M. Piacente, M. Campitelli, D. Conza, C. Nigro, C. Miele, Italy

957 Haemoglobine glycation index based on continuous/flash glucose monitoring is related to microvascular complications in type 1 diabetes

M. Pehr, V. Navrátilová, E. Horová, M. Prázný, J. Škrha Jr, Czech Republic

958 Cathepsin K as an early marker of cardiovascular organ damage in type 2 diabetes

M. Massimino, G.C. Mannino, G. Monea, M. Rubino, C. Averta, A. Palummo, E. Mancuso, A. Sciacqua, E. Succurro, G. Sesti, F. Andreozzi, Italy

959 Association of endotoxaemia with low grade inflammation, metabolic syndrome and distinct response to LPS in type 1 diabetes

A. Fedulovs, L. Pahirko, K. Jēkabsons, L. Kunrade, J. Valeinis, U. Riekstiņa, J. Sokolovska, Latvia

960 The relationship between residual insulin secretion and subclinical cardiovascular risk indices in young adults with type 1 diabetes

A. Garbi, A. Barmpagianni, G. Karamanakos, I.A. Anastasiou, S. Driva, A. Kountouri, M. Bonou, J. Barbetseas, V. Lambadiari, S. Liatis, Greece

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

EASD
EFSD

SO 89 Diabetes: a systemic disease

Chair: S. Carlsson, Sweden

961 Effect of glycaemic control on oral health status in patients with diabetes: analysis using a national survey in Korea

H. Jeon, S.-K. Lee, J. Lim, D.-H. Lee, Republic of Korea

962 Trimethylamine n-oxide and impaired kidney function: a chicken and egg situation

I. Konrade, M. Ozola, E. Liepinsh, M. Dambrova, Latvia

963 The impact of diabetes status on total and site-specific cancer risk in the elderly population: a nationwide cohort study

E.-Y. Lee, J.-S. Yun, K.-H. Song, Y.-B. Ahn, K. Kim, K. Han, S.-H. Ko, Republic of Korea

964 Prevalence, determinants and implications of screen positivity for heart failure (using NTProBNP) in people with type 2 diabetes and hypertension with normal ECG

A. Joshi, D. Dalal, H. Singh, S. Patil, India

965 High mannose correlates with surrogate indexes of insulin resistance and predicts cardiovascular events independently of glycaemic status and traditional risk factors

E. Fortin, B. Campi, E. Ferrannini, A. Mari, L. Mellbin, A. Norhammar, P. Näsman, L. Rydén, A. Saba, G. Ferrannini, Sweden, Italy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 90 Epidemiology of cardiovascular disease in diabetes: What is new?

Chair: TBA

966 Impact of previous preeclampsia on preclinical atherosclerosis among women with type 1 diabetes across different risk strata

C.J. Milad, V. Perea, C. Viñals, D. Ayala, I. Conget, M. Giménez, T. Serés-Noriega, M. Claro, A. Mesa, J. Blanco, E. Esmatjes, I. Vinagre, A.J. Amor, Spain

967 Gender inequalities in cardiovascular history, risk factors and care in type 1 diabetes in Germany and France: the data from DPV and SFDT1

E. Cosson, M. Auzanneau, G. Aguayo, M. Heni, J.-P. Riveline, S. Meyhöfer, L. Sablone, S. Mühldorfer, SFDT1 study group, DPV registry, G. Fagherazzi, R. Holl, France, Germany, Luxembourg

968 Clinical inertia on the management of cardiovascular risk factors in patients with type 1 and type 2 diabetes: data from the AMD Annals

A. Da Porto, R. Candido, A. Rocca, V. Manicardi, P. Di Bartolo, G. Di Cianni, G. Russo, Italy

969 Cardiovascular outcomes of glucose-lowering pharmacological agents in older adults: systematic review and meta-analysis

H. Taleisnik Halimi, T. Cukierman-Yaffe, Israel

970 Assessment of age in established atherosclerotic disease or high/very high risk among patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study

J. Haddad, W. Almahmeed, S. Salek, H. Alkandari, N. Alamuddin, F. Alawadi, S.H. Assaad-Khalil, T. Cinar, L.L. Husemoen, L. Lombard, R. Malik, H. Sabbour, M. Ngome, G. Yadav, S. Verma, Jordan, United Arab Emirates, UK, Kuwait, Bahrain, Egypt, Turkey, Denmark, South Africa, Qatar, Canada

971 Long-term effectiveness of the national diabetes quality assessment programme in South Korea

K. Ha, J. Huh, S. Han, S. Kwon, G. Kim, B. Kim, D. Kim, Republic of Korea

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

972 Incidence of stroke and related outcomes in people with type 2 diabetes: a real-world database study in France

K. Mohammedi, I. Sibon, L. Fauchier, N. Quignot, A. Khachatryan, T. Banon, R. Kapnang, K. Kikuchi, H. Ren, C. Massien, L. Vigié, S. Larsen, France, UK, Canada, Denmark

Short Oral Discussion Event A

Tuesday, 12:30 - 13:30

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 91 Experimental models of diabetes: related complications

Chair: K. Kankova, Czech Republic

973 Interdependent nuclear co-trafficking of KPNA2 and p53 prevents cardiomyocyte ferroptosis during heart failure with preserved ejection fraction

Y. Luo, F. Ren, H. Tian, K. Zhang, C. Kan, F. Han, N. Hou, X. Sun, J. Zhang, China

974 Oleoylethanolamide mitigates cardiac metabolic alterations secondary to hyperglycaemia and metabolic syndrome induced by high fat diet in C57BL/6J mice

F. Comella, C. Pirozzi, A. Aragón Herrera, A. Lama, C. Annunziata, S. Melini, N. Opallo, R. Meli, M. Lago Paz, G. Mattace Raso, Italy, Spain, Sweden

975 Single-cell RNA sequencing analysis of steroidogenesis and spermatogenesis impairment in the testis of db/db mouse

Y. Hu, B. Ding, J. Ma, China

976 Targeted microRNA profiling reveals that Exendin-4 modulates the expression of several microRNAs to reduce steatosis in HepG2 cells

O. Khalifa, K. Ouararhni, K. Errafii, N. M. Alajez, A. Arredouani, Qatar

977 Insulin prevents palmitate-induced stress kinase activation, autophagy and apoptosis in human cardiac progenitor cells

I. Calderoni, R. D'Oria, C. Caccioppoli, V.A. Genchi, G. Palma, G. Santarpino, A.D. Milano, T. Bottio, A. Leonardini, A. Natalicchio, S. Perrini, A. Cignarelli, F. Giorgino, L. Laviola, Italy

SO 92 Cognitive impairment in diabetes

Chair: N. Jessen, Denmark

978 Hippocampal impairments in a nongenetic mouse model of type 2 diabetes

M.L. Michalani, R.J. Moreira, M.M. Okamoto, C.Y. Yonamine, U.F. Machado, Brazil, Denmark

979 Astrocytic SCAP deletion attenuates neurodegeneration in the diabetes-associated cognitive dysfunction via astrocyte-neuron crosstalk through C3-C3R signalling

T. Niu, H. Zhang, W. Zhu, K. Liu, S. Wang, China

980 WWOX: the missing link in neurodegenerative-associated pathways in a mouse model of type 2 diabetes

C. Carvalho, S. Cardoso, S. Correia, M. Laranjo, P.I. Moreira, Portugal

981 The effect of dual amylin and calcitonin receptor agonist treatment on spatial memory in rat models of metabolic syndrome

K.E. Mohamed, A.T. Larsen, S.A. Melander, M.A. Karsdal, K. Henriksen, Denmark, Switzerland

982 Clinical characteristics and healthcare utilisation associated with undiagnosed cognitive impairment in elderly patients with diabetes

E. Merzon, M. Shpigelman, S. Vinker, A. Golan-Cohen, I. Green, A.Y. Israel, T. Cukierman-Yaffe, R. Eldor, Israel

983 Glyoxalase 1 overexpression improves neurovascular coupling response and reduces cognitive decline in an animal model of type 1 diabetes

E. Berends, M.G. Pencheva, D.J. Hermes, J.L. Scheijen, R.J. Van Oostenbrugge, S. Foulquier, C.G. Schalkwijk, Netherlands

984 The association of circulating chemerin level with mild cognitive impairment in patients with type 2 diabetes based on resting-state fMRI analysis

X. Yang, W. Wang, Y. Yang, B. Yang, B. Lu, X. Hui, P. Gu, J. Shao, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 93 The Liver: from cell to clinic

Chair: R. Ritzel, Germany

985 Longitudinal intraocular imaging of liver spheroids to uncover novel aspects of liver physiology and pathology

N. Moruzzi, F. Lazzeri-Barcelo, N. Oliva-Vilarnau, M. Baniol, B. Leibiger, O. Bergmann, V.M. Lauschke, I.B. Leibiger, P.-O. Berggren, Sweden

986 TXNIP contributes to NAFLD and related fibrosis by activating the cGAS-STING-PERK pathway

W. Deng, Y. Li, D. Liu, China

987 Systematic screening for advanced fibrosis due to NAFLD using transient elastography performed in diabetology: the NAFLD-Care prospective study

C. Caussy, B. Vergès, S. Beland-Bonenfant, V. Hervieu, M. Mayanard-Muet, D. Delaunay, S. Hadjadj, J. Thureau, J.-M. Petit, S. Charrière, P. Moulin, M. Levrero, B. Cariou, E. Disse, France

988 Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with NAFLD but is not altered by six weeks of exercise training

S.A. Willis, S. Malaikah, S. Bawden, J.A. Sargeant, C.R. Bradley, T. Yates, D.J. Sensusel, D.R. Webb, M.J. Davies, G.P. Aithal, J.A. King, UK

989 Identifying novel subtypes of non-alcoholic fatty liver disease with distinct risks of hepatic and extrahepatic outcomes: a data-driven cluster analysis

T. Gu, D. Fang, W. Zhou, Y. Shi, Y. Bi, China

990 Physical activity clusters among persons with type 2 diabetes: a secondary cross-sectional analysis

I.K. Thorsen, C.G. Durrer, J.C. Brønd, J.S. Nielsen, M. Ried-Larsen, Denmark

Short Oral Discussion Event D

Wednesday, 14:00 - 15:00

SO 94 Diabetes and NAFLD

Chair: M.A. Nauck, Germany

991 Association between ketogenic capacity and metabolic-associated fatty liver disease in patients with type 2 diabetes

J. Bae, S. Lee, M. Lee, Y.-H. Lee, E.S. Kang, B.-S. Cha, B.-W. Lee, Republic of Korea

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

992 Combined effects of diabetic kidney disease (DKD) and non-alcoholic fatty liver disease (NAFLD) on all-cause mortality and risk of cardiovascular events in type 2 diabetes

M. Garofolo, D. Lucchesi, M. Giambalvo, M. Capobianco, G. Mancini, P. Francesconi, G. Penno, S. Del Prato, Italy

993 Association of thyroid function with nonalcoholic fatty liver disease in recent-onset diabetes

N. Saatmann, M. Schön, O.-P. Zaharia, M. Huttasch, K. Strassburger, S. Trenkamp, Y. Kupriyanova, V. Schrauwen-Hinderling, S. Kahl, V. Burkart, R. Wagner, M. Roden, Germany

994 Impaired HDL cholesterol efflux capacity in people with type 1 diabetes and non-alcoholic fatty liver disease (prospective InLipoDiab1 Study)

A. Grzelka-Wozniak, A. Uruska, A. Rohatgi, S. Saldanha, J. Flotynska, A. Cieluch, A. Kaczmarek, A. Pypec, D. Zozulinska-Ziolkiewicz, Poland, USA

995 Adaptation of liver sinusoidal endothelial cell metabolism in diabetes-related fatty liver disease

B. Dewidar, M. Ouwens, E. Rohbeck, M. Reina Do Fundo, H. Al-Hasani, M. Roden, Germany

996 The deubiquitinase UCHL1 is downregulated in the liver of men with type 2 diabetes and regulates mitochondrial metabolism

B. Stocks, I. Bradic, E. Näslund, J.R. Zierath, A.S. Deshmukh, Denmark, Sweden

Short Oral Discussion Event E

Thursday, 12:45 - 13:45

SO 95 NAFLD: relevant biomarkers

Chair: M. Rydén, Sweden

997 A composite blood biomarker including AKR1B10 and cytokeratin 18 performs well in the diagnosis of NASH, advanced hepatic fibrosis, and high-risk NASH

D. Lee, B.-C. Oh, S. Kim, Republic of Korea

998 miRNA-149-5p and miRNA-21-5p contribute to NAFLD progression by regulating hepatic glucose uptake

J. Britsemmer, C. Krause, S. Schriever, H. Kirchner, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

999 Microrna-34a-5p regulates thyroid hormone metabolism in non-alcoholic fatty liver disease

A.-M. Naujack, J. Mittag, H. Kirchner, Germany

1000 12,13-diHOME ameliorates non-alcoholic fatty liver disease by regulating sestrin2-mediated ampk/ulr1/lipophagy pathway in obese mice

K. Zhang, C. Kan, J. Zhang, F. Han, N. Hou, X. Sun, China

EASD
EFSD

1001 Mechanism of ZBED3 regulating hepatocyte apoptosis in NASH through Bim

Y. Wu, X. Luo, China

GENERAL
INFO

1002 Chemerin as a potential biomarker for sex-specific metabolic dysregulation in subjects with NAFLD and diabetes

M.P. Macedo, M.J. Meneses, R.S. Patarrao, H. Shanmungam, P. Portincasa, A. Gastaldelli, J. Raposo, Portugal, Italy

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Discussion Event F, Thursday, 14:00 - 15:00

SO 96 NAFLD: future treatment

Chair: F. Knop, Denmark

1003 Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease (NAFLD)

M. Roden, T. Okanoue, M. Sundby Palle, A.-S. Sejlting, M. Tawfik, M.J. Armstrong, Germany, Japan, Denmark, UK

1004 The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with non-alcoholic fatty liver disease

E. Vrentzos, G. Pavlidis, K. Katogiannis, E. Korakas, A. Kountouri, L. Pliouta, E. Michalopoulou, G. Kostelli, E. Pelekanou, L. Lanaras, M. Bristianou, D. Boumpas, I. Ikonmidis, V. Lambadiari, Greece

1005 Beneficial effects of a curcumin derivative and transforming growth factor-beta receptor I inhibitor combination on non-alcoholic steatohepatitis

C.H. Chung, E.S. Lee, S.H. Jo, K.B. Ha, Republic of Korea

1006 The antipsychotic agent pimozide alleviates non-alcoholic fatty liver disease in experimental obesity

C.T. Saed, S. Dakhili, A.A. Greenwell, K. Yang, J.S. Chan, K. Almahfoud, F. Eaton, K. Gopal, J.R. Ussher, Canada

1007 Effects of thermoneutral housing in a mouse model of non-alcoholic fatty liver disease

C.M. Martin, A. Polizzi, V. Alquier-Bacquie, F. Laserre, M. Huillet, C. Rives, J. Bertrand-Michel, Y. Lippi, S. Lotersztajn, L. Gamet-Payrastre, H. Guillou, S. Ellero-Simatos, A. Fougerat, N. Loiseau, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

PRESENTING AUTHORS OF ORALS AND SHORT ORAL DISCUSSIONS

Last Name, Initials, Presentation Number

EASD EFSD	Abbas, Z. G.	731	Aslanzadeh, V.	404
	Abitbol, A.	61	Auddino, S.	357
	Aboolian, A.	888	Auzanneau, M.	138
	Abou Samra, M.	710	Avdic, T.	300
	Abu-Farha, M.	46	Aziz, F.	920
GENERAL INFO	Acosta Manzano, P.	231	Baagar, K.	335
	Adolfsson, P.	153	Bae, J.	991
	Adriouch, S.	323	Bæk, A.	508
	Afi Leslie, K.	275	Baez, N.	274
	Ahmed, F.	616	Bagirathi, N.	853
PROGRAMME	Ahn, Y.-B.	544	Bajaj, H. S.	778
TUESDAY	Ahrén, B.	527	Bakker, J. J.	805
WEDNESDAY	Aiello, E.	360	Bala, C.	911
	Aihara, M.	296	Balboa, D.	166
	Al-Khawi, L.	732	Ballesteros-Pla, C.	430
	Al-Sofiani, M.	766	Bally, L.	842
	Alban, S.	378	Banah, A. K.	487
THURSDAY	Albiero, M.	222	Bangshaab, M.	719
	Alexiou Chatzaki, E.	445	Barbaresko, J.	330
	Alhamar, G.	440	Barbut, D.	98
	Allen, L. A.	849	Battelino, T.	748
	Allouch, A.	182	Batterham, R. L.	673
FRIDAY	Altalhi, R.	939	Baumann, P. M.	794
	Altun, I.	158	Beato-Víbor, P.	228
	Amarajeewa, A. W. P.	346	Beaupere, C.	272
	Amaro, A.	579	Bell, T.	751
	Amendolara, R.	94	Bellido, V.	807
SHORT ORAL DISCUSSIONS	Amigó, J.	852	Bem, R.	769
	Amouyal, C.	526	Benetti, E.	545
	Andersen, J. D.	829	Benova, A.	589
	Andersson, O.	423	Bereket, A.	604
	Andreasen, C. R.	922	Berends, E.	983
PRESENTER INDEX	Anwar, D.	639	Bergental, R.	775
	Arietti, P.	826	Bergman, B. K.	4
	Armour, S. L.	505	Beulens, J. W. J.	725
	Aronne, L.	60	Bezerra Parente, E.	251
	Arrieta, A.	224	Bi, Y.	189
SATELLITE SYMPOSIA	Ásbjörnsdóttir, B.	777	Billert, M.	39
	Ashik, T.	587	Bizzotto, R.	412
INDUSTRY				
PROGRAMME				
EXHIBITION				

Last Name, Initials, Presentation Number

Bjorgvinsdottir, A. H.	953	Casana, E.	246
Björnbak Holst, C.	532	Castaneda, J.	223
Bjornstad, P.	709	Caussey, C.	987
Blanchi, B.	473	Cefalo, C. M. A.	933
Boateng-Kuffour, A.	816	Cegarra Baños, M.	752
Bódis, K.	391	Cerletti, P.	856
Bonadonna, R. C.	257	Chakaroun, R.	205
Bonnet, F.	878	Chakka, S.	358
Borbjerg, M. K.	904	Chakravarthy, M. V.	55
Borg, M. J.	501	Chan, J. S. F.	652
Boss, M.	653	Chapeau, D.	426
Botagarova, A.	446	Charleer, S.	771
Boughton, C. K.	757	Chatur, S.	366
Bouman, E. J.	324	Chen, C.	519
Boye, K.	624	Chen, S.	384
Brachs, S.	34	Chen, W.	808
Brady, E. M.	248	Cheng, A. Y. Y.	863
Brandt, C. B.	895	Chepulis, L.	380
Brännholm Syrjälä, M.	319	Chiriaco, M.	160
Britsemmer, J.	998	Chiu, Y.-T.	792
Brødsgaard, R. B.	906	Cho, S.	827
Brown, J. V. E. 1	14	Cho, Y.	110
Buch, A.	198	Chopra, S.	75
Bue-Valleskey, J.	736	Choudhary, P.	741
Buhl, E. Selmer.	371	Chow, E.	22
Burade, V.	641	Christensen, M. B.	755
Busch, C. B. E.	101	Christensen, M. H.	143
Busik, J.	121	Christofides, E. A.	809
Buur Stougaard, E.	106	Chu, J.	418
Buzzetti, R.	620	Chung, C. H.	1005
Byberg, S.	477	Ciccarelli, G.	468
Calderoni, I.	977	Cinakova, A.	689
Cannon, S.	401	Citro, F.	803
Capece, U.	944	Clemente-Postigo, M.	614
Caramelo, B.	918	Clemmensen, K. K. B.	52
Cardarelli, F.	458	Climent, E.	932
Cardella, A.	946	Cohen, C. C.	310
Cardoso, P.	54	Cohrs, C. M.	96
Carlton, J.	831	Colclough, K.	408
Carretero Gómez, J.	605	Coleman, L.	695
Carrieri, F.	523	Coleman, R. L.	179
Carvalho, C.	980	Comella, F.	974

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Corrales-Cordon, P.	234	Dorweiler, T. F.	123
	Cos, X.	855	Dreher, S. I.	393
	Cosentino, F.	687	Drenthen, L. C. A.	482
	Coskun, T.	56	Du, J.	739
	Cosson, E.	967	Du, Y.	877
	Cowan, E.	435	Duan, Y.	122
EASD	Cox, E.	113	Dubsky, M.	25
EFSD	Crabtree, T. S. J.	367	Duijvestijn, P. H. L.	383
	Croosu, S.	913	Durrer, C.	197
GENERAL	Cuevas, S.	889	Eastwood, S. V.	703
INFO	Cunningham, S. G.	295	Ebekozien, O.	814
	Da Porto, A.	968	Eberle, C.	518
PROGRAMME	Dafoulas, G. E.	151	Ebert, T.	124
	Dai, H.	305	Eccles-Smith, J.	13
TUESDAY	Daian, L.-M.	457	Edstorp, J.	338
	Dance, A.	82	Eeg-Olofsson, K.	818
WEDNESDAY	Danne, T.	846	Ehrmann, D.	834
	Darawshi, S.	479	Eid, A.	238
THURSDAY	Das, V.	245	El-Agroudy, N. N.	145
	Daultrey, H.	789	Eldor, R.	658
FRIDAY	Davies, M. J.	621	Eleftheriadou, A.	137
	Davies, M. J.	682	Elias, I.	307
SHORT ORAL	Davies, M. R. B.	277	Elingaard-Larsen, L. O.	559
DISCUSSIONS	Davis, T. M. E.	72	Engel, S. S.	115
	Davis, W. A.	128	Engelhard, L. M.	283
PRESENTER	De Fano, M.	811	Englund, A.	611
INDEX	De Meulemeester, J.	226	Ennis, M. J. S.	873
	Delgadillo Silva, L.	164	Faarvang, A.-S.A.	923
SATELLITE	Deng, K.	414	Faber, J.	387
SYMPOSIA	Deng, W.	986	Fadini, G.	880
	Dennis, J. M.	867	Fahlbusch, P.	188
INDUSTRY	Deshmukh, H.	788	Falkenhain, K.	97
	Dewidar, B.	995	Fanni, G.	43
PROGRAMME	Di Giuseppe, G.	73	Farrell, C. M.	62
	Di Pietrantonio, N.	394	Farrelly, R.	16
EXHIBITION	Dichman, M.-L.	674	Fedulovs, A.	959
	Dikaiou, P.	170	Feiner, J.	407
	Dinter, K. A.	617	Fejfarova, V.	900
	Dirks, M. L.	196	Feodor, T.	947
	Diurlin, S.	521	Ferrannini, G.	478
	Divilly, P.	793	Finke-Groene, K.	845
	Domazet, S. L.	218	Flotyńska, J.	320

Last Name, Initials, Presentation Number

Folli, F.	715	Grass, I.	70
Forteach, C.	795	Grieco, G. E.	931
Fortin, E.	965	Grøndahl, M. F. G.	499
Fortuin-de Smidt, M. C.	354	Grzelka-Wozniak, A.	994
Francis, E. C.	140	Gu, T.	989
Frías, J. P.	6	Gullaksen, S.	893
Frueh, A.	506	Günes-Altan, M.	692
Fu, Y.	634	Guo, L.	253
Fuhri Snethlage, C. M.	258	Gupta, A.	854
Gabriel, B. M.	491	Gurgul Convey, E.	459
Gaffuri, A.-L.	185	Guzmán, T. J.	464
Gaglia, J. L.	685	Ha, K.	971
Galassetti, P.	663	Haahr, H.	738
Gallardo, N.	537	Habets, I. S. J.	718
Galli, A.	163	Haddad, J.	970
Galuška, D.	694	Hagelqvist, P. G.	174
Gangadhara, P.	861	Hagerf, B.	806
Ganla, M.	678	Hajj Hassan, Y.	434
Gao, L.	707	Hakaste, L.	342
Gao, M.	774	Hamilton, A.	504
Gao, R.	79	Han, S.	321
Garbi, A.	960	Han, Y.-M.	183
Garcia-Martinez, I.	117	Hansen, A. L.	242
Garofolo, M.	992	Hansen, C.	914
Gasbjerg, L. S.	288	Harms, P. P.	172
Gauffin, E.	930	Harris, S.	744
Genchi, V. A.	509	Hart, K.	278
Gheibi, S.	356	Hasan, N.	754
Ghosh, S.	131	Hassanein, M.	136
Giambalvo, M.	884	Hastrup, S.	681
Gill, J.	474	Hauge, J. W.	45
Giorgino, F.	626	Haupt-Jorgensen, M.	392
Gisinger, T.	865	Haxha, S.	173
Goldenberg, R.	776	He, W.	557
Goldet, G.	370	Heald, A. H.	390
Gong, Y.	233	Hecquet, S.	733
Gooding, K. M.	892	Heilmann, G.	348
Goodman, J. D. H.	646	Heise, T.	11
Goonoo, M.	917	Helleputte, S.	493
Goubar, A.	130	Hellman, Y.	437
Grancini, V.	654	Herder, C.	905
Granowitz, C.	926	Hermanns, N.	812

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Hernandez-Baraza, L.	515	Jeon, H.	961
	Herzig, D.	785	Jepson, L.	742
	Hetty, S.	612	Jethwani, P.	729
	Hill, T. G.	92	Jha, J. C.	132
	Hingst, J. R.	737	Ji, L.	632
	Hirsch, I. B.	292	Jo, S.	167
EASD EFSD	Hjeje, S.	773	Johansson, K.	178
	Hofwimmer, K.	219	Jones, H.	704
	Høj Jensen, M.	337	Jose, M.	289
GENERAL INFO	Holstein, A.	749	Joshi, A.	964
	Holt, J.	540	Joshi, S.	844
	Hompesch, M.	90	Jude, E.	352
PROGRAMME	Hong, T.	303	Julkunen, H.	211
TUESDAY	Honka, M.-J.	281	Julla, J.-B.	767
	Hopkins, R.	254	Jumpertz von Schwartzberg, R.	260
WEDNESDAY	Horová, E.	294	Jung, H.	71
	Horowitz, M.	717	Jung, I.	860
THURSDAY	Horváth, L.	756	Juza, A.	511
	Hövelmann, U.	779	Kabbani, N.	517
FRIDAY	Hribar, K.	520	Kahl, S.	191
	Hu, H.	24	Kahleova, H.	193
	Hu, K.	945	Kaiser, K.	613
SHORT ORAL DISCUSSIONS	Hu, L.	919	Kampmann, U.	389
	Hu, Y.	975	Kan, C.	571
	Huan, Z.	186	Kanai, A.	84
PRESENTER INDEX	Huang, N.	891	Kantartzis, K.	213
	Huhn, E. A.	15	Karagiannis, T.	5
	Huynh, L. Q.	655	Karagiannopoulos, A.	41
SATELLITE SYMPOSIA	Hwang, D.-E.	700	Karamanakos, G.	530
	Hwang, H.-J.	943	Karayiannides, S.	280
	Iafate-Luterbacher, F.	941	Kardalas, E.	955
INDUSTRY	Incedal Nilsson, T.	165	Karsai, M.	301
PROGRAMME	Inzucchi, S. E.	698	Karusheva, Y.	161
	J. Moreira, R.	706	Kashima, K.	882
EXHIBITION	Jacob, C.	822	Katte, J. Claude.	529
	Jacobs, M.	210	Kay, T.	684
	Janevica, J.	872	Kazda, C.	10
	Janiszewski, M.	697	Kedenko, L.	209
	Jansson, S. P. O.	216	Kelly, R. C.	839
	Jarosz-Chobot, P.	772	Kender, Z.	915
	Jastreboff, A. M.	57	Kerr, J.	836
	Jaworski, T.	202	Khalifa, O.	976

Last Name, Initials, Presentation Number

Khuntti, K.	119	Laitinen, A.	86
Kidron, M.	120	Laitinen, I.	207
Kim, H.	311	Lakshman, R.	760
Kim, H.	476	Lallouet, M.	425
Kim, J.	261	Lamba, E.-M.	471
Kim, J.	759	Lampousi, A.-M.	332
Kim, N.	285	Lang, A.	327
Kim, S.	111	Larsen, A. T.	649
Kjaergaard, A. D.	317	Latva-Rasku, A.	133
Kliim-Hansen, V.	954	Lavens, A.	312
Klötzsch, A.-T.	676	Le Roux, C. W.	59
Knoch, K.-P.	336	le Stunff, H.	306
Knop, F. K.	648	Lee, D.	997
Knupp, J.	411	Lee, E.	127
Koide, Y.	672	Lee, E.	87
Konečná, J.	112	Lee, E.-Y.	963
Konrade, I.	962	Lee, K.-J.	369
Koronowski, K. B.	485	Lee, M. H.	74
Kosjerina, V.	50	Lee, S. N.	635
Kotte, M.	148	Lee-Ødegård, S.	525
Kotzaeridi, G.	17	Leelarathna, L.	763
Koudelkova, K.	483	Lehner, C. T.	349
Kountouri, A.	263	Lei, K.	439
Kouw, I. W. K.	712	Lei, Y.	453
Kremers, S. H. M.	386	Lei, Y.	498
Kretschmar, L.-M.	427	Leibowitz, G.	135
Kristensen, F. P. B.	201	Lemaitre, M.	513
Kristoffersen, S. F.	316	Leohr, J.	12
Krogh, L.	500	Leone, A.	956
Kronborg, T.	743	Lesniewska, A.	565
Kroon, T.	308	Lever, C. S.	802
Kruse, R.	47	Lewis, G. A.	912
Kubitz, P.	206	Li, G.	598
Kufaishi, H.	204	Li, H.	462
Kuhre, R. E.	547	Li, J.	452
Kulzer, B.	156	Li, P.	701
Kutz, A.	177	Li, T.	329
Kuusela, S.	344	Li, W.	489
Kway, Y. M.	573	Li, X.	512
Kyrönniemi, A.	104	Li, X.	597
Laffel, L.	797	Li, X.	857
Laichuthai, N.	843	Li, Y.	553

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Li-Gao, R.	21	Malbert, C.	89
	Liggins, R.	64	Malinska, H.	590
	LiJuan, N.	77	Manco, M.	488
	Lim, G. E.	38	Mandal, S.	593
	Lim, S.	256	Manley, S. E.	820
	Lin, E.	864	Mannino, G. C.	363
EASD EFSD	Lin, K.	26	Mao, T.	637
	Linares-Pineda, T.	142	Marathe, C.	726
	Lind, M.	373	Marathe, J. A.	869
GENERAL INFO	Lindegaard, B.	560	Marhefková, N.	790
	Linder, T.	480	Markova, I.	567
	Linge, J.	1	Marrano, N.	438
PROGRAMME	Lingvay, I.	8	Marroqui, L.	463
TUESDAY	Lithovius, R.	868	Martin, C. M. P.	1007
	Liu, H.	874	Martin Diaz, L.	431
WEDNESDAY	Liu, J.-L.	569	Martin Perez, E.	284
	Liu, S.	890	Martine-Edith, G.	798
THURSDAY	Liu, Y.	442	Martinez-Huenchullan, S.	494
	Llaurado, G.	325	Martins, F.	608
FRIDAY	Lluch, A.	271	Maruthur, N. M.	443
	Lobato, C. B.	422	Massimino, M.	958
	Løgstrup, P.	290	Mather, K. J.	287
SHORT ORAL DISCUSSIONS	Loh, W. Jia.	570	Mathisen, A. F.	420
	London, A.	187	Maurin, L.	244
	Lopes, E.	580	Mazzieri, A.	835
PRESENTER INDEX	López-Alba, A.	813	McCay, K.	924
	Lortz, S.	456	Mchaina, E.	406
	Lorza-Gil, E.	619	McNeilly, A. D.	265
SATELLITE SYMPOSIA	Louis, M.	784	Meek, C. L.	232
	Louvet, I.	81	Melander, S. A.	686
	Lunati, M. E.	669	Melhem, A. L.	241
	Lundqvist, M. H.	556	Melin, E. O.	896
INDUSTRY	Luo, Y.	973	Melnyk, O.	95
PROGRAMME	Lyu, Y.	927	Melzer-Cohen, C.	666
	Lyu, Z.	531	Mendham, A. E.	610
EXHIBITION	Macedo, M. P.	1002	Meneses, M. J.	118
	MacGregor, K.	492	Mengozzi, A.	266
	Madduri, M.	93	Mentxaka Salgado, J.	42
	Maedler, K.	23	Merchant, H. J.	796
	Mahmood, Z. S.	469	Merino, B.	99
	Mainali, U.	364	Mertens, J.	78
	Makhdom, E. A.	236	Merzon, E.	982

Last Name, Initials, Presentation Number

Mesa, A.	214	Navarro-Martínez, H.	524
Meskarova, V.	555	Nesti, L.	212
Mianowska, B.	746	Neudorf, H.	563
Michalani, M. L.	978	Nicholas, L.	576
Milad, C. J.	966	Nicolaisen, S. K.	413
Miller, K. M.	340	Nielsen, C.	745
Millership, S. J.	400	Nielsen, J. S.	298
Minab, R.	379	Niinistö, S.	107
Ming, X.	539	Nikitina, E.	273
Ming, Y.	671	Nikolic, A.	952
Mizgier, M. L.	339	Nikontovic, A.	847
Mizrak, H.	203	Nishida, Y.	304
Mohamed, K. E.	981	Niu, T.	979
Mohammedi, K.	972	Noguera Hurtado, H.	455
Møller, P. M.	147	Nørgaard, S.	229
Molsted, S.	381	O'Neal, D. N.	753
Monfort-Pires, M.	592	Ogledzinski, M.	184
Moon, S.	51	Oh, R.	154
Moon, S.	951	Oh, T.	644
Morcillo Espina, S.	397	Olesen, T.	368
Moreno-López, M.	162	Oliveira, B. F.	721
Morón-Ros, S.	596	Oliveira, R. O.	220
Moruzzi, N.	985	Oliveira Torres, J.	688
Moser, O.	786	Olleik, H.	472
Moskva, K.	656	Olsen, M.	315
Mourin, M.	574	Orive Milla, N.	870
Mozaffari, H.	328	Ortega, R.	40
Mraz, M.	134	Osborne, B.	595
Muilwijk, M.	376	Otero, Y. F.	724
Müller, L.	578	Ottarsdottir, K.	375
Müllerová, M.	765	Palma, G.	602
Muralidharan, S.	405	Pan, H.	628
Murphy, H. R.	230	Pan, T.	102
Muthukumar, A.	291	Pankova, O.	503
Mutter, S.	935	Parambath, M.	80
Mynarek, I.	105	Parise, M.	819
Nag, S.	436	Parker, V. E. R.	841
Nahirney, N. S.	361	Parr, E. B.	711
Nakasone, Y.	875	Parzer, V.	550
Nakazato, M.	83	Pasha, A.	851
Nathanson, D.	821	Patange, S.	606
Naujack, A.-M.	999	Patorno, E.	667

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Pazmino, S.	313	Ramos Abellán, H.	894
	Pedersen, L. B. H.	799	Randell, M. J.	341
	Pehr, M.	957	Ranjan, A. G.	783
	Peleshok, J.	625	Rasmussen, I. K. B.	909
	Peña-Montero, N.	395	Rasmussen, N. H.	382
	Pencheva, M. G.	936	Rastogi, A.	28
EASD	Pendergrast, L. A.	149	Ratzki-Leewing, A.	750
EFSD	Peng, L.	950	Rayner, C. K.	429
	Penswick, S.	299	Razzoli, E.	627
GENERAL	Pepe, V. M.	787	Rebelos, E.	76
INFO	Perego, C.	428	Rebière, C.	159
	Pereira, M. J.	581	Reichert, S. M.	668
PROGRAMME	Petersen, E. A.	583	Reichman, T.	449
	Petersen, M. H.	490	Remmelzwaal, S.	365
TUESDAY	Petkovic, M.	902	Ren, Q.	642
	Petrus, P.	566	Ren, Z.	293
WEDNESDAY	Pfeiffer, A. F. H.	562	Renström, F.	925
	Philippe, M. A.	564	Reyes-Garcia, R.	859
THURSDAY	Philis-Tsimikas, A.	781	Reznik, Y.	762
	Pieber, T.	622	Ribas, V.	568
FRIDAY	Pilla, S. J.	444	Ribeiro, A.	541
	Pinhancos, S.	465	Riccio, A.	486
SHORT ORAL	Piribauer, M.	282	Ritsinger, V.	247
DISCUSSIONS	Pirozzi, C.	603	Robertson, D.	58
	Pirro, V.	623	Roden, M.	1003
PRESENTER	Pletsch-Borba, L.	326	Rodríguez, Á.	659
INDEX	Pointeau, O.	239	Röhm, N.	705
	Pollom, R. K.	770	Rolver, M. G.	934
SATELLITE	Polonsky, W.	780	Romero Gregori, A.	7
SYMPOSIA	Pontrelli, P.	129	Romero Ugalde, H.	734
	Pop-Busui, R.	29	Rosário, F.	833
INDUSTRY	Poulsen, C. G.	879	Rosenbauer, J.	108
PROGRAMME	Priettl, B.	441	Rosendo-Silva, D.	609
	Prystupa, K.	252	Rosenstock, J.	782
EXHIBITION	Puder, J. J.	18	Rossi, A.	735
	Pylypchuk, R.	353	Rossi, C.	259
	Qin, R.	217	Rossing, P.	702
	Qiu, S.	533	Rudofsky, G.	662
	Quast, D. R.	679	Ruhrmann, S.	399
	Rahimian, R.	942	Ruiz, P. L. D.	388
	Rajagopalan, H.	100	Russell-Jones, D.	9
	Ramich, O.	714	Russo, G. 2.	79

Last Name, Initials, Presentation Number

Rust, W.	448	Shamanna, P.	858
Rutters, F.	385	Shamoon, M.	362
Ryder, R. E. J.	727	Shao, X.	885
Saatmann, N.	993	Sharma, A.	921
Sabaratnam, R.	150	Sharmine, S.	402
Sacchetta, L.	582	Sharp, L.	180
Sacre, J. W.	372	She, R.	507
Saed, C. T.	1006	Shehadeh, N.	691
Sajjadi, S.	416	Sheppard, L.	66
Salaiwarakul, A.	862	Shi, J.	554
Sampaio-Pires, D. S.	650	Shields, B.	409
Sánchez-Ceinos, J.	268	Sidahmed, S.	824
Sandforth, L.	415	Siddiqui, M. K.	359
Sandsdal, R.	543	Siegelaar, S. E.	713
Santos-Pardo, I.	651	Silva, B.	514
Sanyal, D.	355	Silva Junior, J. A. da	599
Sanz Villanueva, L.	683	Simo, R.	899
Sattar, N.	2	Sinha, N.	424
Scaffidi, C.	615	Siolos, A.	801
Scarica, R.	850	Sivalingam, S.	235
Schaarup, J. R.	907	Sjøgaard, M.	903
Schain, M.	68	Sjöholm, K.	215
Scheel, A. K.	35	Skaria, M. A.	848
Schierbauer, J.	804	Skopkova, M.	343
Schlesinger, S.	331	Slebe, R.	318
Schlicht, K.	561	Sloan, G.	199
Schlögl, H.	552	Smith, E.	19
Schmidt, S.	722	Smith, M. B.	758
Schmitner, N.	633	Smith, M. L.	44
Schön, M.	267	Smits, M. M.	708
Schouwink, M.	577	Sofizadeh, S.	126
Schürfeld, R.	594	Søholm, J. C.	510
Schuurman, M. A.	600	Sojakova, D.	901
Seelig, E.	677	Sola, C.	481
Seipone, I. D.	528	Søndergaard, E.	723
Selvarajah, D.	916	Song, K.-H.	461
Sen, I.	146	Song, S. H.	747
Senesi, P.	928	Sorondo, B.	680
Sepúlveda, E.	832	Sousa, D.	572
Serhiyenko, V.	910	Spinelli, R.	269
Serranito, M. S.	657	Stadler, M.	817
Seyed Ahmadi, S.	125	Stahl-Pehe, A.	103

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

EASD EFSD	Stanić, S.	585	Thorsen, I. K.	990
	Stedman, M.	815	Thybo, T.	351
GENERAL INFO	Stemberkova Hubackova, S.	270	Tibballs, K.	825
	Stene, L.	144	Tigas, S.	314
PROGRAMME	Stenkula, K. G.	33	Tokgöz, S.	470
	Stentebjerg, L. L.	14	Tong, Y.	243
TUESDAY	Sterner Isaksson, S.	194	Tozzi, M.	48
	Stocks, B.	996	Trask, L.	731
WEDNESDAY	Stoltenberg, C. W.	840	Trico, D.	157
	Stover, H.	451	Tsuno, T.	276
THURSDAY	Stratmann, B.	940	Turchi, F.	761
	Subramanian, V.	502	Tuttle, K. R.	664
FRIDAY	Sugawara, K.	696	U-Din, M.	591
	Sun, D.	558	Ueki, K.	37
SHORT ORAL DISCUSSIONS	Sun, J.	450	Uhlemeyer, C.	575
	Sun, Z.	374	Ukropcová, B.	495
PRESENTER INDEX	Suppli, M. P.	85	Umpierrez, G.	728
	Szalo, G.	377	Unger, L.	181
SATELLITE SYMPOSIA	Szczerba, E.	20	Urbanová, J.	350
	Szczerbinski, L.	49	Ussher, J. R.	937
INDUSTRY	Tabák, A. G.	522	Vaag, A. A.	309
	Tabasum, A.	417	Vaduganathan, M.	171
PROGRAMME	Taege, N.	398	Valentim Bitencourt, F.	949
	Tahrani, A. A.	30	Valverde Tercedor, C.	396
EXHIBITION	Takasawa, S.	262	Vambergue, A.	516
	Takuma, K.	690	van Bon, A. C.	227
	Talaeerad, Z.	91	van den Berg, J. M.	334
	Taleisnik Halimi, H.	969	van den Heuvel, T.	830
	Tan-Chen, S.	588	van der Klauw, M. M.	65
	Tang, L.	938	van Eeghen, S.	240
	Tang, Y.	454	Van Gaal, L. F.	661
	Tatulashvili, S.	897	van Heck, J. I. P.	221
	Taurbekova, B.	410	van Raalte, D. H.	237
	Tentolouris, N.	27	Vandercappellen, E. J.	837
	Teshima, A.	546	Varkevisser, R.	791
	Tesic, D. S.	929	Vávra, D.	898
	Tessem, J. S.	419	Veedefald, S.	88
	Thennati, R.	636	Veli, Ö.	467
	Thieu, V.	665	Verboven, K.	551
	Thomas, T.	823	Verissimo, D.	800
	Thomsen, C. H. N.	152	Verma, M.	31
	Thomsen, R. W.	881	Vidal Trecan, T. 1	92

Last Name, Initials, Presentation Number

Vigersky, R. A.	768	Wu, J.	629
Viggers, R.	176	Wu, T.	255
Vila-Bedmar, R.	584	Wu, Y.	1001
Vilsbøll, T.	643	Wu, Z.	764
Vrentzos, E.	1004	Würfel, M.	208
Vuorela, L.	549	Würtz, P.	297
Waage, C.	139	Wystrychowski, G.	618
Waara, E.	675	Xia, X.	535
Waddell, T.	607	Xiang, C.	716
Wagner, S.	948	Xie, C.	195
Waheed, U.	548	Xu, M.	638
Wallenius, K.	631	Yakala, G. K.	699
Wang, J.	155	Yale, J.-F.	670
Wang, J.	538	Yamaguchi, Y.	838
Wang, N.	109	Yan, B.	264
Wang, Q.	640	Yang, S.	534
Wang, W.	200	Yang, X.	984
Wang, X.	345	Yasuda, T.	601
Wang, Z.	496	Yepmo, M.	484
Wang, Z.	730	Yi, D.	536
Wasehuus, V.	883	Yu, J.-M.	249
Watanabe, M.	871	Yu, S.	908
Wedén, L.	169	Yuan, Z.	693
Wei, Y.	322	Yue, L.	586
Wellberg, E. A.	32	Yun, J.-S.	250
Wen, Q.	421	Zaharia, O. P.	876
Wen, Q.	647	Zareini, B.	53
Wenhui, D.	887	Zethelius, B.	828
Wharton, S.	630	Zhang, J. A.	432
Wickramaratne, V.	720	Zhang, K.	1000
Wiese, R. J.	3	Zhang, M.	886
Wijkstrom, M.	347	Zhang, P.	116
Wilding, J.	660	Zhang, W.	866
Willi, S.	475	Zhang, X.	810
Williams, A.	466	Zhang, Z.	433
Williams, R.	333	Zhang, Z.	67
Willis, S. A.	988	Zhao, L.	542
Wilmot, E. G.	225	Zhao, T.	403
Winhofer, Y.	740	Zheng, J.	141
Wolffenbuttel, B. H. R.	63	Zheng, J.	190
Wong, A.	302	Zhou, Y.	168
Wrublewsky, S.	447	Zhu, W.	69

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

Zhu, X. 460
Zimmer, R. T. 497
Zimmermann, T. 645
Zoungas, S. 175

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INVITED SPEAKERS

Last Name, First Name, Page

Alonso-Magdalena, Paloma . . . 92	Gastaldelli, Amalia 80, 92
Al-Sharafi, Butheinah A. 128	Glintborg, Dorte 111
Anderson, Simon H. C. 104	Gribble, Fiona M. 80
Anker, Stefan D. 78	Heerspink, Hiddo J. L. 106
Araújo-Vilar, David 53	Heller, Simon R. 57
Aronne, Louis J. 104	Herzig, Stephan 50, 78
Barkmeier, Andrew J. 105	Holst, Jens J. 80
Bartelt, Alexander 105	Hovorka, Roman 77
Battelino, Tadej 67	Iversen, Marjolein M. 105
Benedict, Christian 53	Jensen, Troels S. 129
Bengtsson, Tore 110	Johansson, Lars 82
Bergman, Michael 42	Jones, Timothy W. 52
Blondin, Denis P. 110	Kavarthapu, Venu 104
Blüher, Matthias 54	Kazak, Lawrence 110
Boughton, Charlotte 56	Kelly, Andrea 56
Braune, Katerina 69	Khunti, Kamlesh 79
Campbell, Jonathan Edward . . . 80	Kim, Sun H. 80
Carlton, Jill 57	Knip, Mikael 127
Chan, Juliana C. N. 105	Knop, Filip K. 104
Choudhary, Pratik 57	Langenberg, Claudia 83
Chowdhury, Tahseen 111	Lernmark, Ake 30
Cnop, Miriam 109	Leslie, Richard D. 56
Cohen, Catherine C. 79	Lind, Lars 80
Cole, Joanne B. 129	Loft, Anne 105
Coll, Anthony P. 78	Lopaschuk, Gary D. 106
Cummings, Bethany P. 53	Luchsinger, Jose A. 129
Dayan, Colin M. 94	Luk, Andrea O. Y. 83
Dibner, Charna 53	Makkar, Brij M. 128
DiStefano, Johanna K. 79	Mankovsky, Boris 128
D'Onofrio, Luca 81	Mathiesen, Elisabeth R. 78
Dor, Yuval 55	Mathieu, Chantal 30, 92
Elmqvist, Joel K. 53	McCrimmon, Rory 130
Evans, Marc 83	Mengozi, Alessandro 81
Fex, Malin 109	Mensah, Evelyn 79
Frankel, Andrew H. 110	Misra, Shivani 83
Franks, Paul W. 83	Mosenzon, Ofri 111
Frier, Brian M. 57	Mottl, Amy K. 57
Gabriel, Rafael 42	Müller, Timo D. 102
Gaede, Peter 40	Mulvihill, Erin 80
Gasbjerg, Larke Smidt 81	Murphy, Helen R. 78

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, First Name, Page

	Natali, Andrea	80	Tuomilehto, Jaakko	42
	Otonkoski, Timo	109	Tuttle, Katherine R.	52, 106
	Ozanne, Susan E.	82	Uchihara, Masaki	83
	Phillip, Moshe	67	Umpierrez, Guillermo	110
	Perkins, Bruce A.	129	Urbina, Elaine M.	57
	Polonsky, William	52	Valenti, Luca V. C.	79
EASD EFSD	Pospisilik, John A.	82	van Raalte, Daniel R.	110
	Rane, Sushil G.	130	van Sloten, Thomas T.	130
	Redondo, Maria J.	56	Wei, Zong	53
GENERAL INFO	Resl, Michael	110	Williams, Rachel M.	53
	Roden, Michael	78	Wilson, Parker C.	129
PROGRAMME	Rossing, Peter	106		
TUESDAY	Rotbain Curovic, Viktor	79		
	Rungby, Jørgen	130		
	Rutters, Femke	80		
WEDNESDAY	Rydén, Mikael	54		
	Sarabhai, Theresia	81		
	Sattar, Naveed	104		
THURSDAY	Scheen, Andre J. L.	52		
	Scheer, Frank A. J. L.	53		
FRIDAY	Schernthaner, Guntram	78		
	Schrauwen-Hinderling, Vera	82		
SHORT ORAL DISCUSSIONS	Selvarajah, Dinesh	129		
	Senior, Peter A.	69, 94		
	Shah, Hetal	129		
PRESENTER INDEX	Shaw, James A. M.	56		
	Shulman, Gerald I.	108		
	Sims, Emily K.	56		
	Snell-Bergeon, Janet	57		
SATELLITE SYMPOSIA	Sourij, Harald	40		
	Sparks, Lauren M.	105		
	Stefan, Norbert	52		
INDUSTRY	Stewart, Rose	83		
PROGRAMME	Streed, Carl G.	111		
	Szadkowska, Agnieszka	52		
EXHIBITION	Tahrani, Abd	92		
	Taylor, Roy	54, 79		
	Teperino, Raffaele	82		
	Thomas, Louise E.	82		
	Thorn, Peter	130		
	Tomaszuk-Kazberuk, Anna	104		
	Tsapas, Apostolos	52		

**SATELLITE
SYMPOSIA
ON THE
OCCASION
OF THE
59TH
EASD
ANNUAL
MEETING**

DPSG SYMPOSIUM

Tue, 3 October 2023

09:00 - 10:30

Chicago Hall

Chair: Katrien Benhalima Belgium

Speaker: Helen R Murphy, UK:
Pregnancy outcomes of women with early-onset type 2 diabetes

Fidelma Dunne Ireland:
Metformin for the management of GDM: Friend or foe?

David Simmons Australia:
TOBOGM: Time to screen for GDM in early pregnancy?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

D&CVD SYMPOSIUM

Type 2 Diabetes: novel insights into CV risk prediction and focus of management

Tue, 3 October 2023

11:00 - 13:00

Chicago Hall

Chair: Nebojsa Lalic, Serbia, Jan Škrha, Czech Republic
Paul Valensi, France, Katarina Lalic, Serbia

Speaker: Antonio Ceriello, Milano, Italy:
The relevant role of weight variability in the development of diabetic complication

Eberhard Standl, Germany:
SCORE2-Diabetes – the new gold standard for assessing 10y CV risk of individuals with T2D in Europe?

Oliver Schnell, Germany:
Expanding notions on benefits and harms of diabetes medications: dwellings from a “living” network meta-analysis

Doina Catrinou, Romania:
Cardio-Renal-Metabolic Interplay: Emerging Notions and Basic Clinical Treatment Strategies

Mahmoud Ibrahim, USA:
New Interdisciplinary Subspecialty Training in Medicine for Dealing with the Cardio-Renal-Metabolic Challenge in T2D?

Panel Discussion:
Should we move management focus towards the Cardio-Renal-Metabolic focus?

Katarina Lalic, Serbia:
Summary and close

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

NAFLD SYMPOSIUM

Tue, 3 October 2023

13:30 - 15:30

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

IHSG SYMPOSIUM

Has technology solved the problems around hypoglycaemia?

Tue, 3 October 2023

16:30 - 18:30

Chicago Hall

Speaker: Simon Heller, UK:
Introduction

EASD
EFSD

Julia Mader, Austria:
Using technology to assess risk

GENERAL
INFO

Michael Rickels, USA:
Using technology to manage risk

PROGRAMME

TUESDAY

Michael Riddell, Canada:
Exercise induced hypoglycaemia: leveraging technology to mitigate risk

WEDNESDAY

THURSDAY

Stephanie Amiel UK:
Psychoeducational solutions amidst the emergence of new technology

FRIDAY

All speakers:
Panel discussion

SHORT ORAL
DISCUSSIONS

Simon Heller, UK:
Closing remarks

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

PSAD SYMPOSIUM

Wed, 4 October 2023

09:00 - 11:00

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

#dedoc° SYMPOSIUM

The patient perspective: What we wish you knew - and why

Wed, 4 October 2023

12:00 - 13:30

Chicago Hall

Chair: B. Hauck, Germany, R. Scibilia, Austria

Speaker: C. Mathieu, Belgium:

Words of welcome

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EUDF SYMPOSIUM

From concept to coalition: national responses to the diabetes epidemic

Wed, 4 October 2023

14:00 - 16:00

Chicago Hall

EASD
EFSD

Chair: S. Del Prato, Italy
Welcome and opening remarks, the potential of multi-stakeholder alignment in diabetes

GENERAL
INFO

Speaker: A. Consoli, Italy:
Best practice examples: Italian Diabetes Forum

PROGRAMME

TUESDAY

J.-F. Gautier, France:
Best practice examples: Diabetes cooperation in France

WEDNESDAY

C.G. Bala, Romania:
Best practice examples: Romanian Diabetes Forum

THURSDAY

F. Nobels, Belgium:
Best practice examples: Belgian Diabetes Forum

FRIDAY

SHORT ORAL
DISCUSSIONS

J.-B. Gallwitz, Germany:
Best practice examples: Diabetes cooperation in Germany

PRESENTER
INDEX

Panel Q&A: Establishing National Cooperation

C. Mathieu, Belgium:
Closure

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

PCDE SYMPOSIUM

Wed, 4 October 2023

16:30 - 18:30

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

NEUROdiab SYMPOSIUM
Diabetic neuropathy: new perspectives

Thu, 5 October 2023

09:00 - 10:30

Chicago Hall

Chair: Vincenza Spallone, Italy, Solomon Tesfaye, UK

Speaker: Christian Stevns Hansen, Denmark:
Who is at risk? The epidemiology in this new era

Gidon J Bönhof Germany:

How to screen and to diagnose? The compromise of ease and accuracy looking to the future

Shazli Azmi UK:

How to prevent and to treat: multiple targets, multiple tools

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DESG SYMPOSIUM

Thu, 5 October 2023

11:00 - 13:00

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

IDF SYMPOSIUM

Thu, 5 October 2023

14:00 - 15:30

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EGIR SYMPOSIUM

Thu, 5 October 2023

16:00 - 18:00

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INCSG SYMPOSIUM

Fri, 6 October 2023

09:00 - 11:00

Chicago Hall

Chair: Tricia Tan, UK, Fiona Gribble, UK

Speaker: Mette M Rosenkilde, Denmark
Differential Impacts of variants of the GIP and the GLP-1 receptor

EASD
EFSD

GENERAL
INFO

Anna Gloyn, USA

Type 2 diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists

Ben Jones, UK

Pharmacology of incretin receptor variants: biased signalling and ligand-specific effects

Ralf Jockers, France

Functional rescue of human GLP1R variants with impaired GLP1R cell surface expression and associated with impaired glucose control and increased adiposity

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

ExPAS SYMPOSIUM

Fri, 6 October 2023

12:30 - 14:00

Chicago Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA



INDUSTRY

PROGRAMME



EXHIBITION

Diabetologia

Journal of the European Association for the Study of Diabetes (EASD)



Cutting-edge articles on all aspects of diabetes,
from basic science through translational work to
clinical research



Themed issues on timely topics published annually

Web: diabetologia-journal.org

Twitter: @DiabetologiaJnl



2-6 October 2023
Hamburg, Germany

Industry Sessions

on the occasion of the

59th ANNUAL MEETING

OF THE EUROPEAN ASSOCIATION
FOR THE STUDY OF DIABETES



www.easd-industry.com

Organised by



INTERPLAN
media & service gmbh

INDUSTRY SYMPOSIA SCHEDULE

Monday, 2 October 2023

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Hamburg Hall	Paris Hall	Barcelona Hall	Mumbai Hall	Lima Hall	Cairo Hall
Novo Nordisk A/S 09:00 – 15:35	Sanofi 09:00 – 18:00				
		Eli Lilly and Company 12:00 – 13:30			Boehringer Ingelheim and Eli Lilly and Company 11:30 – 12:00
			Dexcom 13:30 – 15:00		Boehringer Ingelheim International GmbH 13:30 – 14:30
		Sanofi 15:00 – 16:30		Abbott Diabetes Care 14:30 – 16:00	
					Boehringer Ingelheim and Eli Lilly and Company 16:00 – 17:00

INDUSTRY SYMPOSIA SCHEDULE

Monday, 2 October 2023

Sydney Hall	Vienna Hall	Seoul Hall	Warsaw Hall	Sofia Hall
Madrigal Pharmaceuticals 13:30 – 14:30	Sinocare Meditech Inc. 13:00 – 14:00	AstraZeneca 13:30 – 15:00		
Insulet 16:00 – 17:00	Roche Diabetes Care GmbH 16:00 – 17:30	AstraZeneca 15:30 – 17:00		CCO – Clinical Care Options, LLC 15:30 – 17:00
			Eli Lilly and Company 17:00 – 18:00	

All stated times in CEST
Status June 2023, details are subject to change.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Tuesday, 3 October 2023

Lima Hall	Warsaw Hall	Vienna Hall

EASD
EFSD

GENERAL INFO

	MSD 18:30 – 19:30	Menarini Group 18:30 – 19:30
Novo Nordisk A/S 19:00 – 20:00		

Wednesday, 4 October 2023

PROGRAMME

TUESDAYWEDNESDAYTHURSDAYFRIDAY

Warsaw Hall
Servier Affaires Medicales 18:45 - 19:45

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Tuesday, 3 October 2023

Sydney Hall	Seoul Hall	Sofia Hall
Ypsomed AG 07:45 – 08:45	Medtronic International Trading Sàrl 07:45 – 08:45	Eli Lilly and Company 07:45 – 08:45
Abbott 18:30 – 19:30	Merck Healthcare KGaA 18:30 – 19:30	Sanofi 18:30 – 19:00

**EASD
EFSD**

**GENERAL
INFO**

Wednesday, 4 October 2023

Virtual
Ypsomed AG 18:35 – 18:45

Sofia Hall
Tandem Diabetes Care 18:45 – 19:45

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

*All stated times in CEST
Status June 2023, details are subject to change.*

HOT TOPIC SESSIONS**SPOTLIGHT STAGE****Tuesday, 3 October 2023**

12:00 – 12:30	Eli Lilly and Company
14:45 – 15:15	Dexcom
16:45 – 17:15	Novo Nordisk A/S and ECHOSSENS

**EASD
EFSD****GENERAL
INFO****PROGRAMME****TUESDAY****WEDNESDAY****THURSDAY****FRIDAY****SHORT ORAL
DISCUSSIONS****PRESENTER
INDEX****SATELLITE
SYMPOSIA****INDUSTRY****PROGRAMME****EXHIBITION****Wednesday, 4 October 2023**

12:15 – 12:45	Abbott
15:00 – 15:30	Novo Nordisk A/S
17:00 – 17:30	Eli Lilly and Company

Thursday, 5 October 2023

12:15 – 12:45	Medtronic International Trading Sàrl
15:00 – 15:30	Bayer AG
17:00 – 17:30	Diabeloop

Friday, 6 October 2023

10:00 – 10:30	Dexcom
11:30 – 12:00	Medtronic International Trading Sàrl
13:00 – 13:30	Wörwag Pharma GmbH & Co. KG

*All stated times in CEST
Status June 2023, details are subject to change.*

The detailed Industry Programme can be found on this website: www.easd-industry.com

VISIT THE INDUSTRY EXHIBITION IN HALL A1

Don't miss out on the opportunity to explore this dynamic space, filled with valuable resources and engaging experiences.



Seating areas and recharge lounge

Take a moment to relax and recharge in our comfortable seating areas. Whether you need a quick break between sessions or want to network with fellow attendees, these designated spaces provide the perfect opportunity to unwind and refuel.



Free fruits and coffee

We believe in keeping you refreshed and energised throughout the day. Enjoy complimentary fruits and freshly brewed coffee, available for your convenience.



Virtual Meeting station

Our dedicated Virtual Meeting station allows you to follow the live sessions virtually and access on-demand content, so you won't miss a beat as you explore the industry exhibition.

Opening hours

Tuesday, 3 October	09:00 – 16:30
Wednesday, 4 October	09:30 – 16:30
Thursday, 5 October	09:30 – 16:30
Friday, 6 October	09:30 – 15:00

See you there!

Organised by



**THEN AND NOW: 100 YEARS OF MAKING A DIFFERENCE IN
DIABETES AND BEYOND****Chairs:** Filip K. Knop (DNK),
Ania Jastreboff (USA)EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 – 09:10 Welcome and introductions
Chairs**09:10 – 09:20 100 years in diabetes history**
Stephen Gough (DNK)**09:20 – 09:30 Basal insulin in clinical practice**
Vanita Aroda (USA)**09:30 – 09:50 Innovation and basal insulin therapy in T2D**
Harpreet Bajaj (CAN)**09:50 – 10:05 Optimising care with basal insulins in T2D**
Julio Rosenstock (USA)**10:05 – 10:15 Future of basal insulins in clinical practice**
Alice Cheng (CAN)**10:15 – 10:30 Discussion + Q&A**
All faculty**10:30 – 10:50 Coffee break sessions****10:50 – 10:55 Welcome back**
Chairs**10:55 – 11:05 A journey of innovation: past and future advancement of
GLP-1RAs**
Michael Nauck (GER)**11:05 – 11:20 Illuminating the interconnection between metabolic
disorders and cardiovascular disease**
Sue Pedersen (CAN)**11:20 – 11:35 A new wave: advancements with GLP-1RAs in weight
management**
Jens Aberle (GER)**11:35 – 11:50 Addressing obesity in adolescents: challenges and
opportunities for intervention**
Aaron Kelly (USA)**11:50 – 12:05 From guidelines to practice: the role of the obesity, T2D
and NASH link**
Lise Lotte Gluud (DNK)

MONDAY, 2 OCTOBER 2023

**09:00 – 15:35
HAMBURG HALL**

- 12:05 – 12:20 Discussion + Q&A**
All faculty
- 12:20 – 13:15 Lunch break sessions**
- 13:15 – 13:20 Welcome back**
Chairs
- 13:20 – 13:35 Can GLP-1RAs be used to achieve effective, early control?**
Alice Cheng (CAN)
- 13:35 – 13:50 Exploring the potential of treatment intensification with GLP-1RAs**
Vanita Aroda (USA)
- 13:50 – 14:10 Cardiorenal disease: can reducing the risks improve outcomes?**
Francesco Cosentino (SWE)
Katherine Tuttle (USA)
- 14:10 – 14:20 Putting individuals at the centre of a guideline-based approach to care**
Kamlesh Khunti (UK)
- 14:20 – 14:30 Discussion + Q&A**
All faculty
- 14:30 – 14:45 Coffee break sessions**
- 14:45 – 14:50 Welcome back**
Chairs
- 14:50 – 15:05 The future of combination therapies**
Juan Frias (USA)
- 15:05 – 15:20 Discussion: Reconstructing the picture from the cardiometabolic puzzle pieces**
Filip K. Knop (DNK)
Ania Jastreboff (USA)
Harpreet Bajaj (CAN)
Francesco Cosentino (SWE)
Lise Lotte Gluud (DNK)
- 15:20 – 15:30 Future directions for cardiometabolic diseases**
Peter Kurtzhals (DNK)
- 15:30 – 15:35 Meeting close**
Chairs

Organised by: Novo Nordisk A/S

**EASD
EFSD**

**GENERAL
INFO**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

MONDAY, 2 OCTOBER 2023

**13:00 – 14:00
VIENNA HALL**

**iCan, A NEW COMMERCIAL STAGE,
INNOVATIVE GLUCOSE SENSOR**

Our science to date including USA and Chinese clinical experience.

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY PROGRAMME
EXHIBITION

Organised by: **Sinocare Meditech Inc.**

**EMERGING ROLE OF THE HEPATIC THYROID HORMONE
PATHWAY IN THE PATHOPHYSIOLOGY OF NASH**

Chair:	Michael Roden (GER)
13:30 – 13:35	Introduction Michael Roden (GER)
13:35 – 13:50	NASH: a growing unmet therapeutic need Jörn Schattenberg (GER)
13:50 – 14:05	The underestimated role of thyroid hormone pathway in the pathophysiology of NASH Eveline Bruinstroop (NLD)
14:05 – 14:20	Discussion and Q&As Michael Roden (GER) Jörn Schattenberg (GER) Eveline Bruinstroop (NLD)
14:20 – 14:30	Key take home messages and close Michael Roden (GER)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Madrigal Pharmaceuticals**

MOVING BEYOND HBA1C: NEW STANDARDS AND
TARGET DESTINATIONS FOR OPTIMIZING GLYCEMIC
CONTROL WITH CGM

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY PROGRAMME
EXHIBITION

Organised by: [Abbott Diabetes Care](#)

MONDAY, 2 OCTOBER 2023

15:30 – 17:00
SOFIA HALL

EXPERT UPDATES ON THE LATEST ADVANCES IN THE DEVELOPMENT OF WEEKLY INSULIN FORMULATIONS

Chair: Rodolfo Galindo (USA)

15:30 – 15:55 **Tracking the Evolution of Insulin and the Impetus for Change**
Stefano Del Prato (ITA)

EASD
EFSD

15:55 – 16:15 **The Latest Clinical Trial Data of Weekly Insulin Formulations**
Julia Mader (AUT)

GENERAL
INFO

16:15 – 16:35 **Practical Considerations and Addressing Concerns**
Rodolfo Galindo (USA)

PROGRAMME

TUESDAY

16:35 – 17:00 **Question and Answer Session**
All faculty

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **CCO – Clinical Care Options, LLC**

**SGLT2 INHIBITORS:
THE SCIENCE BEHIND MULTI-ORGAN BENEFITS; WHAT'S NEXT?**

15:30 – 15:35 Chair welcome and introductions

15:35 – 15:55 Cellular energetics and the positive impact of SGLT2 inhibition

15:55 – 16:15 The science supporting SGLT2 inhibitors renal benefits

16:15 – 16:35 The underlying mechanisms of SGLT2 inhibitors across the ejection fraction spectrum

16:35 – 16:55 SGLT2 inhibitors: Where do we go from here?

16:55 – 17:00 Summary and close

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: [AstraZeneca](#)

WHAT IF WE COULD GO BACK IN TIME? OPTIMISING CARE OF PEOPLE WITH CARDIOVASCULAR, RENAL, AND METABOLIC CONDITIONS USING SGLT2 INHIBITORS

Chair: Alice Cheng (CAN)

- 16:00 – 16:05** **Welcome, introduction to faculty and the patient story**
Alice Cheng (CAN)
- 16:05 – 16:10** **Turning back time: how could we have intervened earlier in the patient journey?**
Nikolaus Marx (GER)
- 16:10 – 16:20** **Discussion: how would your approach differ if the individual had a history of T2D and established CV disease, or HF?**
All faculty
- 16:20 – 16:25** **Let's be proactive now! Optimising patient care across the cardiovascular, renal and metabolic spectrum in clinical practice**
Pamela Kushner (USA)
- 16:25 – 16:35** **Discussion: considering the importance of cardio-renal protection alongside glycaemic, weight and cardiovascular risk factor management**
All faculty
- 16:35 – 16:40** **It's not too late to change your patient's future: implications of recent evidence for cardiovascular, renal and metabolic management**
Merlin Thomas (AUS)
- 16:40 – 16:45** **Discussion: how can we reduce future risk of cardiovascular, renal and metabolic complications in people with T2D and established CV disease, or people with HF?**
All faculty
- 16:45 – 16:55** **Audience Q&A**
All faculty
- 16:55 – 17:00** **Summary and close**
Alice Cheng (CAN)

Organised by: **Boehringer Ingelheim and Eli Lilly and Company**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

TRANSLATING DATA INTO INSIGHTS FOR TAILORED VALUE-BASED CARE

Chairs: Partha Kar (UK)
Bernhard Kulzer (GER)

EASD
EFSD

16:00 – 16:05 Introduction
Partha Kar (UK)
Bernhard Kulzer (GER)

GENERAL
INFO

16:05 – 16:30 How effective is a digital logbook in reducing individual levels of diabetes distress? – Results from the mySugr PRO study
Dominic Ehrmann (GER)

PROGRAMME

TUESDAY

16:30 – 16:55 How can connected digital solutions support optimal care provision? – An example from Thailand
Nitchakarn Laichuthai (THA)

WEDNESDAY

THURSDAY

16:55 – 17:20 How can we put theory into practice in secondary prevention? – Early identification and management of heart failure risk
Rodica Pop-Busui (USA)

FRIDAY

SHORT ORAL
DISCUSSIONS

17:20 – 17:30 Discussion & Closing
All faculty

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Roche Diabetes Care GmbH**

MONDAY, 2 OCTOBER 2023

**17:00 – 18:00
WARSAW HALL**

**SHOULD FASTER RAPID-ACTING INSULINS BE THE STANDARD
FOR FIRST LINE THERAPY?**

**EASD
EFSD**

**GENERAL
INFO**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Eli Lilly and Company

TUESDAY, 3 OCTOBER 2023

12:00 – 12:30
SPOTLIGHT STAGE

**ADDRESSING WEIGHT MANAGEMENT IN PEOPLE WITH
TYPE 2 DIABETES**

Chair: Rachel Batterham (UK)

**12:00 – 12:30 Addressing Weight Management in People with
Type 2 Diabetes**
Alice Cheng (CAN)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Eli Lilly and Company

**THE TIME IS NOW: IMPLEMENTING A MULTIDISCIPLINARY
APPROACH TO NAFLD/NASH MANAGEMENT****Chair:** Lise Lotte Gluud (DNK)**16:45 – 16:47 Introduction**
Lise Lotte Gluud (DNK)**16:47 – 16:52 Screening for NAFLD/NASH:
the who, when and why now**
Lise Lotte Gluud (DNK)**16:52 – 17:07 Integrating NAFLD/NASH management into
multidisciplinary care**
Lise Lotte Gluud (DNK)**17:07 – 17:14 Q & A**
Lise Lotte Gluud (DNK)**17:14 – 17:15 Summary and closure**
Lise Lotte Gluud (DNK)EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S and ECHOSENS

**TRIPLE ACTION IN TYPE 2 DIABETES MANAGEMENT:
CANAGLIFLOZIN IN FOCUS****Chair:** Stefano Del Prato (ITA)EASD
EFSD**18:30 – 18:32 General introduction: from active to proactive diabetes management**
Stefano Del Prato (ITA)GENERAL
INFO**18:32 – 18:39 Prioritize early glycaemic control**
John Wilding (UK)

PROGRAMME

TUESDAY

18:39 – 18:46 Kidney Protection: CREDENCE study under the magnifying glass
David Wheeler (UK)

WEDNESDAY

18:46 – 18:53 Do not forget the heart: Diabetes and Cardiovascular risk management
Petar Seferovic (SRB)

THURSDAY

FRIDAY

18:53 – 19:00 Approaching Holistic Management in Type 2 Diabetes: Outcomes That Matter
Stefano Del Prato (ITA)SHORT ORAL
DISCUSSIONS**19:00 – 19:28 Panel Discussion**
All facultyPRESENTER
INDEX**19:28 – 19:30 Closing remarks**
Stefano Del Prato (ITA)SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Menarini Group

METFORMIN – FOR NEWBIES AND EXPERTS**Chair:** Clifford J. Bailey (UK)**18:30 – 18:33 Introduction**

Clifford J. Bailey (UK)

18:33 – 18:50 Why metformin is good at its job

Clifford J. Bailey (UK)

18:50 – 19:07 Make the best of metformin

Nemencio A. Nicodemus (PHL)

19:07 – 19:24 Metformin in the long run

José Silva-Nunes (PRT)

19:24 – 19:30 Questions and answers

All faculty

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Merck Healthcare KGaA

TUESDAY, 3 OCTOBER 2023

18:30 – 19:30
WARSAW HALL

ERTUGLIFLOZIN IN THE HOLISTIC-PERSON CENTERED APPROACH TO T2DM MANAGEMENT

Co-Chair: Mariana Monteiro (PRT)

18:30 – 18:35 **Opening Remarks**
Co-Chair

18:35 – 18:45 **Ertugliflozin & Glycemic Management in the Holistic-
Person Centered Approach to T2DM Management**
Sam Dagogo-Jack (USA)

18:45 – 18:55 **Ertugliflozin & Weight Management in the Holistic-Person
Centered Approach to T2DM Management**
Linong Ji (CHN)

18:55 – 19:05 **Ertugliflozin & Cardiovascular Risk Factor and Cardiorenal
Protection Management in the Holistic-Person Centered
Approach to T2DM Management**

19:05 – 19:25 **Panel Discussion**
All faculty

19:25 – 19:30 **Closing Remarks**
Co-Chair

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Merck Sharp & Dohme LLC. –
a subsidiary of Merck & Co., Inc.**

**A MULTIDISCIPLINARY APPROACH TO T2D, OBESITY, AND CVD:
CURRENT EVIDENCE AND A LOOK TO THE FUTURE****Chair:** Ildiko Lingvay (USA)**19:00 – 19:10 Welcome and introductions: CV risk in people with T2D and/or obesity**
Ildiko Lingvay (USA)EASD
EFSD**19:10 – 19:28 The effect of GLP-1RAs on CVD and cardio-renal-metabolic risk factors in patients with obesity and/or T2D**
Subodh Verma (CAN)GENERAL
INFO**19:28 – 19:40 GLP-1RAs: What does the future hold?**
Nikolaus Marx (GER)

PROGRAMME

TUESDAY

19:40 – 19:58 Panel discussion and Q&A: Multidisciplinary management for optimal patient care
Ildiko Lingvay (USA)
Subodh Verma (CAN)
Nikolaus Marx (GER)

WEDNESDAY

THURSDAY

19:58 – 20:00 Closing
Ildiko Lingvay (USA)

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S

**DIGITAL DIABETES MANAGEMENT:
NEW PERSPECTIVES FOR INDIVIDUALISED CARE****Chair:** Richard Bergenstal (USA)**15:00 – 15:05 Welcome and introduction**

Richard Bergenstal (USA)

EASD
EFSD**15:05 – 15:10 Clinical spotlight in T2D: how digital health can make a difference in diabetes management**

Julia Mader (AUT)

GENERAL
INFO**15:10 – 15:15 Empowering people with diabetes – the potential of digital titration tools**

Susanne Reger-Tan (GER)

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

15:15 – 15:28 Panel discussion: Diabetes treatment solutions in a digital world

Richard Bergenstal (USA)

Julia Mader (AUT)

Susanne Reger-Tan (GER)

SHORT ORAL
DISCUSSIONS**15:28 – 15:30 Summary and close**

Richard Bergenstal (USA)

PRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S

CONNECTED INSULIN PENS:
REAL WORLD EXPERIENCE

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY PROGRAMME
EXHIBITION

Organised by: **Eli Lilly and Company**

WEDNESDAY, 4 OCTOBER 2023

18:45 – 19:45
WARSAW HALL

ENHANCING QUALITY OF LIFE THROUGH GLYCEMIC CONTROL: A PATIENT CENTRIC APPROACH

Chair: Kamlesh Khunti (UK)

18:45 – 18:50 Introduction

Kamlesh Khunti (UK)

18:50 – 19:05 Glycemic control today, an overview of the state of the art

Kamlesh Khunti (UK)

19:05 – 19:20 Glycemic control, the cornerstone of the quality of life of people living with type 2 diabetes

Juliana Chan (HKG)

19:20 – 19:35 Impact of various fasting situations on type 2 diabetes

Mohamed Hassanein (ARE)

19:35 – 19:45 Panel discussion

Kamlesh Khunti (UK)

Juliana Chan (HKG)

Mohamed Hassanein (ARE)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Servier Affaires Medicales**

EASING DIABETES BURDEN IN
AN AUTONOMOUS FUTURE

Chair: Jordan Pinsker (USA)

Speakers: Steph Habib (USA)
Alex Constantin (USA)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Tandem Diabetes Care**

THURSDAY, 5 OCTOBER 2023

15:00 – 15:30
SPOTLIGHT STAGE

**TIME TO ACT IN CKD:
FINERENONE AS A PILLAR OF TREATMENT IN T2D PATIENTS**

Chair: Lori Berard (CAN)

15:00 – 15:05 Welcome and introduction

Lori Berard (CAN)

EASD
EFSD

15:05 – 15:25 Round table

Time to act in CKD: Finerenone as a pillar of treatment in T2D patients

- Time to act in T2D and CKD
 - The Heart of the Matter
 - The holistic approach for my T2D CKD patient
- Ana Maria Cebrián Cuenca (ESP)
Paola Fioretto (ITA)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

15:25 – 15:30 Take home messages

Lori Berard (CAN)

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Bayer AG

FRIDAY, 6 OCTOBER 2023

13:00 – 13:30
SPOTLIGHT STAGE

**DIABETIC POLYNEUROPATHY –
WHAT’S NEW IN MULTIMODAL MANAGEMENT?**

13:00 – 13:30 **Diabetic Polyneuropathy – What’s new in multimodal management?**
Dan Ziegler (GER)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Wörwag Pharma GmbH & Co. KG**

LIST OF SPONSORS

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

A.Menarini Diagnostics
Abbott
Ascensia Diabetes Care Holdings AG
AstraZeneca
Bayer AG
BGI Europe A/S
Bionime Corporation
Boehringer Ingelheim and Eli Lilly
and Company
Boehringer Ingelheim International
GmbH
CCO – Clinical Care Options, LLC
Dexcom
Diabeloop
ECHOSENS
Eli Lilly and Company
Endra Life Sciences
Eva Pharma
Glooko GmbH
GlucoRx
Hedia
iCare
Impeto Medical
Infinovo Medical Co., Ltd
Innovation Zed
Inreda Diabetic
Insulet
i-SENS
Liberum IME
LumiraDx
Madrigal Pharmaceuticals

MED TRUST Handelsges.m.b.H
Medtronic International Trading Sàrl
Medtrum Technologies Inc.
Menarini Group
Merck Healthcare KGaA
Merck Sharp & Dohme LLC.
– a subsidiary of Merck & Co., Inc.
MESI, development of medical devices
MicroTech Medical
Neodyne Biosciences, Inc.
Ningbo Medsun Medical Co., Ltd.
Novo Nordisk A/S
PharmaSens AG
ProSciento, Inc.
Roche Diabetes Care GmbH
Sanofi
Servier Affaires Medicales
Servier International
SHENZHEN SIBIONICS
TECHNOLOGY CO., LTD
Sinocare Meditech Inc.
SOOIL Development Co., Ltd
Springer Healthcare
Tandem Diabetes Care
Vertex Pharmaceuticals
Wisepress Medical Bookshop
Wörwag Pharma GmbH & Co. KG
YOOme
Ypsomed AG
Zhejiang POCTech Co., Ltd.

Disclosure

The compliance/codex publication list is available at www.easd-industry.com/sponsors.
Status June 2023, details are subject to change.



EASD e-Learning

Learn from the best for better diabetes care

With EASD e-Learning you can choose from a wide range of evidence-based modules, authored by international experts and spanning key areas of clinical practice and research.

Modules combine engaging multimedia and case studies with challenging assessments to support your learning needs. Bite-sized clips and news reports, added every week to our unique information hub 'Horizons', make it easier for you to keep up to date with all the latest diabetes trends and breakthroughs.

- Access is FREE
- More than 70 modules covering key diabetes topics
- Includes CPD-accredited content
- Certificates of completion available
- Learning for the whole multidisciplinary team
- Over 8000 registered users, from all around the world

All our modules are developed with and presented by leading authorities in that topic. Authors include:



Prof Chantal
Mathieu, Belgium



Prof Thomas
Danne, Germany



Prof Melanie
Davies, UK



Prof Pratik
Choudhary, UK

Enrol today to gain access to the world's key opinion leaders
in diabetes research and care **easd-elearning.org**

 @EASDelearning  EASD e-Learning

Scan code to access our website



60th ANNUAL MEETING

EASD

9-13 SEPTEMBER 2024

MADRID

Save the date and see you next year in Madrid!



WWW.EASD.ORG

**FOLLOW THE DISCUSSION
LIVE ON TWITTER
#EASD2023**

**Tweet live
#EASD2023
and follow
@EASDnews**

